id	sid	tid	token	lemma	pos
cord-282507-swxs5pr1	1	1	key	key	NN
cord-282507-swxs5pr1	1	2	:	:	:
cord-282507-swxs5pr1	2	1	cord-282507-swxs5pr1	cord-282507-swxs5pr1	NN
cord-282507-swxs5pr1	2	2	authors	author	NNS
cord-282507-swxs5pr1	2	3	:	:	:
cord-282507-swxs5pr1	2	4	Lacaille	Lacaille	NNP
cord-282507-swxs5pr1	2	5	-	-	HYPH
cord-282507-swxs5pr1	2	6	Dubois	Dubois	NNP
cord-282507-swxs5pr1	2	7	,	,	,
cord-282507-swxs5pr1	2	8	Marie	Marie	NNP
cord-282507-swxs5pr1	2	9	-	-	HYPH
cord-282507-swxs5pr1	2	10	Aleth	Aleth	NNP
cord-282507-swxs5pr1	2	11	title	title	NN
cord-282507-swxs5pr1	2	12	:	:	:
cord-282507-swxs5pr1	2	13	Updated	update	VBN
cord-282507-swxs5pr1	2	14	insights	insight	NNS
cord-282507-swxs5pr1	2	15	into	into	IN
cord-282507-swxs5pr1	2	16	the	the	DT
cord-282507-swxs5pr1	2	17	mechanism	mechanism	NN
cord-282507-swxs5pr1	2	18	of	of	IN
cord-282507-swxs5pr1	2	19	action	action	NN
cord-282507-swxs5pr1	2	20	and	and	CC
cord-282507-swxs5pr1	2	21	clinical	clinical	JJ
cord-282507-swxs5pr1	2	22	profile	profile	NN
cord-282507-swxs5pr1	2	23	of	of	IN
cord-282507-swxs5pr1	2	24	the	the	DT
cord-282507-swxs5pr1	2	25	immunoadjuvant	immunoadjuvant	NN
cord-282507-swxs5pr1	2	26	QS-21	QS-21	NNP
cord-282507-swxs5pr1	2	27	:	:	:
cord-282507-swxs5pr1	3	1	A	a	DT
cord-282507-swxs5pr1	3	2	review	review	NN
cord-282507-swxs5pr1	3	3	date	date	NN
cord-282507-swxs5pr1	3	4	:	:	:
cord-282507-swxs5pr1	3	5	2019	2019	CD
cord-282507-swxs5pr1	3	6	-	-	HYPH
cord-282507-swxs5pr1	3	7	07	07	CD
cord-282507-swxs5pr1	3	8	-	-	HYPH
cord-282507-swxs5pr1	3	9	31	31	CD
cord-282507-swxs5pr1	3	10	journal	journal	NN
cord-282507-swxs5pr1	3	11	:	:	:
cord-282507-swxs5pr1	4	1	Phytomedicine	Phytomedicine	NNP
cord-282507-swxs5pr1	4	2	DOI	DOI	NNP
cord-282507-swxs5pr1	4	3	:	:	:
cord-282507-swxs5pr1	4	4	10.1016	10.1016	CD
cord-282507-swxs5pr1	4	5	/	/	SYM
cord-282507-swxs5pr1	4	6	j.phymed.2019.152905	j.phymed.2019.152905	NNP
cord-282507-swxs5pr1	4	7	sha	sha	NNP
cord-282507-swxs5pr1	4	8	:	:	:
cord-282507-swxs5pr1	5	1	2311677b6bab8221ee5d403f9f5de32fad8ec229	2311677b6bab8221ee5d403f9f5de32fad8ec229	CD
cord-282507-swxs5pr1	5	2	doc_id	doc_id	CD
cord-282507-swxs5pr1	5	3	:	:	:
cord-282507-swxs5pr1	5	4	282507	282507	CD
cord-282507-swxs5pr1	5	5	cord_uid	cord_uid	NNS
cord-282507-swxs5pr1	5	6	:	:	:
cord-282507-swxs5pr1	6	1	swxs5pr1	swxs5pr1	NFP
cord-282507-swxs5pr1	6	2	Abstract	Abstract	NNP
cord-282507-swxs5pr1	6	3	Background	Background	NNP
cord-282507-swxs5pr1	6	4	Vaccine	Vaccine	NNP
cord-282507-swxs5pr1	6	5	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	6	6	are	be	VBP
cord-282507-swxs5pr1	6	7	compounds	compound	NNS
cord-282507-swxs5pr1	6	8	that	that	WDT
cord-282507-swxs5pr1	6	9	significantly	significantly	RB
cord-282507-swxs5pr1	6	10	enhance	enhance	VBP
cord-282507-swxs5pr1	6	11	/	/	SYM
cord-282507-swxs5pr1	6	12	prolong	prolong	VB
cord-282507-swxs5pr1	6	13	the	the	DT
cord-282507-swxs5pr1	6	14	immune	immune	JJ
cord-282507-swxs5pr1	6	15	response	response	NN
cord-282507-swxs5pr1	6	16	to	to	IN
cord-282507-swxs5pr1	6	17	a	a	DT
cord-282507-swxs5pr1	6	18	co	co	NN
cord-282507-swxs5pr1	6	19	-	-	JJ
cord-282507-swxs5pr1	6	20	administered	administer	VBN
cord-282507-swxs5pr1	6	21	antigen	antigen	NN
cord-282507-swxs5pr1	6	22	.	.	.
cord-282507-swxs5pr1	7	1	The	the	DT
cord-282507-swxs5pr1	7	2	limitations	limitation	NNS
cord-282507-swxs5pr1	7	3	of	of	IN
cord-282507-swxs5pr1	7	4	the	the	DT
cord-282507-swxs5pr1	7	5	use	use	NN
cord-282507-swxs5pr1	7	6	of	of	IN
cord-282507-swxs5pr1	7	7	aluminium	aluminium	NN
cord-282507-swxs5pr1	7	8	salts	salt	NNS
cord-282507-swxs5pr1	7	9	that	that	WDT
cord-282507-swxs5pr1	7	10	are	be	VBP
cord-282507-swxs5pr1	7	11	unable	unable	JJ
cord-282507-swxs5pr1	7	12	to	to	TO
cord-282507-swxs5pr1	7	13	elicite	elicite	VB
cord-282507-swxs5pr1	7	14	cell	cell	NN
cord-282507-swxs5pr1	7	15	responses	response	NNS
cord-282507-swxs5pr1	7	16	against	against	IN
cord-282507-swxs5pr1	7	17	intracellular	intracellular	JJ
cord-282507-swxs5pr1	7	18	pathogens	pathogen	NNS
cord-282507-swxs5pr1	7	19	such	such	JJ
cord-282507-swxs5pr1	7	20	as	as	IN
cord-282507-swxs5pr1	7	21	those	those	DT
cord-282507-swxs5pr1	7	22	causing	cause	VBG
cord-282507-swxs5pr1	7	23	malaria	malaria	NN
cord-282507-swxs5pr1	7	24	,	,	,
cord-282507-swxs5pr1	7	25	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	7	26	,	,	,
cord-282507-swxs5pr1	7	27	or	or	CC
cord-282507-swxs5pr1	7	28	AIDS	AIDS	NNP
cord-282507-swxs5pr1	7	29	,	,	,
cord-282507-swxs5pr1	7	30	have	have	VBP
cord-282507-swxs5pr1	7	31	driven	drive	VBN
cord-282507-swxs5pr1	7	32	the	the	DT
cord-282507-swxs5pr1	7	33	development	development	NN
cord-282507-swxs5pr1	7	34	of	of	IN
cord-282507-swxs5pr1	7	35	new	new	JJ
cord-282507-swxs5pr1	7	36	alternative	alternative	JJ
cord-282507-swxs5pr1	7	37	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	7	38	such	such	JJ
cord-282507-swxs5pr1	7	39	as	as	IN
cord-282507-swxs5pr1	7	40	QS-21	QS-21	NNP
cord-282507-swxs5pr1	7	41	,	,	,
cord-282507-swxs5pr1	7	42	a	a	DT
cord-282507-swxs5pr1	7	43	triterpene	triterpene	JJ
cord-282507-swxs5pr1	7	44	saponin	saponin	NN
cord-282507-swxs5pr1	7	45	purified	purify	VBN
cord-282507-swxs5pr1	7	46	from	from	IN
cord-282507-swxs5pr1	7	47	Quillaja	Quillaja	NNP
cord-282507-swxs5pr1	7	48	saponaria	saponaria	NNP
cord-282507-swxs5pr1	7	49	.	.	.
cord-282507-swxs5pr1	8	1	Purpose	purpose	NN
cord-282507-swxs5pr1	9	1	The	the	DT
cord-282507-swxs5pr1	9	2	aim	aim	NN
cord-282507-swxs5pr1	9	3	of	of	IN
cord-282507-swxs5pr1	9	4	this	this	DT
cord-282507-swxs5pr1	9	5	review	review	NN
cord-282507-swxs5pr1	9	6	is	be	VBZ
cord-282507-swxs5pr1	9	7	to	to	TO
cord-282507-swxs5pr1	9	8	attempt	attempt	VB
cord-282507-swxs5pr1	9	9	to	to	TO
cord-282507-swxs5pr1	9	10	clarify	clarify	VB
cord-282507-swxs5pr1	9	11	the	the	DT
cord-282507-swxs5pr1	9	12	mechanism	mechanism	NN
cord-282507-swxs5pr1	9	13	of	of	IN
cord-282507-swxs5pr1	9	14	action	action	NN
cord-282507-swxs5pr1	9	15	of	of	IN
cord-282507-swxs5pr1	9	16	QS-21	QS-21	NNP
cord-282507-swxs5pr1	9	17	through	through	IN
cord-282507-swxs5pr1	9	18	either	either	CC
cord-282507-swxs5pr1	9	19	receptors	receptor	NNS
cord-282507-swxs5pr1	9	20	or	or	CC
cord-282507-swxs5pr1	9	21	signaling	signal	VBG
cord-282507-swxs5pr1	9	22	pathways	pathway	NNS
cord-282507-swxs5pr1	9	23	in	in	IN
cord-282507-swxs5pr1	9	24	vitro	vitro	FW
cord-282507-swxs5pr1	9	25	and	and	CC
cord-282507-swxs5pr1	9	26	in	in	IN
cord-282507-swxs5pr1	9	27	vivo	vivo	NN
cord-282507-swxs5pr1	9	28	with	with	IN
cord-282507-swxs5pr1	9	29	special	special	JJ
cord-282507-swxs5pr1	9	30	emphasis	emphasis	NN
cord-282507-swxs5pr1	9	31	on	on	IN
cord-282507-swxs5pr1	9	32	the	the	DT
cord-282507-swxs5pr1	9	33	co	co	NN
cord-282507-swxs5pr1	9	34	-	-	NN
cord-282507-swxs5pr1	9	35	administration	administration	NN
cord-282507-swxs5pr1	9	36	with	with	IN
cord-282507-swxs5pr1	9	37	other	other	JJ
cord-282507-swxs5pr1	9	38	immunostimulants	immunostimulant	NNS
cord-282507-swxs5pr1	9	39	in	in	IN
cord-282507-swxs5pr1	9	40	new	new	JJ
cord-282507-swxs5pr1	9	41	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	9	42	formulations	formulation	NNS
cord-282507-swxs5pr1	9	43	,	,	,
cord-282507-swxs5pr1	9	44	called	call	VBN
cord-282507-swxs5pr1	9	45	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	9	46	systems	system	NNS
cord-282507-swxs5pr1	9	47	(	(	-LRB-
cord-282507-swxs5pr1	9	48	AS	AS	NNP
cord-282507-swxs5pr1	9	49	)	)	-RRB-
cord-282507-swxs5pr1	9	50	.	.	.
cord-282507-swxs5pr1	10	1	Furthermore	furthermore	RB
cord-282507-swxs5pr1	10	2	,	,	,
cord-282507-swxs5pr1	10	3	the	the	DT
cord-282507-swxs5pr1	10	4	most	most	RBS
cord-282507-swxs5pr1	10	5	relevant	relevant	JJ
cord-282507-swxs5pr1	10	6	clinical	clinical	JJ
cord-282507-swxs5pr1	10	7	applications	application	NNS
cord-282507-swxs5pr1	10	8	will	will	MD
cord-282507-swxs5pr1	10	9	be	be	VB
cord-282507-swxs5pr1	10	10	presented	present	VBN
cord-282507-swxs5pr1	10	11	.	.	.
cord-282507-swxs5pr1	11	1	Methods	method	NNS
cord-282507-swxs5pr1	11	2	A	a	DT
cord-282507-swxs5pr1	11	3	literature	literature	NN
cord-282507-swxs5pr1	11	4	search	search	NN
cord-282507-swxs5pr1	11	5	covering	cover	VBG
cord-282507-swxs5pr1	11	6	the	the	DT
cord-282507-swxs5pr1	11	7	period	period	NN
cord-282507-swxs5pr1	11	8	2014–2018	2014–2018	CD
cord-282507-swxs5pr1	11	9	was	be	VBD
cord-282507-swxs5pr1	11	10	performed	perform	VBN
cord-282507-swxs5pr1	11	11	using	use	VBG
cord-282507-swxs5pr1	11	12	electronic	electronic	JJ
cord-282507-swxs5pr1	11	13	databases	database	NNS
cord-282507-swxs5pr1	11	14	from	from	IN
cord-282507-swxs5pr1	11	15	Sci	Sci	NNP
cord-282507-swxs5pr1	11	16	finder	finder	NN
cord-282507-swxs5pr1	11	17	,	,	,
cord-282507-swxs5pr1	11	18	Science	Science	NNP
cord-282507-swxs5pr1	11	19	direct	direct	NN
cord-282507-swxs5pr1	11	20	,	,	,
cord-282507-swxs5pr1	11	21	Medline	Medline	NNP
cord-282507-swxs5pr1	11	22	/	/	SYM
cord-282507-swxs5pr1	11	23	Pubmed	Pubmed	NNP
cord-282507-swxs5pr1	11	24	,	,	,
cord-282507-swxs5pr1	11	25	Scopus	Scopus	NNP
cord-282507-swxs5pr1	11	26	,	,	,
cord-282507-swxs5pr1	11	27	Google	Google	NNP
cord-282507-swxs5pr1	11	28	scholar	scholar	NN
cord-282507-swxs5pr1	11	29	.	.	.
cord-282507-swxs5pr1	12	1	Results	result	NNS
cord-282507-swxs5pr1	12	2	Insights	insight	NNS
cord-282507-swxs5pr1	12	3	into	into	IN
cord-282507-swxs5pr1	12	4	the	the	DT
cord-282507-swxs5pr1	12	5	mechanism	mechanism	NN
cord-282507-swxs5pr1	12	6	of	of	IN
cord-282507-swxs5pr1	12	7	action	action	NN
cord-282507-swxs5pr1	12	8	of	of	IN
cord-282507-swxs5pr1	12	9	QS-21	QS-21	NNP
cord-282507-swxs5pr1	12	10	can	can	MD
cord-282507-swxs5pr1	12	11	be	be	VB
cord-282507-swxs5pr1	12	12	summarized	summarize	VBN
cord-282507-swxs5pr1	12	13	as	as	IN
cord-282507-swxs5pr1	12	14	follows	follow	VBZ
cord-282507-swxs5pr1	12	15	:	:	:
cord-282507-swxs5pr1	13	1	1	1	LS
cord-282507-swxs5pr1	13	2	)	)	-RRB-
cord-282507-swxs5pr1	13	3	in	in	IN
cord-282507-swxs5pr1	13	4	vivo	vivo	NN
cord-282507-swxs5pr1	13	5	stimulation	stimulation	NN
cord-282507-swxs5pr1	13	6	of	of	IN
cord-282507-swxs5pr1	13	7	Th2	th2	CD
cord-282507-swxs5pr1	13	8	humoral	humoral	JJ
cord-282507-swxs5pr1	13	9	and	and	CC
cord-282507-swxs5pr1	13	10	Th1	th1	CD
cord-282507-swxs5pr1	13	11	cell	cell	NN
cord-282507-swxs5pr1	13	12	-	-	HYPH
cord-282507-swxs5pr1	13	13	mediated	mediate	VBN
cord-282507-swxs5pr1	13	14	immune	immune	JJ
cord-282507-swxs5pr1	13	15	responses	response	NNS
cord-282507-swxs5pr1	13	16	through	through	IN
cord-282507-swxs5pr1	13	17	action	action	NN
cord-282507-swxs5pr1	13	18	on	on	IN
cord-282507-swxs5pr1	13	19	antigen	antigen	NN
cord-282507-swxs5pr1	13	20	presenting	present	VBG
cord-282507-swxs5pr1	13	21	cells	cell	NNS
cord-282507-swxs5pr1	13	22	(	(	-LRB-
cord-282507-swxs5pr1	13	23	APCs	apc	NNS
cord-282507-swxs5pr1	13	24	)	)	-RRB-
cord-282507-swxs5pr1	13	25	and	and	CC
cord-282507-swxs5pr1	13	26	T	t	NN
cord-282507-swxs5pr1	13	27	cells	cell	NNS
cord-282507-swxs5pr1	13	28	,	,	,
cord-282507-swxs5pr1	13	29	leading	lead	VBG
cord-282507-swxs5pr1	13	30	to	to	IN
cord-282507-swxs5pr1	13	31	release	release	NN
cord-282507-swxs5pr1	13	32	of	of	IN
cord-282507-swxs5pr1	13	33	Th1	Th1	NNP
cord-282507-swxs5pr1	13	34	cytokines	cytokine	NNS
cord-282507-swxs5pr1	13	35	participating	participate	VBG
cord-282507-swxs5pr1	13	36	in	in	IN
cord-282507-swxs5pr1	13	37	the	the	DT
cord-282507-swxs5pr1	13	38	elimination	elimination	NN
cord-282507-swxs5pr1	13	39	of	of	IN
cord-282507-swxs5pr1	13	40	intracellular	intracellular	JJ
cord-282507-swxs5pr1	13	41	pathogens	pathogen	NNS
cord-282507-swxs5pr1	13	42	.	.	.
cord-282507-swxs5pr1	14	1	2	2	LS
cord-282507-swxs5pr1	14	2	)	)	-RRB-
cord-282507-swxs5pr1	14	3	activation	activation	NN
cord-282507-swxs5pr1	14	4	of	of	IN
cord-282507-swxs5pr1	14	5	the	the	DT
cord-282507-swxs5pr1	14	6	NLRP3	NLRP3	NNP
cord-282507-swxs5pr1	14	7	inflammasome	inflammasome	NNP
cord-282507-swxs5pr1	14	8	in	in	IN
cord-282507-swxs5pr1	14	9	mouse	mouse	NN
cord-282507-swxs5pr1	14	10	APCs	apc	NNS
cord-282507-swxs5pr1	14	11	with	with	IN
cord-282507-swxs5pr1	14	12	subsequent	subsequent	JJ
cord-282507-swxs5pr1	14	13	release	release	NN
cord-282507-swxs5pr1	14	14	of	of	IN
cord-282507-swxs5pr1	14	15	caspase-1	caspase-1	NNP
cord-282507-swxs5pr1	14	16	dependent	dependent	JJ
cord-282507-swxs5pr1	14	17	cytokines	cytokine	NNS
cord-282507-swxs5pr1	14	18	,	,	,
cord-282507-swxs5pr1	14	19	Il-1β	Il-1β	NNP
cord-282507-swxs5pr1	14	20	and	and	CC
cord-282507-swxs5pr1	14	21	Il-18	Il-18	NNP
cord-282507-swxs5pr1	14	22	,	,	,
cord-282507-swxs5pr1	14	23	important	important	JJ
cord-282507-swxs5pr1	14	24	for	for	IN
cord-282507-swxs5pr1	14	25	Th1	th1	NN
cord-282507-swxs5pr1	14	26	responses	response	NNS
cord-282507-swxs5pr1	14	27	.	.	.
cord-282507-swxs5pr1	15	1	3	3	LS
cord-282507-swxs5pr1	15	2	)	)	-RRB-
cord-282507-swxs5pr1	15	3	synthesis	synthesis	NN
cord-282507-swxs5pr1	15	4	of	of	IN
cord-282507-swxs5pr1	15	5	nearly	nearly	RB
cord-282507-swxs5pr1	15	6	50	50	CD
cord-282507-swxs5pr1	15	7	QS-21	QS-21	NNP
cord-282507-swxs5pr1	15	8	analogs	analog	NNS
cord-282507-swxs5pr1	15	9	,	,	,
cord-282507-swxs5pr1	15	10	allowing	allow	VBG
cord-282507-swxs5pr1	15	11	structure	structure	NN
cord-282507-swxs5pr1	15	12	/	/	SYM
cord-282507-swxs5pr1	15	13	activity	activity	NN
cord-282507-swxs5pr1	15	14	relationships	relationship	NNS
cord-282507-swxs5pr1	15	15	and	and	CC
cord-282507-swxs5pr1	15	16	mechanistic	mechanistic	JJ
cord-282507-swxs5pr1	15	17	studies	study	NNS
cord-282507-swxs5pr1	15	18	.	.	.
cord-282507-swxs5pr1	16	1	4	4	LS
cord-282507-swxs5pr1	16	2	)	)	-RRB-
cord-282507-swxs5pr1	16	3	unique	unique	JJ
cord-282507-swxs5pr1	16	4	synergy	synergy	NN
cord-282507-swxs5pr1	16	5	mechanism	mechanism	NN
cord-282507-swxs5pr1	16	6	between	between	IN
cord-282507-swxs5pr1	16	7	monophosphoryl	monophosphoryl	NNP
cord-282507-swxs5pr1	16	8	lipid	lipid	VBG
cord-282507-swxs5pr1	16	9	A	A	NNP
cord-282507-swxs5pr1	16	10	(	(	-LRB-
cord-282507-swxs5pr1	16	11	MPL	MPL	NNP
cord-282507-swxs5pr1	16	12	A	A	NNP
cord-282507-swxs5pr1	16	13	)	)	-RRB-
cord-282507-swxs5pr1	16	14	and	and	CC
cord-282507-swxs5pr1	16	15	QS-21	QS-21	NNP
cord-282507-swxs5pr1	16	16	,	,	,
cord-282507-swxs5pr1	16	17	formulated	formulate	VBN
cord-282507-swxs5pr1	16	18	in	in	IN
cord-282507-swxs5pr1	16	19	a	a	DT
cord-282507-swxs5pr1	16	20	liposome	liposome	NN
cord-282507-swxs5pr1	16	21	(	(	-LRB-
cord-282507-swxs5pr1	16	22	AS01	AS01	NNP
cord-282507-swxs5pr1	16	23	)	)	-RRB-
cord-282507-swxs5pr1	16	24	in	in	IN
cord-282507-swxs5pr1	16	25	the	the	DT
cord-282507-swxs5pr1	16	26	early	early	JJ
cord-282507-swxs5pr1	16	27	IFN	IFN	NNP
cord-282507-swxs5pr1	16	28	-	-	HYPH
cord-282507-swxs5pr1	16	29	γ	γ	NNP
cord-282507-swxs5pr1	16	30	response	response	NN
cord-282507-swxs5pr1	16	31	,	,	,
cord-282507-swxs5pr1	16	32	promoting	promote	VBG
cord-282507-swxs5pr1	16	33	vaccine	vaccine	NN
cord-282507-swxs5pr1	16	34	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	16	35	.	.	.
cord-282507-swxs5pr1	17	1	The	the	DT
cord-282507-swxs5pr1	17	2	second	second	JJ
cord-282507-swxs5pr1	17	3	part	part	NN
cord-282507-swxs5pr1	17	4	of	of	IN
cord-282507-swxs5pr1	17	5	the	the	DT
cord-282507-swxs5pr1	17	6	review	review	NN
cord-282507-swxs5pr1	17	7	is	be	VBZ
cord-282507-swxs5pr1	17	8	related	relate	VBN
cord-282507-swxs5pr1	17	9	to	to	IN
cord-282507-swxs5pr1	17	10	phase	phase	VB
cord-282507-swxs5pr1	17	11	I	-PRON-	PRP
cord-282507-swxs5pr1	17	12	-	-	HYPH
cord-282507-swxs5pr1	17	13	III	III	NNP
cord-282507-swxs5pr1	17	14	clinical	clinical	JJ
cord-282507-swxs5pr1	17	15	trials	trial	NNS
cord-282507-swxs5pr1	17	16	of	of	IN
cord-282507-swxs5pr1	17	17	QS-21	QS-21	NNP
cord-282507-swxs5pr1	17	18	,	,	,
cord-282507-swxs5pr1	17	19	mostly	mostly	RB
cord-282507-swxs5pr1	17	20	formulated	formulate	VBN
cord-282507-swxs5pr1	17	21	in	in	IN
cord-282507-swxs5pr1	17	22	ASs	ass	NN
cord-282507-swxs5pr1	17	23	,	,	,
cord-282507-swxs5pr1	17	24	to	to	TO
cord-282507-swxs5pr1	17	25	evaluate	evaluate	VB
cord-282507-swxs5pr1	17	26	efficacy	efficacy	NN
cord-282507-swxs5pr1	17	27	,	,	,
cord-282507-swxs5pr1	17	28	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	17	29	and	and	CC
cord-282507-swxs5pr1	17	30	safety	safety	NN
cord-282507-swxs5pr1	17	31	of	of	IN
cord-282507-swxs5pr1	17	32	adjuvanted	adjuvanted	JJ
cord-282507-swxs5pr1	17	33	prophylactic	prophylactic	JJ
cord-282507-swxs5pr1	17	34	vaccines	vaccine	NNS
cord-282507-swxs5pr1	17	35	against	against	IN
cord-282507-swxs5pr1	17	36	infectious	infectious	JJ
cord-282507-swxs5pr1	17	37	diseases	disease	NNS
cord-282507-swxs5pr1	17	38	,	,	,
cord-282507-swxs5pr1	17	39	e.g.	e.g.	RB
cord-282507-swxs5pr1	17	40	malaria	malaria	NN
cord-282507-swxs5pr1	17	41	,	,	,
cord-282507-swxs5pr1	17	42	herpes	herpes	NNP
cord-282507-swxs5pr1	17	43	zoster	zoster	NN
cord-282507-swxs5pr1	17	44	,	,	,
cord-282507-swxs5pr1	17	45	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	17	46	,	,	,
cord-282507-swxs5pr1	17	47	AIDS	AIDS	NNP
cord-282507-swxs5pr1	17	48	and	and	CC
cord-282507-swxs5pr1	17	49	therapeutic	therapeutic	JJ
cord-282507-swxs5pr1	17	50	vaccines	vaccine	NNS
cord-282507-swxs5pr1	17	51	against	against	IN
cord-282507-swxs5pr1	17	52	cancer	cancer	NN
cord-282507-swxs5pr1	17	53	and	and	CC
cord-282507-swxs5pr1	17	54	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	17	55	's	's	POS
cord-282507-swxs5pr1	17	56	disease	disease	NN
cord-282507-swxs5pr1	17	57	.	.	.
cord-282507-swxs5pr1	18	1	Conclusion	conclusion	NN
cord-282507-swxs5pr1	18	2	The	the	DT
cord-282507-swxs5pr1	18	3	most	most	RBS
cord-282507-swxs5pr1	18	4	advanced	advanced	JJ
cord-282507-swxs5pr1	18	5	phase	phase	NN
cord-282507-swxs5pr1	18	6	III	iii	CD
cord-282507-swxs5pr1	18	7	clinical	clinical	JJ
cord-282507-swxs5pr1	18	8	applications	application	NNS
cord-282507-swxs5pr1	18	9	led	lead	VBD
cord-282507-swxs5pr1	18	10	to	to	IN
cord-282507-swxs5pr1	18	11	the	the	DT
cord-282507-swxs5pr1	18	12	development	development	NN
cord-282507-swxs5pr1	18	13	of	of	IN
cord-282507-swxs5pr1	18	14	two	two	CD
cord-282507-swxs5pr1	18	15	vaccines	vaccine	NNS
cord-282507-swxs5pr1	18	16	containing	contain	VBG
cord-282507-swxs5pr1	18	17	QS-21	QS-21	NNP
cord-282507-swxs5pr1	18	18	as	as	IN
cord-282507-swxs5pr1	18	19	part	part	NN
cord-282507-swxs5pr1	18	20	of	of	IN
cord-282507-swxs5pr1	18	21	the	the	DT
cord-282507-swxs5pr1	18	22	AS	AS	NNP
cord-282507-swxs5pr1	18	23	,	,	,
cord-282507-swxs5pr1	18	24	the	the	DT
cord-282507-swxs5pr1	18	25	Herpes	Herpes	NNP
cord-282507-swxs5pr1	18	26	Zoster	Zoster	NNP
cord-282507-swxs5pr1	18	27	vaccine	vaccine	NN
cord-282507-swxs5pr1	18	28	(	(	-LRB-
cord-282507-swxs5pr1	18	29	HZ	HZ	NNP
cord-282507-swxs5pr1	18	30	/	/	SYM
cord-282507-swxs5pr1	18	31	su	su	NNP
cord-282507-swxs5pr1	18	32	)	)	-RRB-
cord-282507-swxs5pr1	18	33	(	(	-LRB-
cord-282507-swxs5pr1	18	34	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	18	35	™	™	NN
cord-282507-swxs5pr1	18	36	)	)	-RRB-
cord-282507-swxs5pr1	18	37	which	which	WDT
cord-282507-swxs5pr1	18	38	received	receive	VBD
cord-282507-swxs5pr1	18	39	a	a	DT
cord-282507-swxs5pr1	18	40	license	license	NN
cord-282507-swxs5pr1	18	41	in	in	IN
cord-282507-swxs5pr1	18	42	2017	2017	CD
cord-282507-swxs5pr1	18	43	from	from	IN
cord-282507-swxs5pr1	18	44	the	the	DT
cord-282507-swxs5pr1	18	45	FDA	FDA	NNP
cord-282507-swxs5pr1	18	46	and	and	CC
cord-282507-swxs5pr1	18	47	a	a	DT
cord-282507-swxs5pr1	18	48	marketing	marketing	NN
cord-282507-swxs5pr1	18	49	authorization	authorization	NN
cord-282507-swxs5pr1	18	50	in	in	IN
cord-282507-swxs5pr1	18	51	the	the	DT
cord-282507-swxs5pr1	18	52	EU	EU	NNP
cord-282507-swxs5pr1	18	53	in	in	IN
cord-282507-swxs5pr1	18	54	2018	2018	CD
cord-282507-swxs5pr1	18	55	and	and	CC
cord-282507-swxs5pr1	18	56	the	the	DT
cord-282507-swxs5pr1	18	57	RTS	RTS	NNP
cord-282507-swxs5pr1	18	58	,	,	,
cord-282507-swxs5pr1	18	59	S	S	NNP
cord-282507-swxs5pr1	18	60	/	/	SYM
cord-282507-swxs5pr1	18	61	AS01	AS01	NNP
cord-282507-swxs5pr1	18	62	vaccine	vaccine	NN
cord-282507-swxs5pr1	18	63	(	(	-LRB-
cord-282507-swxs5pr1	18	64	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	18	65	™	™	CD
cord-282507-swxs5pr1	18	66	)	)	-RRB-
cord-282507-swxs5pr1	18	67	against	against	IN
cord-282507-swxs5pr1	18	68	malaria	malaria	NN
cord-282507-swxs5pr1	18	69	,	,	,
cord-282507-swxs5pr1	18	70	which	which	WDT
cord-282507-swxs5pr1	18	71	was	be	VBD
cord-282507-swxs5pr1	18	72	approved	approve	VBN
cord-282507-swxs5pr1	18	73	by	by	IN
cord-282507-swxs5pr1	18	74	the	the	DT
cord-282507-swxs5pr1	18	75	EMA	EMA	NNP
cord-282507-swxs5pr1	18	76	in	in	IN
cord-282507-swxs5pr1	18	77	2015	2015	CD
cord-282507-swxs5pr1	18	78	for	for	IN
cord-282507-swxs5pr1	18	79	further	further	JJ
cord-282507-swxs5pr1	18	80	implementation	implementation	NN
cord-282507-swxs5pr1	18	81	in	in	IN
cord-282507-swxs5pr1	18	82	Sub	sub	JJ
cord-282507-swxs5pr1	18	83	-	-	HYPH
cord-282507-swxs5pr1	18	84	Saharan	saharan	JJ
cord-282507-swxs5pr1	18	85	countries	country	NNS
cord-282507-swxs5pr1	18	86	for	for	IN
cord-282507-swxs5pr1	18	87	routine	routine	JJ
cord-282507-swxs5pr1	18	88	use	use	NN
cord-282507-swxs5pr1	18	89	.	.	.
cord-282507-swxs5pr1	19	1	Vaccines	vaccine	NNS
cord-282507-swxs5pr1	19	2	are	be	VBP
cord-282507-swxs5pr1	19	3	the	the	DT
cord-282507-swxs5pr1	19	4	most	most	RBS
cord-282507-swxs5pr1	19	5	effective	effective	JJ
cord-282507-swxs5pr1	19	6	and	and	CC
cord-282507-swxs5pr1	19	7	least	least	RBS
cord-282507-swxs5pr1	19	8	expensive	expensive	JJ
cord-282507-swxs5pr1	19	9	methodology	methodology	NN
cord-282507-swxs5pr1	19	10	for	for	IN
cord-282507-swxs5pr1	19	11	preventing	prevent	VBG
cord-282507-swxs5pr1	19	12	diseases	disease	NNS
cord-282507-swxs5pr1	19	13	caused	cause	VBN
cord-282507-swxs5pr1	19	14	by	by	IN
cord-282507-swxs5pr1	19	15	infectious	infectious	JJ
cord-282507-swxs5pr1	19	16	pathogens	pathogen	NNS
cord-282507-swxs5pr1	19	17	.	.	.
cord-282507-swxs5pr1	20	1	Recently	recently	RB
cord-282507-swxs5pr1	20	2	emerging	emerge	VBG
cord-282507-swxs5pr1	20	3	or	or	CC
cord-282507-swxs5pr1	20	4	re	re	VB
cord-282507-swxs5pr1	20	5	-	-	JJ
cord-282507-swxs5pr1	20	6	emerging	emerge	VBG
cord-282507-swxs5pr1	20	7	diseases	disease	NNS
cord-282507-swxs5pr1	20	8	such	such	JJ
cord-282507-swxs5pr1	20	9	as	as	IN
cord-282507-swxs5pr1	20	10	the	the	DT
cord-282507-swxs5pr1	20	11	severe	severe	JJ
cord-282507-swxs5pr1	20	12	acute	acute	JJ
cord-282507-swxs5pr1	20	13	respiratory	respiratory	JJ
cord-282507-swxs5pr1	20	14	syndrome	syndrome	NN
cord-282507-swxs5pr1	20	15	(	(	-LRB-
cord-282507-swxs5pr1	20	16	SARS	SARS	NNP
cord-282507-swxs5pr1	20	17	)	)	-RRB-
cord-282507-swxs5pr1	20	18	in	in	IN
cord-282507-swxs5pr1	20	19	2003	2003	CD
cord-282507-swxs5pr1	20	20	,	,	,
cord-282507-swxs5pr1	20	21	H1N1	H1N1	NNP
cord-282507-swxs5pr1	20	22	influenza	influenza	NN
cord-282507-swxs5pr1	20	23	pandemic	pandemic	NN
cord-282507-swxs5pr1	20	24	in	in	IN
cord-282507-swxs5pr1	20	25	2009	2009	CD
cord-282507-swxs5pr1	20	26	or	or	CC
cord-282507-swxs5pr1	20	27	Ebola	Ebola	NNP
cord-282507-swxs5pr1	20	28	virus	virus	NN
cord-282507-swxs5pr1	20	29	in	in	IN
cord-282507-swxs5pr1	20	30	(	(	-LRB-
cord-282507-swxs5pr1	20	31	meaning	meaning	NN
cord-282507-swxs5pr1	20	32	to	to	TO
cord-282507-swxs5pr1	20	33	help	help	VB
cord-282507-swxs5pr1	20	34	)	)	-RRB-
cord-282507-swxs5pr1	20	35	are	be	VBP
cord-282507-swxs5pr1	20	36	substances	substance	NNS
cord-282507-swxs5pr1	20	37	used	use	VBN
cord-282507-swxs5pr1	20	38	in	in	IN
cord-282507-swxs5pr1	20	39	combination	combination	NN
cord-282507-swxs5pr1	20	40	with	with	IN
cord-282507-swxs5pr1	20	41	a	a	DT
cord-282507-swxs5pr1	20	42	specific	specific	JJ
cord-282507-swxs5pr1	20	43	antigen	antigen	NN
cord-282507-swxs5pr1	20	44	(	(	-LRB-
cord-282507-swxs5pr1	20	45	Ag	Ag	NNP
cord-282507-swxs5pr1	20	46	)	)	-RRB-
cord-282507-swxs5pr1	20	47	to	to	TO
cord-282507-swxs5pr1	20	48	produce	produce	VB
cord-282507-swxs5pr1	20	49	a	a	DT
cord-282507-swxs5pr1	20	50	more	more	RBR
cord-282507-swxs5pr1	20	51	potent	potent	JJ
cord-282507-swxs5pr1	20	52	and	and	CC
cord-282507-swxs5pr1	20	53	persistent	persistent	JJ
cord-282507-swxs5pr1	20	54	immune	immune	JJ
cord-282507-swxs5pr1	20	55	response	response	NN
cord-282507-swxs5pr1	20	56	against	against	IN
cord-282507-swxs5pr1	20	57	a	a	DT
cord-282507-swxs5pr1	20	58	specific	specific	JJ
cord-282507-swxs5pr1	20	59	disease	disease	NN
cord-282507-swxs5pr1	20	60	than	than	IN
cord-282507-swxs5pr1	20	61	the	the	DT
cord-282507-swxs5pr1	20	62	Ag	Ag	NNP
cord-282507-swxs5pr1	20	63	alone	alone	RB
cord-282507-swxs5pr1	20	64	.	.	.
cord-282507-swxs5pr1	21	1	The	the	DT
cord-282507-swxs5pr1	21	2	aim	aim	NN
cord-282507-swxs5pr1	21	3	is	be	VBZ
cord-282507-swxs5pr1	21	4	to	to	TO
cord-282507-swxs5pr1	21	5	confer	confer	VB
cord-282507-swxs5pr1	21	6	longterm	longterm	JJ
cord-282507-swxs5pr1	21	7	protection	protection	NN
cord-282507-swxs5pr1	21	8	,	,	,
cord-282507-swxs5pr1	21	9	and	and	CC
cord-282507-swxs5pr1	21	10	with	with	IN
cord-282507-swxs5pr1	21	11	the	the	DT
cord-282507-swxs5pr1	21	12	additional	additional	JJ
cord-282507-swxs5pr1	21	13	benefit	benefit	NN
cord-282507-swxs5pr1	21	14	that	that	WDT
cord-282507-swxs5pr1	21	15	less	less	JJR
cord-282507-swxs5pr1	21	16	antigen	antigen	NN
cord-282507-swxs5pr1	21	17	and	and	CC
cord-282507-swxs5pr1	21	18	fewer	few	JJR
cord-282507-swxs5pr1	21	19	injections	injection	NNS
cord-282507-swxs5pr1	21	20	are	be	VBP
cord-282507-swxs5pr1	21	21	needed	need	VBN
cord-282507-swxs5pr1	21	22	(	(	-LRB-
cord-282507-swxs5pr1	21	23	Lee	Lee	NNP
cord-282507-swxs5pr1	21	24	and	and	CC
cord-282507-swxs5pr1	21	25	Nguyen	Nguyen	NNP
cord-282507-swxs5pr1	21	26	,	,	,
cord-282507-swxs5pr1	21	27	2015	2015	CD
cord-282507-swxs5pr1	21	28	)	)	-RRB-
cord-282507-swxs5pr1	21	29	.	.	.
cord-282507-swxs5pr1	22	1	Adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	22	2	are	be	VBP
cord-282507-swxs5pr1	22	3	used	use	VBN
cord-282507-swxs5pr1	22	4	in	in	IN
cord-282507-swxs5pr1	22	5	many	many	JJ
cord-282507-swxs5pr1	22	6	vaccines	vaccine	NNS
cord-282507-swxs5pr1	22	7	,	,	,
cord-282507-swxs5pr1	22	8	but	but	CC
cord-282507-swxs5pr1	22	9	their	-PRON-	PRP$
cord-282507-swxs5pr1	22	10	mechanisms	mechanism	NNS
cord-282507-swxs5pr1	22	11	of	of	IN
cord-282507-swxs5pr1	22	12	action	action	NN
cord-282507-swxs5pr1	22	13	have	have	VBP
cord-282507-swxs5pr1	22	14	not	not	RB
cord-282507-swxs5pr1	22	15	been	be	VBN
cord-282507-swxs5pr1	22	16	fully	fully	RB
cord-282507-swxs5pr1	22	17	elucidated	elucidate	VBN
cord-282507-swxs5pr1	22	18	.	.	.
cord-282507-swxs5pr1	23	1	They	-PRON-	PRP
cord-282507-swxs5pr1	23	2	include	include	VBP
cord-282507-swxs5pr1	23	3	diverse	diverse	JJ
cord-282507-swxs5pr1	23	4	classes	class	NNS
cord-282507-swxs5pr1	23	5	of	of	IN
cord-282507-swxs5pr1	23	6	compounds	compound	NNS
cord-282507-swxs5pr1	23	7	such	such	JJ
cord-282507-swxs5pr1	23	8	as	as	IN
cord-282507-swxs5pr1	23	9	mineral	mineral	NN
cord-282507-swxs5pr1	23	10	salts	salt	NNS
cord-282507-swxs5pr1	23	11	,	,	,
cord-282507-swxs5pr1	23	12	microbial	microbial	JJ
cord-282507-swxs5pr1	23	13	products	product	NNS
cord-282507-swxs5pr1	23	14	,	,	,
cord-282507-swxs5pr1	23	15	emulsions	emulsion	NNS
cord-282507-swxs5pr1	23	16	,	,	,
cord-282507-swxs5pr1	23	17	saponins	saponin	NNS
cord-282507-swxs5pr1	23	18	,	,	,
cord-282507-swxs5pr1	23	19	cytokines	cytokine	NNS
cord-282507-swxs5pr1	23	20	,	,	,
cord-282507-swxs5pr1	23	21	polymers	polymer	NNS
cord-282507-swxs5pr1	23	22	,	,	,
cord-282507-swxs5pr1	23	23	microparticules	microparticule	NNS
cord-282507-swxs5pr1	23	24	and	and	CC
cord-282507-swxs5pr1	23	25	liposomes	liposome	NNS
cord-282507-swxs5pr1	23	26	(	(	-LRB-
cord-282507-swxs5pr1	23	27	Awate	Awate	NNP
cord-282507-swxs5pr1	23	28	et	et	NNP
cord-282507-swxs5pr1	23	29	al	al	NNP
cord-282507-swxs5pr1	23	30	.	.	NNP
cord-282507-swxs5pr1	23	31	,	,	,
cord-282507-swxs5pr1	23	32	2013	2013	CD
cord-282507-swxs5pr1	23	33	)	)	-RRB-
cord-282507-swxs5pr1	23	34	.	.	.
cord-282507-swxs5pr1	24	1	Up	up	IN
cord-282507-swxs5pr1	24	2	to	to	IN
cord-282507-swxs5pr1	24	3	now	now	RB
cord-282507-swxs5pr1	24	4	,	,	,
cord-282507-swxs5pr1	24	5	few	few	JJ
cord-282507-swxs5pr1	24	6	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	24	7	have	have	VBP
cord-282507-swxs5pr1	24	8	been	be	VBN
cord-282507-swxs5pr1	24	9	approved	approve	VBN
cord-282507-swxs5pr1	24	10	for	for	IN
cord-282507-swxs5pr1	24	11	use	use	NN
cord-282507-swxs5pr1	24	12	in	in	IN
cord-282507-swxs5pr1	24	13	humans	human	NNS
cord-282507-swxs5pr1	24	14	(	(	-LRB-
cord-282507-swxs5pr1	24	15	Del	Del	NNP
cord-282507-swxs5pr1	24	16	Giudice	Giudice	NNP
cord-282507-swxs5pr1	24	17	et	et	FW
cord-282507-swxs5pr1	24	18	al	al	NNP
cord-282507-swxs5pr1	24	19	.	.	NNP
cord-282507-swxs5pr1	24	20	,	,	,
cord-282507-swxs5pr1	24	21	2018	2018	CD
cord-282507-swxs5pr1	24	22	)	)	-RRB-
cord-282507-swxs5pr1	24	23	.	.	.
cord-282507-swxs5pr1	25	1	Aluminium	aluminium	NN
cord-282507-swxs5pr1	25	2	salts	salt	NNS
cord-282507-swxs5pr1	25	3	,	,	,
cord-282507-swxs5pr1	25	4	which	which	WDT
cord-282507-swxs5pr1	25	5	have	have	VBP
cord-282507-swxs5pr1	25	6	been	be	VBN
cord-282507-swxs5pr1	25	7	extensively	extensively	RB
cord-282507-swxs5pr1	25	8	used	use	VBN
cord-282507-swxs5pr1	25	9	as	as	IN
cord-282507-swxs5pr1	25	10	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	25	11	in	in	IN
cord-282507-swxs5pr1	25	12	vaccines	vaccine	NNS
cord-282507-swxs5pr1	25	13	for	for	IN
cord-282507-swxs5pr1	25	14	more	more	JJR
cord-282507-swxs5pr1	25	15	than	than	IN
cord-282507-swxs5pr1	25	16	80	80	CD
cord-282507-swxs5pr1	25	17	years	year	NNS
cord-282507-swxs5pr1	25	18	,	,	,
cord-282507-swxs5pr1	25	19	induced	induce	VBD
cord-282507-swxs5pr1	25	20	robust	robust	JJ
cord-282507-swxs5pr1	25	21	antibody	antibody	NN
cord-282507-swxs5pr1	25	22	responses	response	NNS
cord-282507-swxs5pr1	25	23	but	but	CC
cord-282507-swxs5pr1	25	24	weak	weak	JJ
cord-282507-swxs5pr1	25	25	Th1	th1	CD
cord-282507-swxs5pr1	25	26	cell	cell	NN
cord-282507-swxs5pr1	25	27	type	type	NN
cord-282507-swxs5pr1	25	28	responses	response	NNS
cord-282507-swxs5pr1	25	29	,	,	,
cord-282507-swxs5pr1	25	30	which	which	WDT
cord-282507-swxs5pr1	25	31	are	be	VBP
cord-282507-swxs5pr1	25	32	instrumental	instrumental	JJ
cord-282507-swxs5pr1	25	33	for	for	IN
cord-282507-swxs5pr1	25	34	protection	protection	NN
cord-282507-swxs5pr1	25	35	against	against	IN
cord-282507-swxs5pr1	25	36	many	many	JJ
cord-282507-swxs5pr1	25	37	pathogens	pathogen	NNS
cord-282507-swxs5pr1	25	38	.	.	.
cord-282507-swxs5pr1	26	1	The	the	DT
cord-282507-swxs5pr1	26	2	new	new	JJ
cord-282507-swxs5pr1	26	3	generation	generation	NN
cord-282507-swxs5pr1	26	4	of	of	IN
cord-282507-swxs5pr1	26	5	vaccines	vaccine	NNS
cord-282507-swxs5pr1	26	6	using	use	VBG
cord-282507-swxs5pr1	26	7	purer	pure	JJR
cord-282507-swxs5pr1	26	8	components	component	NNS
cord-282507-swxs5pr1	26	9	for	for	IN
cord-282507-swxs5pr1	26	10	safer	safe	JJR
cord-282507-swxs5pr1	26	11	vaccines	vaccine	NNS
cord-282507-swxs5pr1	26	12	(	(	-LRB-
cord-282507-swxs5pr1	26	13	e.g	e.g	NNP
cord-282507-swxs5pr1	26	14	.	.	NNP
cord-282507-swxs5pr1	26	15	,subunits	,subunits	.
cord-282507-swxs5pr1	27	1	vaccines	vaccine	NNS
cord-282507-swxs5pr1	27	2	with	with	IN
cord-282507-swxs5pr1	27	3	highly	highly	RB
cord-282507-swxs5pr1	27	4	purified	purify	VBN
cord-282507-swxs5pr1	27	5	recombinant	recombinant	JJ
cord-282507-swxs5pr1	27	6	antigens	antigen	NNS
cord-282507-swxs5pr1	27	7	)	)	-RRB-
cord-282507-swxs5pr1	27	8	are	be	VBP
cord-282507-swxs5pr1	27	9	less	less	RBR
cord-282507-swxs5pr1	27	10	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	27	11	in	in	IN
cord-282507-swxs5pr1	27	12	contrast	contrast	NN
cord-282507-swxs5pr1	27	13	to	to	TO
cord-282507-swxs5pr1	27	14	live	live	VB
cord-282507-swxs5pr1	27	15	attenuated	attenuated	JJ
cord-282507-swxs5pr1	27	16	or	or	CC
cord-282507-swxs5pr1	27	17	inactivated	inactivate	VBN
cord-282507-swxs5pr1	27	18	whole	whole	JJ
cord-282507-swxs5pr1	27	19	-	-	HYPH
cord-282507-swxs5pr1	27	20	cell	cell	NN
cord-282507-swxs5pr1	27	21	vaccines	vaccine	NNS
cord-282507-swxs5pr1	27	22	.	.	.
cord-282507-swxs5pr1	28	1	Therefore	therefore	RB
cord-282507-swxs5pr1	28	2	,	,	,
cord-282507-swxs5pr1	28	3	they	-PRON-	PRP
cord-282507-swxs5pr1	28	4	required	require	VBD
cord-282507-swxs5pr1	28	5	the	the	DT
cord-282507-swxs5pr1	28	6	induction	induction	NN
cord-282507-swxs5pr1	28	7	of	of	IN
cord-282507-swxs5pr1	28	8	strong	strong	JJ
cord-282507-swxs5pr1	28	9	cellular	cellular	JJ
cord-282507-swxs5pr1	28	10	responses	response	NNS
cord-282507-swxs5pr1	28	11	including	include	VBG
cord-282507-swxs5pr1	28	12	CD4	CD4	NNP
cord-282507-swxs5pr1	28	13	+	+	CC
cord-282507-swxs5pr1	28	14	T	t	NN
cord-282507-swxs5pr1	28	15	-	-	HYPH
cord-282507-swxs5pr1	28	16	helper	helper	NN
cord-282507-swxs5pr1	28	17	cells	cell	NNS
cord-282507-swxs5pr1	28	18	(	(	-LRB-
cord-282507-swxs5pr1	28	19	Th	Th	NNP
cord-282507-swxs5pr1	28	20	)	)	-RRB-
cord-282507-swxs5pr1	28	21	and	and	CC
cord-282507-swxs5pr1	28	22	CD8	CD8	NNP
cord-282507-swxs5pr1	28	23	+	+	CC
cord-282507-swxs5pr1	28	24	cytotoxic	cytotoxic	JJ
cord-282507-swxs5pr1	28	25	T	t	NN
cord-282507-swxs5pr1	28	26	lymphocytes	lymphocyte	NNS
cord-282507-swxs5pr1	28	27	(	(	-LRB-
cord-282507-swxs5pr1	28	28	CTL	CTL	NNP
cord-282507-swxs5pr1	28	29	)	)	-RRB-
cord-282507-swxs5pr1	28	30	in	in	IN
cord-282507-swxs5pr1	28	31	addition	addition	NN
cord-282507-swxs5pr1	28	32	to	to	IN
cord-282507-swxs5pr1	28	33	antibody	antibody	NN
cord-282507-swxs5pr1	28	34	(	(	-LRB-
cord-282507-swxs5pr1	28	35	Ab	ab	NN
cord-282507-swxs5pr1	28	36	)	)	-RRB-
cord-282507-swxs5pr1	28	37	responses	response	NNS
cord-282507-swxs5pr1	28	38	.	.	.
cord-282507-swxs5pr1	29	1	Thus	thus	RB
cord-282507-swxs5pr1	29	2	,	,	,
cord-282507-swxs5pr1	29	3	the	the	DT
cord-282507-swxs5pr1	29	4	development	development	NN
cord-282507-swxs5pr1	29	5	of	of	IN
cord-282507-swxs5pr1	29	6	new	new	JJ
cord-282507-swxs5pr1	29	7	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	29	8	is	be	VBZ
cord-282507-swxs5pr1	29	9	necessary	necessary	JJ
cord-282507-swxs5pr1	29	10	for	for	IN
cord-282507-swxs5pr1	29	11	vaccines	vaccine	NNS
cord-282507-swxs5pr1	29	12	that	that	WDT
cord-282507-swxs5pr1	29	13	require	require	VBP
cord-282507-swxs5pr1	29	14	a	a	DT
cord-282507-swxs5pr1	29	15	cell	cell	NN
cord-282507-swxs5pr1	29	16	-	-	HYPH
cord-282507-swxs5pr1	29	17	mediated	mediate	VBN
cord-282507-swxs5pr1	29	18	immune	immune	JJ
cord-282507-swxs5pr1	29	19	response	response	NN
cord-282507-swxs5pr1	29	20	(	(	-LRB-
cord-282507-swxs5pr1	29	21	CMI	CMI	NNP
cord-282507-swxs5pr1	29	22	)	)	-RRB-
cord-282507-swxs5pr1	29	23	.	.	.
cord-282507-swxs5pr1	30	1	Among	among	IN
cord-282507-swxs5pr1	30	2	them	-PRON-	PRP
cord-282507-swxs5pr1	30	3	,	,	,
cord-282507-swxs5pr1	30	4	the	the	DT
cord-282507-swxs5pr1	30	5	triterpene	triterpene	JJ
cord-282507-swxs5pr1	30	6	glycosides	glycoside	NNS
cord-282507-swxs5pr1	30	7	represent	represent	VBP
cord-282507-swxs5pr1	30	8	an	an	DT
cord-282507-swxs5pr1	30	9	interesting	interesting	JJ
cord-282507-swxs5pr1	30	10	class	class	NN
cord-282507-swxs5pr1	30	11	of	of	IN
cord-282507-swxs5pr1	30	12	clinically	clinically	RB
cord-282507-swxs5pr1	30	13	relevant	relevant	JJ
cord-282507-swxs5pr1	30	14	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	30	15	,	,	,
cord-282507-swxs5pr1	30	16	particularly	particularly	RB
cord-282507-swxs5pr1	30	17	those	those	DT
cord-282507-swxs5pr1	30	18	of	of	IN
cord-282507-swxs5pr1	30	19	Quillaja	Quillaja	NNP
cord-282507-swxs5pr1	30	20	saponaria	saponaria	NNP
cord-282507-swxs5pr1	30	21	(	(	-LRB-
cord-282507-swxs5pr1	30	22	QS	QS	NNP
cord-282507-swxs5pr1	30	23	)	)	-RRB-
cord-282507-swxs5pr1	30	24	.	.	.
cord-282507-swxs5pr1	31	1	These	these	DT
cord-282507-swxs5pr1	31	2	amphiphatic	amphiphatic	NN
cord-282507-swxs5pr1	31	3	plant	plant	NN
cord-282507-swxs5pr1	31	4	glycosides	glycoside	NNS
cord-282507-swxs5pr1	31	5	possess	possess	VBP
cord-282507-swxs5pr1	31	6	a	a	DT
cord-282507-swxs5pr1	31	7	variety	variety	NN
cord-282507-swxs5pr1	31	8	of	of	IN
cord-282507-swxs5pr1	31	9	pharmacological	pharmacological	JJ
cord-282507-swxs5pr1	31	10	activities	activity	NNS
cord-282507-swxs5pr1	31	11	including	include	VBG
cord-282507-swxs5pr1	31	12	immunoadjuvant	immunoadjuvant	JJ
cord-282507-swxs5pr1	31	13	,	,	,
cord-282507-swxs5pr1	31	14	antitumor	antitumor	JJ
cord-282507-swxs5pr1	31	15	,	,	,
cord-282507-swxs5pr1	31	16	anti	anti	JJ
cord-282507-swxs5pr1	31	17	-	-	JJ
cord-282507-swxs5pr1	31	18	inflammatory	inflammatory	JJ
cord-282507-swxs5pr1	31	19	,	,	,
cord-282507-swxs5pr1	31	20	and	and	CC
cord-282507-swxs5pr1	31	21	antimicrobial	antimicrobial	JJ
cord-282507-swxs5pr1	31	22	properties	property	NNS
cord-282507-swxs5pr1	31	23	which	which	WDT
cord-282507-swxs5pr1	31	24	have	have	VBP
cord-282507-swxs5pr1	31	25	been	be	VBN
cord-282507-swxs5pr1	31	26	extensively	extensively	RB
cord-282507-swxs5pr1	31	27	studied	study	VBN
cord-282507-swxs5pr1	31	28	in	in	IN
cord-282507-swxs5pr1	31	29	many	many	JJ
cord-282507-swxs5pr1	31	30	in	in	IN
cord-282507-swxs5pr1	31	31	vitro	vitro	FW
cord-282507-swxs5pr1	31	32	and	and	CC
cord-282507-swxs5pr1	31	33	in	in	IN
cord-282507-swxs5pr1	31	34	vivo	vivo	FW
cord-282507-swxs5pr1	31	35	bioassays	bioassays	NNP
cord-282507-swxs5pr1	32	1	(	(	-LRB-
cord-282507-swxs5pr1	32	2	Lacaille	Lacaille	NNP
cord-282507-swxs5pr1	32	3	-	-	HYPH
cord-282507-swxs5pr1	32	4	Dubois	Dubois	NNP
cord-282507-swxs5pr1	32	5	and	and	CC
cord-282507-swxs5pr1	32	6	Wagner	Wagner	NNP
cord-282507-swxs5pr1	32	7	,	,	,
cord-282507-swxs5pr1	32	8	1996	1996	CD
cord-282507-swxs5pr1	32	9	,	,	,
cord-282507-swxs5pr1	32	10	2000	2000	CD
cord-282507-swxs5pr1	32	11	,	,	,
cord-282507-swxs5pr1	32	12	2017	2017	CD
cord-282507-swxs5pr1	32	13	Lacaille	Lacaille	NNP
cord-282507-swxs5pr1	32	14	-	-	HYPH
cord-282507-swxs5pr1	32	15	Dubois	Dubois	NNP
cord-282507-swxs5pr1	32	16	,	,	,
cord-282507-swxs5pr1	32	17	1999	1999	CD
cord-282507-swxs5pr1	32	18	,	,	,
cord-282507-swxs5pr1	32	19	2005	2005	CD
cord-282507-swxs5pr1	32	20	)	)	-RRB-
cord-282507-swxs5pr1	32	21	.	.	.
cord-282507-swxs5pr1	33	1	Despite	despite	IN
cord-282507-swxs5pr1	33	2	the	the	DT
cord-282507-swxs5pr1	33	3	apparent	apparent	JJ
cord-282507-swxs5pr1	33	4	success	success	NN
cord-282507-swxs5pr1	33	5	of	of	IN
cord-282507-swxs5pr1	33	6	QS-21	QS-21	NNP
cord-282507-swxs5pr1	33	7	as	as	IN
cord-282507-swxs5pr1	33	8	vaccine	vaccine	NN
cord-282507-swxs5pr1	33	9	-	-	HYPH
cord-282507-swxs5pr1	33	10	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	33	11	in	in	IN
cord-282507-swxs5pr1	33	12	the	the	DT
cord-282507-swxs5pr1	33	13	last	last	JJ
cord-282507-swxs5pr1	33	14	years	year	NNS
cord-282507-swxs5pr1	33	15	,	,	,
cord-282507-swxs5pr1	33	16	there	there	EX
cord-282507-swxs5pr1	33	17	is	be	VBZ
cord-282507-swxs5pr1	33	18	an	an	DT
cord-282507-swxs5pr1	33	19	urgent	urgent	JJ
cord-282507-swxs5pr1	33	20	need	need	NN
cord-282507-swxs5pr1	33	21	for	for	IN
cord-282507-swxs5pr1	33	22	a	a	DT
cord-282507-swxs5pr1	33	23	deeper	deep	JJR
cord-282507-swxs5pr1	33	24	understanding	understanding	NN
cord-282507-swxs5pr1	33	25	of	of	IN
cord-282507-swxs5pr1	33	26	its	-PRON-	PRP$
cord-282507-swxs5pr1	33	27	mode	mode	NN
cord-282507-swxs5pr1	33	28	of	of	IN
cord-282507-swxs5pr1	33	29	action	action	NN
cord-282507-swxs5pr1	33	30	which	which	WDT
cord-282507-swxs5pr1	33	31	could	could	MD
cord-282507-swxs5pr1	33	32	accelerate	accelerate	VB
cord-282507-swxs5pr1	33	33	the	the	DT
cord-282507-swxs5pr1	33	34	development	development	NN
cord-282507-swxs5pr1	33	35	of	of	IN
cord-282507-swxs5pr1	33	36	new	new	JJ
cord-282507-swxs5pr1	33	37	vaccine	vaccine	NN
cord-282507-swxs5pr1	33	38	strategies	strategy	NNS
cord-282507-swxs5pr1	33	39	.	.	.
cord-282507-swxs5pr1	34	1	This	this	DT
cord-282507-swxs5pr1	34	2	requires	require	VBZ
cord-282507-swxs5pr1	34	3	an	an	DT
cord-282507-swxs5pr1	34	4	interdisciplinary	interdisciplinary	JJ
cord-282507-swxs5pr1	34	5	approach	approach	NN
cord-282507-swxs5pr1	34	6	between	between	IN
cord-282507-swxs5pr1	34	7	chemists	chemist	NNS
cord-282507-swxs5pr1	34	8	,	,	,
cord-282507-swxs5pr1	34	9	biochemists	biochemist	NNS
cord-282507-swxs5pr1	34	10	,	,	,
cord-282507-swxs5pr1	34	11	molecular	molecular	JJ
cord-282507-swxs5pr1	34	12	biologists	biologist	NNS
cord-282507-swxs5pr1	34	13	and	and	CC
cord-282507-swxs5pr1	34	14	immunologists	immunologist	NNS
cord-282507-swxs5pr1	34	15	.	.	.
cord-282507-swxs5pr1	35	1	The	the	DT
cord-282507-swxs5pr1	35	2	following	following	JJ
cord-282507-swxs5pr1	35	3	review	review	NN
cord-282507-swxs5pr1	35	4	will	will	MD
cord-282507-swxs5pr1	35	5	summarize	summarize	VB
cord-282507-swxs5pr1	35	6	updated	update	VBN
cord-282507-swxs5pr1	35	7	insights	insight	NNS
cord-282507-swxs5pr1	35	8	into	into	IN
cord-282507-swxs5pr1	35	9	the	the	DT
cord-282507-swxs5pr1	35	10	modes	mode	NNS
cord-282507-swxs5pr1	35	11	of	of	IN
cord-282507-swxs5pr1	35	12	action	action	NN
cord-282507-swxs5pr1	35	13	,	,	,
cord-282507-swxs5pr1	35	14	the	the	DT
cord-282507-swxs5pr1	35	15	structure	structure	NN
cord-282507-swxs5pr1	35	16	/	/	SYM
cord-282507-swxs5pr1	35	17	activity	activity	NN
cord-282507-swxs5pr1	35	18	relationships	relationship	NNS
cord-282507-swxs5pr1	35	19	allowing	allow	VBG
cord-282507-swxs5pr1	35	20	detailed	detailed	JJ
cord-282507-swxs5pr1	35	21	mechanistic	mechanistic	JJ
cord-282507-swxs5pr1	35	22	studies	study	NNS
cord-282507-swxs5pr1	35	23	,	,	,
cord-282507-swxs5pr1	35	24	and	and	CC
cord-282507-swxs5pr1	35	25	the	the	DT
cord-282507-swxs5pr1	35	26	clinical	clinical	JJ
cord-282507-swxs5pr1	35	27	status	status	NN
cord-282507-swxs5pr1	35	28	of	of	IN
cord-282507-swxs5pr1	35	29	the	the	DT
cord-282507-swxs5pr1	35	30	vaccine	vaccine	NN
cord-282507-swxs5pr1	35	31	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	35	32	QS-21	QS-21	NNP
cord-282507-swxs5pr1	35	33	.	.	.
cord-282507-swxs5pr1	36	1	With	with	IN
cord-282507-swxs5pr1	36	2	a	a	DT
cord-282507-swxs5pr1	36	3	growing	grow	VBG
cord-282507-swxs5pr1	36	4	understanding	understanding	NN
cord-282507-swxs5pr1	36	5	of	of	IN
cord-282507-swxs5pr1	36	6	the	the	DT
cord-282507-swxs5pr1	36	7	innate	innate	JJ
cord-282507-swxs5pr1	36	8	immune	immune	JJ
cord-282507-swxs5pr1	36	9	system	system	NN
cord-282507-swxs5pr1	36	10	(	(	-LRB-
cord-282507-swxs5pr1	36	11	response	response	NN
cord-282507-swxs5pr1	36	12	first	first	RB
cord-282507-swxs5pr1	36	13	mediated	mediate	VBN
cord-282507-swxs5pr1	36	14	by	by	IN
cord-282507-swxs5pr1	36	15	antigen	antigen	NN
cord-282507-swxs5pr1	36	16	presenting	present	VBG
cord-282507-swxs5pr1	36	17	cells	cell	NNS
cord-282507-swxs5pr1	36	18	(	(	-LRB-
cord-282507-swxs5pr1	36	19	APCs	apc	NNS
cord-282507-swxs5pr1	36	20	)	)	-RRB-
cord-282507-swxs5pr1	36	21	)	)	-RRB-
cord-282507-swxs5pr1	36	22	and	and	CC
cord-282507-swxs5pr1	36	23	its	-PRON-	PRP$
cord-282507-swxs5pr1	36	24	role	role	NN
cord-282507-swxs5pr1	36	25	in	in	IN
cord-282507-swxs5pr1	36	26	activation	activation	NN
cord-282507-swxs5pr1	36	27	and	and	CC
cord-282507-swxs5pr1	36	28	modulation	modulation	NN
cord-282507-swxs5pr1	36	29	of	of	IN
cord-282507-swxs5pr1	36	30	adaptive	adaptive	JJ
cord-282507-swxs5pr1	36	31	immune	immune	JJ
cord-282507-swxs5pr1	36	32	responses	response	NNS
cord-282507-swxs5pr1	36	33	(	(	-LRB-
cord-282507-swxs5pr1	36	34	Ag	Ag	NNP
cord-282507-swxs5pr1	36	35	-	-	HYPH
cord-282507-swxs5pr1	36	36	specific	specific	JJ
cord-282507-swxs5pr1	36	37	B	B	NNP
cord-282507-swxs5pr1	36	38	and	and	CC
cord-282507-swxs5pr1	36	39	T	t	NN
cord-282507-swxs5pr1	36	40	cell	cell	NN
cord-282507-swxs5pr1	36	41	responses	response	NNS
cord-282507-swxs5pr1	36	42	)	)	-RRB-
cord-282507-swxs5pr1	37	1	Di	Di	NNP
cord-282507-swxs5pr1	37	2	Pasquale	Pasquale	NNP
cord-282507-swxs5pr1	37	3	et	et	NNP
cord-282507-swxs5pr1	37	4	al	al	NNP
cord-282507-swxs5pr1	37	5	.	.	.
cord-282507-swxs5pr1	38	1	,	,	,
cord-282507-swxs5pr1	38	2	2015	2015	CD
cord-282507-swxs5pr1	38	3	)	)	-RRB-
cord-282507-swxs5pr1	38	4	,	,	,
cord-282507-swxs5pr1	38	5	the	the	DT
cord-282507-swxs5pr1	38	6	mechanisms	mechanism	NNS
cord-282507-swxs5pr1	38	7	of	of	IN
cord-282507-swxs5pr1	38	8	action	action	NN
cord-282507-swxs5pr1	38	9	of	of	IN
cord-282507-swxs5pr1	38	10	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	38	11	are	be	VBP
cord-282507-swxs5pr1	38	12	being	be	VBG
cord-282507-swxs5pr1	38	13	elucidated	elucidate	VBN
cord-282507-swxs5pr1	38	14	.	.	.
cord-282507-swxs5pr1	39	1	They	-PRON-	PRP
cord-282507-swxs5pr1	39	2	can	can	MD
cord-282507-swxs5pr1	39	3	act	act	VB
cord-282507-swxs5pr1	39	4	on	on	IN
cord-282507-swxs5pr1	39	5	one	one	CD
cord-282507-swxs5pr1	39	6	or	or	CC
cord-282507-swxs5pr1	39	7	more	more	JJR
cord-282507-swxs5pr1	39	8	of	of	IN
cord-282507-swxs5pr1	39	9	the	the	DT
cord-282507-swxs5pr1	39	10	following	follow	VBG
cord-282507-swxs5pr1	39	11	targets	target	NNS
cord-282507-swxs5pr1	39	12	to	to	TO
cord-282507-swxs5pr1	39	13	increase	increase	VB
cord-282507-swxs5pr1	39	14	response	response	NN
cord-282507-swxs5pr1	39	15	to	to	IN
cord-282507-swxs5pr1	39	16	Ags	Ags	NNP
cord-282507-swxs5pr1	39	17	:	:	:
cord-282507-swxs5pr1	39	18	(	(	-LRB-
cord-282507-swxs5pr1	39	19	1	1	LS
cord-282507-swxs5pr1	39	20	)	)	-RRB-
cord-282507-swxs5pr1	39	21	sustaining	sustain	VBG
cord-282507-swxs5pr1	39	22	release	release	NN
cord-282507-swxs5pr1	39	23	at	at	IN
cord-282507-swxs5pr1	39	24	the	the	DT
cord-282507-swxs5pr1	39	25	injection	injection	NN
cord-282507-swxs5pr1	39	26	site	site	NN
cord-282507-swxs5pr1	39	27	(	(	-LRB-
cord-282507-swxs5pr1	39	28	depot	depot	NN
cord-282507-swxs5pr1	39	29	effect	effect	NN
cord-282507-swxs5pr1	39	30	)	)	-RRB-
cord-282507-swxs5pr1	39	31	,	,	,
cord-282507-swxs5pr1	39	32	(	(	-LRB-
cord-282507-swxs5pr1	39	33	2	2	LS
cord-282507-swxs5pr1	39	34	)	)	-RRB-
cord-282507-swxs5pr1	39	35	transient	transient	JJ
cord-282507-swxs5pr1	39	36	secretion	secretion	NN
cord-282507-swxs5pr1	39	37	of	of	IN
cord-282507-swxs5pr1	39	38	cytokines	cytokine	NNS
cord-282507-swxs5pr1	39	39	and	and	CC
cord-282507-swxs5pr1	39	40	chemokines	chemokine	NNS
cord-282507-swxs5pr1	39	41	,	,	,
cord-282507-swxs5pr1	39	42	(	(	-LRB-
cord-282507-swxs5pr1	39	43	3	3	CD
cord-282507-swxs5pr1	39	44	)	)	-RRB-
cord-282507-swxs5pr1	39	45	recruitement	recruitement	NN
cord-282507-swxs5pr1	39	46	of	of	IN
cord-282507-swxs5pr1	39	47	various	various	JJ
cord-282507-swxs5pr1	39	48	immune	immune	JJ
cord-282507-swxs5pr1	39	49	cells	cell	NNS
cord-282507-swxs5pr1	39	50	(	(	-LRB-
cord-282507-swxs5pr1	39	51	neutrophils	neutrophil	NNS
cord-282507-swxs5pr1	39	52	,	,	,
cord-282507-swxs5pr1	39	53	monocytes	monocyte	NNS
cord-282507-swxs5pr1	39	54	,	,	,
cord-282507-swxs5pr1	39	55	eosinophils	eosinophil	NNS
cord-282507-swxs5pr1	39	56	,	,	,
cord-282507-swxs5pr1	39	57	macrophages	macrophage	NNS
cord-282507-swxs5pr1	39	58	and	and	CC
cord-282507-swxs5pr1	39	59	Dendritic	Dendritic	NNP
cord-282507-swxs5pr1	39	60	Cells	Cells	NNPS
cord-282507-swxs5pr1	39	61	(	(	-LRB-
cord-282507-swxs5pr1	39	62	DCs	DCs	NNP
cord-282507-swxs5pr1	39	63	)	)	-RRB-
cord-282507-swxs5pr1	39	64	at	at	IN
cord-282507-swxs5pr1	39	65	the	the	DT
cord-282507-swxs5pr1	39	66	injection	injection	NN
cord-282507-swxs5pr1	39	67	site	site	NN
cord-282507-swxs5pr1	39	68	leading	lead	VBG
cord-282507-swxs5pr1	39	69	to	to	IN
cord-282507-swxs5pr1	39	70	a	a	DT
cord-282507-swxs5pr1	39	71	local	local	JJ
cord-282507-swxs5pr1	39	72	immune	immune	NN
cord-282507-swxs5pr1	39	73	-	-	HYPH
cord-282507-swxs5pr1	39	74	competent	competent	JJ
cord-282507-swxs5pr1	39	75	environment	environment	NN
cord-282507-swxs5pr1	39	76	,	,	,
cord-282507-swxs5pr1	39	77	(	(	-LRB-
cord-282507-swxs5pr1	39	78	4	4	LS
cord-282507-swxs5pr1	39	79	)	)	-RRB-
cord-282507-swxs5pr1	39	80	expression	expression	NN
cord-282507-swxs5pr1	39	81	by	by	IN
cord-282507-swxs5pr1	39	82	the	the	DT
cord-282507-swxs5pr1	39	83	recruited	recruit	VBN
cord-282507-swxs5pr1	39	84	APCs	apc	NNS
cord-282507-swxs5pr1	39	85	of	of	IN
cord-282507-swxs5pr1	39	86	various	various	JJ
cord-282507-swxs5pr1	39	87	Pathogen	Pathogen	NNP
cord-282507-swxs5pr1	39	88	Recognition	Recognition	NNP
cord-282507-swxs5pr1	39	89	Receptors	Receptors	NNPS
cord-282507-swxs5pr1	39	90	(	(	-LRB-
cord-282507-swxs5pr1	39	91	PRRs	PRRs	NNP
cord-282507-swxs5pr1	39	92	)	)	-RRB-
cord-282507-swxs5pr1	40	1	both	both	DT
cord-282507-swxs5pr1	40	2	on	on	IN
cord-282507-swxs5pr1	40	3	their	-PRON-	PRP$
cord-282507-swxs5pr1	40	4	surface	surface	NN
cord-282507-swxs5pr1	40	5	(	(	-LRB-
cord-282507-swxs5pr1	40	6	Toll	toll	NN
cord-282507-swxs5pr1	40	7	-	-	HYPH
cord-282507-swxs5pr1	40	8	like	like	JJ
cord-282507-swxs5pr1	40	9	receptors	receptor	NNS
cord-282507-swxs5pr1	40	10	,	,	,
cord-282507-swxs5pr1	40	11	TLRs	TLRs	NNP
cord-282507-swxs5pr1	40	12	,	,	,
cord-282507-swxs5pr1	40	13	C	c	NN
cord-282507-swxs5pr1	40	14	-	-	HYPH
cord-282507-swxs5pr1	40	15	type	type	NN
cord-282507-swxs5pr1	40	16	lectin	lectin	NN
cord-282507-swxs5pr1	40	17	receptors	receptor	NNS
cord-282507-swxs5pr1	40	18	,	,	,
cord-282507-swxs5pr1	40	19	CLRs	CLRs	NNP
cord-282507-swxs5pr1	40	20	)	)	-RRB-
cord-282507-swxs5pr1	40	21	,	,	,
cord-282507-swxs5pr1	40	22	and	and	CC
cord-282507-swxs5pr1	40	23	intracellularly	intracellularly	RB
cord-282507-swxs5pr1	40	24	(	(	-LRB-
cord-282507-swxs5pr1	40	25	Nucleotide	Nucleotide	NNP
cord-282507-swxs5pr1	40	26	Oligomerization	Oligomerization	NNP
cord-282507-swxs5pr1	40	27	Domain	Domain	NNP
cord-282507-swxs5pr1	40	28	(	(	-LRB-
cord-282507-swxs5pr1	40	29	NOD)-like	nod)-like	CD
cord-282507-swxs5pr1	40	30	receptors	receptor	NNS
cord-282507-swxs5pr1	40	31	(	(	-LRB-
cord-282507-swxs5pr1	40	32	NLRs	NLRs	NNP
cord-282507-swxs5pr1	40	33	)	)	-RRB-
cord-282507-swxs5pr1	40	34	and	and	CC
cord-282507-swxs5pr1	40	35	Retinoic	Retinoic	NNP
cord-282507-swxs5pr1	40	36	Inducible	Inducible	NNP
cord-282507-swxs5pr1	40	37	Gene-1	Gene-1	NNP
cord-282507-swxs5pr1	41	1	(	(	-LRB-
cord-282507-swxs5pr1	41	2	RIG)-like	rig)-like	NN
cord-282507-swxs5pr1	41	3	receptors	receptor	NNS
cord-282507-swxs5pr1	41	4	(	(	-LRB-
cord-282507-swxs5pr1	41	5	RLRs	RLRs	NNP
cord-282507-swxs5pr1	41	6	)	)	-RRB-
cord-282507-swxs5pr1	41	7	)	)	-RRB-
cord-282507-swxs5pr1	41	8	,	,	,
cord-282507-swxs5pr1	41	9	which	which	WDT
cord-282507-swxs5pr1	41	10	are	be	VBP
cord-282507-swxs5pr1	41	11	recognized	recognize	VBN
cord-282507-swxs5pr1	41	12	and/or	and/or	CC
cord-282507-swxs5pr1	41	13	activated	activate	VBN
cord-282507-swxs5pr1	41	14	by	by	IN
cord-282507-swxs5pr1	41	15	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	41	16	,	,	,
cord-282507-swxs5pr1	41	17	(	(	-LRB-
cord-282507-swxs5pr1	41	18	5	5	LS
cord-282507-swxs5pr1	41	19	)	)	-RRB-
cord-282507-swxs5pr1	41	20	maturation	maturation	NN
cord-282507-swxs5pr1	41	21	and	and	CC
cord-282507-swxs5pr1	41	22	activation	activation	NN
cord-282507-swxs5pr1	41	23	of	of	IN
cord-282507-swxs5pr1	41	24	recruited	recruit	VBN
cord-282507-swxs5pr1	41	25	APCs	apc	NNS
cord-282507-swxs5pr1	41	26	which	which	WDT
cord-282507-swxs5pr1	41	27	up	up	RB
cord-282507-swxs5pr1	41	28	-	-	HYPH
cord-282507-swxs5pr1	41	29	regulate	regulate	VB
cord-282507-swxs5pr1	41	30	the	the	DT
cord-282507-swxs5pr1	41	31	expression	expression	NN
cord-282507-swxs5pr1	41	32	of	of	IN
cord-282507-swxs5pr1	41	33	Major	Major	NNP
cord-282507-swxs5pr1	41	34	Histocompatibility	Histocompatibility	NNP
cord-282507-swxs5pr1	41	35	Complex	Complex	NNP
cord-282507-swxs5pr1	41	36	(	(	-LRB-
cord-282507-swxs5pr1	41	37	MHC)-I	MHC)-I	NNP
cord-282507-swxs5pr1	41	38	and/or	and/or	CC
cord-282507-swxs5pr1	41	39	MHC	MHC	NNP
cord-282507-swxs5pr1	41	40	-	-	HYPH
cord-282507-swxs5pr1	41	41	II	II	NNP
cord-282507-swxs5pr1	41	42	and	and	CC
cord-282507-swxs5pr1	41	43	activation	activation	NN
cord-282507-swxs5pr1	41	44	of	of	IN
cord-282507-swxs5pr1	41	45	co	co	JJ
cord-282507-swxs5pr1	41	46	-	-	JJ
cord-282507-swxs5pr1	41	47	stimulatory	stimulatory	JJ
cord-282507-swxs5pr1	41	48	signals	signal	NNS
cord-282507-swxs5pr1	42	1	CD40	CD40	NNP
cord-282507-swxs5pr1	42	2	,	,	,
cord-282507-swxs5pr1	42	3	CD80/86	cd80/86	CD
cord-282507-swxs5pr1	42	4	,	,	,
cord-282507-swxs5pr1	42	5	(	(	-LRB-
cord-282507-swxs5pr1	42	6	6	6	LS
cord-282507-swxs5pr1	42	7	)	)	-RRB-
cord-282507-swxs5pr1	42	8	increased	increase	VBN
cord-282507-swxs5pr1	42	9	capacity	capacity	NN
cord-282507-swxs5pr1	42	10	of	of	IN
cord-282507-swxs5pr1	42	11	APCs	apc	NNS
cord-282507-swxs5pr1	42	12	for	for	IN
cord-282507-swxs5pr1	42	13	Ag	Ag	NNP
cord-282507-swxs5pr1	42	14	processing	processing	NN
cord-282507-swxs5pr1	42	15	and	and	CC
cord-282507-swxs5pr1	42	16	presentation	presentation	NN
cord-282507-swxs5pr1	42	17	by	by	IN
cord-282507-swxs5pr1	42	18	MHC	MHC	NNP
cord-282507-swxs5pr1	42	19	,	,	,
cord-282507-swxs5pr1	42	20	(	(	-LRB-
cord-282507-swxs5pr1	42	21	7	7	LS
cord-282507-swxs5pr1	42	22	)	)	-RRB-
cord-282507-swxs5pr1	42	23	migration	migration	NN
cord-282507-swxs5pr1	42	24	of	of	IN
cord-282507-swxs5pr1	42	25	the	the	DT
cord-282507-swxs5pr1	42	26	mature	mature	JJ
cord-282507-swxs5pr1	42	27	APCs	apc	NNS
cord-282507-swxs5pr1	42	28	to	to	IN
cord-282507-swxs5pr1	42	29	the	the	DT
cord-282507-swxs5pr1	42	30	draining	drain	VBG
cord-282507-swxs5pr1	42	31	lymph	lymph	NN
cord-282507-swxs5pr1	42	32	nodes	node	NNS
cord-282507-swxs5pr1	42	33	(	(	-LRB-
cord-282507-swxs5pr1	42	34	dLNs	dlns	FW
cord-282507-swxs5pr1	42	35	)	)	-RRB-
cord-282507-swxs5pr1	42	36	to	to	TO
cord-282507-swxs5pr1	42	37	interact	interact	VB
cord-282507-swxs5pr1	42	38	with	with	IN
cord-282507-swxs5pr1	42	39	Ag	Ag	NNP
cord-282507-swxs5pr1	42	40	-	-	HYPH
cord-282507-swxs5pr1	42	41	specific	specific	JJ
cord-282507-swxs5pr1	42	42	B	b	NN
cord-282507-swxs5pr1	42	43	or	or	CC
cord-282507-swxs5pr1	42	44	T	t	NN
cord-282507-swxs5pr1	42	45	lymphocytes	lymphocyte	NNS
cord-282507-swxs5pr1	42	46	(	(	-LRB-
cord-282507-swxs5pr1	42	47	through	through	IN
cord-282507-swxs5pr1	42	48	receptor	receptor	NN
cord-282507-swxs5pr1	42	49	-	-	HYPH
cord-282507-swxs5pr1	42	50	ligand	ligand	NN
cord-282507-swxs5pr1	42	51	interactions	interaction	NNS
cord-282507-swxs5pr1	42	52	,	,	,
cord-282507-swxs5pr1	42	53	MHC	MHC	NNP
cord-282507-swxs5pr1	42	54	-	-	HYPH
cord-282507-swxs5pr1	42	55	T	T	NNP
cord-282507-swxs5pr1	42	56	cell	cell	NN
cord-282507-swxs5pr1	42	57	receptor	receptor	NN
cord-282507-swxs5pr1	42	58	(	(	-LRB-
cord-282507-swxs5pr1	42	59	MHC	MHC	NNP
cord-282507-swxs5pr1	42	60	-	-	HYPH
cord-282507-swxs5pr1	42	61	TCR	TCR	NNP
cord-282507-swxs5pr1	42	62	)	)	-RRB-
cord-282507-swxs5pr1	42	63	,	,	,
cord-282507-swxs5pr1	42	64	CD40-CD40L	cd40-cd40l	CD
cord-282507-swxs5pr1	42	65	,	,	,
cord-282507-swxs5pr1	42	66	CD80/86-CD28	CD80/86-CD28	NNP
cord-282507-swxs5pr1	42	67	)	)	-RRB-
cord-282507-swxs5pr1	42	68	which	which	WDT
cord-282507-swxs5pr1	42	69	are	be	VBP
cord-282507-swxs5pr1	42	70	activated	activate	VBN
cord-282507-swxs5pr1	42	71	to	to	TO
cord-282507-swxs5pr1	42	72	produce	produce	VB
cord-282507-swxs5pr1	42	73	potent	potent	JJ
cord-282507-swxs5pr1	42	74	Ab	ab	NN
cord-282507-swxs5pr1	42	75	-	-	HYPH
cord-282507-swxs5pr1	42	76	secreting	secrete	VBG
cord-282507-swxs5pr1	42	77	B	b	NN
cord-282507-swxs5pr1	42	78	cells	cell	NNS
cord-282507-swxs5pr1	43	1	and/or	and/or	CC
cord-282507-swxs5pr1	43	2	effector	effector	VB
cord-282507-swxs5pr1	43	3	CD8	CD8	NNP
cord-282507-swxs5pr1	43	4	+	+	CC
cord-282507-swxs5pr1	43	5	T	T	NNP
cord-282507-swxs5pr1	43	6	cell	cell	NN
cord-282507-swxs5pr1	43	7	responses	response	NNS
cord-282507-swxs5pr1	43	8	(	(	-LRB-
cord-282507-swxs5pr1	43	9	Awate	Awate	NNP
cord-282507-swxs5pr1	43	10	et	et	NNP
cord-282507-swxs5pr1	43	11	al	al	NNP
cord-282507-swxs5pr1	43	12	.	.	NNP
cord-282507-swxs5pr1	43	13	,	,	,
cord-282507-swxs5pr1	43	14	2013	2013	CD
cord-282507-swxs5pr1	43	15	)	)	-RRB-
cord-282507-swxs5pr1	43	16	.	.	.
cord-282507-swxs5pr1	44	1	Researchers	researcher	NNS
cord-282507-swxs5pr1	44	2	continue	continue	VBP
cord-282507-swxs5pr1	44	3	to	to	TO
cord-282507-swxs5pr1	44	4	characterize	characterize	VB
cord-282507-swxs5pr1	44	5	the	the	DT
cord-282507-swxs5pr1	44	6	adaptive	adaptive	JJ
cord-282507-swxs5pr1	44	7	immune	immune	JJ
cord-282507-swxs5pr1	44	8	response	response	NN
cord-282507-swxs5pr1	44	9	and	and	CC
cord-282507-swxs5pr1	44	10	to	to	TO
cord-282507-swxs5pr1	44	11	clarify	clarify	VB
cord-282507-swxs5pr1	44	12	the	the	DT
cord-282507-swxs5pr1	44	13	respective	respective	JJ
cord-282507-swxs5pr1	44	14	roles	role	NNS
cord-282507-swxs5pr1	44	15	of	of	IN
cord-282507-swxs5pr1	44	16	vaccine	vaccine	NN
cord-282507-swxs5pr1	44	17	-	-	HYPH
cord-282507-swxs5pr1	44	18	induced	induce	VBN
cord-282507-swxs5pr1	44	19	immune	immune	JJ
cord-282507-swxs5pr1	44	20	effectors	effector	NNS
cord-282507-swxs5pr1	44	21	(	(	-LRB-
cord-282507-swxs5pr1	44	22	Fig	Fig	NNP
cord-282507-swxs5pr1	44	23	.	.	.
cord-282507-swxs5pr1	44	24	1	1	CD
cord-282507-swxs5pr1	44	25	)	)	-RRB-
cord-282507-swxs5pr1	44	26	.	.	.
cord-282507-swxs5pr1	45	1	They	-PRON-	PRP
cord-282507-swxs5pr1	45	2	include	include	VBP
cord-282507-swxs5pr1	45	3	Abs	Abs	NNP
cord-282507-swxs5pr1	45	4	produced	produce	VBN
cord-282507-swxs5pr1	45	5	by	by	IN
cord-282507-swxs5pr1	45	6	B	b	NN
cord-282507-swxs5pr1	45	7	lymphocytes	lymphocyte	NNS
cord-282507-swxs5pr1	45	8	that	that	WDT
cord-282507-swxs5pr1	45	9	bind	bind	VBP
cord-282507-swxs5pr1	45	10	specifically	specifically	RB
cord-282507-swxs5pr1	45	11	to	to	IN
cord-282507-swxs5pr1	45	12	a	a	DT
cord-282507-swxs5pr1	45	13	toxin	toxin	NN
cord-282507-swxs5pr1	45	14	or	or	CC
cord-282507-swxs5pr1	45	15	a	a	DT
cord-282507-swxs5pr1	45	16	pathogen	pathogen	NN
cord-282507-swxs5pr1	45	17	,	,	,
cord-282507-swxs5pr1	45	18	memory	memory	NN
cord-282507-swxs5pr1	45	19	B	b	NN
cord-282507-swxs5pr1	45	20	cells	cell	NNS
cord-282507-swxs5pr1	45	21	produced	produce	VBN
cord-282507-swxs5pr1	45	22	only	only	RB
cord-282507-swxs5pr1	45	23	when	when	WRB
cord-282507-swxs5pr1	45	24	B	b	NN
cord-282507-swxs5pr1	45	25	cells	cell	NNS
cord-282507-swxs5pr1	45	26	received	receive	VBD
cord-282507-swxs5pr1	45	27	T	t	NN
cord-282507-swxs5pr1	45	28	cell	cell	NN
cord-282507-swxs5pr1	45	29	help	help	NN
cord-282507-swxs5pr1	45	30	having	have	VBG
cord-282507-swxs5pr1	45	31	the	the	DT
cord-282507-swxs5pr1	45	32	ability	ability	NN
cord-282507-swxs5pr1	45	33	to	to	TO
cord-282507-swxs5pr1	45	34	respond	respond	VB
cord-282507-swxs5pr1	45	35	rapidely	rapidely	RB
cord-282507-swxs5pr1	45	36	on	on	IN
cord-282507-swxs5pr1	45	37	reexposure	reexposure	NN
cord-282507-swxs5pr1	45	38	of	of	IN
cord-282507-swxs5pr1	45	39	the	the	DT
cord-282507-swxs5pr1	45	40	same	same	JJ
cord-282507-swxs5pr1	45	41	antigen	antigen	NN
cord-282507-swxs5pr1	45	42	,	,	,
cord-282507-swxs5pr1	45	43	cytotoxic	cytotoxic	JJ
cord-282507-swxs5pr1	45	44	CD8	CD8	NNP
cord-282507-swxs5pr1	45	45	+	+	CC
cord-282507-swxs5pr1	45	46	T	t	NN
cord-282507-swxs5pr1	45	47	lymphocytes	lymphocyte	NNS
cord-282507-swxs5pr1	45	48	that	that	WDT
cord-282507-swxs5pr1	45	49	limit	limit	VBP
cord-282507-swxs5pr1	45	50	the	the	DT
cord-282507-swxs5pr1	45	51	spread	spread	NN
cord-282507-swxs5pr1	45	52	of	of	IN
cord-282507-swxs5pr1	45	53	infectious	infectious	JJ
cord-282507-swxs5pr1	45	54	agents	agent	NNS
cord-282507-swxs5pr1	45	55	by	by	IN
cord-282507-swxs5pr1	45	56	killing	kill	VBG
cord-282507-swxs5pr1	45	57	infected	infected	JJ
cord-282507-swxs5pr1	45	58	cells	cell	NNS
cord-282507-swxs5pr1	45	59	or	or	CC
cord-282507-swxs5pr1	45	60	secreting	secrete	VBG
cord-282507-swxs5pr1	45	61	specific	specific	JJ
cord-282507-swxs5pr1	45	62	cytokines	cytokine	NNS
cord-282507-swxs5pr1	45	63	,	,	,
cord-282507-swxs5pr1	45	64	and	and	CC
cord-282507-swxs5pr1	45	65	CD4	CD4	NNP
cord-282507-swxs5pr1	45	66	+	+	CC
cord-282507-swxs5pr1	45	67	T	T	NNP
cord-282507-swxs5pr1	45	68	helper	helper	NN
cord-282507-swxs5pr1	45	69	(	(	-LRB-
cord-282507-swxs5pr1	45	70	Th	Th	NNP
cord-282507-swxs5pr1	45	71	)	)	-RRB-
cord-282507-swxs5pr1	45	72	lymphocytes	lymphocyte	NNS
cord-282507-swxs5pr1	45	73	.	.	.
cord-282507-swxs5pr1	46	1	Various	various	JJ
cord-282507-swxs5pr1	46	2	Th	Th	NNP
cord-282507-swxs5pr1	46	3	subsets	subset	NNS
cord-282507-swxs5pr1	46	4	have	have	VBP
cord-282507-swxs5pr1	46	5	been	be	VBN
cord-282507-swxs5pr1	46	6	defined	define	VBN
cord-282507-swxs5pr1	46	7	through	through	IN
cord-282507-swxs5pr1	46	8	their	-PRON-	PRP$
cord-282507-swxs5pr1	46	9	cytokine	cytokine	NN
cord-282507-swxs5pr1	46	10	profiles	profile	NNS
cord-282507-swxs5pr1	46	11	and	and	CC
cord-282507-swxs5pr1	46	12	ability	ability	NN
cord-282507-swxs5pr1	46	13	to	to	TO
cord-282507-swxs5pr1	46	14	induce	induce	VB
cord-282507-swxs5pr1	46	15	B	b	NN
cord-282507-swxs5pr1	46	16	cell	cell	NN
cord-282507-swxs5pr1	46	17	and	and	CC
cord-282507-swxs5pr1	46	18	CD8	CD8	NNP
cord-282507-swxs5pr1	46	19	+	+	CC
cord-282507-swxs5pr1	46	20	T	T	NNP
cord-282507-swxs5pr1	46	21	cell	cell	NN
cord-282507-swxs5pr1	46	22	responses	response	NNS
cord-282507-swxs5pr1	46	23	(	(	-LRB-
cord-282507-swxs5pr1	46	24	Reed	Reed	NNP
cord-282507-swxs5pr1	46	25	et	et	FW
cord-282507-swxs5pr1	46	26	al	al	NNP
cord-282507-swxs5pr1	46	27	.	.	NNP
cord-282507-swxs5pr1	46	28	,	,	,
cord-282507-swxs5pr1	46	29	2013	2013	CD
cord-282507-swxs5pr1	46	30	;	;	:
cord-282507-swxs5pr1	46	31	Siegrist	Siegrist	NNP
cord-282507-swxs5pr1	46	32	2013	2013	CD
cord-282507-swxs5pr1	46	33	)	)	-RRB-
cord-282507-swxs5pr1	46	34	.	.	.
cord-282507-swxs5pr1	47	1	The	the	DT
cord-282507-swxs5pr1	47	2	Th1-type	Th1-type	NNP
cord-282507-swxs5pr1	47	3	CD4	CD4	NNP
cord-282507-swxs5pr1	47	4	+	+	CC
cord-282507-swxs5pr1	47	5	T	t	NN
cord-282507-swxs5pr1	47	6	cells	cell	NNS
cord-282507-swxs5pr1	47	7	essentially	essentially	RB
cord-282507-swxs5pr1	47	8	release	release	VBP
cord-282507-swxs5pr1	47	9	the	the	DT
cord-282507-swxs5pr1	47	10	Awate	Awate	NNP
cord-282507-swxs5pr1	47	11	et	et	NNP
cord-282507-swxs5pr1	47	12	al	al	NNP
cord-282507-swxs5pr1	47	13	.	.	.
cord-282507-swxs5pr1	48	1	,	,	,
cord-282507-swxs5pr1	48	2	2013	2013	CD
cord-282507-swxs5pr1	48	3	;	;	:
cord-282507-swxs5pr1	48	4	Reed	Reed	NNP
cord-282507-swxs5pr1	48	5	et	et	FW
cord-282507-swxs5pr1	48	6	al	al	NNP
cord-282507-swxs5pr1	48	7	.	.	.
cord-282507-swxs5pr1	49	1	,	,	,
cord-282507-swxs5pr1	49	2	2013	2013	CD
cord-282507-swxs5pr1	49	3	;	;	:
cord-282507-swxs5pr1	49	4	Lacaille	Lacaille	NNP
cord-282507-swxs5pr1	49	5	-	-	HYPH
cord-282507-swxs5pr1	49	6	Dubois	Dubois	NNP
cord-282507-swxs5pr1	49	7	and	and	CC
cord-282507-swxs5pr1	49	8	Wagner	Wagner	NNP
cord-282507-swxs5pr1	49	9	,	,	,
cord-282507-swxs5pr1	49	10	2017	2017	CD
cord-282507-swxs5pr1	49	11	)	)	-RRB-
cord-282507-swxs5pr1	49	12	.	.	.
cord-282507-swxs5pr1	50	1	Phytomedicine	Phytomedicine	NNP
cord-282507-swxs5pr1	50	2	60	60	CD
cord-282507-swxs5pr1	50	3	(	(	-LRB-
cord-282507-swxs5pr1	50	4	2019	2019	CD
cord-282507-swxs5pr1	50	5	)	)	-RRB-
cord-282507-swxs5pr1	51	1	152905	152905	CD
cord-282507-swxs5pr1	51	2	proinflammatory	proinflammatory	JJ
cord-282507-swxs5pr1	51	3	cytokines	cytokine	NNS
cord-282507-swxs5pr1	51	4	interleukin-2	interleukin-2	IN
cord-282507-swxs5pr1	51	5	(	(	-LRB-
cord-282507-swxs5pr1	51	6	Il-2	Il-2	NNP
cord-282507-swxs5pr1	51	7	)	)	-RRB-
cord-282507-swxs5pr1	51	8	,	,	,
cord-282507-swxs5pr1	51	9	interferon	interferon	NN
cord-282507-swxs5pr1	51	10	-	-	HYPH
cord-282507-swxs5pr1	51	11	γ	γ	NN
cord-282507-swxs5pr1	51	12	(	(	-LRB-
cord-282507-swxs5pr1	51	13	IFN	IFN	NNP
cord-282507-swxs5pr1	51	14	-	-	HYPH
cord-282507-swxs5pr1	51	15	γ	γ	NNP
cord-282507-swxs5pr1	51	16	)	)	-RRB-
cord-282507-swxs5pr1	51	17	,	,	,
cord-282507-swxs5pr1	51	18	tumor	tumor	NN
cord-282507-swxs5pr1	51	19	necrosis	necrosis	NN
cord-282507-swxs5pr1	51	20	factor	factor	NN
cord-282507-swxs5pr1	51	21	-	-	HYPH
cord-282507-swxs5pr1	51	22	α	α	NN
cord-282507-swxs5pr1	51	23	(	(	-LRB-
cord-282507-swxs5pr1	51	24	TNF	TNF	NNP
cord-282507-swxs5pr1	51	25	-	-	HYPH
cord-282507-swxs5pr1	51	26	α	α	NNP
cord-282507-swxs5pr1	51	27	)	)	-RRB-
cord-282507-swxs5pr1	51	28	,	,	,
cord-282507-swxs5pr1	51	29	which	which	WDT
cord-282507-swxs5pr1	51	30	participate	participate	VBP
cord-282507-swxs5pr1	51	31	in	in	IN
cord-282507-swxs5pr1	51	32	the	the	DT
cord-282507-swxs5pr1	51	33	elimination	elimination	NN
cord-282507-swxs5pr1	51	34	of	of	IN
cord-282507-swxs5pr1	51	35	intracellular	intracellular	JJ
cord-282507-swxs5pr1	51	36	pathogens	pathogen	NNS
cord-282507-swxs5pr1	51	37	both	both	DT
cord-282507-swxs5pr1	51	38	directly	directly	RB
cord-282507-swxs5pr1	51	39	(	(	-LRB-
cord-282507-swxs5pr1	51	40	cytokine	cytokine	JJ
cord-282507-swxs5pr1	51	41	response	response	NN
cord-282507-swxs5pr1	51	42	)	)	-RRB-
cord-282507-swxs5pr1	51	43	or	or	CC
cord-282507-swxs5pr1	51	44	indirectly	indirectly	RB
cord-282507-swxs5pr1	51	45	via	via	IN
cord-282507-swxs5pr1	51	46	CD8	CD8	NNP
cord-282507-swxs5pr1	51	47	+	+	CC
cord-282507-swxs5pr1	51	48	T	T	NNP
cord-282507-swxs5pr1	51	49	cell	cell	NN
cord-282507-swxs5pr1	51	50	activation	activation	NN
cord-282507-swxs5pr1	51	51	and	and	CC
cord-282507-swxs5pr1	51	52	differentiation	differentiation	NN
cord-282507-swxs5pr1	51	53	in	in	IN
cord-282507-swxs5pr1	51	54	CTLs	CTLs	NNP
cord-282507-swxs5pr1	51	55	(	(	-LRB-
cord-282507-swxs5pr1	51	56	cellular	cellular	JJ
cord-282507-swxs5pr1	51	57	immune	immune	JJ
cord-282507-swxs5pr1	51	58	response	response	NN
cord-282507-swxs5pr1	51	59	)	)	-RRB-
cord-282507-swxs5pr1	51	60	and	and	CC
cord-282507-swxs5pr1	51	61	the	the	DT
cord-282507-swxs5pr1	51	62	generation	generation	NN
cord-282507-swxs5pr1	51	63	in	in	IN
cord-282507-swxs5pr1	51	64	mice	mouse	NNS
cord-282507-swxs5pr1	51	65	of	of	IN
cord-282507-swxs5pr1	51	66	the	the	DT
cord-282507-swxs5pr1	51	67	complement	complement	NN
cord-282507-swxs5pr1	51	68	-	-	HYPH
cord-282507-swxs5pr1	51	69	fixing	fix	VBG
cord-282507-swxs5pr1	51	70	Abs	Abs	NNP
cord-282507-swxs5pr1	51	71	IgG2a	IgG2a	NNP
cord-282507-swxs5pr1	51	72	and	and	CC
cord-282507-swxs5pr1	51	73	IgG3	IgG3	NNP
cord-282507-swxs5pr1	51	74	.	.	.
cord-282507-swxs5pr1	52	1	The	the	DT
cord-282507-swxs5pr1	52	2	Th2-type	Th2-type	NNP
cord-282507-swxs5pr1	52	3	CD4	CD4	NNP
cord-282507-swxs5pr1	52	4	+	+	CC
cord-282507-swxs5pr1	52	5	T	t	NN
cord-282507-swxs5pr1	52	6	cell	cell	NN
cord-282507-swxs5pr1	52	7	response	response	NN
cord-282507-swxs5pr1	52	8	is	be	VBZ
cord-282507-swxs5pr1	52	9	characterized	characterize	VBN
cord-282507-swxs5pr1	52	10	by	by	IN
cord-282507-swxs5pr1	52	11	secretion	secretion	NN
cord-282507-swxs5pr1	52	12	of	of	IN
cord-282507-swxs5pr1	52	13	Il-4	Il-4	NNP
cord-282507-swxs5pr1	52	14	,	,	,
cord-282507-swxs5pr1	52	15	Il-5	Il-5	NNP
cord-282507-swxs5pr1	52	16	and	and	CC
cord-282507-swxs5pr1	52	17	Il-6	Il-6	NNP
cord-282507-swxs5pr1	52	18	providing	provide	VBG
cord-282507-swxs5pr1	52	19	B	b	NN
cord-282507-swxs5pr1	52	20	cell	cell	NN
cord-282507-swxs5pr1	52	21	help	help	NN
cord-282507-swxs5pr1	52	22	and	and	CC
cord-282507-swxs5pr1	52	23	the	the	DT
cord-282507-swxs5pr1	52	24	preferential	preferential	JJ
cord-282507-swxs5pr1	52	25	induction	induction	NN
cord-282507-swxs5pr1	52	26	of	of	IN
cord-282507-swxs5pr1	52	27	IgG1	IgG1	NNP
cord-282507-swxs5pr1	52	28	,	,	,
cord-282507-swxs5pr1	52	29	IgE	IgE	NNP
cord-282507-swxs5pr1	52	30	,	,	,
cord-282507-swxs5pr1	52	31	and	and	CC
cord-282507-swxs5pr1	52	32	IgA	IgA	NNP
cord-282507-swxs5pr1	52	33	in	in	IN
cord-282507-swxs5pr1	52	34	mice	mouse	NNS
cord-282507-swxs5pr1	52	35	,	,	,
cord-282507-swxs5pr1	52	36	and	and	CC
cord-282507-swxs5pr1	52	37	IgE	IgE	NNP
cord-282507-swxs5pr1	52	38	and	and	CC
cord-282507-swxs5pr1	52	39	IgG4	igg4	NN
cord-282507-swxs5pr1	52	40	in	in	IN
cord-282507-swxs5pr1	52	41	humans	human	NNS
cord-282507-swxs5pr1	52	42	(	(	-LRB-
cord-282507-swxs5pr1	52	43	humoral	humoral	JJ
cord-282507-swxs5pr1	52	44	response	response	NN
cord-282507-swxs5pr1	52	45	)	)	-RRB-
cord-282507-swxs5pr1	53	1	(	(	-LRB-
cord-282507-swxs5pr1	53	2	Guy	Guy	NNP
cord-282507-swxs5pr1	53	3	,	,	,
cord-282507-swxs5pr1	53	4	2007	2007	CD
cord-282507-swxs5pr1	53	5	)	)	-RRB-
cord-282507-swxs5pr1	53	6	.	.	.
cord-282507-swxs5pr1	54	1	The	the	DT
cord-282507-swxs5pr1	54	2	saponin	saponin	NN
cord-282507-swxs5pr1	54	3	QS-21	QS-21	NNP
cord-282507-swxs5pr1	54	4	has	have	VBZ
cord-282507-swxs5pr1	54	5	been	be	VBN
cord-282507-swxs5pr1	54	6	isolated	isolate	VBN
cord-282507-swxs5pr1	54	7	from	from	IN
cord-282507-swxs5pr1	54	8	Quillaja	Quillaja	NNP
cord-282507-swxs5pr1	54	9	saponaria	saponaria	NNP
cord-282507-swxs5pr1	54	10	tree	tree	NN
cord-282507-swxs5pr1	54	11	bark	bark	NN
cord-282507-swxs5pr1	54	12	(	(	-LRB-
cord-282507-swxs5pr1	54	13	Kensil	Kensil	NNP
cord-282507-swxs5pr1	54	14	et	et	FW
cord-282507-swxs5pr1	54	15	al	al	NNP
cord-282507-swxs5pr1	54	16	.	.	NNP
cord-282507-swxs5pr1	54	17	,	,	,
cord-282507-swxs5pr1	54	18	1991	1991	CD
cord-282507-swxs5pr1	54	19	)	)	-RRB-
cord-282507-swxs5pr1	54	20	and	and	CC
cord-282507-swxs5pr1	54	21	is	be	VBZ
cord-282507-swxs5pr1	54	22	one	one	CD
cord-282507-swxs5pr1	54	23	of	of	IN
cord-282507-swxs5pr1	54	24	the	the	DT
cord-282507-swxs5pr1	54	25	most	most	RBS
cord-282507-swxs5pr1	54	26	potent	potent	JJ
cord-282507-swxs5pr1	54	27	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	54	28	known	know	VBN
cord-282507-swxs5pr1	54	29	which	which	WDT
cord-282507-swxs5pr1	54	30	is	be	VBZ
cord-282507-swxs5pr1	54	31	currently	currently	RB
cord-282507-swxs5pr1	54	32	used	use	VBN
cord-282507-swxs5pr1	54	33	in	in	IN
cord-282507-swxs5pr1	54	34	exploratory	exploratory	NN
cord-282507-swxs5pr1	54	35	,	,	,
cord-282507-swxs5pr1	54	36	and	and	CC
cord-282507-swxs5pr1	54	37	a	a	DT
cord-282507-swxs5pr1	54	38	few	few	JJ
cord-282507-swxs5pr1	54	39	licensed	license	VBN
cord-282507-swxs5pr1	54	40	,	,	,
cord-282507-swxs5pr1	54	41	vaccines	vaccine	NNS
cord-282507-swxs5pr1	54	42	.	.	.
cord-282507-swxs5pr1	55	1	QS-21	QS-21	NNP
cord-282507-swxs5pr1	55	2	is	be	VBZ
cord-282507-swxs5pr1	55	3	a	a	DT
cord-282507-swxs5pr1	55	4	mixture	mixture	NN
cord-282507-swxs5pr1	55	5	of	of	IN
cord-282507-swxs5pr1	55	6	two	two	CD
cord-282507-swxs5pr1	55	7	isomeric	isomeric	JJ
cord-282507-swxs5pr1	55	8	molecules	molecule	NNS
cord-282507-swxs5pr1	55	9	,	,	,
cord-282507-swxs5pr1	55	10	QS-21	QS-21	NNP
cord-282507-swxs5pr1	55	11	Apiose	Apiose	NNP
cord-282507-swxs5pr1	55	12	(	(	-LRB-
cord-282507-swxs5pr1	55	13	QS-21	QS-21	NNP
cord-282507-swxs5pr1	55	14	Api	Api	NNP
cord-282507-swxs5pr1	55	15	)	)	-RRB-
cord-282507-swxs5pr1	55	16	,	,	,
cord-282507-swxs5pr1	55	17	and	and	CC
cord-282507-swxs5pr1	55	18	QS-21	QS-21	NNP
cord-282507-swxs5pr1	55	19	Xylose	Xylose	NNP
cord-282507-swxs5pr1	55	20	(	(	-LRB-
cord-282507-swxs5pr1	55	21	QS-21-Xyl	QS-21-Xyl	NNP
cord-282507-swxs5pr1	55	22	)	)	-RRB-
cord-282507-swxs5pr1	55	23	(	(	-LRB-
cord-282507-swxs5pr1	55	24	2:1	2:1	LS
cord-282507-swxs5pr1	55	25	)	)	-RRB-
cord-282507-swxs5pr1	55	26	,	,	,
cord-282507-swxs5pr1	55	27	each	each	DT
cord-282507-swxs5pr1	55	28	having	have	VBG
cord-282507-swxs5pr1	55	29	four	four	CD
cord-282507-swxs5pr1	55	30	domains	domain	NNS
cord-282507-swxs5pr1	55	31	:	:	:
cord-282507-swxs5pr1	55	32	the	the	DT
cord-282507-swxs5pr1	55	33	triterpene	triterpene	NNP
cord-282507-swxs5pr1	55	34	quillaic	quillaic	NNP
cord-282507-swxs5pr1	55	35	acid	acid	NNP
cord-282507-swxs5pr1	55	36	,	,	,
cord-282507-swxs5pr1	55	37	a	a	DT
cord-282507-swxs5pr1	55	38	branched	branched	JJ
cord-282507-swxs5pr1	55	39	trisaccharide	trisaccharide	NN
cord-282507-swxs5pr1	55	40	linked	link	VBN
cord-282507-swxs5pr1	55	41	at	at	IN
cord-282507-swxs5pr1	55	42	C-3	C-3	NNP
cord-282507-swxs5pr1	55	43	through	through	IN
cord-282507-swxs5pr1	55	44	an	an	DT
cord-282507-swxs5pr1	55	45	O	O	NNP
cord-282507-swxs5pr1	55	46	-	-	HYPH
cord-282507-swxs5pr1	55	47	heterosidic	heterosidic	NN
cord-282507-swxs5pr1	55	48	bound	bind	VBN
cord-282507-swxs5pr1	55	49	,	,	,
cord-282507-swxs5pr1	55	50	a	a	DT
cord-282507-swxs5pr1	55	51	linear	linear	JJ
cord-282507-swxs5pr1	55	52	tetrasaccharide	tetrasaccharide	NN
cord-282507-swxs5pr1	55	53	linked	link	VBN
cord-282507-swxs5pr1	55	54	at	at	IN
cord-282507-swxs5pr1	55	55	C-28	C-28	NNP
cord-282507-swxs5pr1	55	56	through	through	IN
cord-282507-swxs5pr1	55	57	an	an	DT
cord-282507-swxs5pr1	55	58	ester	ester	NN
cord-282507-swxs5pr1	55	59	bound	bind	VBN
cord-282507-swxs5pr1	55	60	,	,	,
cord-282507-swxs5pr1	55	61	and	and	CC
cord-282507-swxs5pr1	55	62	a	a	DT
cord-282507-swxs5pr1	55	63	glycosylated	glycosylated	JJ
cord-282507-swxs5pr1	55	64	pseudodimeric	pseudodimeric	JJ
cord-282507-swxs5pr1	55	65	acyl	acyl	NN
cord-282507-swxs5pr1	55	66	chain	chain	NN
cord-282507-swxs5pr1	55	67	attached	attach	VBN
cord-282507-swxs5pr1	55	68	through	through	IN
cord-282507-swxs5pr1	55	69	a	a	DT
cord-282507-swxs5pr1	55	70	labile	labile	JJ
cord-282507-swxs5pr1	55	71	ester	ester	NN
cord-282507-swxs5pr1	55	72	linkage	linkage	NN
cord-282507-swxs5pr1	55	73	at	at	IN
cord-282507-swxs5pr1	55	74	C-4	C-4	NNP
cord-282507-swxs5pr1	55	75	of	of	IN
cord-282507-swxs5pr1	55	76	the	the	DT
cord-282507-swxs5pr1	55	77	fucose	fucose	JJ
cord-282507-swxs5pr1	55	78	unit	unit	NN
cord-282507-swxs5pr1	55	79	of	of	IN
cord-282507-swxs5pr1	55	80	the	the	DT
cord-282507-swxs5pr1	55	81	tetrasaccharide	tetrasaccharide	NN
cord-282507-swxs5pr1	55	82	(	(	-LRB-
cord-282507-swxs5pr1	55	83	Fig	fig	NN
cord-282507-swxs5pr1	55	84	.	.	NNP
cord-282507-swxs5pr1	55	85	2	2	CD
cord-282507-swxs5pr1	55	86	)	)	-RRB-
cord-282507-swxs5pr1	55	87	.	.	.
cord-282507-swxs5pr1	56	1	This	this	DT
cord-282507-swxs5pr1	56	2	compound	compound	NN
cord-282507-swxs5pr1	56	3	showed	show	VBD
cord-282507-swxs5pr1	56	4	a	a	DT
cord-282507-swxs5pr1	56	5	potent	potent	JJ
cord-282507-swxs5pr1	56	6	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	56	7	activity	activity	NN
cord-282507-swxs5pr1	56	8	against	against	IN
cord-282507-swxs5pr1	56	9	a	a	DT
cord-282507-swxs5pr1	56	10	wide	wide	JJ
cord-282507-swxs5pr1	56	11	variety	variety	NN
cord-282507-swxs5pr1	56	12	of	of	IN
cord-282507-swxs5pr1	56	13	Ags	Ags	NNP
cord-282507-swxs5pr1	56	14	with	with	IN
cord-282507-swxs5pr1	56	15	low	low	JJ
cord-282507-swxs5pr1	56	16	toxicity	toxicity	NN
cord-282507-swxs5pr1	56	17	in	in	IN
cord-282507-swxs5pr1	56	18	preclinical	preclinical	JJ
cord-282507-swxs5pr1	56	19	studies	study	NNS
cord-282507-swxs5pr1	56	20	in	in	IN
cord-282507-swxs5pr1	56	21	mice	mice	NN
cord-282507-swxs5pr1	56	22	,	,	,
cord-282507-swxs5pr1	56	23	guinea	guinea	NN
cord-282507-swxs5pr1	56	24	pigs	pig	NNS
cord-282507-swxs5pr1	56	25	,	,	,
cord-282507-swxs5pr1	56	26	monkeys	monkey	NNS
cord-282507-swxs5pr1	56	27	and	and	CC
cord-282507-swxs5pr1	56	28	baboons	baboon	NNS
cord-282507-swxs5pr1	56	29	.	.	.
cord-282507-swxs5pr1	57	1	It	-PRON-	PRP
cord-282507-swxs5pr1	57	2	was	be	VBD
cord-282507-swxs5pr1	57	3	shown	show	VBN
cord-282507-swxs5pr1	57	4	to	to	TO
cord-282507-swxs5pr1	57	5	stimulate	stimulate	VB
cord-282507-swxs5pr1	57	6	Th1	th1	NN
cord-282507-swxs5pr1	57	7	and	and	CC
cord-282507-swxs5pr1	57	8	Th2	th2	CD
cord-282507-swxs5pr1	57	9	immune	immune	JJ
cord-282507-swxs5pr1	57	10	responses	response	NNS
cord-282507-swxs5pr1	57	11	,	,	,
cord-282507-swxs5pr1	57	12	when	when	WRB
cord-282507-swxs5pr1	57	13	added	add	VBN
cord-282507-swxs5pr1	57	14	to	to	IN
cord-282507-swxs5pr1	57	15	vaccine	vaccine	NN
cord-282507-swxs5pr1	57	16	(	(	-LRB-
cord-282507-swxs5pr1	57	17	Kensil	Kensil	NNP
cord-282507-swxs5pr1	57	18	,	,	,
cord-282507-swxs5pr1	57	19	1996	1996	CD
cord-282507-swxs5pr1	57	20	)	)	-RRB-
cord-282507-swxs5pr1	57	21	.	.	.
cord-282507-swxs5pr1	58	1	This	this	DT
cord-282507-swxs5pr1	58	2	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	58	3	is	be	VBZ
cord-282507-swxs5pr1	58	4	a	a	DT
cord-282507-swxs5pr1	58	5	candidate	candidate	NN
cord-282507-swxs5pr1	58	6	for	for	IN
cord-282507-swxs5pr1	58	7	many	many	JJ
cord-282507-swxs5pr1	58	8	clinical	clinical	JJ
cord-282507-swxs5pr1	58	9	trials	trial	NNS
cord-282507-swxs5pr1	58	10	of	of	IN
cord-282507-swxs5pr1	58	11	vaccines	vaccine	NNS
cord-282507-swxs5pr1	58	12	directed	direct	VBN
cord-282507-swxs5pr1	58	13	against	against	IN
cord-282507-swxs5pr1	58	14	infectious	infectious	JJ
cord-282507-swxs5pr1	58	15	diseases	disease	NNS
cord-282507-swxs5pr1	58	16	,	,	,
cord-282507-swxs5pr1	58	17	cancer	cancer	NN
cord-282507-swxs5pr1	58	18	,	,	,
cord-282507-swxs5pr1	58	19	and	and	CC
cord-282507-swxs5pr1	58	20	others	other	NNS
cord-282507-swxs5pr1	58	21	.	.	.
cord-282507-swxs5pr1	59	1	However	however	RB
cord-282507-swxs5pr1	59	2	,	,	,
cord-282507-swxs5pr1	59	3	the	the	DT
cord-282507-swxs5pr1	59	4	exact	exact	JJ
cord-282507-swxs5pr1	59	5	role	role	NN
cord-282507-swxs5pr1	59	6	of	of	IN
cord-282507-swxs5pr1	59	7	QS-21	QS-21	NNP
cord-282507-swxs5pr1	59	8	,	,	,
cord-282507-swxs5pr1	59	9	either	either	CC
cord-282507-swxs5pr1	59	10	through	through	IN
cord-282507-swxs5pr1	59	11	activation	activation	NN
cord-282507-swxs5pr1	59	12	of	of	IN
cord-282507-swxs5pr1	59	13	receptors	receptor	NNS
cord-282507-swxs5pr1	59	14	or	or	CC
cord-282507-swxs5pr1	59	15	signaling	signal	VBG
cord-282507-swxs5pr1	59	16	pathways	pathway	NNS
cord-282507-swxs5pr1	59	17	,	,	,
cord-282507-swxs5pr1	59	18	is	be	VBZ
cord-282507-swxs5pr1	59	19	poorly	poorly	RB
cord-282507-swxs5pr1	59	20	characterized	characterize	VBN
cord-282507-swxs5pr1	59	21	.	.	.
cord-282507-swxs5pr1	60	1	Some	some	DT
cord-282507-swxs5pr1	60	2	hypotheses	hypothesis	NNS
cord-282507-swxs5pr1	60	3	advanced	advance	VBD
cord-282507-swxs5pr1	60	4	that	that	IN
cord-282507-swxs5pr1	60	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	60	6	may	may	MD
cord-282507-swxs5pr1	60	7	facilitate	facilitate	VB
cord-282507-swxs5pr1	60	8	Ag	Ag	NNP
cord-282507-swxs5pr1	60	9	uptake	uptake	NN
cord-282507-swxs5pr1	60	10	into	into	IN
cord-282507-swxs5pr1	60	11	APCs	apc	NNS
cord-282507-swxs5pr1	60	12	by	by	IN
cord-282507-swxs5pr1	60	13	binding	bind	VBG
cord-282507-swxs5pr1	60	14	to	to	IN
cord-282507-swxs5pr1	60	15	cell	cell	NN
cord-282507-swxs5pr1	60	16	surface	surface	NN
cord-282507-swxs5pr1	60	17	lectins	lectin	NNS
cord-282507-swxs5pr1	60	18	through	through	IN
cord-282507-swxs5pr1	60	19	its	-PRON-	PRP$
cord-282507-swxs5pr1	60	20	carbohydrate	carbohydrate	NN
cord-282507-swxs5pr1	60	21	domains	domain	NNS
cord-282507-swxs5pr1	60	22	,	,	,
cord-282507-swxs5pr1	60	23	leading	lead	VBG
cord-282507-swxs5pr1	60	24	to	to	IN
cord-282507-swxs5pr1	60	25	specific	specific	JJ
cord-282507-swxs5pr1	60	26	cytokine	cytokine	NN
cord-282507-swxs5pr1	60	27	profiles	profile	NNS
cord-282507-swxs5pr1	60	28	that	that	WDT
cord-282507-swxs5pr1	60	29	enhance	enhance	VBP
cord-282507-swxs5pr1	60	30	the	the	DT
cord-282507-swxs5pr1	60	31	T	t	NN
cord-282507-swxs5pr1	60	32	and/or	and/or	CC
cord-282507-swxs5pr1	60	33	B	B	NNP
cord-282507-swxs5pr1	60	34	cells	cell	NNS
cord-282507-swxs5pr1	60	35	'	'	POS
cord-282507-swxs5pr1	60	36	response	response	NN
cord-282507-swxs5pr1	60	37	(	(	-LRB-
cord-282507-swxs5pr1	60	38	Marciani	Marciani	NNP
cord-282507-swxs5pr1	60	39	,	,	,
cord-282507-swxs5pr1	60	40	2003	2003	CD
cord-282507-swxs5pr1	60	41	)	)	-RRB-
cord-282507-swxs5pr1	60	42	.	.	.
cord-282507-swxs5pr1	61	1	An	an	DT
cord-282507-swxs5pr1	61	2	effective	effective	JJ
cord-282507-swxs5pr1	61	3	mechanism	mechanism	NN
cord-282507-swxs5pr1	61	4	of	of	IN
cord-282507-swxs5pr1	61	5	action	action	NN
cord-282507-swxs5pr1	61	6	in	in	IN
cord-282507-swxs5pr1	61	7	which	which	WDT
cord-282507-swxs5pr1	61	8	QS-21	QS-21	NNP
cord-282507-swxs5pr1	61	9	apparently	apparently	RB
cord-282507-swxs5pr1	61	10	acts	act	VBZ
cord-282507-swxs5pr1	61	11	on	on	IN
cord-282507-swxs5pr1	61	12	both	both	DT
cord-282507-swxs5pr1	61	13	DCs	dc	NNS
cord-282507-swxs5pr1	61	14	and	and	CC
cord-282507-swxs5pr1	61	15	T	T	NNP
cord-282507-swxs5pr1	61	16	cells	cell	NNS
cord-282507-swxs5pr1	61	17	was	be	VBD
cord-282507-swxs5pr1	61	18	proposed	propose	VBN
cord-282507-swxs5pr1	61	19	(	(	-LRB-
cord-282507-swxs5pr1	61	20	Marciani	Marciani	NNP
cord-282507-swxs5pr1	61	21	,	,	,
cord-282507-swxs5pr1	61	22	2018	2018	CD
cord-282507-swxs5pr1	61	23	)	)	-RRB-
cord-282507-swxs5pr1	62	1	(	(	-LRB-
cord-282507-swxs5pr1	62	2	Fig	Fig	NNP
cord-282507-swxs5pr1	62	3	.	.	.
cord-282507-swxs5pr1	62	4	3	3	CD
cord-282507-swxs5pr1	62	5	)	)	-RRB-
cord-282507-swxs5pr1	62	6	.	.	.
cord-282507-swxs5pr1	63	1	Exogenous	exogenous	JJ
cord-282507-swxs5pr1	63	2	Ags	Ags	NNP
cord-282507-swxs5pr1	63	3	and	and	CC
cord-282507-swxs5pr1	63	4	QS-21	QS-21	NNP
cord-282507-swxs5pr1	63	5	enter	enter	VB
cord-282507-swxs5pr1	63	6	DCs	dc	NNS
cord-282507-swxs5pr1	63	7	by	by	IN
cord-282507-swxs5pr1	63	8	cholesterol	cholesterol	NN
cord-282507-swxs5pr1	63	9	-	-	HYPH
cord-282507-swxs5pr1	63	10	dependent	dependent	JJ
cord-282507-swxs5pr1	63	11	endocytosis	endocytosis	NN
cord-282507-swxs5pr1	63	12	.	.	.
cord-282507-swxs5pr1	64	1	The	the	DT
cord-282507-swxs5pr1	64	2	high	high	JJ
cord-282507-swxs5pr1	64	3	affinity	affinity	NN
cord-282507-swxs5pr1	64	4	of	of	IN
cord-282507-swxs5pr1	64	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	64	6	for	for	IN
cord-282507-swxs5pr1	64	7	endosomal	endosomal	NNP
cord-282507-swxs5pr1	64	8	membrane	membrane	NN
cord-282507-swxs5pr1	64	9	cholesterol	cholesterol	NN
cord-282507-swxs5pr1	64	10	resulted	result	VBD
cord-282507-swxs5pr1	64	11	in	in	IN
cord-282507-swxs5pr1	64	12	the	the	DT
cord-282507-swxs5pr1	64	13	destabilization	destabilization	NN
cord-282507-swxs5pr1	64	14	of	of	IN
cord-282507-swxs5pr1	64	15	the	the	DT
cord-282507-swxs5pr1	64	16	membrane	membrane	NN
cord-282507-swxs5pr1	64	17	(	(	-LRB-
cord-282507-swxs5pr1	64	18	Lorent	Lorent	NNP
cord-282507-swxs5pr1	64	19	et	et	FW
cord-282507-swxs5pr1	64	20	al	al	NNP
cord-282507-swxs5pr1	64	21	.	.	NNP
cord-282507-swxs5pr1	64	22	,	,	,
cord-282507-swxs5pr1	64	23	2014	2014	CD
cord-282507-swxs5pr1	64	24	)	)	-RRB-
cord-282507-swxs5pr1	64	25	leading	lead	VBG
cord-282507-swxs5pr1	64	26	to	to	IN
cord-282507-swxs5pr1	64	27	pore	pore	NN
cord-282507-swxs5pr1	64	28	formation	formation	NN
cord-282507-swxs5pr1	64	29	,	,	,
cord-282507-swxs5pr1	64	30	thus	thus	RB
cord-282507-swxs5pr1	64	31	facilitating	facilitate	VBG
cord-282507-swxs5pr1	64	32	the	the	DT
cord-282507-swxs5pr1	64	33	escape	escape	NN
cord-282507-swxs5pr1	64	34	of	of	IN
cord-282507-swxs5pr1	64	35	the	the	DT
cord-282507-swxs5pr1	64	36	antigen	antigen	NN
cord-282507-swxs5pr1	64	37	to	to	IN
cord-282507-swxs5pr1	64	38	the	the	DT
cord-282507-swxs5pr1	64	39	cytosol	cytosol	NN
cord-282507-swxs5pr1	64	40	for	for	IN
cord-282507-swxs5pr1	64	41	further	further	JJ
cord-282507-swxs5pr1	64	42	processing	processing	NN
cord-282507-swxs5pr1	64	43	inside	inside	IN
cord-282507-swxs5pr1	64	44	the	the	DT
cord-282507-swxs5pr1	64	45	cell	cell	NN
cord-282507-swxs5pr1	64	46	into	into	IN
cord-282507-swxs5pr1	64	47	peptides	peptide	NNS
cord-282507-swxs5pr1	64	48	.	.	.
cord-282507-swxs5pr1	65	1	They	-PRON-	PRP
cord-282507-swxs5pr1	65	2	are	be	VBP
cord-282507-swxs5pr1	65	3	then	then	RB
cord-282507-swxs5pr1	65	4	loaded	load	VBN
cord-282507-swxs5pr1	65	5	to	to	IN
cord-282507-swxs5pr1	65	6	MHC	MHC	NNP
cord-282507-swxs5pr1	65	7	-	-	:
cord-282507-swxs5pr1	65	8	I	I	NNP
cord-282507-swxs5pr1	65	9	and	and	CC
cord-282507-swxs5pr1	65	10	presented	present	VBD
cord-282507-swxs5pr1	65	11	on	on	IN
cord-282507-swxs5pr1	65	12	the	the	DT
cord-282507-swxs5pr1	65	13	DC	DC	NNP
cord-282507-swxs5pr1	65	14	surface	surface	NN
cord-282507-swxs5pr1	65	15	to	to	IN
cord-282507-swxs5pr1	65	16	naïve	naïve	JJ
cord-282507-swxs5pr1	65	17	CD8	CD8	NNP
cord-282507-swxs5pr1	65	18	+	+	CC
cord-282507-swxs5pr1	65	19	T	T	NNP
cord-282507-swxs5pr1	65	20	cells	cell	NNS
cord-282507-swxs5pr1	65	21	to	to	TO
cord-282507-swxs5pr1	65	22	yield	yield	VB
cord-282507-swxs5pr1	65	23	CTLs	ctl	NNS
cord-282507-swxs5pr1	65	24	.	.	.
cord-282507-swxs5pr1	66	1	The	the	DT
cord-282507-swxs5pr1	66	2	role	role	NN
cord-282507-swxs5pr1	66	3	of	of	IN
cord-282507-swxs5pr1	66	4	aldehyde	aldehyde	NN
cord-282507-swxs5pr1	66	5	in	in	IN
cord-282507-swxs5pr1	66	6	QS-21	QS-21	NNP
cord-282507-swxs5pr1	66	7	was	be	VBD
cord-282507-swxs5pr1	66	8	highlighted	highlight	VBN
cord-282507-swxs5pr1	66	9	in	in	IN
cord-282507-swxs5pr1	66	10	the	the	DT
cord-282507-swxs5pr1	66	11	T	T	NNP
cord-282507-swxs5pr1	66	12	cell	cell	NN
cord-282507-swxs5pr1	66	13	by	by	IN
cord-282507-swxs5pr1	66	14	forming	form	VBG
cord-282507-swxs5pr1	66	15	an	an	DT
cord-282507-swxs5pr1	66	16	imine	imine	NN
cord-282507-swxs5pr1	66	17	with	with	IN
cord-282507-swxs5pr1	66	18	the	the	DT
cord-282507-swxs5pr1	66	19	amino	amino	NN
cord-282507-swxs5pr1	66	20	group	group	NN
cord-282507-swxs5pr1	66	21	of	of	IN
cord-282507-swxs5pr1	66	22	the	the	DT
cord-282507-swxs5pr1	66	23	T	T	NNP
cord-282507-swxs5pr1	66	24	cell	cell	NN
cord-282507-swxs5pr1	66	25	surface	surface	NN
cord-282507-swxs5pr1	66	26	receptor	receptor	NN
cord-282507-swxs5pr1	66	27	such	such	JJ
cord-282507-swxs5pr1	66	28	as	as	IN
cord-282507-swxs5pr1	66	29	CD2	CD2	NNP
cord-282507-swxs5pr1	66	30	,	,	,
cord-282507-swxs5pr1	66	31	providing	provide	VBG
cord-282507-swxs5pr1	66	32	a	a	DT
cord-282507-swxs5pr1	66	33	costimulatory	costimulatory	NN
cord-282507-swxs5pr1	66	34	signal	signal	NN
cord-282507-swxs5pr1	66	35	to	to	IN
cord-282507-swxs5pr1	66	36	the	the	DT
cord-282507-swxs5pr1	66	37	T	T	NNP
cord-282507-swxs5pr1	66	38	cell	cell	NN
cord-282507-swxs5pr1	66	39	.	.	.
cord-282507-swxs5pr1	67	1	This	this	DT
cord-282507-swxs5pr1	67	2	signal	signal	NN
cord-282507-swxs5pr1	67	3	together	together	RB
cord-282507-swxs5pr1	67	4	with	with	IN
cord-282507-swxs5pr1	67	5	the	the	DT
cord-282507-swxs5pr1	67	6	mitogen	mitogen	NN
cord-282507-swxs5pr1	67	7	-	-	HYPH
cord-282507-swxs5pr1	67	8	activated	activate	VBN
cord-282507-swxs5pr1	67	9	protein	protein	NN
cord-282507-swxs5pr1	67	10	kinase	kinase	NN
cord-282507-swxs5pr1	67	11	(	(	-LRB-
cord-282507-swxs5pr1	67	12	MAPK	MAPK	NNP
cord-282507-swxs5pr1	67	13	)	)	-RRB-
cord-282507-swxs5pr1	67	14	ERK2	ERK2	NNP
cord-282507-swxs5pr1	67	15	resulting	result	VBG
cord-282507-swxs5pr1	67	16	from	from	IN
cord-282507-swxs5pr1	67	17	the	the	DT
cord-282507-swxs5pr1	67	18	activation	activation	NN
cord-282507-swxs5pr1	67	19	of	of	IN
cord-282507-swxs5pr1	67	20	the	the	DT
cord-282507-swxs5pr1	67	21	TCR	TCR	NNP
cord-282507-swxs5pr1	67	22	-	-	HYPH
cord-282507-swxs5pr1	67	23	MHC	MHC	NNP
cord-282507-swxs5pr1	67	24	interaction	interaction	NN
cord-282507-swxs5pr1	67	25	,	,	,
cord-282507-swxs5pr1	67	26	and	and	CC
cord-282507-swxs5pr1	67	27	the	the	DT
cord-282507-swxs5pr1	67	28	changes	change	NNS
cord-282507-swxs5pr1	67	29	of	of	IN
cord-282507-swxs5pr1	67	30	the	the	DT
cord-282507-swxs5pr1	67	31	ionic	ionic	JJ
cord-282507-swxs5pr1	67	32	balance	balance	NN
cord-282507-swxs5pr1	67	33	Na	Na	NNP
cord-282507-swxs5pr1	67	34	+	+	CC
cord-282507-swxs5pr1	67	35	/K	/K	.
cord-282507-swxs5pr1	68	1	+	+	UH
cord-282507-swxs5pr1	68	2	,	,	,
cord-282507-swxs5pr1	68	3	stimulates	stimulate	VBZ
cord-282507-swxs5pr1	68	4	T	T	NNP
cord-282507-swxs5pr1	68	5	cell	cell	NN
cord-282507-swxs5pr1	68	6	activation	activation	NN
cord-282507-swxs5pr1	68	7	resulting	result	VBG
cord-282507-swxs5pr1	68	8	in	in	IN
cord-282507-swxs5pr1	68	9	the	the	DT
cord-282507-swxs5pr1	68	10	secretion	secretion	NN
cord-282507-swxs5pr1	68	11	of	of	IN
cord-282507-swxs5pr1	68	12	Th1	th1	NN
cord-282507-swxs5pr1	68	13	cytokines	cytokine	NNS
cord-282507-swxs5pr1	68	14	(	(	-LRB-
cord-282507-swxs5pr1	68	15	Marciani	Marciani	NNPS
cord-282507-swxs5pr1	68	16	,	,	,
cord-282507-swxs5pr1	68	17	2018	2018	CD
cord-282507-swxs5pr1	68	18	)	)	-RRB-
cord-282507-swxs5pr1	69	1	(	(	-LRB-
cord-282507-swxs5pr1	69	2	Fig	Fig	NNP
cord-282507-swxs5pr1	69	3	.	.	.
cord-282507-swxs5pr1	69	4	3	3	CD
cord-282507-swxs5pr1	69	5	)	)	-RRB-
cord-282507-swxs5pr1	69	6	.	.	.
cord-282507-swxs5pr1	70	1	Recently	recently	RB
cord-282507-swxs5pr1	70	2	,	,	,
cord-282507-swxs5pr1	70	3	studies	study	NNS
cord-282507-swxs5pr1	70	4	in	in	IN
cord-282507-swxs5pr1	70	5	mouse	mouse	NN
cord-282507-swxs5pr1	70	6	APCs	apc	NNS
cord-282507-swxs5pr1	70	7	(	(	-LRB-
cord-282507-swxs5pr1	70	8	DCs	DCs	NNP
cord-282507-swxs5pr1	70	9	and	and	CC
cord-282507-swxs5pr1	70	10	macrophages	macrophage	NNS
cord-282507-swxs5pr1	70	11	)	)	-RRB-
cord-282507-swxs5pr1	70	12	identified	identify	VBD
cord-282507-swxs5pr1	70	13	QS-21	QS-21	NNP
cord-282507-swxs5pr1	70	14	as	as	IN
cord-282507-swxs5pr1	70	15	an	an	DT
cord-282507-swxs5pr1	70	16	activator	activator	NN
cord-282507-swxs5pr1	70	17	of	of	IN
cord-282507-swxs5pr1	70	18	the	the	DT
cord-282507-swxs5pr1	70	19	NLRP3	NLRP3	NNP
cord-282507-swxs5pr1	70	20	inflammasome	inflammasome	NNP
cord-282507-swxs5pr1	70	21	.	.	.
cord-282507-swxs5pr1	71	1	QS-21	QS-21	NNP
cord-282507-swxs5pr1	71	2	in	in	IN
cord-282507-swxs5pr1	71	3	combination	combination	NN
cord-282507-swxs5pr1	71	4	with	with	IN
cord-282507-swxs5pr1	71	5	the	the	DT
cord-282507-swxs5pr1	71	6	TLR4-agonist	TLR4-agonist	NNP
cord-282507-swxs5pr1	71	7	3-O	3-O	NNPS
cord-282507-swxs5pr1	71	8	-	-	:
cord-282507-swxs5pr1	71	9	deacyl-4′-monophosphoryl	deacyl-4′-monophosphoryl	JJ
cord-282507-swxs5pr1	71	10	lipid	lipid	NN
cord-282507-swxs5pr1	71	11	A	a	NN
cord-282507-swxs5pr1	71	12	(	(	-LRB-
cord-282507-swxs5pr1	71	13	MPL	MPL	NNP
cord-282507-swxs5pr1	71	14	A	A	NNP
cord-282507-swxs5pr1	71	15	)	)	-RRB-
cord-282507-swxs5pr1	71	16	,	,	,
cord-282507-swxs5pr1	71	17	was	be	VBD
cord-282507-swxs5pr1	71	18	shown	show	VBN
cord-282507-swxs5pr1	71	19	to	to	TO
cord-282507-swxs5pr1	71	20	activate	activate	VB
cord-282507-swxs5pr1	71	21	the	the	DT
cord-282507-swxs5pr1	71	22	ACS	ACS	NNP
cord-282507-swxs5pr1	71	23	-	-	HYPH
cord-282507-swxs5pr1	71	24	NLRP3	NLRP3	NNP
cord-282507-swxs5pr1	71	25	inflammasome	inflammasome	NNP
cord-282507-swxs5pr1	71	26	,	,	,
cord-282507-swxs5pr1	71	27	a	a	DT
cord-282507-swxs5pr1	71	28	multiprotein	multiprotein	NN
cord-282507-swxs5pr1	71	29	complex	complex	NN
cord-282507-swxs5pr1	71	30	and	and	CC
cord-282507-swxs5pr1	71	31	cause	cause	VB
cord-282507-swxs5pr1	71	32	subsequent	subsequent	JJ
cord-282507-swxs5pr1	71	33	release	release	NN
cord-282507-swxs5pr1	71	34	of	of	IN
cord-282507-swxs5pr1	71	35	caspase-1	caspase-1	NNP
cord-282507-swxs5pr1	71	36	dependent	dependent	JJ
cord-282507-swxs5pr1	71	37	proinflammatory	proinflammatory	JJ
cord-282507-swxs5pr1	71	38	cytokines	cytokine	NNS
cord-282507-swxs5pr1	71	39	Il-1β	Il-1β	NNP
cord-282507-swxs5pr1	71	40	/	/	SYM
cord-282507-swxs5pr1	71	41	Il-18	Il-18	NNP
cord-282507-swxs5pr1	71	42	that	that	WDT
cord-282507-swxs5pr1	71	43	can	can	MD
cord-282507-swxs5pr1	71	44	promote	promote	VB
cord-282507-swxs5pr1	71	45	Th	Th	NNP
cord-282507-swxs5pr1	71	46	17	17	CD
cord-282507-swxs5pr1	71	47	cell	cell	NN
cord-282507-swxs5pr1	71	48	maturation	maturation	NN
cord-282507-swxs5pr1	71	49	or	or	CC
cord-282507-swxs5pr1	71	50	drive	drive	VB
cord-282507-swxs5pr1	71	51	INF	inf	NN
cord-282507-swxs5pr1	71	52	-	-	HYPH
cord-282507-swxs5pr1	71	53	γ	γ	NN
cord-282507-swxs5pr1	71	54	-	-	HYPH
cord-282507-swxs5pr1	71	55	mediated	mediate	VBN
cord-282507-swxs5pr1	71	56	Th1	th1	NN
cord-282507-swxs5pr1	71	57	responses	response	NNS
cord-282507-swxs5pr1	71	58	,	,	,
cord-282507-swxs5pr1	71	59	respectively	respectively	RB
cord-282507-swxs5pr1	71	60	(	(	-LRB-
cord-282507-swxs5pr1	71	61	Marty	Marty	NNP
cord-282507-swxs5pr1	71	62	-	-	HYPH
cord-282507-swxs5pr1	71	63	Roix	Roix	NNP
cord-282507-swxs5pr1	71	64	et	et	NNP
cord-282507-swxs5pr1	71	65	al	al	NNP
cord-282507-swxs5pr1	71	66	.	.	NNP
cord-282507-swxs5pr1	71	67	,	,	,
cord-282507-swxs5pr1	71	68	2016	2016	CD
cord-282507-swxs5pr1	71	69	)	)	-RRB-
cord-282507-swxs5pr1	71	70	.	.	.
cord-282507-swxs5pr1	72	1	Thus	thus	RB
cord-282507-swxs5pr1	72	2	,	,	,
cord-282507-swxs5pr1	72	3	inflammasome	inflammasome	NNP
cord-282507-swxs5pr1	72	4	signaling	signaling	NN
cord-282507-swxs5pr1	72	5	has	have	VBZ
cord-282507-swxs5pr1	72	6	the	the	DT
cord-282507-swxs5pr1	72	7	potential	potential	NN
cord-282507-swxs5pr1	72	8	to	to	TO
cord-282507-swxs5pr1	72	9	direct	direct	VB
cord-282507-swxs5pr1	72	10	the	the	DT
cord-282507-swxs5pr1	72	11	development	development	NN
cord-282507-swxs5pr1	72	12	of	of	IN
cord-282507-swxs5pr1	72	13	T	T	NNP
cord-282507-swxs5pr1	72	14	helper	helper	NN
cord-282507-swxs5pr1	72	15	subsets	subset	NNS
cord-282507-swxs5pr1	72	16	.	.	.
cord-282507-swxs5pr1	73	1	However	however	RB
cord-282507-swxs5pr1	73	2	,	,	,
cord-282507-swxs5pr1	73	3	the	the	DT
cord-282507-swxs5pr1	73	4	role	role	NN
cord-282507-swxs5pr1	73	5	of	of	IN
cord-282507-swxs5pr1	73	6	this	this	DT
cord-282507-swxs5pr1	73	7	signaling	signal	VBG
cord-282507-swxs5pr1	73	8	pathway	pathway	NN
cord-282507-swxs5pr1	73	9	in	in	IN
cord-282507-swxs5pr1	73	10	vivo	vivo	NN
cord-282507-swxs5pr1	73	11	remained	remain	VBD
cord-282507-swxs5pr1	73	12	to	to	TO
cord-282507-swxs5pr1	73	13	be	be	VB
cord-282507-swxs5pr1	73	14	clarified	clarify	VBN
cord-282507-swxs5pr1	73	15	.	.	.
cord-282507-swxs5pr1	74	1	Although	although	IN
cord-282507-swxs5pr1	74	2	QS-21	QS-21	NNP
cord-282507-swxs5pr1	74	3	has	have	VBZ
cord-282507-swxs5pr1	74	4	been	be	VBN
cord-282507-swxs5pr1	74	5	used	use	VBN
cord-282507-swxs5pr1	74	6	in	in	IN
cord-282507-swxs5pr1	74	7	many	many	JJ
cord-282507-swxs5pr1	74	8	clinical	clinical	JJ
cord-282507-swxs5pr1	74	9	investigations	investigation	NNS
cord-282507-swxs5pr1	74	10	of	of	IN
cord-282507-swxs5pr1	74	11	vaccines	vaccine	NNS
cord-282507-swxs5pr1	74	12	,	,	,
cord-282507-swxs5pr1	74	13	several	several	JJ
cord-282507-swxs5pr1	74	14	drawbacks	drawback	NNS
cord-282507-swxs5pr1	74	15	inherent	inherent	JJ
cord-282507-swxs5pr1	74	16	to	to	IN
cord-282507-swxs5pr1	74	17	the	the	DT
cord-282507-swxs5pr1	74	18	natural	natural	JJ
cord-282507-swxs5pr1	74	19	product	product	NN
cord-282507-swxs5pr1	74	20	,	,	,
cord-282507-swxs5pr1	74	21	such	such	JJ
cord-282507-swxs5pr1	74	22	as	as	IN
cord-282507-swxs5pr1	74	23	its	-PRON-	PRP$
cord-282507-swxs5pr1	74	24	chemical	chemical	NN
cord-282507-swxs5pr1	74	25	instability	instability	NN
cord-282507-swxs5pr1	74	26	,	,	,
cord-282507-swxs5pr1	74	27	scarcity	scarcity	NN
cord-282507-swxs5pr1	74	28	,	,	,
cord-282507-swxs5pr1	74	29	heterogeneity	heterogeneity	NN
cord-282507-swxs5pr1	74	30	,	,	,
cord-282507-swxs5pr1	74	31	dose	dose	RB
cord-282507-swxs5pr1	74	32	-	-	HYPH
cord-282507-swxs5pr1	74	33	limiting	limit	VBG
cord-282507-swxs5pr1	74	34	toxicity	toxicity	NN
cord-282507-swxs5pr1	74	35	and	and	CC
cord-282507-swxs5pr1	74	36	poorly	poorly	RB
cord-282507-swxs5pr1	74	37	understood	understand	VBN
cord-282507-swxs5pr1	74	38	mechanism	mechanism	NN
cord-282507-swxs5pr1	74	39	of	of	IN
cord-282507-swxs5pr1	74	40	action	action	NN
cord-282507-swxs5pr1	74	41	have	have	VBP
cord-282507-swxs5pr1	74	42	limited	limit	VBN
cord-282507-swxs5pr1	74	43	its	-PRON-	PRP$
cord-282507-swxs5pr1	74	44	widespread	widespread	JJ
cord-282507-swxs5pr1	74	45	clinical	clinical	JJ
cord-282507-swxs5pr1	74	46	advancement	advancement	NN
cord-282507-swxs5pr1	74	47	,	,	,
cord-282507-swxs5pr1	74	48	except	except	IN
cord-282507-swxs5pr1	74	49	for	for	IN
cord-282507-swxs5pr1	74	50	the	the	DT
cord-282507-swxs5pr1	74	51	recent	recent	JJ
cord-282507-swxs5pr1	74	52	malaria	malaria	NN
cord-282507-swxs5pr1	74	53	(	(	-LRB-
cord-282507-swxs5pr1	74	54	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	74	55	™	™	CD
cord-282507-swxs5pr1	74	56	)	)	-RRB-
cord-282507-swxs5pr1	74	57	and	and	CC
cord-282507-swxs5pr1	74	58	shingles	shingle	NNS
cord-282507-swxs5pr1	74	59	(	(	-LRB-
cord-282507-swxs5pr1	74	60	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	74	61	™	™	CD
cord-282507-swxs5pr1	74	62	)	)	-RRB-
cord-282507-swxs5pr1	74	63	vaccines	vaccine	NNS
cord-282507-swxs5pr1	74	64	developed	develop	VBN
cord-282507-swxs5pr1	74	65	by	by	IN
cord-282507-swxs5pr1	74	66	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-282507-swxs5pr1	74	67	(	(	-LRB-
cord-282507-swxs5pr1	74	68	GSK	GSK	NNP
cord-282507-swxs5pr1	74	69	)	)	-RRB-
cord-282507-swxs5pr1	74	70	.	.	.
cord-282507-swxs5pr1	75	1	To	to	TO
cord-282507-swxs5pr1	75	2	overcome	overcome	VB
cord-282507-swxs5pr1	75	3	these	these	DT
cord-282507-swxs5pr1	75	4	limitations	limitation	NNS
cord-282507-swxs5pr1	75	5	,	,	,
cord-282507-swxs5pr1	75	6	structural	structural	JJ
cord-282507-swxs5pr1	75	7	modifications	modification	NNS
cord-282507-swxs5pr1	75	8	of	of	IN
cord-282507-swxs5pr1	75	9	the	the	DT
cord-282507-swxs5pr1	75	10	natural	natural	JJ
cord-282507-swxs5pr1	75	11	product	product	NN
cord-282507-swxs5pr1	75	12	through	through	IN
cord-282507-swxs5pr1	75	13	chemical	chemical	JJ
cord-282507-swxs5pr1	75	14	synthesis	synthesis	NN
cord-282507-swxs5pr1	75	15	have	have	VBP
cord-282507-swxs5pr1	75	16	been	be	VBN
cord-282507-swxs5pr1	75	17	undertaken	undertake	VBN
cord-282507-swxs5pr1	75	18	during	during	IN
cord-282507-swxs5pr1	75	19	the	the	DT
cord-282507-swxs5pr1	75	20	last	last	JJ
cord-282507-swxs5pr1	75	21	decade	decade	NN
cord-282507-swxs5pr1	75	22	,	,	,
cord-282507-swxs5pr1	75	23	leading	lead	VBG
cord-282507-swxs5pr1	75	24	to	to	IN
cord-282507-swxs5pr1	75	25	the	the	DT
cord-282507-swxs5pr1	75	26	preparation	preparation	NN
cord-282507-swxs5pr1	75	27	of	of	IN
cord-282507-swxs5pr1	75	28	nearly	nearly	RB
cord-282507-swxs5pr1	75	29	50	50	CD
cord-282507-swxs5pr1	75	30	saponin	saponin	NN
cord-282507-swxs5pr1	75	31	analogs	analog	NNS
cord-282507-swxs5pr1	75	32	,	,	,
cord-282507-swxs5pr1	75	33	which	which	WDT
cord-282507-swxs5pr1	75	34	have	have	VBP
cord-282507-swxs5pr1	75	35	provided	provide	VBN
cord-282507-swxs5pr1	75	36	key	key	JJ
cord-282507-swxs5pr1	75	37	insights	insight	NNS
cord-282507-swxs5pr1	75	38	into	into	IN
cord-282507-swxs5pr1	75	39	structure	structure	NN
cord-282507-swxs5pr1	75	40	/	/	SYM
cord-282507-swxs5pr1	75	41	activity	activity	NN
cord-282507-swxs5pr1	75	42	relationships	relationship	NNS
cord-282507-swxs5pr1	75	43	(	(	-LRB-
cord-282507-swxs5pr1	75	44	SAR	SAR	NNP
cord-282507-swxs5pr1	75	45	)	)	-RRB-
cord-282507-swxs5pr1	75	46	which	which	WDT
cord-282507-swxs5pr1	75	47	are	be	VBP
cord-282507-swxs5pr1	75	48	summarized	summarize	VBN
cord-282507-swxs5pr1	75	49	in	in	IN
cord-282507-swxs5pr1	75	50	Fig	Fig	NNP
cord-282507-swxs5pr1	75	51	.	.	.
cord-282507-swxs5pr1	76	1	4	4	LS
cord-282507-swxs5pr1	76	2	.	.	.
cord-282507-swxs5pr1	77	1	These	these	DT
cord-282507-swxs5pr1	77	2	achievements	achievement	NNS
cord-282507-swxs5pr1	77	3	allowed	allow	VBD
cord-282507-swxs5pr1	77	4	the	the	DT
cord-282507-swxs5pr1	77	5	identification	identification	NN
cord-282507-swxs5pr1	77	6	of	of	IN
cord-282507-swxs5pr1	77	7	new	new	JJ
cord-282507-swxs5pr1	77	8	novel	novel	JJ
cord-282507-swxs5pr1	77	9	saponins	saponin	NNS
cord-282507-swxs5pr1	77	10	probes	probe	NNS
cord-282507-swxs5pr1	77	11	with	with	IN
cord-282507-swxs5pr1	77	12	potent	potent	JJ
cord-282507-swxs5pr1	77	13	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	77	14	activities	activity	NNS
cord-282507-swxs5pr1	77	15	,	,	,
cord-282507-swxs5pr1	77	16	increased	increase	VBN
cord-282507-swxs5pr1	77	17	stability	stability	NN
cord-282507-swxs5pr1	77	18	,	,	,
cord-282507-swxs5pr1	77	19	and	and	CC
cord-282507-swxs5pr1	77	20	decreased	decrease	VBD
cord-282507-swxs5pr1	77	21	toxicity	toxicity	NN
cord-282507-swxs5pr1	77	22	,	,	,
cord-282507-swxs5pr1	77	23	and	and	CC
cord-282507-swxs5pr1	77	24	the	the	DT
cord-282507-swxs5pr1	77	25	investigation	investigation	NN
cord-282507-swxs5pr1	77	26	into	into	IN
cord-282507-swxs5pr1	77	27	their	-PRON-	PRP$
cord-282507-swxs5pr1	77	28	mechanisms	mechanism	NNS
cord-282507-swxs5pr1	77	29	of	of	IN
cord-282507-swxs5pr1	77	30	action	action	NN
cord-282507-swxs5pr1	77	31	(	(	-LRB-
cord-282507-swxs5pr1	77	32	Fernández	Fernández	NNP
cord-282507-swxs5pr1	77	33	-	-	HYPH
cord-282507-swxs5pr1	77	34	Tajeda	Tajeda	NNP
cord-282507-swxs5pr1	77	35	et	et	NNP
cord-282507-swxs5pr1	77	36	al	al	NNP
cord-282507-swxs5pr1	77	37	.	.	NNP
cord-282507-swxs5pr1	77	38	,	,	,
cord-282507-swxs5pr1	77	39	2016	2016	CD
cord-282507-swxs5pr1	77	40	;	;	:
cord-282507-swxs5pr1	77	41	Fernández	Fernández	NNP
cord-282507-swxs5pr1	77	42	-	-	HYPH
cord-282507-swxs5pr1	77	43	Tejada	Tejada	NNP
cord-282507-swxs5pr1	77	44	,	,	,
cord-282507-swxs5pr1	77	45	2017	2017	CD
cord-282507-swxs5pr1	77	46	)	)	-RRB-
cord-282507-swxs5pr1	77	47	.	.	.
cord-282507-swxs5pr1	78	1	Firstly	firstly	RB
cord-282507-swxs5pr1	78	2	,	,	,
cord-282507-swxs5pr1	78	3	the	the	DT
cord-282507-swxs5pr1	78	4	total	total	JJ
cord-282507-swxs5pr1	78	5	synthesis	synthesis	NN
cord-282507-swxs5pr1	78	6	of	of	IN
cord-282507-swxs5pr1	78	7	each	each	DT
cord-282507-swxs5pr1	78	8	isomeric	isomeric	JJ
cord-282507-swxs5pr1	78	9	QS-21	QS-21	NNP
cord-282507-swxs5pr1	78	10	produced	produce	VBD
cord-282507-swxs5pr1	78	11	this	this	DT
cord-282507-swxs5pr1	78	12	potent	potent	JJ
cord-282507-swxs5pr1	78	13	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	78	14	in	in	IN
cord-282507-swxs5pr1	78	15	high	high	JJ
cord-282507-swxs5pr1	78	16	purity	purity	NN
cord-282507-swxs5pr1	78	17	and	and	CC
cord-282507-swxs5pr1	78	18	homogeneous	homogeneous	JJ
cord-282507-swxs5pr1	78	19	composition	composition	NN
cord-282507-swxs5pr1	78	20	.	.	.
cord-282507-swxs5pr1	79	1	Then	then	RB
cord-282507-swxs5pr1	79	2	,	,	,
cord-282507-swxs5pr1	79	3	some	some	DT
cord-282507-swxs5pr1	79	4	QS-21	QS-21	NNP
cord-282507-swxs5pr1	79	5	variants	variant	NNS
cord-282507-swxs5pr1	79	6	(	(	-LRB-
cord-282507-swxs5pr1	79	7	SQS-101	sqs-101	XX
cord-282507-swxs5pr1	79	8	,	,	,
cord-282507-swxs5pr1	79	9	SQS-102	SQS-102	NNPS
cord-282507-swxs5pr1	79	10	,	,	,
cord-282507-swxs5pr1	79	11	SQS-103	SQS-103	NNP
cord-282507-swxs5pr1	79	12	)	)	-RRB-
cord-282507-swxs5pr1	79	13	were	be	VBD
cord-282507-swxs5pr1	79	14	chemically	chemically	RB
cord-282507-swxs5pr1	79	15	synthesized	synthesize	VBN
cord-282507-swxs5pr1	79	16	with	with	IN
cord-282507-swxs5pr1	79	17	more	more	RBR
cord-282507-swxs5pr1	79	18	stable	stable	JJ
cord-282507-swxs5pr1	79	19	amide	amide	NN
cord-282507-swxs5pr1	79	20	linkages	linkage	NNS
cord-282507-swxs5pr1	79	21	in	in	IN
cord-282507-swxs5pr1	79	22	the	the	DT
cord-282507-swxs5pr1	79	23	acyl	acyl	NN
cord-282507-swxs5pr1	79	24	chain	chain	NN
cord-282507-swxs5pr1	79	25	instead	instead	RB
cord-282507-swxs5pr1	79	26	of	of	IN
cord-282507-swxs5pr1	79	27	the	the	DT
cord-282507-swxs5pr1	79	28	unstable	unstable	JJ
cord-282507-swxs5pr1	79	29	native	native	JJ
cord-282507-swxs5pr1	79	30	esters	ester	NNS
cord-282507-swxs5pr1	79	31	(	(	-LRB-
cord-282507-swxs5pr1	79	32	Fig	Fig	NNP
cord-282507-swxs5pr1	79	33	.	.	NNP
cord-282507-swxs5pr1	79	34	5	5	CD
cord-282507-swxs5pr1	79	35	)	)	-RRB-
cord-282507-swxs5pr1	79	36	.	.	.
cord-282507-swxs5pr1	80	1	Their	-PRON-	PRP$
cord-282507-swxs5pr1	80	2	immunological	immunological	JJ
cord-282507-swxs5pr1	80	3	evaluation	evaluation	NN
cord-282507-swxs5pr1	80	4	in	in	IN
cord-282507-swxs5pr1	80	5	mice	mouse	NNS
cord-282507-swxs5pr1	80	6	demonstrated	demonstrate	VBD
cord-282507-swxs5pr1	80	7	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	80	8	activities	activity	NNS
cord-282507-swxs5pr1	80	9	comparable	comparable	JJ
cord-282507-swxs5pr1	80	10	to	to	IN
cord-282507-swxs5pr1	80	11	QS-21	QS-21	NNP
cord-282507-swxs5pr1	80	12	,	,	,
cord-282507-swxs5pr1	80	13	as	as	IN
cord-282507-swxs5pr1	80	14	assessed	assess	VBN
cord-282507-swxs5pr1	80	15	by	by	IN
cord-282507-swxs5pr1	80	16	measuring	measure	VBG
cord-282507-swxs5pr1	80	17	Ab	Ab	NNP
cord-282507-swxs5pr1	80	18	responses	response	NNS
cord-282507-swxs5pr1	80	19	by	by	IN
cord-282507-swxs5pr1	80	20	ELISA	ELISA	NNP
cord-282507-swxs5pr1	80	21	one	one	CD
cord-282507-swxs5pr1	80	22	week	week	NN
cord-282507-swxs5pr1	80	23	after	after	IN
cord-282507-swxs5pr1	80	24	booster	booster	NN
cord-282507-swxs5pr1	80	25	injection	injection	NN
cord-282507-swxs5pr1	80	26	(	(	-LRB-
cord-282507-swxs5pr1	80	27	day	day	NN
cord-282507-swxs5pr1	80	28	72	72	CD
cord-282507-swxs5pr1	80	29	)	)	-RRB-
cord-282507-swxs5pr1	80	30	and	and	CC
cord-282507-swxs5pr1	80	31	significantly	significantly	RB
cord-282507-swxs5pr1	80	32	lower	low	JJR
cord-282507-swxs5pr1	80	33	toxicity	toxicity	NN
cord-282507-swxs5pr1	80	34	than	than	IN
cord-282507-swxs5pr1	80	35	the	the	DT
cord-282507-swxs5pr1	80	36	natural	natural	JJ
cord-282507-swxs5pr1	80	37	product	product	NN
cord-282507-swxs5pr1	80	38	,	,	,
cord-282507-swxs5pr1	80	39	except	except	IN
cord-282507-swxs5pr1	80	40	for	for	IN
cord-282507-swxs5pr1	80	41	SQS-102	SQS-102	NNS
cord-282507-swxs5pr1	80	42	.	.	.
cord-282507-swxs5pr1	81	1	Further	further	JJ
cord-282507-swxs5pr1	81	2	modifications	modification	NNS
cord-282507-swxs5pr1	81	3	in	in	IN
cord-282507-swxs5pr1	81	4	the	the	DT
cord-282507-swxs5pr1	81	5	acyl	acyl	NN
cord-282507-swxs5pr1	81	6	chain	chain	NN
cord-282507-swxs5pr1	81	7	with	with	IN
cord-282507-swxs5pr1	81	8	a	a	DT
cord-282507-swxs5pr1	81	9	dodecanedioic	dodecanedioic	NN
cord-282507-swxs5pr1	81	10	acid	acid	NN
cord-282507-swxs5pr1	81	11	and	and	CC
cord-282507-swxs5pr1	81	12	truncation	truncation	NN
cord-282507-swxs5pr1	81	13	of	of	IN
cord-282507-swxs5pr1	81	14	the	the	DT
cord-282507-swxs5pr1	81	15	tetrasaccharide	tetrasaccharide	NN
cord-282507-swxs5pr1	81	16	led	lead	VBD
cord-282507-swxs5pr1	81	17	to	to	IN
cord-282507-swxs5pr1	81	18	a	a	DT
cord-282507-swxs5pr1	81	19	trisaccharide	trisaccharide	NN
cord-282507-swxs5pr1	81	20	variant	variant	NN
cord-282507-swxs5pr1	81	21	with	with	IN
cord-282507-swxs5pr1	81	22	potent	potent	JJ
cord-282507-swxs5pr1	81	23	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	81	24	activity	activity	NN
cord-282507-swxs5pr1	81	25	and	and	CC
cord-282507-swxs5pr1	81	26	whose	whose	WP$
cord-282507-swxs5pr1	81	27	toxicity	toxicity	NN
cord-282507-swxs5pr1	81	28	issue	issue	NN
cord-282507-swxs5pr1	81	29	is	be	VBZ
cord-282507-swxs5pr1	81	30	not	not	RB
cord-282507-swxs5pr1	81	31	completely	completely	RB
cord-282507-swxs5pr1	81	32	resolved	resolve	VBN
cord-282507-swxs5pr1	81	33	.	.	.
cord-282507-swxs5pr1	82	1	This	this	DT
cord-282507-swxs5pr1	82	2	simplification	simplification	NN
cord-282507-swxs5pr1	82	3	led	lead	VBD
cord-282507-swxs5pr1	82	4	to	to	IN
cord-282507-swxs5pr1	82	5	further	further	JJ
cord-282507-swxs5pr1	82	6	structural	structural	JJ
cord-282507-swxs5pr1	82	7	variations	variation	NNS
cord-282507-swxs5pr1	82	8	at	at	IN
cord-282507-swxs5pr1	82	9	the	the	DT
cord-282507-swxs5pr1	82	10	linker	linker	NN
cord-282507-swxs5pr1	82	11	(	(	-LRB-
cord-282507-swxs5pr1	82	12	ester	ester	NN
cord-282507-swxs5pr1	82	13	linkage	linkage	NN
cord-282507-swxs5pr1	82	14	at	at	IN
cord-282507-swxs5pr1	82	15	C-28	C-28	NNP
cord-282507-swxs5pr1	82	16	)	)	-RRB-
cord-282507-swxs5pr1	82	17	between	between	IN
cord-282507-swxs5pr1	82	18	the	the	DT
cord-282507-swxs5pr1	82	19	triterpene	triterpene	NNP
cord-282507-swxs5pr1	82	20	and	and	CC
cord-282507-swxs5pr1	82	21	the	the	DT
cord-282507-swxs5pr1	82	22	linear	linear	JJ
cord-282507-swxs5pr1	82	23	oligosaccharide	oligosaccharide	NN
cord-282507-swxs5pr1	82	24	in	in	IN
cord-282507-swxs5pr1	82	25	order	order	NN
cord-282507-swxs5pr1	82	26	to	to	TO
cord-282507-swxs5pr1	82	27	modulate	modulate	VB
cord-282507-swxs5pr1	82	28	the	the	DT
cord-282507-swxs5pr1	82	29	distance	distance	NN
cord-282507-swxs5pr1	82	30	and	and	CC
cord-282507-swxs5pr1	82	31	orientation	orientation	NN
cord-282507-swxs5pr1	82	32	of	of	IN
cord-282507-swxs5pr1	82	33	these	these	DT
cord-282507-swxs5pr1	82	34	two	two	CD
cord-282507-swxs5pr1	82	35	domains	domain	NNS
cord-282507-swxs5pr1	82	36	.	.	.
cord-282507-swxs5pr1	83	1	The	the	DT
cord-282507-swxs5pr1	83	2	variants	variant	NNS
cord-282507-swxs5pr1	83	3	exhibit	exhibit	VBP
cord-282507-swxs5pr1	83	4	striking	strike	VBG
cord-282507-swxs5pr1	83	5	differences	difference	NNS
cord-282507-swxs5pr1	83	6	in	in	IN
cord-282507-swxs5pr1	83	7	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	83	8	activity	activity	NN
cord-282507-swxs5pr1	83	9	and	and	CC
cord-282507-swxs5pr1	83	10	toxicity	toxicity	NN
cord-282507-swxs5pr1	83	11	in	in	IN
cord-282507-swxs5pr1	83	12	mouse	mouse	NN
cord-282507-swxs5pr1	83	13	vaccination	vaccination	NN
cord-282507-swxs5pr1	83	14	models	model	NNS
cord-282507-swxs5pr1	83	15	,	,	,
cord-282507-swxs5pr1	83	16	yielding	yield	VBG
cord-282507-swxs5pr1	83	17	new	new	JJ
cord-282507-swxs5pr1	83	18	insights	insight	NNS
cord-282507-swxs5pr1	83	19	into	into	IN
cord-282507-swxs5pr1	83	20	the	the	DT
cord-282507-swxs5pr1	83	21	structural	structural	JJ
cord-282507-swxs5pr1	83	22	requirements	requirement	NNS
cord-282507-swxs5pr1	83	23	for	for	IN
cord-282507-swxs5pr1	83	24	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	83	25	activity	activity	NN
cord-282507-swxs5pr1	83	26	.	.	.
cord-282507-swxs5pr1	84	1	Molecular	molecular	JJ
cord-282507-swxs5pr1	84	2	dynamics	dynamic	NNS
cord-282507-swxs5pr1	84	3	simulations	simulation	NNS
cord-282507-swxs5pr1	84	4	of	of	IN
cord-282507-swxs5pr1	84	5	these	these	DT
cord-282507-swxs5pr1	84	6	compounds	compound	NNS
cord-282507-swxs5pr1	84	7	and	and	CC
cord-282507-swxs5pr1	84	8	QS-21	QS-21	NNP
cord-282507-swxs5pr1	84	9	Api	Api	NNP
cord-282507-swxs5pr1	84	10	have	have	VBP
cord-282507-swxs5pr1	84	11	revealed	reveal	VBN
cord-282507-swxs5pr1	84	12	distinctive	distinctive	JJ
cord-282507-swxs5pr1	84	13	conformational	conformational	JJ
cord-282507-swxs5pr1	84	14	features	feature	NNS
cord-282507-swxs5pr1	84	15	correlating	correlate	VBG
cord-282507-swxs5pr1	84	16	with	with	IN
cord-282507-swxs5pr1	84	17	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	84	18	activity	activity	NN
cord-282507-swxs5pr1	84	19	,	,	,
cord-282507-swxs5pr1	84	20	which	which	WDT
cord-282507-swxs5pr1	84	21	may	may	MD
cord-282507-swxs5pr1	84	22	help	help	VB
cord-282507-swxs5pr1	84	23	in	in	IN
cord-282507-swxs5pr1	84	24	the	the	DT
cord-282507-swxs5pr1	84	25	design	design	NN
cord-282507-swxs5pr1	84	26	of	of	IN
cord-282507-swxs5pr1	84	27	new	new	JJ
cord-282507-swxs5pr1	84	28	analogs	analog	NNS
cord-282507-swxs5pr1	84	29	(	(	-LRB-
cord-282507-swxs5pr1	84	30	Walkowicz	Walkowicz	NNP
cord-282507-swxs5pr1	84	31	et	et	NNP
cord-282507-swxs5pr1	84	32	al	al	NNP
cord-282507-swxs5pr1	84	33	.	.	NNP
cord-282507-swxs5pr1	84	34	,	,	,
cord-282507-swxs5pr1	84	35	2016	2016	CD
cord-282507-swxs5pr1	84	36	)	)	-RRB-
cord-282507-swxs5pr1	84	37	.	.	.
cord-282507-swxs5pr1	85	1	The	the	DT
cord-282507-swxs5pr1	85	2	modifications	modification	NNS
cord-282507-swxs5pr1	85	3	of	of	IN
cord-282507-swxs5pr1	85	4	the	the	DT
cord-282507-swxs5pr1	85	5	tetrasaccharide	tetrasaccharide	NN
cord-282507-swxs5pr1	85	6	into	into	IN
cord-282507-swxs5pr1	85	7	a	a	DT
cord-282507-swxs5pr1	85	8	trisaccharide	trisaccharide	NN
cord-282507-swxs5pr1	85	9	variant	variant	NN
cord-282507-swxs5pr1	85	10	,	,	,
cord-282507-swxs5pr1	85	11	and	and	CC
cord-282507-swxs5pr1	85	12	the	the	DT
cord-282507-swxs5pr1	85	13	acyl	acyl	NN
cord-282507-swxs5pr1	85	14	chain	chain	NN
cord-282507-swxs5pr1	85	15	into	into	IN
cord-282507-swxs5pr1	85	16	a	a	DT
cord-282507-swxs5pr1	85	17	terminal	terminal	JJ
cord-282507-swxs5pr1	85	18	amine	amine	NN
cord-282507-swxs5pr1	85	19	variant	variant	NN
cord-282507-swxs5pr1	85	20	enables	enable	VBZ
cord-282507-swxs5pr1	85	21	the	the	DT
cord-282507-swxs5pr1	85	22	synthesis	synthesis	NN
cord-282507-swxs5pr1	85	23	of	of	IN
cord-282507-swxs5pr1	85	24	novel	novel	JJ
cord-282507-swxs5pr1	85	25	acyl	acyl	NN
cord-282507-swxs5pr1	85	26	chain	chain	NN
cord-282507-swxs5pr1	85	27	variants	variant	NNS
cord-282507-swxs5pr1	85	28	bearing	bear	VBG
cord-282507-swxs5pr1	85	29	fluorescent	fluorescent	NN
cord-282507-swxs5pr1	85	30	and	and	CC
cord-282507-swxs5pr1	85	31	iodinated	iodinate	VBN
cord-282507-swxs5pr1	85	32	substituents	substituent	NNS
cord-282507-swxs5pr1	85	33	for	for	IN
cord-282507-swxs5pr1	85	34	subsequent	subsequent	JJ
cord-282507-swxs5pr1	85	35	imaging	imaging	NN
cord-282507-swxs5pr1	85	36	and	and	CC
cord-282507-swxs5pr1	85	37	in	in	IN
cord-282507-swxs5pr1	85	38	vivo	vivo	NNP
cord-282507-swxs5pr1	85	39	biodistribution	biodistribution	NNP
cord-282507-swxs5pr1	85	40	studies	study	NNS
cord-282507-swxs5pr1	85	41	(	(	-LRB-
cord-282507-swxs5pr1	85	42	Fernández	Fernández	NNP
cord-282507-swxs5pr1	85	43	-	-	HYPH
cord-282507-swxs5pr1	85	44	Tejada	Tejada	NNP
cord-282507-swxs5pr1	85	45	et	et	NNP
cord-282507-swxs5pr1	85	46	al	al	NNP
cord-282507-swxs5pr1	85	47	.	.	NNP
cord-282507-swxs5pr1	85	48	,	,	,
cord-282507-swxs5pr1	85	49	2014	2014	CD
cord-282507-swxs5pr1	85	50	)	)	-RRB-
cord-282507-swxs5pr1	85	51	.	.	.
cord-282507-swxs5pr1	86	1	They	-PRON-	PRP
cord-282507-swxs5pr1	86	2	were	be	VBD
cord-282507-swxs5pr1	86	3	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	86	4	-	-	HYPH
cord-282507-swxs5pr1	86	5	active	active	JJ
cord-282507-swxs5pr1	86	6	in	in	IN
cord-282507-swxs5pr1	86	7	several	several	JJ
cord-282507-swxs5pr1	86	8	mouse	mouse	NN
cord-282507-swxs5pr1	86	9	-	-	HYPH
cord-282507-swxs5pr1	86	10	vaccination	vaccination	NN
cord-282507-swxs5pr1	86	11	models	model	NNS
cord-282507-swxs5pr1	86	12	and	and	CC
cord-282507-swxs5pr1	86	13	less	less	RBR
cord-282507-swxs5pr1	86	14	toxic	toxic	JJ
cord-282507-swxs5pr1	86	15	than	than	IN
cord-282507-swxs5pr1	86	16	QS-21	QS-21	NNP
cord-282507-swxs5pr1	86	17	.	.	.
cord-282507-swxs5pr1	87	1	Early	early	JJ
cord-282507-swxs5pr1	87	2	studies	study	NNS
cord-282507-swxs5pr1	87	3	of	of	IN
cord-282507-swxs5pr1	87	4	biodistribution	biodistribution	NN
cord-282507-swxs5pr1	87	5	and	and	CC
cord-282507-swxs5pr1	87	6	fluorescence	fluorescence	NN
cord-282507-swxs5pr1	87	7	imaging	imaging	NN
cord-282507-swxs5pr1	87	8	allowed	allow	VBD
cord-282507-swxs5pr1	87	9	investigations	investigation	NNS
cord-282507-swxs5pr1	87	10	into	into	IN
cord-282507-swxs5pr1	87	11	the	the	DT
cord-282507-swxs5pr1	87	12	enigmatic	enigmatic	JJ
cord-282507-swxs5pr1	87	13	mechanism	mechanism	NN
cord-282507-swxs5pr1	87	14	of	of	IN
cord-282507-swxs5pr1	87	15	action	action	NN
cord-282507-swxs5pr1	87	16	of	of	IN
cord-282507-swxs5pr1	87	17	these	these	DT
cord-282507-swxs5pr1	87	18	saponins	saponin	NNS
cord-282507-swxs5pr1	87	19	.	.	.
cord-282507-swxs5pr1	88	1	Preliminary	preliminary	JJ
cord-282507-swxs5pr1	88	2	results	result	NNS
cord-282507-swxs5pr1	88	3	in	in	IN
cord-282507-swxs5pr1	88	4	vaccinated	vaccinate	VBN
cord-282507-swxs5pr1	88	5	mice	mouse	NNS
cord-282507-swxs5pr1	88	6	suggested	suggest	VBD
cord-282507-swxs5pr1	88	7	the	the	DT
cord-282507-swxs5pr1	88	8	potential	potential	JJ
cord-282507-swxs5pr1	88	9	role	role	NN
cord-282507-swxs5pr1	88	10	of	of	IN
cord-282507-swxs5pr1	88	11	these	these	DT
cord-282507-swxs5pr1	88	12	fluorescent	fluorescent	JJ
cord-282507-swxs5pr1	88	13	probes	probe	NNS
cord-282507-swxs5pr1	88	14	in	in	IN
cord-282507-swxs5pr1	88	15	Ag	Ag	NNP
cord-282507-swxs5pr1	88	16	ovalbumin	ovalbumin	XX
cord-282507-swxs5pr1	88	17	(	(	-LRB-
cord-282507-swxs5pr1	88	18	OVA	ova	NN
cord-282507-swxs5pr1	88	19	)	)	-RRB-
cord-282507-swxs5pr1	88	20	trafficking	trafficking	NN
cord-282507-swxs5pr1	88	21	by	by	IN
cord-282507-swxs5pr1	88	22	APCs	apc	NNS
cord-282507-swxs5pr1	88	23	from	from	IN
cord-282507-swxs5pr1	88	24	the	the	DT
cord-282507-swxs5pr1	88	25	site	site	NN
cord-282507-swxs5pr1	88	26	of	of	IN
cord-282507-swxs5pr1	88	27	injection	injection	NN
cord-282507-swxs5pr1	88	28	to	to	IN
cord-282507-swxs5pr1	88	29	the	the	DT
cord-282507-swxs5pr1	88	30	LNs	ln	NNS
cord-282507-swxs5pr1	88	31	for	for	IN
cord-282507-swxs5pr1	88	32	its	-PRON-	PRP$
cord-282507-swxs5pr1	88	33	presentation	presentation	NN
cord-282507-swxs5pr1	88	34	to	to	IN
cord-282507-swxs5pr1	88	35	the	the	DT
cord-282507-swxs5pr1	88	36	immune	immune	JJ
cord-282507-swxs5pr1	88	37	system	system	NN
cord-282507-swxs5pr1	88	38	and	and	CC
cord-282507-swxs5pr1	88	39	yielded	yield	VBD
cord-282507-swxs5pr1	88	40	some	some	DT
cord-282507-swxs5pr1	88	41	mechanistic	mechanistic	JJ
cord-282507-swxs5pr1	88	42	understanding	understanding	NN
cord-282507-swxs5pr1	88	43	of	of	IN
cord-282507-swxs5pr1	88	44	the	the	DT
cord-282507-swxs5pr1	88	45	potentiation	potentiation	NN
cord-282507-swxs5pr1	88	46	of	of	IN
cord-282507-swxs5pr1	88	47	the	the	DT
cord-282507-swxs5pr1	88	48	immune	immune	JJ
cord-282507-swxs5pr1	88	49	response	response	NN
cord-282507-swxs5pr1	88	50	(	(	-LRB-
cord-282507-swxs5pr1	88	51	Fernández	Fernández	NNP
cord-282507-swxs5pr1	88	52	-	-	HYPH
cord-282507-swxs5pr1	88	53	Tejada	Tejada	NNP
cord-282507-swxs5pr1	88	54	et	et	NNP
cord-282507-swxs5pr1	88	55	al	al	NNP
cord-282507-swxs5pr1	88	56	.	.	NNP
cord-282507-swxs5pr1	88	57	,	,	,
cord-282507-swxs5pr1	88	58	2014	2014	CD
cord-282507-swxs5pr1	88	59	)	)	-RRB-
cord-282507-swxs5pr1	88	60	.	.	.
cord-282507-swxs5pr1	89	1	Extensive	extensive	JJ
cord-282507-swxs5pr1	89	2	structure	structure	NN
cord-282507-swxs5pr1	89	3	/	/	SYM
cord-282507-swxs5pr1	89	4	function	function	NN
cord-282507-swxs5pr1	89	5	studies	study	NNS
cord-282507-swxs5pr1	89	6	have	have	VBP
cord-282507-swxs5pr1	89	7	shown	show	VBN
cord-282507-swxs5pr1	89	8	that	that	DT
cord-282507-swxs5pr1	89	9	aryl	aryl	NN
cord-282507-swxs5pr1	89	10	iodide	iodide	NN
cord-282507-swxs5pr1	89	11	derivatives	derivative	NNS
cord-282507-swxs5pr1	89	12	with	with	IN
cord-282507-swxs5pr1	89	13	a	a	DT
cord-282507-swxs5pr1	89	14	free	free	JJ
cord-282507-swxs5pr1	89	15	C-3	C-3	NNP
cord-282507-swxs5pr1	89	16	OH	OH	NNP
cord-282507-swxs5pr1	89	17	display	display	VB
cord-282507-swxs5pr1	89	18	a	a	DT
cord-282507-swxs5pr1	89	19	good	good	JJ
cord-282507-swxs5pr1	89	20	efficacy/	efficacy/	CD
cord-282507-swxs5pr1	89	21	toxicity	toxicity	NN
cord-282507-swxs5pr1	89	22	profile	profile	NN
cord-282507-swxs5pr1	89	23	.	.	.
cord-282507-swxs5pr1	90	1	It	-PRON-	PRP
cord-282507-swxs5pr1	90	2	was	be	VBD
cord-282507-swxs5pr1	90	3	concluded	conclude	VBN
cord-282507-swxs5pr1	90	4	that	that	IN
cord-282507-swxs5pr1	90	5	the	the	DT
cord-282507-swxs5pr1	90	6	trisaccharide	trisaccharide	NN
cord-282507-swxs5pr1	90	7	at	at	IN
cord-282507-swxs5pr1	90	8	C-3	C-3	NNP
cord-282507-swxs5pr1	90	9	was	be	VBD
cord-282507-swxs5pr1	90	10	not	not	RB
cord-282507-swxs5pr1	90	11	required	require	VBN
cord-282507-swxs5pr1	90	12	for	for	IN
cord-282507-swxs5pr1	90	13	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	90	14	activity	activity	NN
cord-282507-swxs5pr1	90	15	.	.	.
cord-282507-swxs5pr1	91	1	Modifications	modification	NNS
cord-282507-swxs5pr1	91	2	at	at	IN
cord-282507-swxs5pr1	91	3	C-4	C-4	NNP
cord-282507-swxs5pr1	91	4	aldehyde	aldehyde	NN
cord-282507-swxs5pr1	91	5	and	and	CC
cord-282507-swxs5pr1	91	6	C-16	C-16	NNP
cord-282507-swxs5pr1	91	7	hydroxyl	hydroxyl	NNS
cord-282507-swxs5pr1	91	8	have	have	VBP
cord-282507-swxs5pr1	91	9	shown	show	VBN
cord-282507-swxs5pr1	91	10	that	that	IN
cord-282507-swxs5pr1	91	11	echinocystic	echinocystic	JJ
cord-282507-swxs5pr1	91	12	acid	acid	NN
cord-282507-swxs5pr1	91	13	aryl	aryl	NN
cord-282507-swxs5pr1	91	14	iodide	iodide	NN
cord-282507-swxs5pr1	91	15	derivatives	derivative	NNS
cord-282507-swxs5pr1	91	16	lacking	lack	VBG
cord-282507-swxs5pr1	91	17	the	the	DT
cord-282507-swxs5pr1	91	18	C-4	C-4	NNP
cord-282507-swxs5pr1	91	19	aldehyde	aldehyde	NN
cord-282507-swxs5pr1	91	20	but	but	CC
cord-282507-swxs5pr1	91	21	retaining	retain	VBG
cord-282507-swxs5pr1	91	22	the	the	DT
cord-282507-swxs5pr1	91	23	C-16	C-16	NNP
cord-282507-swxs5pr1	91	24	alcoholic	alcoholic	JJ
cord-282507-swxs5pr1	91	25	function	function	NN
cord-282507-swxs5pr1	91	26	(	(	-LRB-
cord-282507-swxs5pr1	91	27	Fig	fig	NN
cord-282507-swxs5pr1	91	28	.	.	.
cord-282507-swxs5pr1	91	29	6	6	CD
cord-282507-swxs5pr1	91	30	)	)	-RRB-
cord-282507-swxs5pr1	91	31	exhibited	exhibit	VBD
cord-282507-swxs5pr1	91	32	potent	potent	JJ
cord-282507-swxs5pr1	91	33	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	91	34	activity	activity	NN
cord-282507-swxs5pr1	91	35	and	and	CC
cord-282507-swxs5pr1	91	36	no	no	DT
cord-282507-swxs5pr1	91	37	toxicity	toxicity	NN
cord-282507-swxs5pr1	91	38	in	in	IN
cord-282507-swxs5pr1	91	39	a	a	DT
cord-282507-swxs5pr1	91	40	preclinical	preclinical	JJ
cord-282507-swxs5pr1	91	41	vaccination	vaccination	NN
cord-282507-swxs5pr1	91	42	model	model	NN
cord-282507-swxs5pr1	91	43	using	use	VBG
cord-282507-swxs5pr1	91	44	a	a	DT
cord-282507-swxs5pr1	91	45	four	four	CD
cord-282507-swxs5pr1	91	46	-	-	HYPH
cord-282507-swxs5pr1	91	47	component	component	NN
cord-282507-swxs5pr1	91	48	vaccine	vaccine	NN
cord-282507-swxs5pr1	91	49	(	(	-LRB-
cord-282507-swxs5pr1	91	50	MUC1-KLH	MUC1-KLH	NNP
cord-282507-swxs5pr1	91	51	,	,	,
cord-282507-swxs5pr1	91	52	OVA	OVA	NNP
cord-282507-swxs5pr1	91	53	,	,	,
cord-282507-swxs5pr1	91	54	GD3-KLH	GD3-KLH	NNP
cord-282507-swxs5pr1	91	55	)	)	-RRB-
cord-282507-swxs5pr1	91	56	when	when	WRB
cord-282507-swxs5pr1	91	57	tested	test	VBN
cord-282507-swxs5pr1	91	58	at	at	IN
cord-282507-swxs5pr1	91	59	doses	dose	NNS
cord-282507-swxs5pr1	91	60	of	of	IN
cord-282507-swxs5pr1	91	61	20	20	CD
cord-282507-swxs5pr1	91	62	and	and	CC
cord-282507-swxs5pr1	91	63	50	50	CD
cord-282507-swxs5pr1	91	64	μg	μg	NNS
cord-282507-swxs5pr1	91	65	.	.	.
cord-282507-swxs5pr1	92	1	These	these	DT
cord-282507-swxs5pr1	92	2	data	datum	NNS
cord-282507-swxs5pr1	92	3	indicated	indicate	VBD
cord-282507-swxs5pr1	92	4	that	that	IN
cord-282507-swxs5pr1	92	5	the	the	DT
cord-282507-swxs5pr1	92	6	C-4	C-4	NNP
cord-282507-swxs5pr1	92	7	aldehyde	aldehyde	NN
cord-282507-swxs5pr1	92	8	previously	previously	RB
cord-282507-swxs5pr1	92	9	suggested	suggest	VBD
cord-282507-swxs5pr1	92	10	to	to	TO
cord-282507-swxs5pr1	92	11	participate	participate	VB
cord-282507-swxs5pr1	92	12	in	in	IN
cord-282507-swxs5pr1	92	13	Schiff	Schiff	NNP
cord-282507-swxs5pr1	92	14	's	's	POS
cord-282507-swxs5pr1	92	15	base	base	NN
cord-282507-swxs5pr1	92	16	formation	formation	NN
cord-282507-swxs5pr1	92	17	with	with	IN
cord-282507-swxs5pr1	92	18	a	a	DT
cord-282507-swxs5pr1	92	19	presumed	presume	VBN
cord-282507-swxs5pr1	92	20	T	t	NN
cord-282507-swxs5pr1	92	21	cell	cell	NN
cord-282507-swxs5pr1	92	22	surface	surface	NN
cord-282507-swxs5pr1	92	23	receptor	receptor	NN
cord-282507-swxs5pr1	92	24	target	target	NN
cord-282507-swxs5pr1	92	25	(	(	-LRB-
cord-282507-swxs5pr1	92	26	Marciani	Marciani	NNP
cord-282507-swxs5pr1	92	27	,	,	,
cord-282507-swxs5pr1	92	28	2003	2003	CD
cord-282507-swxs5pr1	92	29	)	)	-RRB-
cord-282507-swxs5pr1	92	30	,	,	,
cord-282507-swxs5pr1	92	31	is	be	VBZ
cord-282507-swxs5pr1	92	32	not	not	RB
cord-282507-swxs5pr1	92	33	required	require	VBN
cord-282507-swxs5pr1	92	34	for	for	IN
cord-282507-swxs5pr1	92	35	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	92	36	activity	activity	NN
cord-282507-swxs5pr1	92	37	and	and	CC
cord-282507-swxs5pr1	92	38	revealed	reveal	VBD
cord-282507-swxs5pr1	92	39	the	the	DT
cord-282507-swxs5pr1	92	40	previously	previously	RB
cord-282507-swxs5pr1	92	41	unknown	unknown	JJ
cord-282507-swxs5pr1	92	42	role	role	NN
cord-282507-swxs5pr1	92	43	of	of	IN
cord-282507-swxs5pr1	92	44	the	the	DT
cord-282507-swxs5pr1	92	45	C-16	C-16	NNP
cord-282507-swxs5pr1	92	46	alcohol	alcohol	NN
cord-282507-swxs5pr1	92	47	in	in	IN
cord-282507-swxs5pr1	92	48	enhancing	enhance	VBG
cord-282507-swxs5pr1	92	49	activity	activity	NN
cord-282507-swxs5pr1	92	50	.	.	.
cord-282507-swxs5pr1	93	1	This	this	DT
cord-282507-swxs5pr1	93	2	opens	open	VBZ
cord-282507-swxs5pr1	93	3	the	the	DT
cord-282507-swxs5pr1	93	4	door	door	NN
cord-282507-swxs5pr1	93	5	to	to	IN
cord-282507-swxs5pr1	93	6	semi	semi	JJ
cord-282507-swxs5pr1	93	7	-	-	JJ
cord-282507-swxs5pr1	93	8	synthesis	synthesis	NN
cord-282507-swxs5pr1	93	9	from	from	IN
cord-282507-swxs5pr1	93	10	easily	easily	RB
cord-282507-swxs5pr1	93	11	available	available	JJ
cord-282507-swxs5pr1	93	12	alternative	alternative	JJ
cord-282507-swxs5pr1	93	13	precursors	precursor	NNS
cord-282507-swxs5pr1	93	14	and	and	CC
cord-282507-swxs5pr1	93	15	allowed	allow	VBD
cord-282507-swxs5pr1	93	16	detailed	detailed	JJ
cord-282507-swxs5pr1	93	17	mechanistic	mechanistic	JJ
cord-282507-swxs5pr1	93	18	studies	study	NNS
cord-282507-swxs5pr1	93	19	(	(	-LRB-
cord-282507-swxs5pr1	93	20	Fernández	Fernández	NNP
cord-282507-swxs5pr1	93	21	-	-	HYPH
cord-282507-swxs5pr1	93	22	Tejada	Tejada	NNP
cord-282507-swxs5pr1	93	23	et	et	NNP
cord-282507-swxs5pr1	93	24	al	al	NNP
cord-282507-swxs5pr1	93	25	.	.	NNP
cord-282507-swxs5pr1	93	26	,	,	,
cord-282507-swxs5pr1	93	27	2014	2014	CD
cord-282507-swxs5pr1	93	28	)	)	-RRB-
cord-282507-swxs5pr1	93	29	.	.	.
cord-282507-swxs5pr1	94	1	One	one	CD
cord-282507-swxs5pr1	94	2	of	of	IN
cord-282507-swxs5pr1	94	3	the	the	DT
cord-282507-swxs5pr1	94	4	promising	promising	JJ
cord-282507-swxs5pr1	94	5	approaches	approach	NNS
cord-282507-swxs5pr1	94	6	to	to	IN
cord-282507-swxs5pr1	94	7	improving	improve	VBG
cord-282507-swxs5pr1	94	8	efficiency	efficiency	NN
cord-282507-swxs5pr1	94	9	of	of	IN
cord-282507-swxs5pr1	94	10	newly	newly	RB
cord-282507-swxs5pr1	94	11	developed	develop	VBN
cord-282507-swxs5pr1	94	12	vaccines	vaccine	NNS
cord-282507-swxs5pr1	94	13	is	be	VBZ
cord-282507-swxs5pr1	94	14	given	give	VBN
cord-282507-swxs5pr1	94	15	by	by	IN
cord-282507-swxs5pr1	94	16	the	the	DT
cord-282507-swxs5pr1	94	17	combination	combination	NN
cord-282507-swxs5pr1	94	18	of	of	IN
cord-282507-swxs5pr1	94	19	several	several	JJ
cord-282507-swxs5pr1	94	20	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	94	21	into	into	IN
cord-282507-swxs5pr1	94	22	single	single	JJ
cord-282507-swxs5pr1	94	23	formulations	formulation	NNS
cord-282507-swxs5pr1	94	24	,	,	,
cord-282507-swxs5pr1	94	25	such	such	JJ
cord-282507-swxs5pr1	94	26	as	as	IN
cord-282507-swxs5pr1	94	27	the	the	DT
cord-282507-swxs5pr1	94	28	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	94	29	systems	system	NNS
cord-282507-swxs5pr1	94	30	AS01	AS01	NNP
cord-282507-swxs5pr1	94	31	,	,	,
cord-282507-swxs5pr1	94	32	AS02	AS02	NNP
cord-282507-swxs5pr1	94	33	,	,	,
cord-282507-swxs5pr1	94	34	AS015	as015	NN
cord-282507-swxs5pr1	95	1	(	(	-LRB-
cord-282507-swxs5pr1	95	2	Garçon	Garçon	NNP
cord-282507-swxs5pr1	95	3	et	et	FW
cord-282507-swxs5pr1	95	4	al	al	NNP
cord-282507-swxs5pr1	95	5	.	.	NNP
cord-282507-swxs5pr1	95	6	,	,	,
cord-282507-swxs5pr1	95	7	2011	2011	CD
cord-282507-swxs5pr1	95	8	)	)	-RRB-
cord-282507-swxs5pr1	95	9	.	.	.
cord-282507-swxs5pr1	96	1	AS01	AS01	NNP
cord-282507-swxs5pr1	96	2	,	,	,
cord-282507-swxs5pr1	96	3	developed	develop	VBD
cord-282507-swxs5pr1	96	4	more	more	JJR
cord-282507-swxs5pr1	96	5	than	than	IN
cord-282507-swxs5pr1	96	6	20	20	CD
cord-282507-swxs5pr1	96	7	years	year	NNS
cord-282507-swxs5pr1	96	8	ago	ago	RB
cord-282507-swxs5pr1	96	9	,	,	,
cord-282507-swxs5pr1	96	10	is	be	VBZ
cord-282507-swxs5pr1	96	11	a	a	DT
cord-282507-swxs5pr1	96	12	liposome	liposome	NN
cord-282507-swxs5pr1	96	13	-	-	HYPH
cord-282507-swxs5pr1	96	14	based	base	VBN
cord-282507-swxs5pr1	96	15	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	96	16	comprising	comprise	VBG
cord-282507-swxs5pr1	96	17	two	two	CD
cord-282507-swxs5pr1	96	18	immunostimulants	immunostimulant	NNS
cord-282507-swxs5pr1	96	19	,	,	,
cord-282507-swxs5pr1	96	20	MPL	MPL	NNP
cord-282507-swxs5pr1	96	21	and	and	CC
cord-282507-swxs5pr1	96	22	QS-21	QS-21	NNP
cord-282507-swxs5pr1	96	23	.	.	.
cord-282507-swxs5pr1	96	24	Liposomes	liposome	NNS
cord-282507-swxs5pr1	96	25	are	be	VBP
cord-282507-swxs5pr1	96	26	synthetic	synthetic	JJ
cord-282507-swxs5pr1	96	27	nanospheres	nanosphere	NNS
cord-282507-swxs5pr1	96	28	consisting	consist	VBG
cord-282507-swxs5pr1	96	29	of	of	IN
cord-282507-swxs5pr1	96	30	phospholipid	phospholipid	NN
cord-282507-swxs5pr1	96	31	bilayers	bilayer	NNS
cord-282507-swxs5pr1	96	32	that	that	WDT
cord-282507-swxs5pr1	96	33	can	can	MD
cord-282507-swxs5pr1	96	34	encapsulate	encapsulate	VB
cord-282507-swxs5pr1	96	35	antigens	antigen	NNS
cord-282507-swxs5pr1	96	36	and	and	CC
cord-282507-swxs5pr1	96	37	act	act	VB
cord-282507-swxs5pr1	96	38	as	as	IN
cord-282507-swxs5pr1	96	39	antigen	antigen	NN
cord-282507-swxs5pr1	96	40	delivery	delivery	NN
cord-282507-swxs5pr1	96	41	vehicles	vehicle	NNS
cord-282507-swxs5pr1	96	42	(	(	-LRB-
cord-282507-swxs5pr1	96	43	Garçon	Garçon	NNP
cord-282507-swxs5pr1	96	44	et	et	FW
cord-282507-swxs5pr1	96	45	al	al	NNP
cord-282507-swxs5pr1	96	46	.	.	NNP
cord-282507-swxs5pr1	96	47	,	,	,
cord-282507-swxs5pr1	96	48	2011	2011	CD
cord-282507-swxs5pr1	96	49	)	)	-RRB-
cord-282507-swxs5pr1	96	50	.	.	.
cord-282507-swxs5pr1	97	1	MPL	MPL	NNP
cord-282507-swxs5pr1	97	2	is	be	VBZ
cord-282507-swxs5pr1	97	3	a	a	DT
cord-282507-swxs5pr1	97	4	detoxified	detoxify	VBN
cord-282507-swxs5pr1	97	5	synthetic	synthetic	JJ
cord-282507-swxs5pr1	97	6	derivative	derivative	NN
cord-282507-swxs5pr1	97	7	of	of	IN
cord-282507-swxs5pr1	97	8	the	the	DT
cord-282507-swxs5pr1	97	9	lipopolysaccharide	lipopolysaccharide	NN
cord-282507-swxs5pr1	97	10	(	(	-LRB-
cord-282507-swxs5pr1	97	11	LPS	LPS	NNP
cord-282507-swxs5pr1	97	12	)	)	-RRB-
cord-282507-swxs5pr1	97	13	from	from	IN
cord-282507-swxs5pr1	97	14	the	the	DT
cord-282507-swxs5pr1	97	15	bacteria	bacteria	NNS
cord-282507-swxs5pr1	97	16	Salmonella	Salmonella	NNP
cord-282507-swxs5pr1	97	17	minnesota	minnesota	NNP
cord-282507-swxs5pr1	97	18	and	and	CC
cord-282507-swxs5pr1	97	19	induces	induce	VBZ
cord-282507-swxs5pr1	97	20	activation	activation	NN
cord-282507-swxs5pr1	97	21	of	of	IN
cord-282507-swxs5pr1	97	22	innate	innate	JJ
cord-282507-swxs5pr1	97	23	immunity	immunity	NN
cord-282507-swxs5pr1	97	24	via	via	IN
cord-282507-swxs5pr1	97	25	TLR-4	TLR-4	NNP
cord-282507-swxs5pr1	97	26	,	,	,
cord-282507-swxs5pr1	97	27	stimulating	stimulate	VBG
cord-282507-swxs5pr1	97	28	NF	nf	NN
cord-282507-swxs5pr1	97	29	-	-	HYPH
cord-282507-swxs5pr1	97	30	kB	kb	CD
cord-282507-swxs5pr1	97	31	transcriptional	transcriptional	JJ
cord-282507-swxs5pr1	97	32	activity	activity	NN
cord-282507-swxs5pr1	97	33	.	.	.
cord-282507-swxs5pr1	98	1	It	-PRON-	PRP
cord-282507-swxs5pr1	98	2	stimulates	stimulate	VBZ
cord-282507-swxs5pr1	98	3	the	the	DT
cord-282507-swxs5pr1	98	4	induction	induction	NN
cord-282507-swxs5pr1	98	5	of	of	IN
cord-282507-swxs5pr1	98	6	Ag	Ag	NNP
cord-282507-swxs5pr1	98	7	-	-	HYPH
cord-282507-swxs5pr1	98	8	specific	specific	JJ
cord-282507-swxs5pr1	98	9	T	t	NN
cord-282507-swxs5pr1	98	10	cells	cell	NNS
cord-282507-swxs5pr1	98	11	producing	produce	VBG
cord-282507-swxs5pr1	98	12	interferon	interferon	NN
cord-282507-swxs5pr1	98	13	-	-	HYPH
cord-282507-swxs5pr1	98	14	γ	γ	NN
cord-282507-swxs5pr1	98	15	(	(	-LRB-
cord-282507-swxs5pr1	98	16	IFN	IFN	NNP
cord-282507-swxs5pr1	98	17	-	-	HYPH
cord-282507-swxs5pr1	98	18	γ	γ	NNP
cord-282507-swxs5pr1	98	19	)	)	-RRB-
cord-282507-swxs5pr1	98	20	and	and	CC
cord-282507-swxs5pr1	98	21	IgG2A	IgG2A	NNP
cord-282507-swxs5pr1	98	22	antibodies	antibody	NNS
cord-282507-swxs5pr1	98	23	.	.	.
cord-282507-swxs5pr1	99	1	QS-21	QS-21	NNP
cord-282507-swxs5pr1	99	2	from	from	IN
cord-282507-swxs5pr1	99	3	Q.	Q.	NNP
cord-282507-swxs5pr1	99	4	Saponaria	Saponaria	NNP
cord-282507-swxs5pr1	99	5	(	(	-LRB-
cord-282507-swxs5pr1	99	6	licensed	license	VBN
cord-282507-swxs5pr1	99	7	by	by	IN
cord-282507-swxs5pr1	99	8	GSK	GSK	NNP
cord-282507-swxs5pr1	99	9	from	from	IN
cord-282507-swxs5pr1	99	10	Antigenics	Antigenics	NNP
cord-282507-swxs5pr1	99	11	Inc.	Inc.	NNP
cord-282507-swxs5pr1	99	12	,	,	,
cord-282507-swxs5pr1	99	13	a	a	DT
cord-282507-swxs5pr1	99	14	wholly	wholly	RB
cord-282507-swxs5pr1	99	15	owned	own	VBN
cord-282507-swxs5pr1	99	16	subsidiary	subsidiary	NN
cord-282507-swxs5pr1	99	17	of	of	IN
cord-282507-swxs5pr1	99	18	Agenus	Agenus	NNP
cord-282507-swxs5pr1	99	19	Inc.	Inc.	NNP
cord-282507-swxs5pr1	99	20	,	,	,
cord-282507-swxs5pr1	99	21	Lexington	Lexington	NNP
cord-282507-swxs5pr1	99	22	,	,	,
cord-282507-swxs5pr1	99	23	MA	MA	NNP
cord-282507-swxs5pr1	99	24	,	,	,
cord-282507-swxs5pr1	99	25	USA	USA	NNP
cord-282507-swxs5pr1	99	26	)	)	-RRB-
cord-282507-swxs5pr1	99	27	in	in	IN
cord-282507-swxs5pr1	99	28	the	the	DT
cord-282507-swxs5pr1	99	29	early	early	JJ
cord-282507-swxs5pr1	99	30	evaluations	evaluation	NNS
cord-282507-swxs5pr1	99	31	as	as	IN
cord-282507-swxs5pr1	99	32	an	an	DT
cord-282507-swxs5pr1	99	33	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	99	34	was	be	VBD
cord-282507-swxs5pr1	99	35	suggested	suggest	VBN
cord-282507-swxs5pr1	99	36	to	to	TO
cord-282507-swxs5pr1	99	37	promote	promote	VB
cord-282507-swxs5pr1	99	38	high	high	JJ
cord-282507-swxs5pr1	99	39	Agspecific	Agspecific	NNP
cord-282507-swxs5pr1	99	40	Ab	Ab	NNP
cord-282507-swxs5pr1	99	41	responses	response	NNS
cord-282507-swxs5pr1	99	42	and	and	CC
cord-282507-swxs5pr1	99	43	CD8	CD8	NNP
cord-282507-swxs5pr1	99	44	+	+	CC
cord-282507-swxs5pr1	99	45	T	T	NNP
cord-282507-swxs5pr1	99	46	cell	cell	NN
cord-282507-swxs5pr1	99	47	responses	response	NNS
cord-282507-swxs5pr1	99	48	in	in	IN
cord-282507-swxs5pr1	99	49	mice	mouse	NNS
cord-282507-swxs5pr1	99	50	and	and	CC
cord-282507-swxs5pr1	99	51	high	high	JJ
cord-282507-swxs5pr1	99	52	Agspecific	Agspecific	NNP
cord-282507-swxs5pr1	99	53	Ab	Ab	NNP
cord-282507-swxs5pr1	99	54	responses	response	NNS
cord-282507-swxs5pr1	99	55	in	in	IN
cord-282507-swxs5pr1	99	56	humans	human	NNS
cord-282507-swxs5pr1	100	1	(	(	-LRB-
cord-282507-swxs5pr1	100	2	Didierlaurent	Didierlaurent	NNP
cord-282507-swxs5pr1	100	3	et	et	NNP
cord-282507-swxs5pr1	100	4	al	al	NNP
cord-282507-swxs5pr1	100	5	.	.	.
cord-282507-swxs5pr1	101	1	,	,	,
cord-282507-swxs5pr1	101	2	2014	2014	CD
cord-282507-swxs5pr1	101	3	)	)	-RRB-
cord-282507-swxs5pr1	101	4	.	.	.
cord-282507-swxs5pr1	102	1	QS-21	QS-21	NNP
cord-282507-swxs5pr1	102	2	,	,	,
cord-282507-swxs5pr1	102	3	as	as	IN
cord-282507-swxs5pr1	102	4	an	an	DT
cord-282507-swxs5pr1	102	5	amphiphilic	amphiphilic	JJ
cord-282507-swxs5pr1	102	6	compound	compound	NN
cord-282507-swxs5pr1	102	7	is	be	VBZ
cord-282507-swxs5pr1	102	8	known	know	VBN
cord-282507-swxs5pr1	102	9	for	for	IN
cord-282507-swxs5pr1	102	10	its	-PRON-	PRP$
cord-282507-swxs5pr1	102	11	hemolytic	hemolytic	JJ
cord-282507-swxs5pr1	102	12	properties	property	NNS
cord-282507-swxs5pr1	102	13	,	,	,
cord-282507-swxs5pr1	102	14	which	which	WDT
cord-282507-swxs5pr1	102	15	can	can	MD
cord-282507-swxs5pr1	102	16	be	be	VB
cord-282507-swxs5pr1	102	17	abrogated	abrogate	VBN
cord-282507-swxs5pr1	102	18	through	through	IN
cord-282507-swxs5pr1	102	19	formulation	formulation	NN
cord-282507-swxs5pr1	102	20	in	in	IN
cord-282507-swxs5pr1	102	21	liposomes	liposome	NNS
cord-282507-swxs5pr1	102	22	in	in	IN
cord-282507-swxs5pr1	102	23	the	the	DT
cord-282507-swxs5pr1	102	24	presence	presence	NN
cord-282507-swxs5pr1	102	25	of	of	IN
cord-282507-swxs5pr1	102	26	cholesterol	cholesterol	NN
cord-282507-swxs5pr1	102	27	such	such	JJ
cord-282507-swxs5pr1	102	28	as	as	IN
cord-282507-swxs5pr1	102	29	in	in	IN
cord-282507-swxs5pr1	102	30	AS01	AS01	NNP
cord-282507-swxs5pr1	102	31	(	(	-LRB-
cord-282507-swxs5pr1	102	32	Beck	Beck	NNP
cord-282507-swxs5pr1	102	33	et	et	NNP
cord-282507-swxs5pr1	102	34	al	al	NNP
cord-282507-swxs5pr1	102	35	.	.	NNP
cord-282507-swxs5pr1	102	36	,	,	,
cord-282507-swxs5pr1	102	37	2015	2015	CD
cord-282507-swxs5pr1	102	38	;	;	:
cord-282507-swxs5pr1	102	39	Garçon	Garçon	NNP
cord-282507-swxs5pr1	102	40	and	and	CC
cord-282507-swxs5pr1	102	41	Di	Di	NNP
cord-282507-swxs5pr1	102	42	Pasquale	Pasquale	NNP
cord-282507-swxs5pr1	102	43	,	,	,
cord-282507-swxs5pr1	102	44	2017	2017	CD
cord-282507-swxs5pr1	102	45	)	)	-RRB-
cord-282507-swxs5pr1	102	46	.	.	.
cord-282507-swxs5pr1	103	1	This	this	DT
cord-282507-swxs5pr1	103	2	resulted	result	VBD
cord-282507-swxs5pr1	103	3	in	in	IN
cord-282507-swxs5pr1	103	4	an	an	DT
cord-282507-swxs5pr1	103	5	acceptable	acceptable	JJ
cord-282507-swxs5pr1	103	6	tolerability	tolerability	NN
cord-282507-swxs5pr1	103	7	profile	profile	NN
cord-282507-swxs5pr1	103	8	for	for	IN
cord-282507-swxs5pr1	103	9	its	-PRON-	PRP$
cord-282507-swxs5pr1	103	10	use	use	NN
cord-282507-swxs5pr1	103	11	in	in	IN
cord-282507-swxs5pr1	103	12	human	human	JJ
cord-282507-swxs5pr1	103	13	vaccines	vaccine	NNS
cord-282507-swxs5pr1	103	14	.	.	.
cord-282507-swxs5pr1	104	1	AS02	AS02	NNP
cord-282507-swxs5pr1	104	2	contains	contain	VBZ
cord-282507-swxs5pr1	104	3	MPL	MPL	NNP
cord-282507-swxs5pr1	104	4	/	/	SYM
cord-282507-swxs5pr1	104	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	104	6	in	in	IN
cord-282507-swxs5pr1	104	7	an	an	DT
cord-282507-swxs5pr1	104	8	oil	oil	NN
cord-282507-swxs5pr1	104	9	-	-	HYPH
cord-282507-swxs5pr1	104	10	in	in	IN
cord-282507-swxs5pr1	104	11	-	-	HYPH
cord-282507-swxs5pr1	104	12	water	water	NN
cord-282507-swxs5pr1	104	13	emulsion	emulsion	NN
cord-282507-swxs5pr1	104	14	.	.	.
cord-282507-swxs5pr1	105	1	AS015	as015	JJ
cord-282507-swxs5pr1	105	2	,	,	,
cord-282507-swxs5pr1	105	3	combining	combine	VBG
cord-282507-swxs5pr1	105	4	QS-21	QS-21	NNP
cord-282507-swxs5pr1	105	5	,	,	,
cord-282507-swxs5pr1	105	6	MPL	MPL	NNP
cord-282507-swxs5pr1	105	7	,	,	,
cord-282507-swxs5pr1	105	8	and	and	CC
cord-282507-swxs5pr1	105	9	CpG	CpG	NNP
cord-282507-swxs5pr1	105	10	7909	7909	CD
cord-282507-swxs5pr1	105	11	(	(	-LRB-
cord-282507-swxs5pr1	105	12	an	an	DT
cord-282507-swxs5pr1	105	13	oligodesoxynucleotide	oligodesoxynucleotide	NN
cord-282507-swxs5pr1	105	14	and	and	CC
cord-282507-swxs5pr1	105	15	TLR-9	TLR-9	NNP
cord-282507-swxs5pr1	105	16	agonist	agonist	NN
cord-282507-swxs5pr1	105	17	)	)	-RRB-
cord-282507-swxs5pr1	105	18	,	,	,
cord-282507-swxs5pr1	105	19	in	in	IN
cord-282507-swxs5pr1	105	20	a	a	DT
cord-282507-swxs5pr1	105	21	liposome	liposome	NN
cord-282507-swxs5pr1	105	22	is	be	VBZ
cord-282507-swxs5pr1	105	23	the	the	DT
cord-282507-swxs5pr1	105	24	most	most	RBS
cord-282507-swxs5pr1	105	25	complex	complex	JJ
cord-282507-swxs5pr1	105	26	combination	combination	NN
cord-282507-swxs5pr1	105	27	of	of	IN
cord-282507-swxs5pr1	105	28	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	105	29	which	which	WDT
cord-282507-swxs5pr1	105	30	has	have	VBZ
cord-282507-swxs5pr1	105	31	been	be	VBN
cord-282507-swxs5pr1	105	32	used	use	VBN
cord-282507-swxs5pr1	105	33	for	for	IN
cord-282507-swxs5pr1	105	34	applications	application	NNS
cord-282507-swxs5pr1	105	35	in	in	IN
cord-282507-swxs5pr1	105	36	cancer	cancer	NN
cord-282507-swxs5pr1	105	37	immunotherapy	immunotherapy	NN
cord-282507-swxs5pr1	105	38	.	.	.
cord-282507-swxs5pr1	106	1	The	the	DT
cord-282507-swxs5pr1	106	2	mechanism	mechanism	NN
cord-282507-swxs5pr1	106	3	of	of	IN
cord-282507-swxs5pr1	106	4	action	action	NN
cord-282507-swxs5pr1	106	5	of	of	IN
cord-282507-swxs5pr1	106	6	QS-21	QS-21	NNP
cord-282507-swxs5pr1	106	7	in	in	IN
cord-282507-swxs5pr1	106	8	a	a	DT
cord-282507-swxs5pr1	106	9	liposome	liposome	NN
cord-282507-swxs5pr1	106	10	is	be	VBZ
cord-282507-swxs5pr1	106	11	poorly	poorly	RB
cord-282507-swxs5pr1	106	12	understood	understand	VBN
cord-282507-swxs5pr1	106	13	despite	despite	IN
cord-282507-swxs5pr1	106	14	the	the	DT
cord-282507-swxs5pr1	106	15	clinical	clinical	JJ
cord-282507-swxs5pr1	106	16	efficacy	efficacy	NN
cord-282507-swxs5pr1	106	17	of	of	IN
cord-282507-swxs5pr1	106	18	AS01	AS01	NNP
cord-282507-swxs5pr1	106	19	.	.	.
cord-282507-swxs5pr1	107	1	Therefore	therefore	RB
cord-282507-swxs5pr1	107	2	,	,	,
cord-282507-swxs5pr1	107	3	some	some	DT
cord-282507-swxs5pr1	107	4	studies	study	NNS
cord-282507-swxs5pr1	107	5	were	be	VBD
cord-282507-swxs5pr1	107	6	carried	carry	VBN
cord-282507-swxs5pr1	107	7	out	out	RP
cord-282507-swxs5pr1	107	8	in	in	IN
cord-282507-swxs5pr1	107	9	order	order	NN
cord-282507-swxs5pr1	107	10	to	to	TO
cord-282507-swxs5pr1	107	11	tentatively	tentatively	RB
cord-282507-swxs5pr1	107	12	elucidate	elucidate	VB
cord-282507-swxs5pr1	107	13	the	the	DT
cord-282507-swxs5pr1	107	14	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	107	15	effect	effect	NN
cord-282507-swxs5pr1	107	16	of	of	IN
cord-282507-swxs5pr1	107	17	QS-21	QS-21	NNP
cord-282507-swxs5pr1	107	18	in	in	IN
cord-282507-swxs5pr1	107	19	such	such	PDT
cord-282507-swxs5pr1	107	20	a	a	DT
cord-282507-swxs5pr1	107	21	formulation	formulation	NN
cord-282507-swxs5pr1	107	22	.	.	.
cord-282507-swxs5pr1	108	1	It	-PRON-	PRP
cord-282507-swxs5pr1	108	2	was	be	VBD
cord-282507-swxs5pr1	108	3	observed	observe	VBN
cord-282507-swxs5pr1	108	4	after	after	IN
cord-282507-swxs5pr1	108	5	an	an	DT
cord-282507-swxs5pr1	108	6	intramuscular	intramuscular	NN
cord-282507-swxs5pr1	108	7	(	(	-LRB-
cord-282507-swxs5pr1	108	8	i	-PRON-	PRP
cord-282507-swxs5pr1	108	9	m	be	VBP
cord-282507-swxs5pr1	108	10	)	)	-RRB-
cord-282507-swxs5pr1	108	11	immunization	immunization	NN
cord-282507-swxs5pr1	108	12	in	in	IN
cord-282507-swxs5pr1	108	13	mice	mouse	NNS
cord-282507-swxs5pr1	108	14	against	against	IN
cord-282507-swxs5pr1	108	15	two	two	CD
cord-282507-swxs5pr1	108	16	model	model	NN
cord-282507-swxs5pr1	108	17	antigens	antigen	NNS
cord-282507-swxs5pr1	108	18	,	,	,
cord-282507-swxs5pr1	108	19	Hepatitis	Hepatitis	NNP
cord-282507-swxs5pr1	108	20	B	B	NNP
cord-282507-swxs5pr1	108	21	surface	surface	NN
cord-282507-swxs5pr1	108	22	antigen	antigen	NN
cord-282507-swxs5pr1	108	23	(	(	-LRB-
cord-282507-swxs5pr1	108	24	HBsAg	hbsag	ADD
cord-282507-swxs5pr1	108	25	)	)	-RRB-
cord-282507-swxs5pr1	108	26	and	and	CC
cord-282507-swxs5pr1	108	27	OVA	OVA	NNP
cord-282507-swxs5pr1	108	28	that	that	IN
cord-282507-swxs5pr1	108	29	QS-21	QS-21	NNP
cord-282507-swxs5pr1	108	30	,	,	,
cord-282507-swxs5pr1	108	31	rapidly	rapidly	RB
cord-282507-swxs5pr1	108	32	accumulated	accumulate	VBN
cord-282507-swxs5pr1	108	33	in	in	IN
cord-282507-swxs5pr1	108	34	CD169	CD169	NNP
cord-282507-swxs5pr1	108	35	+	+	CC
cord-282507-swxs5pr1	108	36	resident	resident	JJ
cord-282507-swxs5pr1	108	37	macrophages	macrophage	NNS
cord-282507-swxs5pr1	108	38	of	of	IN
cord-282507-swxs5pr1	108	39	the	the	DT
cord-282507-swxs5pr1	108	40	dLN	dln	NN
cord-282507-swxs5pr1	108	41	,	,	,
cord-282507-swxs5pr1	108	42	where	where	WRB
cord-282507-swxs5pr1	108	43	it	-PRON-	PRP
cord-282507-swxs5pr1	108	44	induces	induce	VBZ
cord-282507-swxs5pr1	108	45	caspase-1	caspase-1	NNP
cord-282507-swxs5pr1	108	46	activation	activation	NN
cord-282507-swxs5pr1	108	47	.	.	.
cord-282507-swxs5pr1	109	1	These	these	DT
cord-282507-swxs5pr1	109	2	early	early	JJ
cord-282507-swxs5pr1	109	3	events	event	NNS
cord-282507-swxs5pr1	109	4	then	then	RB
cord-282507-swxs5pr1	109	5	organized	organize	VBD
cord-282507-swxs5pr1	109	6	the	the	DT
cord-282507-swxs5pr1	109	7	recruitment	recruitment	NN
cord-282507-swxs5pr1	109	8	of	of	IN
cord-282507-swxs5pr1	109	9	innate	innate	JJ
cord-282507-swxs5pr1	109	10	immune	immune	JJ
cord-282507-swxs5pr1	109	11	cells	cell	NNS
cord-282507-swxs5pr1	109	12	and	and	CC
cord-282507-swxs5pr1	109	13	activation	activation	NN
cord-282507-swxs5pr1	109	14	of	of	IN
cord-282507-swxs5pr1	109	15	DCs	DCs	NNP
cord-282507-swxs5pr1	109	16	and	and	CC
cord-282507-swxs5pr1	109	17	subsequent	subsequent	JJ
cord-282507-swxs5pr1	109	18	T	T	NNP
cord-282507-swxs5pr1	109	19	cell	cell	NN
cord-282507-swxs5pr1	109	20	priming	priming	NN
cord-282507-swxs5pr1	109	21	.	.	.
cord-282507-swxs5pr1	110	1	Further	further	JJ
cord-282507-swxs5pr1	110	2	analysis	analysis	NN
cord-282507-swxs5pr1	110	3	showed	show	VBD
cord-282507-swxs5pr1	110	4	that	that	IN
cord-282507-swxs5pr1	110	5	the	the	DT
cord-282507-swxs5pr1	110	6	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	110	7	effect	effect	NN
cord-282507-swxs5pr1	110	8	of	of	IN
cord-282507-swxs5pr1	110	9	QS-21	QS-21	NNP
cord-282507-swxs5pr1	110	10	depended	depend	VBD
cord-282507-swxs5pr1	110	11	on	on	IN
cord-282507-swxs5pr1	110	12	the	the	DT
cord-282507-swxs5pr1	110	13	integration	integration	NN
cord-282507-swxs5pr1	110	14	of	of	IN
cord-282507-swxs5pr1	110	15	caspase-1	caspase-1	NNP
cord-282507-swxs5pr1	110	16	and	and	CC
cord-282507-swxs5pr1	110	17	MyD88	myd88	JJ
cord-282507-swxs5pr1	110	18	pathways	pathway	NNS
cord-282507-swxs5pr1	110	19	at	at	IN
cord-282507-swxs5pr1	110	20	least	least	JJS
cord-282507-swxs5pr1	110	21	in	in	IN
cord-282507-swxs5pr1	110	22	part	part	NN
cord-282507-swxs5pr1	110	23	through	through	IN
cord-282507-swxs5pr1	110	24	local	local	JJ
cord-282507-swxs5pr1	110	25	release	release	NN
cord-282507-swxs5pr1	110	26	of	of	IN
cord-282507-swxs5pr1	110	27	HMGB1	HMGB1	NNP
cord-282507-swxs5pr1	110	28	(	(	-LRB-
cord-282507-swxs5pr1	110	29	High	High	NNP
cord-282507-swxs5pr1	110	30	-	-	HYPH
cord-282507-swxs5pr1	110	31	Mobility	Mobility	NNP
cord-282507-swxs5pr1	110	32	-	-	HYPH
cord-282507-swxs5pr1	110	33	Group	Group	NNP
cord-282507-swxs5pr1	110	34	protein	protein	NN
cord-282507-swxs5pr1	110	35	B1	b1	NN
cord-282507-swxs5pr1	110	36	)	)	-RRB-
cord-282507-swxs5pr1	111	1	(	(	-LRB-
cord-282507-swxs5pr1	111	2	Detienne	Detienne	NNP
cord-282507-swxs5pr1	111	3	et	et	NNP
cord-282507-swxs5pr1	111	4	al	al	NNP
cord-282507-swxs5pr1	111	5	.	.	NNP
cord-282507-swxs5pr1	111	6	,	,	,
cord-282507-swxs5pr1	111	7	2016	2016	CD
cord-282507-swxs5pr1	111	8	)	)	-RRB-
cord-282507-swxs5pr1	111	9	.	.	.
cord-282507-swxs5pr1	112	1	A	a	DT
cord-282507-swxs5pr1	112	2	recent	recent	JJ
cord-282507-swxs5pr1	112	3	study	study	NN
cord-282507-swxs5pr1	112	4	reported	report	VBD
cord-282507-swxs5pr1	112	5	that	that	IN
cord-282507-swxs5pr1	112	6	QS-21	QS-21	NNP
cord-282507-swxs5pr1	112	7	directly	directly	RB
cord-282507-swxs5pr1	112	8	activated	activate	VBD
cord-282507-swxs5pr1	112	9	human	human	JJ
cord-282507-swxs5pr1	112	10	monocyte	monocyte	NNP
cord-282507-swxs5pr1	112	11	-	-	HYPH
cord-282507-swxs5pr1	112	12	derived	derive	VBN
cord-282507-swxs5pr1	112	13	dendritic	dendritic	JJ
cord-282507-swxs5pr1	112	14	cells	cell	NNS
cord-282507-swxs5pr1	112	15	(	(	-LRB-
cord-282507-swxs5pr1	112	16	mo	mo	NNP
cord-282507-swxs5pr1	112	17	-	-	HYPH
cord-282507-swxs5pr1	112	18	DCs	DCs	NNP
cord-282507-swxs5pr1	112	19	)	)	-RRB-
cord-282507-swxs5pr1	112	20	and	and	CC
cord-282507-swxs5pr1	112	21	promoted	promote	VBD
cord-282507-swxs5pr1	112	22	a	a	DT
cord-282507-swxs5pr1	112	23	pro	pro	JJ
cord-282507-swxs5pr1	112	24	-	-	JJ
cord-282507-swxs5pr1	112	25	inflammatory	inflammatory	JJ
cord-282507-swxs5pr1	112	26	transcriptional	transcriptional	JJ
cord-282507-swxs5pr1	112	27	program	program	NN
cord-282507-swxs5pr1	112	28	.	.	.
cord-282507-swxs5pr1	113	1	In	in	IN
cord-282507-swxs5pr1	113	2	this	this	DT
cord-282507-swxs5pr1	113	3	model	model	NN
cord-282507-swxs5pr1	113	4	,	,	,
cord-282507-swxs5pr1	113	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	113	6	was	be	VBD
cord-282507-swxs5pr1	113	7	endocytosed	endocytose	VBN
cord-282507-swxs5pr1	113	8	via	via	IN
cord-282507-swxs5pr1	113	9	a	a	DT
cord-282507-swxs5pr1	113	10	cholesterol	cholesterol	NN
cord-282507-swxs5pr1	113	11	-	-	HYPH
cord-282507-swxs5pr1	113	12	dependent	dependent	JJ
cord-282507-swxs5pr1	113	13	mechanism	mechanism	NN
cord-282507-swxs5pr1	113	14	and	and	CC
cord-282507-swxs5pr1	113	15	accumulated	accumulate	VBN
cord-282507-swxs5pr1	113	16	in	in	IN
cord-282507-swxs5pr1	113	17	lysosomes	lysosome	NNS
cord-282507-swxs5pr1	113	18	where	where	WRB
cord-282507-swxs5pr1	113	19	it	-PRON-	PRP
cord-282507-swxs5pr1	113	20	induces	induce	VBZ
cord-282507-swxs5pr1	113	21	their	-PRON-	PRP$
cord-282507-swxs5pr1	113	22	destabilization	destabilization	NN
cord-282507-swxs5pr1	113	23	through	through	IN
cord-282507-swxs5pr1	113	24	pore	pore	NN
cord-282507-swxs5pr1	113	25	formation	formation	NN
cord-282507-swxs5pr1	113	26	and	and	CC
cord-282507-swxs5pr1	113	27	potential	potential	JJ
cord-282507-swxs5pr1	113	28	release	release	NN
cord-282507-swxs5pr1	113	29	of	of	IN
cord-282507-swxs5pr1	113	30	their	-PRON-	PRP$
cord-282507-swxs5pr1	113	31	contents	content	NNS
cord-282507-swxs5pr1	113	32	.	.	.
cord-282507-swxs5pr1	114	1	This	this	DT
cord-282507-swxs5pr1	114	2	resulted	result	VBD
cord-282507-swxs5pr1	114	3	in	in	IN
cord-282507-swxs5pr1	114	4	inflammasome	inflammasome	NN
cord-282507-swxs5pr1	114	5	activation	activation	NN
cord-282507-swxs5pr1	114	6	,	,	,
cord-282507-swxs5pr1	114	7	Syk-(a	Syk-(a	NNP
cord-282507-swxs5pr1	114	8	tyrosine	tyrosine	NN
cord-282507-swxs5pr1	114	9	kinase	kinase	NN
cord-282507-swxs5pr1	114	10	)	)	-RRB-
cord-282507-swxs5pr1	114	11	and	and	CC
cord-282507-swxs5pr1	114	12	cathepsin	cathepsin	NN
cord-282507-swxs5pr1	114	13	-	-	HYPH
cord-282507-swxs5pr1	114	14	B	b	NN
cord-282507-swxs5pr1	114	15	(	(	-LRB-
cord-282507-swxs5pr1	114	16	a	a	DT
cord-282507-swxs5pr1	114	17	cysteine	cysteine	NN
cord-282507-swxs5pr1	114	18	protease	protease	NN
cord-282507-swxs5pr1	114	19	)	)	-RRB-
cord-282507-swxs5pr1	114	20	dependent	dependent	JJ
cord-282507-swxs5pr1	114	21	cell	cell	NN
cord-282507-swxs5pr1	114	22	activation	activation	NN
cord-282507-swxs5pr1	114	23	and	and	CC
cord-282507-swxs5pr1	114	24	cytokine	cytokine	NN
cord-282507-swxs5pr1	114	25	production	production	NN
cord-282507-swxs5pr1	114	26	in	in	IN
cord-282507-swxs5pr1	114	27	mo	mo	NNP
cord-282507-swxs5pr1	114	28	-	-	HYPH
cord-282507-swxs5pr1	114	29	DCs	DCs	NNP
cord-282507-swxs5pr1	114	30	.	.	.
cord-282507-swxs5pr1	115	1	Lysosomal	Lysosomal	NNP
cord-282507-swxs5pr1	115	2	disruption	disruption	NN
cord-282507-swxs5pr1	115	3	could	could	MD
cord-282507-swxs5pr1	115	4	also	also	RB
cord-282507-swxs5pr1	115	5	affect	affect	VB
cord-282507-swxs5pr1	115	6	Ag	Ag	NNP
cord-282507-swxs5pr1	115	7	processing	processing	NN
cord-282507-swxs5pr1	115	8	and	and	CC
cord-282507-swxs5pr1	115	9	translocation	translocation	NN
cord-282507-swxs5pr1	115	10	to	to	IN
cord-282507-swxs5pr1	115	11	the	the	DT
cord-282507-swxs5pr1	115	12	cytosol	cytosol	NN
cord-282507-swxs5pr1	115	13	for	for	IN
cord-282507-swxs5pr1	115	14	presentation	presentation	NN
cord-282507-swxs5pr1	115	15	on	on	IN
cord-282507-swxs5pr1	115	16	MHCs	mhc	NNS
cord-282507-swxs5pr1	115	17	.	.	.
cord-282507-swxs5pr1	116	1	Finally	finally	RB
cord-282507-swxs5pr1	116	2	it	-PRON-	PRP
cord-282507-swxs5pr1	116	3	was	be	VBD
cord-282507-swxs5pr1	116	4	shown	show	VBN
cord-282507-swxs5pr1	116	5	that	that	DT
cord-282507-swxs5pr1	116	6	cathepsin	cathepsin	NN
cord-282507-swxs5pr1	116	7	B	b	NN
cord-282507-swxs5pr1	116	8	contributes	contribute	VBZ
cord-282507-swxs5pr1	116	9	to	to	IN
cord-282507-swxs5pr1	116	10	the	the	DT
cord-282507-swxs5pr1	116	11	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	116	12	properties	property	NNS
cord-282507-swxs5pr1	116	13	of	of	IN
cord-282507-swxs5pr1	116	14	QS-21	QS-21	NNP
cord-282507-swxs5pr1	116	15	on	on	IN
cord-282507-swxs5pr1	116	16	both	both	CC
cord-282507-swxs5pr1	116	17	CD4	CD4	NNP
cord-282507-swxs5pr1	116	18	+	+	CC
cord-282507-swxs5pr1	116	19	and	and	CC
cord-282507-swxs5pr1	116	20	CD8	CD8	NNP
cord-282507-swxs5pr1	116	21	+	+	CC
cord-282507-swxs5pr1	116	22	Ag	Ag	NNP
cord-282507-swxs5pr1	116	23	-	-	HYPH
cord-282507-swxs5pr1	116	24	specific	specific	JJ
cord-282507-swxs5pr1	116	25	T	t	NN
cord-282507-swxs5pr1	116	26	-	-	HYPH
cord-282507-swxs5pr1	116	27	cell	cell	NN
cord-282507-swxs5pr1	116	28	responses	response	NNS
cord-282507-swxs5pr1	116	29	in	in	IN
cord-282507-swxs5pr1	116	30	vivo	vivo	NN
cord-282507-swxs5pr1	116	31	.	.	.
cord-282507-swxs5pr1	117	1	The	the	DT
cord-282507-swxs5pr1	117	2	Adjuvant	Adjuvant	NNP
cord-282507-swxs5pr1	117	3	Systems	Systems	NNPS
cord-282507-swxs5pr1	117	4	containing	contain	VBG
cord-282507-swxs5pr1	117	5	MPL	MPL	NNP
cord-282507-swxs5pr1	117	6	/	/	SYM
cord-282507-swxs5pr1	117	7	QS21	QS21	NNP
cord-282507-swxs5pr1	117	8	in	in	IN
cord-282507-swxs5pr1	117	9	combination	combination	NN
cord-282507-swxs5pr1	117	10	with	with	IN
cord-282507-swxs5pr1	117	11	HBsAg	HBsAg	NNP
cord-282507-swxs5pr1	117	12	were	be	VBD
cord-282507-swxs5pr1	117	13	shown	show	VBN
cord-282507-swxs5pr1	117	14	to	to	TO
cord-282507-swxs5pr1	117	15	induce	induce	VB
cord-282507-swxs5pr1	117	16	very	very	RB
cord-282507-swxs5pr1	117	17	strong	strong	JJ
cord-282507-swxs5pr1	117	18	and	and	CC
cord-282507-swxs5pr1	117	19	persistent	persistent	JJ
cord-282507-swxs5pr1	117	20	humoral	humoral	JJ
cord-282507-swxs5pr1	117	21	and	and	CC
cord-282507-swxs5pr1	117	22	cellular	cellular	JJ
cord-282507-swxs5pr1	117	23	immune	immune	JJ
cord-282507-swxs5pr1	117	24	responses	response	NNS
cord-282507-swxs5pr1	117	25	in	in	IN
cord-282507-swxs5pr1	117	26	healthy	healthy	JJ
cord-282507-swxs5pr1	117	27	adults	adult	NNS
cord-282507-swxs5pr1	117	28	,	,	,
cord-282507-swxs5pr1	117	29	AS01	AS01	NNP
cord-282507-swxs5pr1	117	30	B	B	NNP
cord-282507-swxs5pr1	117	31	inducing	induce	VBG
cord-282507-swxs5pr1	117	32	the	the	DT
cord-282507-swxs5pr1	117	33	strongest	strong	JJS
cord-282507-swxs5pr1	117	34	and	and	CC
cord-282507-swxs5pr1	117	35	most	most	RBS
cord-282507-swxs5pr1	117	36	durable	durable	JJ
cord-282507-swxs5pr1	117	37	specific	specific	JJ
cord-282507-swxs5pr1	117	38	CMI	CMI	NNP
cord-282507-swxs5pr1	117	39	after	after	IN
cord-282507-swxs5pr1	117	40	two	two	CD
cord-282507-swxs5pr1	117	41	doses	dose	NNS
cord-282507-swxs5pr1	117	42	,	,	,
cord-282507-swxs5pr1	117	43	without	without	IN
cord-282507-swxs5pr1	117	44	serious	serious	JJ
cord-282507-swxs5pr1	117	45	adverse	adverse	JJ
cord-282507-swxs5pr1	117	46	events	event	NNS
cord-282507-swxs5pr1	117	47	.	.	.
cord-282507-swxs5pr1	118	1	The	the	DT
cord-282507-swxs5pr1	118	2	CD4	CD4	NNP
cord-282507-swxs5pr1	118	3	+	+	CC
cord-282507-swxs5pr1	118	4	response	response	NN
cord-282507-swxs5pr1	118	5	was	be	VBD
cord-282507-swxs5pr1	118	6	characterized	characterize	VBN
cord-282507-swxs5pr1	118	7	in	in	IN
cord-282507-swxs5pr1	118	8	vitro	vitro	FW
cord-282507-swxs5pr1	118	9	by	by	IN
cord-282507-swxs5pr1	118	10	high	high	JJ
cord-282507-swxs5pr1	118	11	lymphoproliferation	lymphoproliferation	NN
cord-282507-swxs5pr1	118	12	,	,	,
cord-282507-swxs5pr1	118	13	high	high	JJ
cord-282507-swxs5pr1	118	14	IFN	IFN	NNP
cord-282507-swxs5pr1	118	15	-	-	HYPH
cord-282507-swxs5pr1	118	16	γ	γ	NNP
cord-282507-swxs5pr1	118	17	and	and	CC
cord-282507-swxs5pr1	118	18	moderate	moderate	JJ
cord-282507-swxs5pr1	118	19	Il-5	il-5	JJ
cord-282507-swxs5pr1	118	20	production	production	NN
cord-282507-swxs5pr1	118	21	.	.	.
cord-282507-swxs5pr1	119	1	This	this	DT
cord-282507-swxs5pr1	119	2	response	response	NN
cord-282507-swxs5pr1	119	3	was	be	VBD
cord-282507-swxs5pr1	119	4	confirmed	confirm	VBN
cord-282507-swxs5pr1	119	5	ex	ex	FW
cord-282507-swxs5pr1	119	6	vivo	vivo	NN
cord-282507-swxs5pr1	119	7	by	by	IN
cord-282507-swxs5pr1	119	8	detection	detection	NN
cord-282507-swxs5pr1	119	9	of	of	IN
cord-282507-swxs5pr1	119	10	Il-2	Il-2	NNP
cord-282507-swxs5pr1	119	11	and	and	CC
cord-282507-swxs5pr1	119	12	IFN	IFN	NNP
cord-282507-swxs5pr1	119	13	-	-	HYPH
cord-282507-swxs5pr1	119	14	γ	γ	NNP
cord-282507-swxs5pr1	119	15	producing	produce	VBG
cord-282507-swxs5pr1	119	16	CD4	CD4	NNP
cord-282507-swxs5pr1	119	17	+	+	CC
cord-282507-swxs5pr1	119	18	T	t	NN
cord-282507-swxs5pr1	119	19	cells	cell	NNS
cord-282507-swxs5pr1	119	20	and	and	CC
cord-282507-swxs5pr1	119	21	in	in	IN
cord-282507-swxs5pr1	119	22	vivo	vivo	NN
cord-282507-swxs5pr1	119	23	by	by	IN
cord-282507-swxs5pr1	119	24	measuring	measure	VBG
cord-282507-swxs5pr1	119	25	increased	increase	VBN
cord-282507-swxs5pr1	119	26	levels	level	NNS
cord-282507-swxs5pr1	119	27	of	of	IN
cord-282507-swxs5pr1	119	28	IFN	IFN	NNP
cord-282507-swxs5pr1	119	29	-	-	HYPH
cord-282507-swxs5pr1	119	30	γ	γ	NNP
cord-282507-swxs5pr1	119	31	in	in	IN
cord-282507-swxs5pr1	119	32	the	the	DT
cord-282507-swxs5pr1	119	33	serum	serum	NN
cord-282507-swxs5pr1	119	34	(	(	-LRB-
cord-282507-swxs5pr1	119	35	Vandepapelière	Vandepapelière	NNP
cord-282507-swxs5pr1	119	36	et	et	NNP
cord-282507-swxs5pr1	119	37	al	al	NNP
cord-282507-swxs5pr1	119	38	.	.	NNP
cord-282507-swxs5pr1	119	39	,	,	,
cord-282507-swxs5pr1	119	40	2008	2008	CD
cord-282507-swxs5pr1	119	41	)	)	-RRB-
cord-282507-swxs5pr1	119	42	.	.	.
cord-282507-swxs5pr1	120	1	Therefore	therefore	RB
cord-282507-swxs5pr1	120	2	AS01	AS01	NNP
cord-282507-swxs5pr1	120	3	B	B	NNP
cord-282507-swxs5pr1	120	4	has	have	VBZ
cord-282507-swxs5pr1	120	5	been	be	VBN
cord-282507-swxs5pr1	120	6	selected	select	VBN
cord-282507-swxs5pr1	120	7	as	as	IN
cord-282507-swxs5pr1	120	8	lead	lead	NN
cord-282507-swxs5pr1	120	9	AS	as	IN
cord-282507-swxs5pr1	120	10	for	for	IN
cord-282507-swxs5pr1	120	11	the	the	DT
cord-282507-swxs5pr1	120	12	development	development	NN
cord-282507-swxs5pr1	120	13	of	of	IN
cord-282507-swxs5pr1	120	14	vaccines	vaccine	NNS
cord-282507-swxs5pr1	120	15	.	.	.
cord-282507-swxs5pr1	121	1	Experiments	experiment	NNS
cord-282507-swxs5pr1	121	2	were	be	VBD
cord-282507-swxs5pr1	121	3	conducted	conduct	VBN
cord-282507-swxs5pr1	121	4	in	in	IN
cord-282507-swxs5pr1	121	5	mouse	mouse	NN
cord-282507-swxs5pr1	121	6	models	model	NNS
cord-282507-swxs5pr1	121	7	with	with	IN
cord-282507-swxs5pr1	121	8	a	a	DT
cord-282507-swxs5pr1	121	9	recombinant	recombinant	JJ
cord-282507-swxs5pr1	121	10	varicella	varicella	NN
cord-282507-swxs5pr1	121	11	-	-	HYPH
cord-282507-swxs5pr1	121	12	zoster	zoster	NN
cord-282507-swxs5pr1	121	13	virus	virus	NN
cord-282507-swxs5pr1	121	14	(	(	-LRB-
cord-282507-swxs5pr1	121	15	VZV	VZV	NNP
cord-282507-swxs5pr1	121	16	)	)	-RRB-
cord-282507-swxs5pr1	121	17	glycoprotein	glycoprotein	NN
cord-282507-swxs5pr1	121	18	E	e	NN
cord-282507-swxs5pr1	121	19	(	(	-LRB-
cord-282507-swxs5pr1	121	20	gE	gE	NNP
cord-282507-swxs5pr1	121	21	)	)	-RRB-
cord-282507-swxs5pr1	121	22	and	and	CC
cord-282507-swxs5pr1	121	23	the	the	DT
cord-282507-swxs5pr1	121	24	fluorescently	fluorescently	RB
cord-282507-swxs5pr1	121	25	labeled	label	VBN
cord-282507-swxs5pr1	121	26	QS-21	QS-21	NNP
cord-282507-swxs5pr1	121	27	incorporated	incorporate	VBN
cord-282507-swxs5pr1	121	28	in	in	IN
cord-282507-swxs5pr1	121	29	AS01	AS01	NNP
cord-282507-swxs5pr1	121	30	(	(	-LRB-
cord-282507-swxs5pr1	121	31	HZ	HZ	NNP
cord-282507-swxs5pr1	121	32	(	(	-LRB-
cord-282507-swxs5pr1	121	33	shingle	shingle	NN
cord-282507-swxs5pr1	121	34	)	)	-RRB-
cord-282507-swxs5pr1	121	35	vaccine	vaccine	NN
cord-282507-swxs5pr1	121	36	formulation	formulation	NN
cord-282507-swxs5pr1	121	37	)	)	-RRB-
cord-282507-swxs5pr1	121	38	.	.	.
cord-282507-swxs5pr1	122	1	AS01	AS01	NNP
cord-282507-swxs5pr1	122	2	induces	induce	VBZ
cord-282507-swxs5pr1	122	3	a	a	DT
cord-282507-swxs5pr1	122	4	rapid	rapid	JJ
cord-282507-swxs5pr1	122	5	and	and	CC
cord-282507-swxs5pr1	122	6	transient	transient	JJ
cord-282507-swxs5pr1	122	7	activation	activation	NN
cord-282507-swxs5pr1	122	8	of	of	IN
cord-282507-swxs5pr1	122	9	the	the	DT
cord-282507-swxs5pr1	122	10	innate	innate	JJ
cord-282507-swxs5pr1	122	11	immune	immune	JJ
cord-282507-swxs5pr1	122	12	system	system	NN
cord-282507-swxs5pr1	122	13	,	,	,
cord-282507-swxs5pr1	122	14	both	both	CC
cord-282507-swxs5pr1	122	15	at	at	IN
cord-282507-swxs5pr1	122	16	the	the	DT
cord-282507-swxs5pr1	122	17	injection	injection	NN
cord-282507-swxs5pr1	122	18	site	site	NN
cord-282507-swxs5pr1	122	19	and	and	CC
cord-282507-swxs5pr1	122	20	in	in	IN
cord-282507-swxs5pr1	122	21	the	the	DT
cord-282507-swxs5pr1	122	22	dLN	dln	NN
cord-282507-swxs5pr1	122	23	,	,	,
cord-282507-swxs5pr1	122	24	leading	lead	VBG
cord-282507-swxs5pr1	122	25	to	to	IN
cord-282507-swxs5pr1	122	26	the	the	DT
cord-282507-swxs5pr1	122	27	generation	generation	NN
cord-282507-swxs5pr1	122	28	of	of	IN
cord-282507-swxs5pr1	122	29	high	high	JJ
cord-282507-swxs5pr1	122	30	number	number	NN
cord-282507-swxs5pr1	122	31	of	of	IN
cord-282507-swxs5pr1	122	32	efficient	efficient	JJ
cord-282507-swxs5pr1	122	33	Ag	Ag	NNP
cord-282507-swxs5pr1	122	34	-	-	HYPH
cord-282507-swxs5pr1	122	35	loaded	load	VBN
cord-282507-swxs5pr1	122	36	DCs	dc	NNS
cord-282507-swxs5pr1	122	37	in	in	IN
cord-282507-swxs5pr1	122	38	the	the	DT
cord-282507-swxs5pr1	122	39	dLN	dln	NN
cord-282507-swxs5pr1	122	40	to	to	TO
cord-282507-swxs5pr1	122	41	promote	promote	VB
cord-282507-swxs5pr1	122	42	Ag	Ag	NNP
cord-282507-swxs5pr1	122	43	-	-	HYPH
cord-282507-swxs5pr1	122	44	specific	specific	JJ
cord-282507-swxs5pr1	122	45	adaptive	adaptive	JJ
cord-282507-swxs5pr1	122	46	immune	immune	JJ
cord-282507-swxs5pr1	122	47	responses	response	NNS
cord-282507-swxs5pr1	122	48	(	(	-LRB-
cord-282507-swxs5pr1	122	49	Didierlaurent	Didierlaurent	NNP
cord-282507-swxs5pr1	122	50	et	et	NNP
cord-282507-swxs5pr1	122	51	al	al	NNP
cord-282507-swxs5pr1	122	52	.	.	NNP
cord-282507-swxs5pr1	122	53	,	,	,
cord-282507-swxs5pr1	122	54	2014	2014	CD
cord-282507-swxs5pr1	122	55	)	)	-RRB-
cord-282507-swxs5pr1	122	56	.	.	.
cord-282507-swxs5pr1	123	1	A	a	DT
cord-282507-swxs5pr1	123	2	comparative	comparative	JJ
cord-282507-swxs5pr1	123	3	study	study	NN
cord-282507-swxs5pr1	123	4	of	of	IN
cord-282507-swxs5pr1	123	5	the	the	DT
cord-282507-swxs5pr1	123	6	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	123	7	of	of	IN
cord-282507-swxs5pr1	123	8	different	different	JJ
cord-282507-swxs5pr1	123	9	formulations	formulation	NNS
cord-282507-swxs5pr1	123	10	containing	contain	VBG
cord-282507-swxs5pr1	123	11	the	the	DT
cord-282507-swxs5pr1	123	12	subunit	subunit	NN
cord-282507-swxs5pr1	123	13	gE	gE	NNP
cord-282507-swxs5pr1	123	14	was	be	VBD
cord-282507-swxs5pr1	123	15	carried	carry	VBN
cord-282507-swxs5pr1	123	16	out	out	RP
cord-282507-swxs5pr1	123	17	in	in	IN
cord-282507-swxs5pr1	123	18	a	a	DT
cord-282507-swxs5pr1	123	19	VZV	VZV	NNP
cord-282507-swxs5pr1	123	20	-	-	HYPH
cord-282507-swxs5pr1	123	21	primed	prime	VBN
cord-282507-swxs5pr1	123	22	mouse	mouse	NN
cord-282507-swxs5pr1	123	23	model	model	NN
cord-282507-swxs5pr1	123	24	(	(	-LRB-
cord-282507-swxs5pr1	123	25	Dendouga	Dendouga	NNP
cord-282507-swxs5pr1	123	26	et	et	NNP
cord-282507-swxs5pr1	123	27	al	al	NNP
cord-282507-swxs5pr1	123	28	.	.	NNP
cord-282507-swxs5pr1	123	29	,	,	,
cord-282507-swxs5pr1	123	30	2012	2012	CD
cord-282507-swxs5pr1	123	31	)	)	-RRB-
cord-282507-swxs5pr1	123	32	.	.	.
cord-282507-swxs5pr1	124	1	This	this	DT
cord-282507-swxs5pr1	124	2	model	model	NN
cord-282507-swxs5pr1	124	3	was	be	VBD
cord-282507-swxs5pr1	124	4	chosen	choose	VBN
cord-282507-swxs5pr1	124	5	in	in	IN
cord-282507-swxs5pr1	124	6	order	order	NN
cord-282507-swxs5pr1	124	7	to	to	TO
cord-282507-swxs5pr1	124	8	mimic	mimic	VB
cord-282507-swxs5pr1	124	9	the	the	DT
cord-282507-swxs5pr1	124	10	clinical	clinical	JJ
cord-282507-swxs5pr1	124	11	setting	setting	NN
cord-282507-swxs5pr1	124	12	,	,	,
cord-282507-swxs5pr1	124	13	in	in	IN
cord-282507-swxs5pr1	124	14	which	which	WDT
cord-282507-swxs5pr1	124	15	the	the	DT
cord-282507-swxs5pr1	124	16	large	large	JJ
cord-282507-swxs5pr1	124	17	majority	majority	NN
cord-282507-swxs5pr1	124	18	of	of	IN
cord-282507-swxs5pr1	124	19	persons	person	NNS
cord-282507-swxs5pr1	124	20	at	at	IN
cord-282507-swxs5pr1	124	21	elevated	elevated	JJ
cord-282507-swxs5pr1	124	22	risk	risk	NN
cord-282507-swxs5pr1	124	23	for	for	IN
cord-282507-swxs5pr1	124	24	HZ	hz	NN
cord-282507-swxs5pr1	124	25	are	be	VBP
cord-282507-swxs5pr1	124	26	VZV	VZV	NNP
cord-282507-swxs5pr1	124	27	sero	sero	NN
cord-282507-swxs5pr1	124	28	-	-	HYPH
cord-282507-swxs5pr1	124	29	positive	positive	JJ
cord-282507-swxs5pr1	124	30	.	.	.
cord-282507-swxs5pr1	125	1	An	an	DT
cord-282507-swxs5pr1	125	2	HZ	HZ	NNP
cord-282507-swxs5pr1	125	3	candidate	candidate	NN
cord-282507-swxs5pr1	125	4	vaccine	vaccine	NN
cord-282507-swxs5pr1	125	5	comprising	comprise	VBG
cord-282507-swxs5pr1	125	6	gE	gE	NNP
cord-282507-swxs5pr1	125	7	(	(	-LRB-
cord-282507-swxs5pr1	125	8	5	5	CD
cord-282507-swxs5pr1	125	9	μg	μg	NNP
cord-282507-swxs5pr1	125	10	)	)	-RRB-
cord-282507-swxs5pr1	125	11	and	and	CC
cord-282507-swxs5pr1	125	12	AS01	AS01	NNP
cord-282507-swxs5pr1	125	13	B	B	NNP
cord-282507-swxs5pr1	126	1	(	(	-LRB-
cord-282507-swxs5pr1	126	2	5	5	CD
cord-282507-swxs5pr1	126	3	μg	μg	NN
cord-282507-swxs5pr1	127	1	each	each	DT
cord-282507-swxs5pr1	127	2	of	of	IN
cord-282507-swxs5pr1	127	3	MPL	MPL	NNP
cord-282507-swxs5pr1	127	4	and	and	CC
cord-282507-swxs5pr1	127	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	127	6	)	)	-RRB-
cord-282507-swxs5pr1	127	7	was	be	VBD
cord-282507-swxs5pr1	127	8	shown	show	VBN
cord-282507-swxs5pr1	127	9	to	to	TO
cord-282507-swxs5pr1	127	10	be	be	VB
cord-282507-swxs5pr1	127	11	highly	highly	RB
cord-282507-swxs5pr1	127	12	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	127	13	in	in	IN
cord-282507-swxs5pr1	127	14	mice	mouse	NNS
cord-282507-swxs5pr1	127	15	,	,	,
cord-282507-swxs5pr1	127	16	inducing	induce	VBG
cord-282507-swxs5pr1	127	17	higher	high	JJR
cord-282507-swxs5pr1	127	18	responses	response	NNS
cord-282507-swxs5pr1	127	19	of	of	IN
cord-282507-swxs5pr1	127	20	CD4	CD4	NNP
cord-282507-swxs5pr1	127	21	+	+	CC
cord-282507-swxs5pr1	127	22	T	t	NN
cord-282507-swxs5pr1	127	23	cells	cell	NNS
cord-282507-swxs5pr1	127	24	expressing	express	VBG
cord-282507-swxs5pr1	127	25	Il-2	Il-2	NNP
cord-282507-swxs5pr1	127	26	and/or	and/or	CC
cord-282507-swxs5pr1	127	27	INF	INF	NNP
cord-282507-swxs5pr1	127	28	-	-	HYPH
cord-282507-swxs5pr1	127	29	γ	γ	NN
cord-282507-swxs5pr1	127	30	and	and	CC
cord-282507-swxs5pr1	127	31	higher	high	JJR
cord-282507-swxs5pr1	127	32	humoral	humoral	JJ
cord-282507-swxs5pr1	127	33	responses	response	NNS
cord-282507-swxs5pr1	127	34	compared	compare	VBN
cord-282507-swxs5pr1	127	35	to	to	IN
cord-282507-swxs5pr1	127	36	other	other	JJ
cord-282507-swxs5pr1	127	37	gE	gE	NNP
cord-282507-swxs5pr1	127	38	/	/	SYM
cord-282507-swxs5pr1	127	39	AS01	AS01	NNP
cord-282507-swxs5pr1	127	40	formulations	formulation	NNS
cord-282507-swxs5pr1	127	41	with	with	IN
cord-282507-swxs5pr1	127	42	different	different	JJ
cord-282507-swxs5pr1	127	43	Ag	Ag	NNP
cord-282507-swxs5pr1	127	44	doses	dose	NNS
cord-282507-swxs5pr1	127	45	(	(	-LRB-
cord-282507-swxs5pr1	127	46	0.5	0.5	CD
cord-282507-swxs5pr1	127	47	,	,	,
cord-282507-swxs5pr1	127	48	2.5	2.5	CD
cord-282507-swxs5pr1	127	49	,	,	,
cord-282507-swxs5pr1	127	50	10	10	CD
cord-282507-swxs5pr1	127	51	μg	μg	NNP
cord-282507-swxs5pr1	127	52	)	)	-RRB-
cord-282507-swxs5pr1	127	53	or	or	CC
cord-282507-swxs5pr1	127	54	with	with	IN
cord-282507-swxs5pr1	127	55	lower	low	JJR
cord-282507-swxs5pr1	127	56	doses	dose	NNS
cord-282507-swxs5pr1	127	57	of	of	IN
cord-282507-swxs5pr1	127	58	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	127	59	(	(	-LRB-
cord-282507-swxs5pr1	127	60	2.5	2.5	CD
cord-282507-swxs5pr1	127	61	and	and	CC
cord-282507-swxs5pr1	127	62	1.25	1.25	CD
cord-282507-swxs5pr1	127	63	μg	μg	NN
cord-282507-swxs5pr1	128	1	each	each	DT
cord-282507-swxs5pr1	128	2	of	of	IN
cord-282507-swxs5pr1	128	3	MPL	MPL	NNP
cord-282507-swxs5pr1	128	4	and	and	CC
cord-282507-swxs5pr1	128	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	128	6	,	,	,
cord-282507-swxs5pr1	128	7	corresponding	correspond	VBG
cord-282507-swxs5pr1	128	8	to	to	IN
cord-282507-swxs5pr1	128	9	AS01	AS01	NNP
cord-282507-swxs5pr1	128	10	E	E	NNP
cord-282507-swxs5pr1	128	11	and	and	CC
cord-282507-swxs5pr1	128	12	AS01	AS01	NNP
cord-282507-swxs5pr1	128	13	F	F	NNP
cord-282507-swxs5pr1	128	14	,	,	,
cord-282507-swxs5pr1	128	15	respectively	respectively	RB
cord-282507-swxs5pr1	128	16	)	)	-RRB-
cord-282507-swxs5pr1	129	1	(	(	-LRB-
cord-282507-swxs5pr1	129	2	Dendouga	Dendouga	NNP
cord-282507-swxs5pr1	129	3	et	et	NNP
cord-282507-swxs5pr1	129	4	al	al	NNP
cord-282507-swxs5pr1	129	5	.	.	NNP
cord-282507-swxs5pr1	129	6	,	,	,
cord-282507-swxs5pr1	129	7	2012	2012	CD
cord-282507-swxs5pr1	129	8	)	)	-RRB-
cord-282507-swxs5pr1	129	9	.	.	.
cord-282507-swxs5pr1	130	1	Furthermore	furthermore	RB
cord-282507-swxs5pr1	130	2	,	,	,
cord-282507-swxs5pr1	130	3	the	the	DT
cord-282507-swxs5pr1	130	4	contribution	contribution	NN
cord-282507-swxs5pr1	130	5	of	of	IN
cord-282507-swxs5pr1	130	6	each	each	DT
cord-282507-swxs5pr1	130	7	component	component	NN
cord-282507-swxs5pr1	130	8	of	of	IN
cord-282507-swxs5pr1	130	9	AS01	AS01	NNP
cord-282507-swxs5pr1	130	10	B	B	NNP
cord-282507-swxs5pr1	130	11	to	to	IN
cord-282507-swxs5pr1	130	12	the	the	DT
cord-282507-swxs5pr1	130	13	induction	induction	NN
cord-282507-swxs5pr1	130	14	of	of	IN
cord-282507-swxs5pr1	130	15	cellular	cellular	JJ
cord-282507-swxs5pr1	130	16	and	and	CC
cord-282507-swxs5pr1	130	17	humoral	humoral	JJ
cord-282507-swxs5pr1	130	18	response	response	NN
cord-282507-swxs5pr1	130	19	was	be	VBD
cord-282507-swxs5pr1	130	20	assessed	assess	VBN
cord-282507-swxs5pr1	130	21	after	after	IN
cord-282507-swxs5pr1	130	22	immunization	immunization	NN
cord-282507-swxs5pr1	130	23	of	of	IN
cord-282507-swxs5pr1	130	24	mice	mouse	NNS
cord-282507-swxs5pr1	130	25	with	with	IN
cord-282507-swxs5pr1	130	26	gE	gE	NNP
cord-282507-swxs5pr1	131	1	either	either	CC
cord-282507-swxs5pr1	131	2	unadjuvanted	unadjuvante	VBN
cord-282507-swxs5pr1	131	3	,	,	,
cord-282507-swxs5pr1	131	4	or	or	CC
cord-282507-swxs5pr1	131	5	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	131	6	with	with	IN
cord-282507-swxs5pr1	131	7	QS-21	QS-21	NNP
cord-282507-swxs5pr1	131	8	(	(	-LRB-
cord-282507-swxs5pr1	131	9	5	5	CD
cord-282507-swxs5pr1	131	10	μg	μg	NNP
cord-282507-swxs5pr1	131	11	)	)	-RRB-
cord-282507-swxs5pr1	131	12	,	,	,
cord-282507-swxs5pr1	131	13	MPL	MPL	NNP
cord-282507-swxs5pr1	131	14	(	(	-LRB-
cord-282507-swxs5pr1	131	15	5	5	CD
cord-282507-swxs5pr1	131	16	μg	μg	NN
cord-282507-swxs5pr1	131	17	)	)	-RRB-
cord-282507-swxs5pr1	131	18	(	(	-LRB-
cord-282507-swxs5pr1	131	19	both	both	DT
cord-282507-swxs5pr1	131	20	in	in	IN
cord-282507-swxs5pr1	131	21	liposomes	liposome	NNS
cord-282507-swxs5pr1	131	22	)	)	-RRB-
cord-282507-swxs5pr1	131	23	,	,	,
cord-282507-swxs5pr1	131	24	and	and	CC
cord-282507-swxs5pr1	131	25	AS01	AS01	NNP
cord-282507-swxs5pr1	131	26	.	.	.
cord-282507-swxs5pr1	132	1	The	the	DT
cord-282507-swxs5pr1	132	2	results	result	NNS
cord-282507-swxs5pr1	132	3	showed	show	VBD
cord-282507-swxs5pr1	132	4	that	that	IN
cord-282507-swxs5pr1	132	5	the	the	DT
cord-282507-swxs5pr1	132	6	gE	gE	NNP
cord-282507-swxs5pr1	132	7	-	-	HYPH
cord-282507-swxs5pr1	132	8	specific	specific	JJ
cord-282507-swxs5pr1	132	9	cytokine	cytokine	NN
cord-282507-swxs5pr1	132	10	(	(	-LRB-
cord-282507-swxs5pr1	132	11	IFN	IFN	NNP
cord-282507-swxs5pr1	132	12	-	-	HYPH
cord-282507-swxs5pr1	132	13	γ	γ	NNP
cord-282507-swxs5pr1	132	14	,	,	,
cord-282507-swxs5pr1	132	15	Il-2	Il-2	NNP
cord-282507-swxs5pr1	132	16	)	)	-RRB-
cord-282507-swxs5pr1	132	17	producing	produce	VBG
cord-282507-swxs5pr1	132	18	CD4	CD4	NNP
cord-282507-swxs5pr1	132	19	+	+	CC
cord-282507-swxs5pr1	132	20	T	t	NN
cord-282507-swxs5pr1	132	21	cell	cell	NN
cord-282507-swxs5pr1	132	22	responses	response	NNS
cord-282507-swxs5pr1	132	23	induced	induce	VBN
cord-282507-swxs5pr1	132	24	by	by	IN
cord-282507-swxs5pr1	132	25	gE	gE	NNP
cord-282507-swxs5pr1	132	26	/	/	SYM
cord-282507-swxs5pr1	132	27	liposome+QS21	liposome+QS21	NNP
cord-282507-swxs5pr1	132	28	and	and	CC
cord-282507-swxs5pr1	133	1	gE	gE	NNP
cord-282507-swxs5pr1	133	2	/	/	SYM
cord-282507-swxs5pr1	133	3	liposome+MPL	liposome+MPL	NNP
cord-282507-swxs5pr1	133	4	were	be	VBD
cord-282507-swxs5pr1	133	5	of	of	IN
cord-282507-swxs5pr1	133	6	similar	similar	JJ
cord-282507-swxs5pr1	133	7	and	and	CC
cord-282507-swxs5pr1	133	8	low	low	JJ
cord-282507-swxs5pr1	133	9	magnitude	magnitude	NN
cord-282507-swxs5pr1	133	10	,	,	,
cord-282507-swxs5pr1	133	11	whereas	whereas	IN
cord-282507-swxs5pr1	133	12	the	the	DT
cord-282507-swxs5pr1	133	13	response	response	NN
cord-282507-swxs5pr1	133	14	induced	induce	VBN
cord-282507-swxs5pr1	133	15	by	by	IN
cord-282507-swxs5pr1	133	16	gE	gE	NNP
cord-282507-swxs5pr1	133	17	/	/	SYM
cord-282507-swxs5pr1	133	18	AS01	AS01	NNP
cord-282507-swxs5pr1	133	19	B	B	NNP
cord-282507-swxs5pr1	133	20	was	be	VBD
cord-282507-swxs5pr1	133	21	significantly	significantly	RB
cord-282507-swxs5pr1	133	22	higher	high	JJR
cord-282507-swxs5pr1	133	23	than	than	IN
cord-282507-swxs5pr1	133	24	gE	gE	NNP
cord-282507-swxs5pr1	133	25	/	/	SYM
cord-282507-swxs5pr1	133	26	liposome+QS21	liposome+QS21	NNP
cord-282507-swxs5pr1	133	27	(	(	-LRB-
cord-282507-swxs5pr1	133	28	8.7	8.7	CD
cord-282507-swxs5pr1	133	29	fold	fold	NN
cord-282507-swxs5pr1	133	30	difference	difference	NN
cord-282507-swxs5pr1	133	31	)	)	-RRB-
cord-282507-swxs5pr1	134	1	and	and	CC
cord-282507-swxs5pr1	134	2	gE	gE	NNP
cord-282507-swxs5pr1	134	3	/	/	SYM
cord-282507-swxs5pr1	134	4	liposome+MPL	liposome+MPL	NNP
cord-282507-swxs5pr1	134	5	(	(	-LRB-
cord-282507-swxs5pr1	134	6	7.5	7.5	CD
cord-282507-swxs5pr1	134	7	fold	fold	JJ
cord-282507-swxs5pr1	134	8	difference	difference	NN
cord-282507-swxs5pr1	134	9	)	)	-RRB-
cord-282507-swxs5pr1	134	10	.	.	.
cord-282507-swxs5pr1	135	1	This	this	DT
cord-282507-swxs5pr1	135	2	clearly	clearly	RB
cord-282507-swxs5pr1	135	3	showed	show	VBD
cord-282507-swxs5pr1	135	4	that	that	IN
cord-282507-swxs5pr1	135	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	135	6	and	and	CC
cord-282507-swxs5pr1	135	7	MPL	MPL	NNP
cord-282507-swxs5pr1	135	8	acted	act	VBD
cord-282507-swxs5pr1	135	9	synergistically	synergistically	RB
cord-282507-swxs5pr1	135	10	to	to	TO
cord-282507-swxs5pr1	135	11	induce	induce	VB
cord-282507-swxs5pr1	135	12	a	a	DT
cord-282507-swxs5pr1	135	13	high	high	JJ
cord-282507-swxs5pr1	135	14	frequency	frequency	NN
cord-282507-swxs5pr1	135	15	of	of	IN
cord-282507-swxs5pr1	135	16	gE	gE	NNP
cord-282507-swxs5pr1	135	17	-	-	HYPH
cord-282507-swxs5pr1	135	18	specific	specific	JJ
cord-282507-swxs5pr1	135	19	CD4	CD4	NNP
cord-282507-swxs5pr1	135	20	+	+	CC
cord-282507-swxs5pr1	135	21	T	t	NN
cord-282507-swxs5pr1	135	22	cells	cell	NNS
cord-282507-swxs5pr1	135	23	.	.	.
cord-282507-swxs5pr1	136	1	For	for	IN
cord-282507-swxs5pr1	136	2	the	the	DT
cord-282507-swxs5pr1	136	3	anti	anti	JJ
cord-282507-swxs5pr1	136	4	-	-	JJ
cord-282507-swxs5pr1	136	5	gE	gE	NNP
cord-282507-swxs5pr1	136	6	antibody	antibody	NN
cord-282507-swxs5pr1	136	7	responses	response	NNS
cord-282507-swxs5pr1	136	8	,	,	,
cord-282507-swxs5pr1	136	9	an	an	DT
cord-282507-swxs5pr1	136	10	additive	additive	NN
cord-282507-swxs5pr1	136	11	effect	effect	NN
cord-282507-swxs5pr1	136	12	,	,	,
cord-282507-swxs5pr1	136	13	rather	rather	RB
cord-282507-swxs5pr1	136	14	than	than	IN
cord-282507-swxs5pr1	136	15	a	a	DT
cord-282507-swxs5pr1	136	16	synergistic	synergistic	JJ
cord-282507-swxs5pr1	136	17	effect	effect	NN
cord-282507-swxs5pr1	136	18	was	be	VBD
cord-282507-swxs5pr1	136	19	observed	observe	VBN
cord-282507-swxs5pr1	137	1	(	(	-LRB-
cord-282507-swxs5pr1	137	2	Dendouga	Dendouga	NNP
cord-282507-swxs5pr1	137	3	et	et	NNP
cord-282507-swxs5pr1	137	4	al	al	NNP
cord-282507-swxs5pr1	137	5	.	.	NNP
cord-282507-swxs5pr1	137	6	,	,	,
cord-282507-swxs5pr1	137	7	2012	2012	CD
cord-282507-swxs5pr1	137	8	;	;	.
cord-282507-swxs5pr1	138	1	Didierlaurent	Didierlaurent	NNP
cord-282507-swxs5pr1	138	2	et	et	NNP
cord-282507-swxs5pr1	138	3	al	al	NNP
cord-282507-swxs5pr1	138	4	.	.	NNP
cord-282507-swxs5pr1	138	5	,	,	,
cord-282507-swxs5pr1	138	6	2017	2017	CD
cord-282507-swxs5pr1	138	7	)	)	-RRB-
cord-282507-swxs5pr1	138	8	.	.	.
cord-282507-swxs5pr1	139	1	These	these	DT
cord-282507-swxs5pr1	139	2	results	result	NNS
cord-282507-swxs5pr1	139	3	suggested	suggest	VBD
cord-282507-swxs5pr1	139	4	that	that	IN
cord-282507-swxs5pr1	139	5	the	the	DT
cord-282507-swxs5pr1	139	6	gE	gE	NNP
cord-282507-swxs5pr1	139	7	/	/	SYM
cord-282507-swxs5pr1	139	8	AS01	AS01	NNP
cord-282507-swxs5pr1	139	9	B	B	NNP
cord-282507-swxs5pr1	139	10	vaccine	vaccine	NN
cord-282507-swxs5pr1	139	11	candidate	candidate	NN
cord-282507-swxs5pr1	139	12	was	be	VBD
cord-282507-swxs5pr1	139	13	appropriate	appropriate	JJ
cord-282507-swxs5pr1	139	14	for	for	IN
cord-282507-swxs5pr1	139	15	further	further	JJ
cord-282507-swxs5pr1	139	16	clinical	clinical	JJ
cord-282507-swxs5pr1	139	17	assessment	assessment	NN
cord-282507-swxs5pr1	139	18	.	.	.
cord-282507-swxs5pr1	140	1	An	an	DT
cord-282507-swxs5pr1	140	2	investigation	investigation	NN
cord-282507-swxs5pr1	140	3	of	of	IN
cord-282507-swxs5pr1	140	4	the	the	DT
cord-282507-swxs5pr1	140	5	molecular	molecular	JJ
cord-282507-swxs5pr1	140	6	and	and	CC
cord-282507-swxs5pr1	140	7	cellular	cellular	JJ
cord-282507-swxs5pr1	140	8	mechanism	mechanism	NN
cord-282507-swxs5pr1	140	9	of	of	IN
cord-282507-swxs5pr1	140	10	AS01	AS01	NNP
cord-282507-swxs5pr1	140	11	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	140	12	vaccines	vaccine	NNS
cord-282507-swxs5pr1	140	13	was	be	VBD
cord-282507-swxs5pr1	140	14	undertaken	undertake	VBN
cord-282507-swxs5pr1	140	15	in	in	IN
cord-282507-swxs5pr1	140	16	order	order	NN
cord-282507-swxs5pr1	140	17	to	to	TO
cord-282507-swxs5pr1	140	18	clarify	clarify	VB
cord-282507-swxs5pr1	140	19	how	how	WRB
cord-282507-swxs5pr1	140	20	immunostimulants	immunostimulant	NNS
cord-282507-swxs5pr1	140	21	function	function	NN
cord-282507-swxs5pr1	140	22	in	in	IN
cord-282507-swxs5pr1	140	23	combination	combination	NN
cord-282507-swxs5pr1	140	24	.	.	.
cord-282507-swxs5pr1	140	25	.	.	.
cord-282507-swxs5pr1	141	1	Results	result	NNS
cord-282507-swxs5pr1	141	2	from	from	IN
cord-282507-swxs5pr1	141	3	in	in	IN
cord-282507-swxs5pr1	141	4	vivo	vivo	NN
cord-282507-swxs5pr1	141	5	and	and	CC
cord-282507-swxs5pr1	141	6	clinical	clinical	JJ
cord-282507-swxs5pr1	141	7	studies	study	NNS
cord-282507-swxs5pr1	141	8	showed	show	VBD
cord-282507-swxs5pr1	141	9	that	that	IN
cord-282507-swxs5pr1	141	10	the	the	DT
cord-282507-swxs5pr1	141	11	combination	combination	NN
cord-282507-swxs5pr1	141	12	of	of	IN
cord-282507-swxs5pr1	141	13	MPL/	MPL/	NNP
cord-282507-swxs5pr1	141	14	QS-21	QS-21	NNP
cord-282507-swxs5pr1	141	15	in	in	IN
cord-282507-swxs5pr1	141	16	AS01	AS01	NNP
cord-282507-swxs5pr1	141	17	resulted	result	VBD
cord-282507-swxs5pr1	141	18	in	in	IN
cord-282507-swxs5pr1	141	19	the	the	DT
cord-282507-swxs5pr1	141	20	stimulation	stimulation	NN
cord-282507-swxs5pr1	141	21	of	of	IN
cord-282507-swxs5pr1	141	22	de	de	FW
cord-282507-swxs5pr1	141	23	novo	novo	NNP
cord-282507-swxs5pr1	141	24	pathways	pathway	NNS
cord-282507-swxs5pr1	141	25	that	that	WDT
cord-282507-swxs5pr1	141	26	were	be	VBD
cord-282507-swxs5pr1	141	27	not	not	RB
cord-282507-swxs5pr1	141	28	triggered	trigger	VBN
cord-282507-swxs5pr1	141	29	by	by	IN
cord-282507-swxs5pr1	141	30	the	the	DT
cord-282507-swxs5pr1	141	31	individual	individual	JJ
cord-282507-swxs5pr1	141	32	components	component	NNS
cord-282507-swxs5pr1	141	33	.	.	.
cord-282507-swxs5pr1	142	1	Mice	mouse	NNS
cord-282507-swxs5pr1	142	2	were	be	VBD
cord-282507-swxs5pr1	142	3	immunized	immunize	VBN
cord-282507-swxs5pr1	142	4	twice	twice	RB
cord-282507-swxs5pr1	142	5	,	,	,
cord-282507-swxs5pr1	142	6	2	2	CD
cord-282507-swxs5pr1	142	7	weeks	week	NNS
cord-282507-swxs5pr1	142	8	apart	apart	RB
cord-282507-swxs5pr1	142	9	,	,	,
cord-282507-swxs5pr1	142	10	with	with	IN
cord-282507-swxs5pr1	142	11	the	the	DT
cord-282507-swxs5pr1	142	12	RTS	RTS	NNP
cord-282507-swxs5pr1	142	13	,	,	,
cord-282507-swxs5pr1	142	14	S	S	NNP
cord-282507-swxs5pr1	142	15	antigen	antigen	NN
cord-282507-swxs5pr1	142	16	of	of	IN
cord-282507-swxs5pr1	142	17	the	the	DT
cord-282507-swxs5pr1	142	18	malaria	malaria	NN
cord-282507-swxs5pr1	142	19	vaccine	vaccine	NN
cord-282507-swxs5pr1	142	20	,	,	,
cord-282507-swxs5pr1	142	21	formulated	formulate	VBN
cord-282507-swxs5pr1	142	22	either	either	CC
cord-282507-swxs5pr1	142	23	without	without	IN
cord-282507-swxs5pr1	142	24	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	142	25	,	,	,
cord-282507-swxs5pr1	142	26	with	with	IN
cord-282507-swxs5pr1	142	27	MPL	MPL	NNP
cord-282507-swxs5pr1	142	28	,	,	,
cord-282507-swxs5pr1	142	29	with	with	IN
cord-282507-swxs5pr1	142	30	QS-21	QS-21	NNP
cord-282507-swxs5pr1	142	31	(	(	-LRB-
cord-282507-swxs5pr1	142	32	both	both	DT
cord-282507-swxs5pr1	142	33	included	include	VBN
cord-282507-swxs5pr1	142	34	in	in	IN
cord-282507-swxs5pr1	142	35	liposomes	liposome	NNS
cord-282507-swxs5pr1	142	36	)	)	-RRB-
cord-282507-swxs5pr1	142	37	or	or	CC
cord-282507-swxs5pr1	142	38	with	with	IN
cord-282507-swxs5pr1	142	39	AS01	AS01	NNP
cord-282507-swxs5pr1	142	40	.	.	.
cord-282507-swxs5pr1	143	1	RTS	RTS	NNP
cord-282507-swxs5pr1	143	2	,	,	,
cord-282507-swxs5pr1	143	3	S	S	NNP
cord-282507-swxs5pr1	143	4	is	be	VBZ
cord-282507-swxs5pr1	143	5	a	a	DT
cord-282507-swxs5pr1	143	6	recombinant	recombinant	JJ
cord-282507-swxs5pr1	143	7	protein	protein	NN
cord-282507-swxs5pr1	143	8	consisting	consist	VBG
cord-282507-swxs5pr1	143	9	of	of	IN
cord-282507-swxs5pr1	143	10	repeated	repeat	VBN
cord-282507-swxs5pr1	143	11	sequences	sequence	NNS
cord-282507-swxs5pr1	143	12	of	of	IN
cord-282507-swxs5pr1	143	13	the	the	DT
cord-282507-swxs5pr1	143	14	Plasmodium	Plasmodium	NNP
cord-282507-swxs5pr1	143	15	falciparum	falciparum	NN
cord-282507-swxs5pr1	143	16	circumsporozoite	circumsporozoite	JJ
cord-282507-swxs5pr1	143	17	protein	protein	NN
cord-282507-swxs5pr1	143	18	(	(	-LRB-
cord-282507-swxs5pr1	143	19	CSP	CSP	NNP
cord-282507-swxs5pr1	143	20	-	-	HYPH
cord-282507-swxs5pr1	143	21	repeat	repeat	NN
cord-282507-swxs5pr1	143	22	region	region	NN
cord-282507-swxs5pr1	143	23	,	,	,
cord-282507-swxs5pr1	143	24	(	(	-LRB-
cord-282507-swxs5pr1	143	25	R	r	NN
cord-282507-swxs5pr1	143	26	)	)	-RRB-
cord-282507-swxs5pr1	143	27	)	)	-RRB-
cord-282507-swxs5pr1	143	28	and	and	CC
cord-282507-swxs5pr1	143	29	T	t	NN
cord-282507-swxs5pr1	143	30	-	-	HYPH
cord-282507-swxs5pr1	143	31	cell	cell	NN
cord-282507-swxs5pr1	143	32	epitope	epitope	NN
cord-282507-swxs5pr1	143	33	domain	domain	NN
cord-282507-swxs5pr1	143	34	(	(	-LRB-
cord-282507-swxs5pr1	143	35	T	T	NNP
cord-282507-swxs5pr1	143	36	)	)	-RRB-
cord-282507-swxs5pr1	143	37	linked	link	VBN
cord-282507-swxs5pr1	143	38	to	to	IN
cord-282507-swxs5pr1	143	39	the	the	DT
cord-282507-swxs5pr1	143	40	hepatitis	hepatitis	NN
cord-282507-swxs5pr1	143	41	B	B	NNP
cord-282507-swxs5pr1	143	42	surface	surface	NN
cord-282507-swxs5pr1	143	43	antigen	antigen	NN
cord-282507-swxs5pr1	143	44	(	(	-LRB-
cord-282507-swxs5pr1	143	45	HBsAg	hbsag	ADD
cord-282507-swxs5pr1	143	46	)	)	-RRB-
cord-282507-swxs5pr1	143	47	(	(	-LRB-
cord-282507-swxs5pr1	143	48	S	S	NNP
cord-282507-swxs5pr1	143	49	)	)	-RRB-
cord-282507-swxs5pr1	143	50	,	,	,
cord-282507-swxs5pr1	143	51	and	and	CC
cord-282507-swxs5pr1	143	52	HBsAg	hbsag	ADD
cord-282507-swxs5pr1	143	53	alone	alone	RB
cord-282507-swxs5pr1	144	1	(	(	-LRB-
cord-282507-swxs5pr1	144	2	S	s	NN
cord-282507-swxs5pr1	144	3	)	)	-RRB-
cord-282507-swxs5pr1	145	1	(	(	-LRB-
cord-282507-swxs5pr1	145	2	Moris	Moris	NNP
cord-282507-swxs5pr1	145	3	et	et	NNP
cord-282507-swxs5pr1	145	4	al	al	NNP
cord-282507-swxs5pr1	145	5	.	.	NNP
cord-282507-swxs5pr1	145	6	,	,	,
cord-282507-swxs5pr1	145	7	2018	2018	CD
cord-282507-swxs5pr1	145	8	)	)	-RRB-
cord-282507-swxs5pr1	145	9	.	.	.
cord-282507-swxs5pr1	146	1	The	the	DT
cord-282507-swxs5pr1	146	2	CSP	CSP	NNP
cord-282507-swxs5pr1	146	3	-	-	HYPH
cord-282507-swxs5pr1	146	4	specific	specific	JJ
cord-282507-swxs5pr1	146	5	immune	immune	JJ
cord-282507-swxs5pr1	146	6	response	response	NN
cord-282507-swxs5pr1	146	7	was	be	VBD
cord-282507-swxs5pr1	146	8	measured	measure	VBN
cord-282507-swxs5pr1	146	9	after	after	IN
cord-282507-swxs5pr1	146	10	the	the	DT
cord-282507-swxs5pr1	146	11	second	second	JJ
cord-282507-swxs5pr1	146	12	dose	dose	NN
cord-282507-swxs5pr1	146	13	.	.	.
cord-282507-swxs5pr1	147	1	The	the	DT
cord-282507-swxs5pr1	147	2	results	result	NNS
cord-282507-swxs5pr1	147	3	clearly	clearly	RB
cord-282507-swxs5pr1	147	4	showed	show	VBD
cord-282507-swxs5pr1	147	5	that	that	IN
cord-282507-swxs5pr1	147	6	MPL	MPL	NNP
cord-282507-swxs5pr1	147	7	and	and	CC
cord-282507-swxs5pr1	147	8	QS-21	QS-21	NNP
cord-282507-swxs5pr1	147	9	act	act	VBP
cord-282507-swxs5pr1	147	10	synergistically	synergistically	RB
cord-282507-swxs5pr1	147	11	to	to	TO
cord-282507-swxs5pr1	147	12	induce	induce	VB
cord-282507-swxs5pr1	147	13	strong	strong	JJ
cord-282507-swxs5pr1	147	14	antibody	antibody	NN
cord-282507-swxs5pr1	147	15	and	and	CC
cord-282507-swxs5pr1	147	16	Agspecific	Agspecific	NNP
cord-282507-swxs5pr1	147	17	CD4	CD4	NNP
cord-282507-swxs5pr1	147	18	+	+	CC
cord-282507-swxs5pr1	147	19	T	t	NN
cord-282507-swxs5pr1	147	20	cell	cell	NN
cord-282507-swxs5pr1	147	21	responses	response	NNS
cord-282507-swxs5pr1	147	22	.	.	.
cord-282507-swxs5pr1	148	1	In	in	IN
cord-282507-swxs5pr1	148	2	contrast	contrast	NN
cord-282507-swxs5pr1	148	3	,	,	,
cord-282507-swxs5pr1	148	4	very	very	RB
cord-282507-swxs5pr1	148	5	low	low	JJ
cord-282507-swxs5pr1	148	6	levels	level	NNS
cord-282507-swxs5pr1	148	7	of	of	IN
cord-282507-swxs5pr1	148	8	CD8	CD8	NNP
cord-282507-swxs5pr1	148	9	+	+	CC
cord-282507-swxs5pr1	148	10	T	T	NNP
cord-282507-swxs5pr1	148	11	cell	cell	NN
cord-282507-swxs5pr1	148	12	responses	response	NNS
cord-282507-swxs5pr1	148	13	were	be	VBD
cord-282507-swxs5pr1	148	14	generated	generate	VBN
cord-282507-swxs5pr1	148	15	against	against	IN
cord-282507-swxs5pr1	148	16	CSP	CSP	NNP
cord-282507-swxs5pr1	148	17	.	.	.
cord-282507-swxs5pr1	149	1	Further	further	JJ
cord-282507-swxs5pr1	149	2	investigations	investigation	NNS
cord-282507-swxs5pr1	149	3	highlighted	highlight	VBD
cord-282507-swxs5pr1	149	4	the	the	DT
cord-282507-swxs5pr1	149	5	key	key	JJ
cord-282507-swxs5pr1	149	6	role	role	NN
cord-282507-swxs5pr1	149	7	of	of	IN
cord-282507-swxs5pr1	149	8	the	the	DT
cord-282507-swxs5pr1	149	9	early	early	JJ
cord-282507-swxs5pr1	149	10	release	release	NN
cord-282507-swxs5pr1	149	11	of	of	IN
cord-282507-swxs5pr1	149	12	IFN	IFN	NNP
cord-282507-swxs5pr1	149	13	-	-	HYPH
cord-282507-swxs5pr1	149	14	γ	γ	NNP
cord-282507-swxs5pr1	149	15	by	by	IN
cord-282507-swxs5pr1	149	16	innate	innate	JJ
cord-282507-swxs5pr1	149	17	resident	resident	NN
cord-282507-swxs5pr1	149	18	cells	cell	NNS
cord-282507-swxs5pr1	149	19	(	(	-LRB-
cord-282507-swxs5pr1	149	20	NK	NK	NNP
cord-282507-swxs5pr1	149	21	and	and	CC
cord-282507-swxs5pr1	149	22	CD8	CD8	NNP
cord-282507-swxs5pr1	149	23	+	+	CC
cord-282507-swxs5pr1	149	24	T	T	NNP
cord-282507-swxs5pr1	149	25	cells	cell	NNS
cord-282507-swxs5pr1	149	26	)	)	-RRB-
cord-282507-swxs5pr1	149	27	in	in	IN
cord-282507-swxs5pr1	149	28	the	the	DT
cord-282507-swxs5pr1	149	29	LN	ln	NN
cord-282507-swxs5pr1	149	30	,	,	,
cord-282507-swxs5pr1	149	31	draining	drain	VBG
cord-282507-swxs5pr1	149	32	the	the	DT
cord-282507-swxs5pr1	149	33	injection	injection	NN
cord-282507-swxs5pr1	149	34	site	site	NN
cord-282507-swxs5pr1	149	35	,	,	,
cord-282507-swxs5pr1	149	36	which	which	WDT
cord-282507-swxs5pr1	149	37	is	be	VBZ
cord-282507-swxs5pr1	149	38	essential	essential	JJ
cord-282507-swxs5pr1	149	39	for	for	IN
cord-282507-swxs5pr1	149	40	the	the	DT
cord-282507-swxs5pr1	149	41	development	development	NN
cord-282507-swxs5pr1	149	42	of	of	IN
cord-282507-swxs5pr1	149	43	the	the	DT
cord-282507-swxs5pr1	149	44	CD4	CD4	NNP
cord-282507-swxs5pr1	149	45	+	+	CC
cord-282507-swxs5pr1	149	46	T	T	NNP
cord-282507-swxs5pr1	149	47	cell	cell	NN
cord-282507-swxs5pr1	149	48	response	response	NN
cord-282507-swxs5pr1	149	49	(	(	-LRB-
cord-282507-swxs5pr1	149	50	Th1	th1	CD
cord-282507-swxs5pr1	149	51	immunity	immunity	NN
cord-282507-swxs5pr1	149	52	)	)	-RRB-
cord-282507-swxs5pr1	149	53	.	.	.
cord-282507-swxs5pr1	150	1	This	this	DT
cord-282507-swxs5pr1	150	2	was	be	VBD
cord-282507-swxs5pr1	150	3	confirmed	confirm	VBN
cord-282507-swxs5pr1	150	4	by	by	IN
cord-282507-swxs5pr1	150	5	measuring	measure	VBG
cord-282507-swxs5pr1	150	6	the	the	DT
cord-282507-swxs5pr1	150	7	levels	level	NNS
cord-282507-swxs5pr1	150	8	of	of	IN
cord-282507-swxs5pr1	150	9	the	the	DT
cord-282507-swxs5pr1	150	10	cytokine	cytokine	NN
cord-282507-swxs5pr1	150	11	after	after	IN
cord-282507-swxs5pr1	150	12	immunization	immunization	NN
cord-282507-swxs5pr1	150	13	of	of	IN
cord-282507-swxs5pr1	150	14	mice	mouse	NNS
cord-282507-swxs5pr1	150	15	with	with	IN
cord-282507-swxs5pr1	150	16	HBs	HBs	NNP
cord-282507-swxs5pr1	150	17	adjuvanted	adjuvante	VBD
cord-282507-swxs5pr1	150	18	with	with	IN
cord-282507-swxs5pr1	150	19	AS01	AS01	NNP
cord-282507-swxs5pr1	150	20	or	or	CC
cord-282507-swxs5pr1	150	21	with	with	IN
cord-282507-swxs5pr1	150	22	its	-PRON-	PRP$
cord-282507-swxs5pr1	150	23	components	component	NNS
cord-282507-swxs5pr1	150	24	.	.	.
cord-282507-swxs5pr1	151	1	AS01	AS01	NNP
cord-282507-swxs5pr1	151	2	induced	induce	VBD
cord-282507-swxs5pr1	151	3	the	the	DT
cord-282507-swxs5pr1	151	4	early	early	JJ
cord-282507-swxs5pr1	151	5	production	production	NN
cord-282507-swxs5pr1	151	6	of	of	IN
cord-282507-swxs5pr1	151	7	IFN	IFN	NNP
cord-282507-swxs5pr1	151	8	-	-	HYPH
cord-282507-swxs5pr1	151	9	γ	γ	NNP
cord-282507-swxs5pr1	151	10	with	with	IN
cord-282507-swxs5pr1	151	11	a	a	DT
cord-282507-swxs5pr1	151	12	peak	peak	NN
cord-282507-swxs5pr1	151	13	in	in	IN
cord-282507-swxs5pr1	151	14	concentration	concentration	NN
cord-282507-swxs5pr1	151	15	at	at	IN
cord-282507-swxs5pr1	151	16	6	6	CD
cord-282507-swxs5pr1	151	17	h	h	NN
cord-282507-swxs5pr1	151	18	post	post	NN
cord-282507-swxs5pr1	151	19	immunization	immunization	NN
cord-282507-swxs5pr1	151	20	(	(	-LRB-
cord-282507-swxs5pr1	151	21	300	300	CD
cord-282507-swxs5pr1	151	22	pg	pg	NN
cord-282507-swxs5pr1	151	23	/	/	SYM
cord-282507-swxs5pr1	151	24	ml	ml	NNP
cord-282507-swxs5pr1	151	25	)	)	-RRB-
cord-282507-swxs5pr1	151	26	,	,	,
cord-282507-swxs5pr1	151	27	whereas	whereas	IN
cord-282507-swxs5pr1	151	28	MPL	MPL	NNP
cord-282507-swxs5pr1	151	29	or	or	CC
cord-282507-swxs5pr1	151	30	QS-21	QS-21	NNP
cord-282507-swxs5pr1	151	31	alone	alone	RB
cord-282507-swxs5pr1	151	32	failed	fail	VBD
cord-282507-swxs5pr1	151	33	to	to	TO
cord-282507-swxs5pr1	151	34	significantly	significantly	RB
cord-282507-swxs5pr1	151	35	induce	induce	VB
cord-282507-swxs5pr1	151	36	IFN	IFN	NNP
cord-282507-swxs5pr1	151	37	-	-	HYPH
cord-282507-swxs5pr1	151	38	γ	γ	NNP
cord-282507-swxs5pr1	151	39	.	.	.
cord-282507-swxs5pr1	152	1	This	this	DT
cord-282507-swxs5pr1	152	2	effect	effect	NN
cord-282507-swxs5pr1	152	3	results	result	VBZ
cord-282507-swxs5pr1	152	4	from	from	IN
cord-282507-swxs5pr1	152	5	the	the	DT
cord-282507-swxs5pr1	152	6	MPL	MPL	NNP
cord-282507-swxs5pr1	152	7	/	/	SYM
cord-282507-swxs5pr1	152	8	QS-21	QS-21	NNP
cord-282507-swxs5pr1	152	9	synergy	synergy	NN
cord-282507-swxs5pr1	152	10	and	and	CC
cord-282507-swxs5pr1	152	11	is	be	VBZ
cord-282507-swxs5pr1	152	12	controlled	control	VBN
cord-282507-swxs5pr1	152	13	by	by	IN
cord-282507-swxs5pr1	152	14	macrophages	macrophage	NNS
cord-282507-swxs5pr1	152	15	,	,	,
cord-282507-swxs5pr1	152	16	Il-11	Il-11	NNP
cord-282507-swxs5pr1	152	17	and	and	CC
cord-282507-swxs5pr1	152	18	Il-18	Il-18	NNP
cord-282507-swxs5pr1	152	19	.	.	.
cord-282507-swxs5pr1	152	20	QS-21	qs-21	XX
cord-282507-swxs5pr1	152	21	containing	contain	VBG
cord-282507-swxs5pr1	152	22	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	152	23	have	have	VBP
cord-282507-swxs5pr1	152	24	been	be	VBN
cord-282507-swxs5pr1	152	25	assessed	assess	VBN
cord-282507-swxs5pr1	152	26	in	in	IN
cord-282507-swxs5pr1	152	27	more	more	JJR
cord-282507-swxs5pr1	152	28	than	than	IN
cord-282507-swxs5pr1	152	29	100	100	CD
cord-282507-swxs5pr1	152	30	human	human	JJ
cord-282507-swxs5pr1	152	31	clinical	clinical	JJ
cord-282507-swxs5pr1	152	32	trials	trial	NNS
cord-282507-swxs5pr1	152	33	.	.	.
cord-282507-swxs5pr1	153	1	AS01	AS01	NNP
cord-282507-swxs5pr1	153	2	is	be	VBZ
cord-282507-swxs5pr1	153	3	a	a	DT
cord-282507-swxs5pr1	153	4	key	key	JJ
cord-282507-swxs5pr1	153	5	component	component	NN
cord-282507-swxs5pr1	153	6	of	of	IN
cord-282507-swxs5pr1	153	7	the	the	DT
cord-282507-swxs5pr1	153	8	recently	recently	RB
cord-282507-swxs5pr1	153	9	developed	develop	VBN
cord-282507-swxs5pr1	153	10	malaria	malaria	NN
cord-282507-swxs5pr1	153	11	and	and	CC
cord-282507-swxs5pr1	153	12	HZ	HZ	NNP
cord-282507-swxs5pr1	153	13	vaccines	vaccine	NNS
cord-282507-swxs5pr1	153	14	and	and	CC
cord-282507-swxs5pr1	153	15	other	other	JJ
cord-282507-swxs5pr1	153	16	candidate	candidate	NN
cord-282507-swxs5pr1	153	17	vaccines	vaccine	NNS
cord-282507-swxs5pr1	153	18	under	under	IN
cord-282507-swxs5pr1	153	19	development	development	NN
cord-282507-swxs5pr1	153	20	against	against	IN
cord-282507-swxs5pr1	153	21	infectious	infectious	JJ
cord-282507-swxs5pr1	153	22	diseases	disease	NNS
cord-282507-swxs5pr1	153	23	,	,	,
cord-282507-swxs5pr1	153	24	and	and	CC
cord-282507-swxs5pr1	153	25	cancer	cancer	NN
cord-282507-swxs5pr1	153	26	Didierlaurent	Didierlaurent	NNP
cord-282507-swxs5pr1	153	27	et	et	NNP
cord-282507-swxs5pr1	153	28	al	al	NNP
cord-282507-swxs5pr1	153	29	.	.	NNP
cord-282507-swxs5pr1	153	30	,	,	,
cord-282507-swxs5pr1	153	31	2017	2017	CD
cord-282507-swxs5pr1	153	32	;	;	:
cord-282507-swxs5pr1	153	33	Garçon	Garçon	NNP
cord-282507-swxs5pr1	153	34	and	and	CC
cord-282507-swxs5pr1	153	35	di	di	NNP
cord-282507-swxs5pr1	153	36	Pasquale	Pasquale	NNP
cord-282507-swxs5pr1	153	37	,	,	,
cord-282507-swxs5pr1	153	38	2017	2017	CD
cord-282507-swxs5pr1	153	39	)	)	-RRB-
cord-282507-swxs5pr1	153	40	.	.	.
cord-282507-swxs5pr1	154	1	Recent	recent	JJ
cord-282507-swxs5pr1	154	2	clinical	clinical	JJ
cord-282507-swxs5pr1	154	3	studies	study	NNS
cord-282507-swxs5pr1	154	4	of	of	IN
cord-282507-swxs5pr1	154	5	prophylactic	prophylactic	JJ
cord-282507-swxs5pr1	154	6	vaccines	vaccine	NNS
cord-282507-swxs5pr1	154	7	against	against	IN
cord-282507-swxs5pr1	154	8	malaria	malaria	NN
cord-282507-swxs5pr1	154	9	,	,	,
cord-282507-swxs5pr1	154	10	HZ	HZ	NNP
cord-282507-swxs5pr1	154	11	,	,	,
cord-282507-swxs5pr1	154	12	HIV	HIV	NNP
cord-282507-swxs5pr1	154	13	,	,	,
cord-282507-swxs5pr1	154	14	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	154	15	from	from	IN
cord-282507-swxs5pr1	154	16	an	an	DT
cord-282507-swxs5pr1	154	17	efficacy	efficacy	NN
cord-282507-swxs5pr1	154	18	,	,	,
cord-282507-swxs5pr1	154	19	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	154	20	and	and	CC
cord-282507-swxs5pr1	154	21	safety	safety	NN
cord-282507-swxs5pr1	154	22	points	point	NNS
cord-282507-swxs5pr1	154	23	of	of	IN
cord-282507-swxs5pr1	154	24	view	view	NN
cord-282507-swxs5pr1	154	25	(	(	-LRB-
cord-282507-swxs5pr1	154	26	Table	table	NN
cord-282507-swxs5pr1	154	27	1	1	CD
cord-282507-swxs5pr1	154	28	)	)	-RRB-
cord-282507-swxs5pr1	155	1	and	and	CC
cord-282507-swxs5pr1	155	2	of	of	IN
cord-282507-swxs5pr1	155	3	therapeutic	therapeutic	JJ
cord-282507-swxs5pr1	155	4	vaccines	vaccine	NNS
cord-282507-swxs5pr1	155	5	against	against	IN
cord-282507-swxs5pr1	155	6	melanoma	melanoma	NN
cord-282507-swxs5pr1	155	7	,	,	,
cord-282507-swxs5pr1	155	8	NSCLC	NSCLC	NNP
cord-282507-swxs5pr1	155	9	and	and	CC
cord-282507-swxs5pr1	155	10	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	155	11	's	's	POS
cord-282507-swxs5pr1	155	12	disease	disease	NN
cord-282507-swxs5pr1	155	13	,	,	,
cord-282507-swxs5pr1	155	14	will	will	MD
cord-282507-swxs5pr1	155	15	be	be	VB
cord-282507-swxs5pr1	155	16	reported	report	VBN
cord-282507-swxs5pr1	155	17	below	below	RB
cord-282507-swxs5pr1	155	18	.	.	.
cord-282507-swxs5pr1	156	1	Despite	despite	IN
cord-282507-swxs5pr1	156	2	effective	effective	JJ
cord-282507-swxs5pr1	156	3	medicines	medicine	NNS
cord-282507-swxs5pr1	156	4	,	,	,
cord-282507-swxs5pr1	156	5	insecticide	insecticide	NN
cord-282507-swxs5pr1	156	6	-	-	HYPH
cord-282507-swxs5pr1	156	7	treated	treat	VBN
cord-282507-swxs5pr1	156	8	nets	net	NNS
cord-282507-swxs5pr1	156	9	and	and	CC
cord-282507-swxs5pr1	156	10	indoor	indoor	JJ
cord-282507-swxs5pr1	156	11	insecticide	insecticide	NN
cord-282507-swxs5pr1	156	12	spraying	spraying	NN
cord-282507-swxs5pr1	156	13	,	,	,
cord-282507-swxs5pr1	156	14	malaria	malaria	NN
cord-282507-swxs5pr1	156	15	killed	kill	VBD
cord-282507-swxs5pr1	156	16	445,000	445,000	CD
cord-282507-swxs5pr1	156	17	people	people	NNS
cord-282507-swxs5pr1	156	18	in	in	IN
cord-282507-swxs5pr1	156	19	2016	2016	CD
cord-282507-swxs5pr1	156	20	,	,	,
cord-282507-swxs5pr1	156	21	particularly	particularly	RB
cord-282507-swxs5pr1	156	22	sub	sub	JJ
cord-282507-swxs5pr1	156	23	-	-	JJ
cord-282507-swxs5pr1	156	24	Saharan	saharan	JJ
cord-282507-swxs5pr1	156	25	African	african	JJ
cord-282507-swxs5pr1	156	26	children	child	NNS
cord-282507-swxs5pr1	156	27	(	(	-LRB-
cord-282507-swxs5pr1	156	28	World	World	NNP
cord-282507-swxs5pr1	156	29	Malaria	Malaria	NNP
cord-282507-swxs5pr1	156	30	Day	Day	NNP
cord-282507-swxs5pr1	156	31	,	,	,
cord-282507-swxs5pr1	156	32	2018	2018	CD
cord-282507-swxs5pr1	156	33	)	)	-RRB-
cord-282507-swxs5pr1	156	34	.	.	.
cord-282507-swxs5pr1	157	1	The	the	DT
cord-282507-swxs5pr1	157	2	Ag	Ag	NNP
cord-282507-swxs5pr1	157	3	of	of	IN
cord-282507-swxs5pr1	157	4	the	the	DT
cord-282507-swxs5pr1	157	5	candidate	candidate	NN
cord-282507-swxs5pr1	157	6	malaria	malaria	NN
cord-282507-swxs5pr1	157	7	vaccine	vaccine	NN
cord-282507-swxs5pr1	157	8	RTS	RTS	NNP
cord-282507-swxs5pr1	157	9	,	,	,
cord-282507-swxs5pr1	157	10	S	S	NNP
cord-282507-swxs5pr1	157	11	targets	target	VBZ
cord-282507-swxs5pr1	157	12	the	the	DT
cord-282507-swxs5pr1	157	13	CSP	CSP	NNP
cord-282507-swxs5pr1	157	14	which	which	WDT
cord-282507-swxs5pr1	157	15	is	be	VBZ
cord-282507-swxs5pr1	157	16	expressed	express	VBN
cord-282507-swxs5pr1	157	17	on	on	IN
cord-282507-swxs5pr1	157	18	the	the	DT
cord-282507-swxs5pr1	157	19	plasmodium	plasmodium	NN
cord-282507-swxs5pr1	157	20	sporozoite	sporozoite	NN
cord-282507-swxs5pr1	157	21	during	during	IN
cord-282507-swxs5pr1	157	22	the	the	DT
cord-282507-swxs5pr1	157	23	pre	pre	JJ
cord-282507-swxs5pr1	157	24	-	-	JJ
cord-282507-swxs5pr1	157	25	erythrocytic	erythrocytic	JJ
cord-282507-swxs5pr1	157	26	stage	stage	NN
cord-282507-swxs5pr1	157	27	of	of	IN
cord-282507-swxs5pr1	157	28	its	-PRON-	PRP$
cord-282507-swxs5pr1	157	29	lifecycle	lifecycle	NN
cord-282507-swxs5pr1	157	30	,	,	,
cord-282507-swxs5pr1	157	31	the	the	DT
cord-282507-swxs5pr1	157	32	stage	stage	NN
cord-282507-swxs5pr1	157	33	between	between	IN
cord-282507-swxs5pr1	157	34	mosquito	mosquito	NN
cord-282507-swxs5pr1	157	35	bite	bite	NN
cord-282507-swxs5pr1	157	36	and	and	CC
cord-282507-swxs5pr1	157	37	liver	liver	NN
cord-282507-swxs5pr1	157	38	infection	infection	NN
cord-282507-swxs5pr1	157	39	.	.	.
cord-282507-swxs5pr1	158	1	RTS	RTS	NNP
cord-282507-swxs5pr1	158	2	,	,	,
cord-282507-swxs5pr1	158	3	S	S	NNP
cord-282507-swxs5pr1	158	4	/AS02	/AS02	NNP
cord-282507-swxs5pr1	158	5	,	,	,
cord-282507-swxs5pr1	158	6	was	be	VBD
cord-282507-swxs5pr1	158	7	the	the	DT
cord-282507-swxs5pr1	158	8	first	first	JJ
cord-282507-swxs5pr1	158	9	malaria	malaria	NN
cord-282507-swxs5pr1	158	10	vaccine	vaccine	NN
cord-282507-swxs5pr1	158	11	candidate	candidate	NN
cord-282507-swxs5pr1	158	12	,	,	,
cord-282507-swxs5pr1	158	13	in	in	IN
cord-282507-swxs5pr1	158	14	which	which	WDT
cord-282507-swxs5pr1	158	15	an	an	DT
cord-282507-swxs5pr1	158	16	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	158	17	system	system	NN
cord-282507-swxs5pr1	158	18	was	be	VBD
cord-282507-swxs5pr1	158	19	used	use	VBN
cord-282507-swxs5pr1	158	20	(	(	-LRB-
cord-282507-swxs5pr1	158	21	Garçon	Garçon	NNP
cord-282507-swxs5pr1	158	22	et	et	FW
cord-282507-swxs5pr1	158	23	al	al	NNP
cord-282507-swxs5pr1	158	24	.	.	NNP
cord-282507-swxs5pr1	158	25	,	,	,
cord-282507-swxs5pr1	158	26	2007	2007	CD
cord-282507-swxs5pr1	158	27	)	)	-RRB-
cord-282507-swxs5pr1	158	28	.	.	.
cord-282507-swxs5pr1	159	1	However	however	RB
cord-282507-swxs5pr1	159	2	,	,	,
cord-282507-swxs5pr1	159	3	RTS	RTS	NNP
cord-282507-swxs5pr1	159	4	,	,	,
cord-282507-swxs5pr1	159	5	S	S	NNP
cord-282507-swxs5pr1	159	6	/	/	SYM
cord-282507-swxs5pr1	159	7	AS01	AS01	NNP
cord-282507-swxs5pr1	159	8	was	be	VBD
cord-282507-swxs5pr1	159	9	shown	show	VBN
cord-282507-swxs5pr1	159	10	in	in	IN
cord-282507-swxs5pr1	159	11	a	a	DT
cord-282507-swxs5pr1	159	12	phase	phase	NN
cord-282507-swxs5pr1	160	1	II	II	NNP
cord-282507-swxs5pr1	160	2	trial	trial	NN
cord-282507-swxs5pr1	160	3	to	to	TO
cord-282507-swxs5pr1	160	4	be	be	VB
cord-282507-swxs5pr1	160	5	well	well	RB
cord-282507-swxs5pr1	160	6	tolerated	tolerate	VBN
cord-282507-swxs5pr1	160	7	,	,	,
cord-282507-swxs5pr1	160	8	to	to	TO
cord-282507-swxs5pr1	160	9	induce	induce	VB
cord-282507-swxs5pr1	160	10	strong	strong	JJ
cord-282507-swxs5pr1	160	11	humoral	humoral	JJ
cord-282507-swxs5pr1	160	12	and	and	CC
cord-282507-swxs5pr1	160	13	cellular	cellular	JJ
cord-282507-swxs5pr1	160	14	immune	immune	JJ
cord-282507-swxs5pr1	160	15	response	response	NN
cord-282507-swxs5pr1	160	16	and	and	CC
cord-282507-swxs5pr1	160	17	to	to	TO
cord-282507-swxs5pr1	160	18	improve	improve	VB
cord-282507-swxs5pr1	160	19	protection	protection	NN
cord-282507-swxs5pr1	160	20	against	against	IN
cord-282507-swxs5pr1	160	21	Plasmodium	Plasmodium	NNP
cord-282507-swxs5pr1	160	22	falciparum	falciparum	NN
cord-282507-swxs5pr1	160	23	challenge	challenge	NN
cord-282507-swxs5pr1	160	24	in	in	IN
cord-282507-swxs5pr1	160	25	comparison	comparison	NN
cord-282507-swxs5pr1	160	26	to	to	IN
cord-282507-swxs5pr1	160	27	RTS	RTS	NNP
cord-282507-swxs5pr1	160	28	,	,	,
cord-282507-swxs5pr1	160	29	S	S	NNP
cord-282507-swxs5pr1	160	30	/	/	SYM
cord-282507-swxs5pr1	160	31	AS02	AS02	NNP
cord-282507-swxs5pr1	161	1	(	(	-LRB-
cord-282507-swxs5pr1	161	2	Kester	Kester	NNP
cord-282507-swxs5pr1	161	3	et	et	NNP
cord-282507-swxs5pr1	161	4	al	al	NNP
cord-282507-swxs5pr1	161	5	.	.	NNP
cord-282507-swxs5pr1	161	6	,	,	,
cord-282507-swxs5pr1	161	7	2009	2009	CD
cord-282507-swxs5pr1	161	8	)	)	-RRB-
cord-282507-swxs5pr1	161	9	.	.	.
cord-282507-swxs5pr1	162	1	Namely	namely	RB
cord-282507-swxs5pr1	162	2	,	,	,
cord-282507-swxs5pr1	162	3	it	-PRON-	PRP
cord-282507-swxs5pr1	162	4	induced	induce	VBD
cord-282507-swxs5pr1	162	5	high	high	JJ
cord-282507-swxs5pr1	162	6	levels	level	NNS
cord-282507-swxs5pr1	162	7	of	of	IN
cord-282507-swxs5pr1	162	8	anti	anti	JJ
cord-282507-swxs5pr1	162	9	-	-	JJ
cord-282507-swxs5pr1	162	10	CSP	CSP	NNP
cord-282507-swxs5pr1	162	11	IgG	igg	NN
cord-282507-swxs5pr1	162	12	titers	titer	NNS
cord-282507-swxs5pr1	162	13	and	and	CC
cord-282507-swxs5pr1	162	14	CSP	CSP	NNP
cord-282507-swxs5pr1	162	15	-	-	HYPH
cord-282507-swxs5pr1	162	16	specific	specific	JJ
cord-282507-swxs5pr1	162	17	polyfunctional	polyfunctional	JJ
cord-282507-swxs5pr1	162	18	CD4	CD4	NNP
cord-282507-swxs5pr1	162	19	+	+	CC
cord-282507-swxs5pr1	162	20	T	T	NNP
cord-282507-swxs5pr1	162	21	cells	cell	NNS
cord-282507-swxs5pr1	162	22	expressing	express	VBG
cord-282507-swxs5pr1	162	23	Il-2	Il-2	NNP
cord-282507-swxs5pr1	162	24	,	,	,
cord-282507-swxs5pr1	162	25	IFNγ	IFNγ	NNS
cord-282507-swxs5pr1	162	26	,	,	,
cord-282507-swxs5pr1	162	27	TNFα	TNFα	NNS
cord-282507-swxs5pr1	162	28	or	or	CC
cord-282507-swxs5pr1	162	29	CD40L	cd40l	NN
cord-282507-swxs5pr1	162	30	which	which	WDT
cord-282507-swxs5pr1	162	31	have	have	VBP
cord-282507-swxs5pr1	162	32	been	be	VBN
cord-282507-swxs5pr1	162	33	associated	associate	VBN
cord-282507-swxs5pr1	162	34	with	with	IN
cord-282507-swxs5pr1	162	35	protection	protection	NN
cord-282507-swxs5pr1	162	36	in	in	IN
cord-282507-swxs5pr1	162	37	the	the	DT
cord-282507-swxs5pr1	162	38	experimental	experimental	JJ
cord-282507-swxs5pr1	162	39	malaria	malaria	NN
cord-282507-swxs5pr1	162	40	challenge	challenge	NN
cord-282507-swxs5pr1	162	41	model	model	NN
cord-282507-swxs5pr1	162	42	in	in	IN
cord-282507-swxs5pr1	162	43	adults	adult	NNS
cord-282507-swxs5pr1	162	44	.	.	.
cord-282507-swxs5pr1	163	1	Other	other	JJ
cord-282507-swxs5pr1	163	2	clinical	clinical	JJ
cord-282507-swxs5pr1	163	3	trials	trial	NNS
cord-282507-swxs5pr1	163	4	in	in	IN
cord-282507-swxs5pr1	163	5	children	child	NNS
cord-282507-swxs5pr1	163	6	and	and	CC
cord-282507-swxs5pr1	163	7	adults	adult	NNS
cord-282507-swxs5pr1	163	8	confirmed	confirm	VBD
cord-282507-swxs5pr1	163	9	these	these	DT
cord-282507-swxs5pr1	163	10	observations	observation	NNS
cord-282507-swxs5pr1	163	11	and	and	CC
cord-282507-swxs5pr1	163	12	no	no	DT
cord-282507-swxs5pr1	163	13	serious	serious	JJ
cord-282507-swxs5pr1	163	14	adverse	adverse	JJ
cord-282507-swxs5pr1	163	15	events	event	NNS
cord-282507-swxs5pr1	163	16	were	be	VBD
cord-282507-swxs5pr1	163	17	reported	report	VBN
cord-282507-swxs5pr1	164	1	(	(	-LRB-
cord-282507-swxs5pr1	164	2	Agnandji	Agnandji	NNP
cord-282507-swxs5pr1	164	3	et	et	NNP
cord-282507-swxs5pr1	164	4	al	al	NNP
cord-282507-swxs5pr1	164	5	.	.	NNP
cord-282507-swxs5pr1	164	6	,	,	,
cord-282507-swxs5pr1	164	7	2010	2010	CD
cord-282507-swxs5pr1	164	8	;	;	:
cord-282507-swxs5pr1	164	9	Olotu	Olotu	NNP
cord-282507-swxs5pr1	164	10	et	et	NNP
cord-282507-swxs5pr1	164	11	al	al	NNP
cord-282507-swxs5pr1	164	12	.	.	NNP
cord-282507-swxs5pr1	164	13	,	,	,
cord-282507-swxs5pr1	164	14	2011	2011	CD
cord-282507-swxs5pr1	164	15	;	;	:
cord-282507-swxs5pr1	164	16	Ansong	Ansong	NNP
cord-282507-swxs5pr1	164	17	et	et	NNP
cord-282507-swxs5pr1	164	18	al	al	NNP
cord-282507-swxs5pr1	164	19	.	.	NNP
cord-282507-swxs5pr1	164	20	,	,	,
cord-282507-swxs5pr1	164	21	2011	2011	CD
cord-282507-swxs5pr1	165	1	;	;	:
cord-282507-swxs5pr1	165	2	White	White	NNP
cord-282507-swxs5pr1	165	3	et	et	NNP
cord-282507-swxs5pr1	165	4	al	al	NNP
cord-282507-swxs5pr1	165	5	.	.	NNP
cord-282507-swxs5pr1	165	6	,	,	,
cord-282507-swxs5pr1	165	7	2013	2013	CD
cord-282507-swxs5pr1	165	8	;	;	:
cord-282507-swxs5pr1	165	9	Levast	Levast	NNP
cord-282507-swxs5pr1	165	10	et	et	NNP
cord-282507-swxs5pr1	165	11	al	al	NNP
cord-282507-swxs5pr1	165	12	.	.	NNP
cord-282507-swxs5pr1	165	13	,	,	,
cord-282507-swxs5pr1	165	14	2014	2014	CD
cord-282507-swxs5pr1	165	15	;	;	:
cord-282507-swxs5pr1	165	16	Leroux	Leroux	NNP
cord-282507-swxs5pr1	165	17	-	-	HYPH
cord-282507-swxs5pr1	165	18	Roels	Roels	NNP
cord-282507-swxs5pr1	165	19	et	et	NNP
cord-282507-swxs5pr1	165	20	al	al	NNP
cord-282507-swxs5pr1	165	21	.	.	NNP
cord-282507-swxs5pr1	165	22	,	,	,
cord-282507-swxs5pr1	165	23	2014a	2014a	CD
cord-282507-swxs5pr1	165	24	)	)	-RRB-
cord-282507-swxs5pr1	165	25	.	.	.
cord-282507-swxs5pr1	166	1	Therefore	therefore	RB
cord-282507-swxs5pr1	166	2	the	the	DT
cord-282507-swxs5pr1	166	3	development	development	NN
cord-282507-swxs5pr1	166	4	of	of	IN
cord-282507-swxs5pr1	166	5	RTS	RTS	NNP
cord-282507-swxs5pr1	166	6	,	,	,
cord-282507-swxs5pr1	166	7	S	S	NNP
cord-282507-swxs5pr1	166	8	/	/	SYM
cord-282507-swxs5pr1	166	9	AS02	AS02	NNP
cord-282507-swxs5pr1	166	10	was	be	VBD
cord-282507-swxs5pr1	166	11	stopped	stop	VBN
cord-282507-swxs5pr1	166	12	and	and	CC
cord-282507-swxs5pr1	166	13	RTS	RTS	NNP
cord-282507-swxs5pr1	166	14	,	,	,
cord-282507-swxs5pr1	166	15	S	S	NNP
cord-282507-swxs5pr1	166	16	/	/	SYM
cord-282507-swxs5pr1	166	17	S	S	NNP
cord-282507-swxs5pr1	167	1	/AS01	/AS01	NNP
cord-282507-swxs5pr1	167	2	was	be	VBD
cord-282507-swxs5pr1	167	3	consequently	consequently	RB
cord-282507-swxs5pr1	167	4	selected	select	VBN
cord-282507-swxs5pr1	167	5	for	for	IN
cord-282507-swxs5pr1	167	6	phase	phase	NN
cord-282507-swxs5pr1	167	7	III	iii	CD
cord-282507-swxs5pr1	167	8	development	development	NN
cord-282507-swxs5pr1	167	9	.	.	.
cord-282507-swxs5pr1	168	1	Analyses	analysis	NNS
cord-282507-swxs5pr1	168	2	of	of	IN
cord-282507-swxs5pr1	168	3	data	datum	NNS
cord-282507-swxs5pr1	168	4	in	in	IN
cord-282507-swxs5pr1	168	5	term	term	NN
cord-282507-swxs5pr1	168	6	of	of	IN
cord-282507-swxs5pr1	168	7	efficacy	efficacy	NN
cord-282507-swxs5pr1	168	8	,	,	,
cord-282507-swxs5pr1	168	9	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	168	10	and	and	CC
cord-282507-swxs5pr1	168	11	safety	safety	NN
cord-282507-swxs5pr1	168	12	of	of	IN
cord-282507-swxs5pr1	168	13	Phase	Phase	NNP
cord-282507-swxs5pr1	168	14	I	I	NNP
cord-282507-swxs5pr1	168	15	-	-	HYPH
cord-282507-swxs5pr1	168	16	III	iii	CD
cord-282507-swxs5pr1	168	17	trials	trial	NNS
cord-282507-swxs5pr1	168	18	including	include	VBG
cord-282507-swxs5pr1	168	19	adults	adult	NNS
cord-282507-swxs5pr1	168	20	,	,	,
cord-282507-swxs5pr1	168	21	infants	infant	NNS
cord-282507-swxs5pr1	168	22	,	,	,
cord-282507-swxs5pr1	168	23	and	and	CC
cord-282507-swxs5pr1	168	24	children	child	NNS
cord-282507-swxs5pr1	168	25	from	from	IN
cord-282507-swxs5pr1	168	26	sub	sub	JJ
cord-282507-swxs5pr1	168	27	-	-	JJ
cord-282507-swxs5pr1	168	28	Saharan	saharan	JJ
cord-282507-swxs5pr1	168	29	countries	country	NNS
cord-282507-swxs5pr1	168	30	were	be	VBD
cord-282507-swxs5pr1	168	31	reviewed	review	VBN
cord-282507-swxs5pr1	169	1	(	(	-LRB-
cord-282507-swxs5pr1	169	2	Agnandji	Agnandji	NNP
cord-282507-swxs5pr1	169	3	et	et	NNP
cord-282507-swxs5pr1	169	4	al	al	NNP
cord-282507-swxs5pr1	169	5	.	.	NNP
cord-282507-swxs5pr1	169	6	,	,	,
cord-282507-swxs5pr1	169	7	2015	2015	CD
cord-282507-swxs5pr1	169	8	)	)	-RRB-
cord-282507-swxs5pr1	169	9	.	.	.
cord-282507-swxs5pr1	170	1	Clinical	clinical	JJ
cord-282507-swxs5pr1	170	2	trials	trial	NNS
cord-282507-swxs5pr1	170	3	in	in	IN
cord-282507-swxs5pr1	170	4	children	child	NNS
cord-282507-swxs5pr1	170	5	with	with	IN
cord-282507-swxs5pr1	170	6	newly	newly	RB
cord-282507-swxs5pr1	170	7	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	170	8	vaccines	vaccine	NNS
cord-282507-swxs5pr1	170	9	led	lead	VBD
cord-282507-swxs5pr1	170	10	to	to	IN
cord-282507-swxs5pr1	170	11	the	the	DT
cord-282507-swxs5pr1	170	12	conclusion	conclusion	NN
cord-282507-swxs5pr1	170	13	of	of	IN
cord-282507-swxs5pr1	170	14	clinical	clinical	JJ
cord-282507-swxs5pr1	170	15	safety	safety	NN
cord-282507-swxs5pr1	170	16	except	except	IN
cord-282507-swxs5pr1	170	17	for	for	IN
cord-282507-swxs5pr1	170	18	some	some	DT
cord-282507-swxs5pr1	170	19	unexplained	unexplained	JJ
cord-282507-swxs5pr1	170	20	cases	case	NNS
cord-282507-swxs5pr1	170	21	of	of	IN
cord-282507-swxs5pr1	170	22	meningitis	meningitis	NN
cord-282507-swxs5pr1	170	23	in	in	IN
cord-282507-swxs5pr1	170	24	one	one	CD
cord-282507-swxs5pr1	170	25	phase	phase	NN
cord-282507-swxs5pr1	170	26	III	iii	CD
cord-282507-swxs5pr1	171	1	AS01	AS01	NNP
cord-282507-swxs5pr1	171	2	adjuvanted	adjuvante	VBD
cord-282507-swxs5pr1	171	3	malaria	malaria	NN
cord-282507-swxs5pr1	171	4	vaccine	vaccine	NN
cord-282507-swxs5pr1	171	5	trial	trial	NN
cord-282507-swxs5pr1	171	6	,	,	,
cord-282507-swxs5pr1	171	7	which	which	WDT
cord-282507-swxs5pr1	171	8	warrant	warrant	VBP
cord-282507-swxs5pr1	171	9	further	further	JJ
cord-282507-swxs5pr1	171	10	safety	safety	NN
cord-282507-swxs5pr1	171	11	evaluations	evaluation	NNS
cord-282507-swxs5pr1	172	1	(	(	-LRB-
cord-282507-swxs5pr1	172	2	Stassijns	Stassijns	NNP
cord-282507-swxs5pr1	172	3	et	et	NNP
cord-282507-swxs5pr1	172	4	al	al	NNP
cord-282507-swxs5pr1	172	5	.	.	NNP
cord-282507-swxs5pr1	172	6	,	,	,
cord-282507-swxs5pr1	172	7	2016	2016	CD
cord-282507-swxs5pr1	172	8	)	)	-RRB-
cord-282507-swxs5pr1	172	9	.	.	.
cord-282507-swxs5pr1	173	1	Important	important	JJ
cord-282507-swxs5pr1	173	2	insights	insight	NNS
cord-282507-swxs5pr1	173	3	into	into	IN
cord-282507-swxs5pr1	173	4	the	the	DT
cord-282507-swxs5pr1	173	5	molecular	molecular	JJ
cord-282507-swxs5pr1	173	6	mechanism	mechanism	NN
cord-282507-swxs5pr1	173	7	of	of	IN
cord-282507-swxs5pr1	173	8	protective	protective	JJ
cord-282507-swxs5pr1	173	9	immunity	immunity	NN
cord-282507-swxs5pr1	173	10	against	against	IN
cord-282507-swxs5pr1	173	11	malaria	malaria	NN
cord-282507-swxs5pr1	173	12	were	be	VBD
cord-282507-swxs5pr1	173	13	achieved	achieve	VBN
cord-282507-swxs5pr1	173	14	involving	involve	VBG
cord-282507-swxs5pr1	173	15	additional	additional	JJ
cord-282507-swxs5pr1	173	16	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	173	17	analyses	analysis	NNS
cord-282507-swxs5pr1	173	18	into	into	IN
cord-282507-swxs5pr1	173	19	the	the	DT
cord-282507-swxs5pr1	173	20	potential	potential	JJ
cord-282507-swxs5pr1	173	21	contributive	contributive	JJ
cord-282507-swxs5pr1	173	22	roles	role	NNS
cord-282507-swxs5pr1	173	23	of	of	IN
cord-282507-swxs5pr1	173	24	CSP	CSP	NNP
cord-282507-swxs5pr1	173	25	-	-	HYPH
cord-282507-swxs5pr1	173	26	specific	specific	JJ
cord-282507-swxs5pr1	173	27	Abs	Abs	NNP
cord-282507-swxs5pr1	173	28	and	and	CC
cord-282507-swxs5pr1	173	29	CSP	CSP	NNP
cord-282507-swxs5pr1	173	30	-	-	HYPH
cord-282507-swxs5pr1	173	31	specific	specific	JJ
cord-282507-swxs5pr1	173	32	CMI	CMI	NNP
cord-282507-swxs5pr1	173	33	to	to	IN
cord-282507-swxs5pr1	173	34	protection	protection	NN
cord-282507-swxs5pr1	173	35	(	(	-LRB-
cord-282507-swxs5pr1	173	36	Moris	Moris	NNP
cord-282507-swxs5pr1	173	37	et	et	NNP
cord-282507-swxs5pr1	173	38	al	al	NNP
cord-282507-swxs5pr1	173	39	.	.	NNP
cord-282507-swxs5pr1	173	40	,	,	,
cord-282507-swxs5pr1	173	41	2018	2018	CD
cord-282507-swxs5pr1	173	42	;	;	:
cord-282507-swxs5pr1	173	43	Kazmin	Kazmin	NNP
cord-282507-swxs5pr1	173	44	et	et	NNP
cord-282507-swxs5pr1	173	45	al	al	NNP
cord-282507-swxs5pr1	173	46	.	.	NNP
cord-282507-swxs5pr1	173	47	,	,	,
cord-282507-swxs5pr1	173	48	2017	2017	CD
cord-282507-swxs5pr1	173	49	)	)	-RRB-
cord-282507-swxs5pr1	173	50	leading	lead	VBG
cord-282507-swxs5pr1	173	51	to	to	IN
cord-282507-swxs5pr1	173	52	the	the	DT
cord-282507-swxs5pr1	173	53	identification	identification	NN
cord-282507-swxs5pr1	173	54	of	of	IN
cord-282507-swxs5pr1	173	55	the	the	DT
cord-282507-swxs5pr1	173	56	NF	NF	NNP
cord-282507-swxs5pr1	173	57	-	-	HYPH
cord-282507-swxs5pr1	173	58	kB	kB	NNP
cord-282507-swxs5pr1	173	59	and	and	CC
cord-282507-swxs5pr1	173	60	IFN	IFN	NNP
cord-282507-swxs5pr1	173	61	-	-	HYPH
cord-282507-swxs5pr1	173	62	γ	γ	NNP
cord-282507-swxs5pr1	173	63	pathways	pathway	NNS
cord-282507-swxs5pr1	173	64	(	(	-LRB-
cord-282507-swxs5pr1	173	65	van	van	NNP
cord-282507-swxs5pr1	173	66	den	den	NNP
cord-282507-swxs5pr1	173	67	Berg	Berg	NNP
cord-282507-swxs5pr1	173	68	et	et	NNP
cord-282507-swxs5pr1	173	69	al	al	NNP
cord-282507-swxs5pr1	173	70	.	.	NNP
cord-282507-swxs5pr1	173	71	,	,	,
cord-282507-swxs5pr1	173	72	2017	2017	CD
cord-282507-swxs5pr1	173	73	)	)	-RRB-
cord-282507-swxs5pr1	173	74	.	.	.
cord-282507-swxs5pr1	174	1	The	the	DT
cord-282507-swxs5pr1	174	2	first	first	JJ
cord-282507-swxs5pr1	174	3	clinical	clinical	JJ
cord-282507-swxs5pr1	174	4	large	large	JJ
cord-282507-swxs5pr1	174	5	-	-	HYPH
cord-282507-swxs5pr1	174	6	scale	scale	NN
cord-282507-swxs5pr1	174	7	Phase	phase	NN
cord-282507-swxs5pr1	174	8	III	iii	CD
cord-282507-swxs5pr1	174	9	trial	trial	NN
cord-282507-swxs5pr1	174	10	(	(	-LRB-
cord-282507-swxs5pr1	174	11	The	the	DT
cord-282507-swxs5pr1	174	12	RTS	RTS	NNP
cord-282507-swxs5pr1	174	13	,	,	,
cord-282507-swxs5pr1	174	14	S	S	NNP
cord-282507-swxs5pr1	174	15	clinical	clinical	JJ
cord-282507-swxs5pr1	174	16	trials	trial	NNS
cord-282507-swxs5pr1	174	17	partnership	partnership	NN
cord-282507-swxs5pr1	174	18	,	,	,
cord-282507-swxs5pr1	174	19	2014	2014	CD
cord-282507-swxs5pr1	174	20	)	)	-RRB-
cord-282507-swxs5pr1	174	21	evaluating	evaluate	VBG
cord-282507-swxs5pr1	174	22	a	a	DT
cord-282507-swxs5pr1	174	23	malaria	malaria	NN
cord-282507-swxs5pr1	174	24	vaccine	vaccine	NN
cord-282507-swxs5pr1	174	25	involving	involve	VBG
cord-282507-swxs5pr1	174	26	15,460	15,460	CD
cord-282507-swxs5pr1	174	27	infants	infant	NNS
cord-282507-swxs5pr1	174	28	and	and	CC
cord-282507-swxs5pr1	174	29	young	young	JJ
cord-282507-swxs5pr1	174	30	children	child	NNS
cord-282507-swxs5pr1	174	31	was	be	VBD
cord-282507-swxs5pr1	174	32	completed	complete	VBN
cord-282507-swxs5pr1	174	33	in	in	IN
cord-282507-swxs5pr1	174	34	December	December	NNP
cord-282507-swxs5pr1	174	35	2013	2013	CD
cord-282507-swxs5pr1	174	36	at	at	IN
cord-282507-swxs5pr1	174	37	11	11	CD
cord-282507-swxs5pr1	174	38	sites	site	NNS
cord-282507-swxs5pr1	174	39	from	from	IN
cord-282507-swxs5pr1	174	40	7	7	CD
cord-282507-swxs5pr1	174	41	African	african	JJ
cord-282507-swxs5pr1	174	42	countries	country	NNS
cord-282507-swxs5pr1	174	43	(	(	-LRB-
cord-282507-swxs5pr1	174	44	Burkina	Burkina	NNP
cord-282507-swxs5pr1	174	45	Faso	Faso	NNP
cord-282507-swxs5pr1	174	46	,	,	,
cord-282507-swxs5pr1	174	47	Gabon	Gabon	NNP
cord-282507-swxs5pr1	174	48	,	,	,
cord-282507-swxs5pr1	174	49	Ghana	Ghana	NNP
cord-282507-swxs5pr1	174	50	,	,	,
cord-282507-swxs5pr1	174	51	Kenya	Kenya	NNP
cord-282507-swxs5pr1	174	52	,	,	,
cord-282507-swxs5pr1	174	53	Malawi	Malawi	NNP
cord-282507-swxs5pr1	174	54	,	,	,
cord-282507-swxs5pr1	174	55	Mozambique	Mozambique	NNP
cord-282507-swxs5pr1	174	56	,	,	,
cord-282507-swxs5pr1	174	57	and	and	CC
cord-282507-swxs5pr1	174	58	Tanzania	Tanzania	NNP
cord-282507-swxs5pr1	174	59	)	)	-RRB-
cord-282507-swxs5pr1	174	60	.	.	.
cord-282507-swxs5pr1	175	1	Safety	safety	NN
cord-282507-swxs5pr1	175	2	and	and	CC
cord-282507-swxs5pr1	175	3	efficacy	efficacy	NN
cord-282507-swxs5pr1	175	4	studies	study	NNS
cord-282507-swxs5pr1	175	5	of	of	IN
cord-282507-swxs5pr1	175	6	the	the	DT
cord-282507-swxs5pr1	175	7	RTS	RTS	NNP
cord-282507-swxs5pr1	175	8	,	,	,
cord-282507-swxs5pr1	175	9	S/	S/	NNP
cord-282507-swxs5pr1	175	10	AS01	AS01	NNP
cord-282507-swxs5pr1	175	11	vaccine	vaccine	NN
cord-282507-swxs5pr1	175	12	(	(	-LRB-
cord-282507-swxs5pr1	175	13	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	175	14	™	™	NN
cord-282507-swxs5pr1	175	15	)	)	-RRB-
cord-282507-swxs5pr1	175	16	showed	show	VBD
cord-282507-swxs5pr1	175	17	that	that	IN
cord-282507-swxs5pr1	175	18	it	-PRON-	PRP
cord-282507-swxs5pr1	175	19	prevented	prevent	VBD
cord-282507-swxs5pr1	175	20	many	many	JJ
cord-282507-swxs5pr1	175	21	cases	case	NNS
cord-282507-swxs5pr1	175	22	of	of	IN
cord-282507-swxs5pr1	175	23	clinical	clinical	JJ
cord-282507-swxs5pr1	175	24	and	and	CC
cord-282507-swxs5pr1	175	25	severe	severe	JJ
cord-282507-swxs5pr1	175	26	malaria	malaria	NN
cord-282507-swxs5pr1	175	27	over	over	IN
cord-282507-swxs5pr1	175	28	the	the	DT
cord-282507-swxs5pr1	175	29	18	18	CD
cord-282507-swxs5pr1	175	30	months	month	NNS
cord-282507-swxs5pr1	175	31	after	after	IN
cord-282507-swxs5pr1	175	32	dose	dose	NN
cord-282507-swxs5pr1	175	33	3	3	CD
cord-282507-swxs5pr1	175	34	.	.	.
cord-282507-swxs5pr1	176	1	Vaccine	vaccine	NN
cord-282507-swxs5pr1	176	2	efficacy	efficacy	NN
cord-282507-swxs5pr1	176	3	was	be	VBD
cord-282507-swxs5pr1	176	4	higher	high	JJR
cord-282507-swxs5pr1	176	5	in	in	IN
cord-282507-swxs5pr1	176	6	children	child	NNS
cord-282507-swxs5pr1	176	7	(	(	-LRB-
cord-282507-swxs5pr1	176	8	5	5	CD
cord-282507-swxs5pr1	176	9	-	-	SYM
cord-282507-swxs5pr1	176	10	17	17	CD
cord-282507-swxs5pr1	176	11	months	month	NNS
cord-282507-swxs5pr1	176	12	)	)	-RRB-
cord-282507-swxs5pr1	176	13	than	than	IN
cord-282507-swxs5pr1	176	14	in	in	IN
cord-282507-swxs5pr1	176	15	infants	infant	NNS
cord-282507-swxs5pr1	176	16	(	(	-LRB-
cord-282507-swxs5pr1	176	17	6	6	CD
cord-282507-swxs5pr1	176	18	-	-	SYM
cord-282507-swxs5pr1	176	19	12	12	CD
cord-282507-swxs5pr1	176	20	weeks	week	NNS
cord-282507-swxs5pr1	176	21	)	)	-RRB-
cord-282507-swxs5pr1	176	22	,	,	,
cord-282507-swxs5pr1	176	23	but	but	CC
cord-282507-swxs5pr1	176	24	even	even	RB
cord-282507-swxs5pr1	176	25	at	at	IN
cord-282507-swxs5pr1	176	26	modest	modest	JJ
cord-282507-swxs5pr1	176	27	levels	level	NNS
cord-282507-swxs5pr1	176	28	(	(	-LRB-
cord-282507-swxs5pr1	176	29	45.7	45.7	CD
cord-282507-swxs5pr1	176	30	%	%	NN
cord-282507-swxs5pr1	176	31	)	)	-RRB-
cord-282507-swxs5pr1	176	32	.	.	.
cord-282507-swxs5pr1	177	1	The	the	DT
cord-282507-swxs5pr1	177	2	final	final	JJ
cord-282507-swxs5pr1	177	3	results	result	NNS
cord-282507-swxs5pr1	177	4	in	in	IN
cord-282507-swxs5pr1	177	5	2015	2015	CD
cord-282507-swxs5pr1	177	6	(	(	-LRB-
cord-282507-swxs5pr1	177	7	The	the	DT
cord-282507-swxs5pr1	177	8	RTS	RTS	NNP
cord-282507-swxs5pr1	177	9	,	,	,
cord-282507-swxs5pr1	177	10	S	S	NNP
cord-282507-swxs5pr1	177	11	clinical	clinical	JJ
cord-282507-swxs5pr1	177	12	trials	trial	NNS
cord-282507-swxs5pr1	177	13	partnership	partnership	NN
cord-282507-swxs5pr1	177	14	,	,	,
cord-282507-swxs5pr1	177	15	2015	2015	CD
cord-282507-swxs5pr1	177	16	)	)	-RRB-
cord-282507-swxs5pr1	177	17	from	from	IN
cord-282507-swxs5pr1	177	18	the	the	DT
cord-282507-swxs5pr1	177	19	same	same	JJ
cord-282507-swxs5pr1	177	20	trial	trial	NN
cord-282507-swxs5pr1	177	21	,	,	,
cord-282507-swxs5pr1	177	22	showed	show	VBD
cord-282507-swxs5pr1	177	23	the	the	DT
cord-282507-swxs5pr1	177	24	enhanced	enhance	VBN
cord-282507-swxs5pr1	177	25	efficacy	efficacy	NN
cord-282507-swxs5pr1	177	26	by	by	IN
cord-282507-swxs5pr1	177	27	administration	administration	NN
cord-282507-swxs5pr1	177	28	of	of	IN
cord-282507-swxs5pr1	177	29	a	a	DT
cord-282507-swxs5pr1	177	30	booster	booster	NN
cord-282507-swxs5pr1	177	31	dose	dose	NN
cord-282507-swxs5pr1	177	32	in	in	IN
cord-282507-swxs5pr1	177	33	both	both	DT
cord-282507-swxs5pr1	177	34	age	age	NN
cord-282507-swxs5pr1	177	35	categories	category	NNS
cord-282507-swxs5pr1	177	36	,	,	,
cord-282507-swxs5pr1	177	37	18	18	CD
cord-282507-swxs5pr1	177	38	months	month	NNS
cord-282507-swxs5pr1	177	39	after	after	IN
cord-282507-swxs5pr1	177	40	the	the	DT
cord-282507-swxs5pr1	177	41	first	first	JJ
cord-282507-swxs5pr1	177	42	three	three	CD
cord-282507-swxs5pr1	177	43	injections	injection	NNS
cord-282507-swxs5pr1	177	44	.	.	.
cord-282507-swxs5pr1	178	1	With	with	IN
cord-282507-swxs5pr1	178	2	regards	regard	NNS
cord-282507-swxs5pr1	178	3	to	to	IN
cord-282507-swxs5pr1	178	4	risks	risk	NNS
cord-282507-swxs5pr1	178	5	,	,	,
cord-282507-swxs5pr1	178	6	the	the	DT
cord-282507-swxs5pr1	178	7	safety	safety	NN
cord-282507-swxs5pr1	178	8	of	of	IN
cord-282507-swxs5pr1	178	9	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	178	10	is	be	VBZ
cord-282507-swxs5pr1	178	11	similar	similar	JJ
cord-282507-swxs5pr1	178	12	to	to	IN
cord-282507-swxs5pr1	178	13	that	that	DT
cord-282507-swxs5pr1	178	14	of	of	IN
cord-282507-swxs5pr1	178	15	other	other	JJ
cord-282507-swxs5pr1	178	16	vaccines	vaccine	NNS
cord-282507-swxs5pr1	178	17	,	,	,
cord-282507-swxs5pr1	178	18	the	the	DT
cord-282507-swxs5pr1	178	19	most	most	RBS
cord-282507-swxs5pr1	178	20	common	common	JJ
cord-282507-swxs5pr1	178	21	side	side	NN
cord-282507-swxs5pr1	178	22	effects	effect	NNS
cord-282507-swxs5pr1	178	23	being	be	VBG
cord-282507-swxs5pr1	178	24	fever	fever	NN
cord-282507-swxs5pr1	178	25	,	,	,
cord-282507-swxs5pr1	178	26	pain	pain	NN
cord-282507-swxs5pr1	178	27	and	and	CC
cord-282507-swxs5pr1	178	28	swelling	swell	VBG
cord-282507-swxs5pr1	178	29	at	at	IN
cord-282507-swxs5pr1	178	30	the	the	DT
cord-282507-swxs5pr1	178	31	injection	injection	NN
cord-282507-swxs5pr1	178	32	sites	site	NNS
cord-282507-swxs5pr1	178	33	.	.	.
cord-282507-swxs5pr1	179	1	Thus	thus	RB
cord-282507-swxs5pr1	179	2	,	,	,
cord-282507-swxs5pr1	179	3	the	the	DT
cord-282507-swxs5pr1	179	4	vaccine	vaccine	NN
cord-282507-swxs5pr1	179	5	has	have	VBZ
cord-282507-swxs5pr1	179	6	the	the	DT
cord-282507-swxs5pr1	179	7	potential	potential	NN
cord-282507-swxs5pr1	179	8	to	to	TO
cord-282507-swxs5pr1	179	9	make	make	VB
cord-282507-swxs5pr1	179	10	a	a	DT
cord-282507-swxs5pr1	179	11	substantial	substantial	JJ
cord-282507-swxs5pr1	179	12	contribution	contribution	NN
cord-282507-swxs5pr1	179	13	to	to	IN
cord-282507-swxs5pr1	179	14	malaria	malaria	NN
cord-282507-swxs5pr1	179	15	control	control	NN
cord-282507-swxs5pr1	179	16	when	when	WRB
cord-282507-swxs5pr1	179	17	used	use	VBN
cord-282507-swxs5pr1	179	18	in	in	IN
cord-282507-swxs5pr1	179	19	combination	combination	NN
cord-282507-swxs5pr1	179	20	with	with	IN
cord-282507-swxs5pr1	179	21	other	other	JJ
cord-282507-swxs5pr1	179	22	effective	effective	JJ
cord-282507-swxs5pr1	179	23	control	control	NN
cord-282507-swxs5pr1	179	24	measures	measure	NNS
cord-282507-swxs5pr1	179	25	,	,	,
cord-282507-swxs5pr1	179	26	especially	especially	RB
cord-282507-swxs5pr1	179	27	in	in	IN
cord-282507-swxs5pr1	179	28	areas	area	NNS
cord-282507-swxs5pr1	179	29	of	of	IN
cord-282507-swxs5pr1	179	30	high	high	JJ
cord-282507-swxs5pr1	179	31	transmission	transmission	NN
cord-282507-swxs5pr1	179	32	.	.	.
cord-282507-swxs5pr1	180	1	The	the	DT
cord-282507-swxs5pr1	180	2	ratio	ratio	NN
cord-282507-swxs5pr1	180	3	benefit	benefit	NN
cord-282507-swxs5pr1	180	4	/	/	SYM
cord-282507-swxs5pr1	180	5	risk	risk	NN
cord-282507-swxs5pr1	180	6	of	of	IN
cord-282507-swxs5pr1	180	7	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	180	8	was	be	VBD
cord-282507-swxs5pr1	180	9	found	find	VBN
cord-282507-swxs5pr1	180	10	to	to	TO
cord-282507-swxs5pr1	180	11	be	be	VB
cord-282507-swxs5pr1	180	12	acceptable	acceptable	JJ
cord-282507-swxs5pr1	180	13	by	by	IN
cord-282507-swxs5pr1	180	14	the	the	DT
cord-282507-swxs5pr1	180	15	European	European	NNP
cord-282507-swxs5pr1	180	16	Medicines	Medicines	NNPS
cord-282507-swxs5pr1	180	17	Agency	Agency	NNP
cord-282507-swxs5pr1	180	18	's	's	POS
cord-282507-swxs5pr1	180	19	committee	committee	NN
cord-282507-swxs5pr1	180	20	for	for	IN
cord-282507-swxs5pr1	180	21	Medicinal	Medicinal	NNP
cord-282507-swxs5pr1	180	22	Products	Products	NNPS
cord-282507-swxs5pr1	180	23	for	for	IN
cord-282507-swxs5pr1	180	24	Human	human	JJ
cord-282507-swxs5pr1	180	25	use	use	NN
cord-282507-swxs5pr1	180	26	(	(	-LRB-
cord-282507-swxs5pr1	180	27	EMA	EMA	NNP
cord-282507-swxs5pr1	180	28	/	/	SYM
cord-282507-swxs5pr1	180	29	CHMP	CHMP	NNP
cord-282507-swxs5pr1	180	30	)	)	-RRB-
cord-282507-swxs5pr1	180	31	which	which	WDT
cord-282507-swxs5pr1	180	32	delivered	deliver	VBD
cord-282507-swxs5pr1	180	33	a	a	DT
cord-282507-swxs5pr1	180	34	positive	positive	JJ
cord-282507-swxs5pr1	180	35	scientific	scientific	JJ
cord-282507-swxs5pr1	180	36	opinion	opinion	NN
cord-282507-swxs5pr1	180	37	in	in	IN
cord-282507-swxs5pr1	180	38	2015	2015	CD
cord-282507-swxs5pr1	180	39	for	for	IN
cord-282507-swxs5pr1	180	40	use	use	NN
cord-282507-swxs5pr1	180	41	outside	outside	IN
cord-282507-swxs5pr1	180	42	the	the	DT
cord-282507-swxs5pr1	180	43	European	European	NNP
cord-282507-swxs5pr1	180	44	Union	Union	NNP
cord-282507-swxs5pr1	180	45	(	(	-LRB-
cord-282507-swxs5pr1	180	46	EU	EU	NNP
cord-282507-swxs5pr1	180	47	)	)	-RRB-
cord-282507-swxs5pr1	181	1	(	(	-LRB-
cord-282507-swxs5pr1	181	2	EMA	EMA	NNP
cord-282507-swxs5pr1	181	3	Press	Press	NNP
cord-282507-swxs5pr1	181	4	release	release	NN
cord-282507-swxs5pr1	181	5	,	,	,
cord-282507-swxs5pr1	181	6	2015	2015	CD
cord-282507-swxs5pr1	181	7	)	)	-RRB-
cord-282507-swxs5pr1	181	8	.	.	.
cord-282507-swxs5pr1	182	1	Furthermore	furthermore	RB
cord-282507-swxs5pr1	182	2	,	,	,
cord-282507-swxs5pr1	182	3	the	the	DT
cord-282507-swxs5pr1	182	4	World	World	NNP
cord-282507-swxs5pr1	182	5	Health	Health	NNP
cord-282507-swxs5pr1	182	6	Organization	Organization	NNP
cord-282507-swxs5pr1	182	7	recommended	recommend	VBD
cord-282507-swxs5pr1	182	8	a	a	DT
cord-282507-swxs5pr1	182	9	large	large	JJ
cord-282507-swxs5pr1	182	10	-	-	HYPH
cord-282507-swxs5pr1	182	11	scale	scale	NN
cord-282507-swxs5pr1	182	12	pilot	pilot	NN
cord-282507-swxs5pr1	182	13	implementation	implementation	NN
cord-282507-swxs5pr1	182	14	of	of	IN
cord-282507-swxs5pr1	182	15	the	the	DT
cord-282507-swxs5pr1	182	16	vaccine	vaccine	NN
cord-282507-swxs5pr1	182	17	in	in	IN
cord-282507-swxs5pr1	182	18	young	young	JJ
cord-282507-swxs5pr1	182	19	children	child	NNS
cord-282507-swxs5pr1	182	20	with	with	IN
cord-282507-swxs5pr1	182	21	a	a	DT
cord-282507-swxs5pr1	182	22	four	four	CD
cord-282507-swxs5pr1	182	23	-	-	HYPH
cord-282507-swxs5pr1	182	24	dose	dose	NN
cord-282507-swxs5pr1	182	25	schedule	schedule	NN
cord-282507-swxs5pr1	182	26	in	in	IN
cord-282507-swxs5pr1	182	27	African	african	JJ
cord-282507-swxs5pr1	182	28	regions	region	NNS
cord-282507-swxs5pr1	182	29	of	of	IN
cord-282507-swxs5pr1	182	30	moderate	moderate	JJ
cord-282507-swxs5pr1	182	31	to	to	IN
cord-282507-swxs5pr1	182	32	high	high	JJ
cord-282507-swxs5pr1	182	33	parasite	parasite	NN
cord-282507-swxs5pr1	182	34	transmission	transmission	NN
cord-282507-swxs5pr1	182	35	(	(	-LRB-
cord-282507-swxs5pr1	182	36	WHO	who	WP
cord-282507-swxs5pr1	182	37	,	,	,
cord-282507-swxs5pr1	182	38	2016	2016	CD
cord-282507-swxs5pr1	182	39	)	)	-RRB-
cord-282507-swxs5pr1	182	40	.	.	.
cord-282507-swxs5pr1	183	1	Three	three	CD
cord-282507-swxs5pr1	183	2	countries	country	NNS
cord-282507-swxs5pr1	183	3	,	,	,
cord-282507-swxs5pr1	183	4	Ghana	Ghana	NNP
cord-282507-swxs5pr1	183	5	,	,	,
cord-282507-swxs5pr1	183	6	Kenya	Kenya	NNP
cord-282507-swxs5pr1	183	7	,	,	,
cord-282507-swxs5pr1	183	8	and	and	CC
cord-282507-swxs5pr1	183	9	Malawi	Malawi	NNP
cord-282507-swxs5pr1	183	10	were	be	VBD
cord-282507-swxs5pr1	183	11	selected	select	VBN
cord-282507-swxs5pr1	183	12	by	by	IN
cord-282507-swxs5pr1	183	13	the	the	DT
cord-282507-swxs5pr1	183	14	WHO	WHO	NNP
cord-282507-swxs5pr1	183	15	in	in	IN
cord-282507-swxs5pr1	183	16	2017	2017	CD
cord-282507-swxs5pr1	183	17	for	for	IN
cord-282507-swxs5pr1	183	18	this	this	DT
cord-282507-swxs5pr1	183	19	largescale	largescale	JJ
cord-282507-swxs5pr1	183	20	pilot	pilot	NN
cord-282507-swxs5pr1	183	21	program	program	NN
cord-282507-swxs5pr1	183	22	which	which	WDT
cord-282507-swxs5pr1	183	23	started	start	VBD
cord-282507-swxs5pr1	183	24	in	in	IN
cord-282507-swxs5pr1	183	25	2018	2018	CD
cord-282507-swxs5pr1	183	26	.	.	.
cord-282507-swxs5pr1	184	1	It	-PRON-	PRP
cord-282507-swxs5pr1	184	2	will	will	MD
cord-282507-swxs5pr1	184	3	be	be	VB
cord-282507-swxs5pr1	184	4	the	the	DT
cord-282507-swxs5pr1	184	5	first	first	JJ
cord-282507-swxs5pr1	184	6	malaria	malaria	NN
cord-282507-swxs5pr1	184	7	Table	table	NN
cord-282507-swxs5pr1	184	8	1	1	CD
cord-282507-swxs5pr1	184	9	Clinical	clinical	JJ
cord-282507-swxs5pr1	184	10	trials	trial	NNS
cord-282507-swxs5pr1	184	11	involving	involve	VBG
cord-282507-swxs5pr1	184	12	newly	newly	RB
cord-282507-swxs5pr1	184	13	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	184	14	prophylactic	prophylactic	JJ
cord-282507-swxs5pr1	184	15	vacccines	vacccine	NNS
cord-282507-swxs5pr1	184	16	.	.	.
cord-282507-swxs5pr1	185	1	vaccine	vaccine	NN
cord-282507-swxs5pr1	185	2	provided	provide	VBN
cord-282507-swxs5pr1	185	3	to	to	IN
cord-282507-swxs5pr1	185	4	young	young	JJ
cord-282507-swxs5pr1	185	5	children	child	NNS
cord-282507-swxs5pr1	185	6	through	through	IN
cord-282507-swxs5pr1	185	7	routine	routine	JJ
cord-282507-swxs5pr1	185	8	immunization	immunization	NN
cord-282507-swxs5pr1	185	9	programmes	programme	NNS
cord-282507-swxs5pr1	185	10	(	(	-LRB-
cord-282507-swxs5pr1	185	11	Malaria	Malaria	NNP
cord-282507-swxs5pr1	185	12	vaccine	vaccine	NN
cord-282507-swxs5pr1	185	13	implementation	implementation	NN
cord-282507-swxs5pr1	185	14	programme	programme	NN
cord-282507-swxs5pr1	185	15	,	,	,
cord-282507-swxs5pr1	185	16	2019	2019	CD
cord-282507-swxs5pr1	185	17	)	)	-RRB-
cord-282507-swxs5pr1	185	18	.	.	.
cord-282507-swxs5pr1	186	1	The	the	DT
cord-282507-swxs5pr1	186	2	results	result	NNS
cord-282507-swxs5pr1	186	3	of	of	IN
cord-282507-swxs5pr1	186	4	two	two	CD
cord-282507-swxs5pr1	186	5	phases	phase	NNS
cord-282507-swxs5pr1	186	6	(	(	-LRB-
cord-282507-swxs5pr1	186	7	2017	2017	CD
cord-282507-swxs5pr1	186	8	-	-	SYM
cord-282507-swxs5pr1	186	9	20	20	CD
cord-282507-swxs5pr1	186	10	,	,	,
cord-282507-swxs5pr1	186	11	and	and	CC
cord-282507-swxs5pr1	186	12	2020	2020	CD
cord-282507-swxs5pr1	186	13	-	-	SYM
cord-282507-swxs5pr1	186	14	21	21	CD
cord-282507-swxs5pr1	186	15	)	)	-RRB-
cord-282507-swxs5pr1	186	16	providing	provide	VBG
cord-282507-swxs5pr1	186	17	insights	insight	NNS
cord-282507-swxs5pr1	186	18	on	on	IN
cord-282507-swxs5pr1	186	19	the	the	DT
cord-282507-swxs5pr1	186	20	feasibility	feasibility	NN
cord-282507-swxs5pr1	186	21	of	of	IN
cord-282507-swxs5pr1	186	22	delivering	deliver	VBG
cord-282507-swxs5pr1	186	23	the	the	DT
cord-282507-swxs5pr1	186	24	vaccine	vaccine	NN
cord-282507-swxs5pr1	186	25	in	in	IN
cord-282507-swxs5pr1	186	26	real	real	JJ
cord-282507-swxs5pr1	186	27	-	-	HYPH
cord-282507-swxs5pr1	186	28	life	life	NN
cord-282507-swxs5pr1	186	29	settings	setting	NNS
cord-282507-swxs5pr1	186	30	and	and	CC
cord-282507-swxs5pr1	186	31	on	on	IN
cord-282507-swxs5pr1	186	32	its	-PRON-	PRP$
cord-282507-swxs5pr1	186	33	safety	safety	NN
cord-282507-swxs5pr1	186	34	profile	profile	NN
cord-282507-swxs5pr1	186	35	in	in	IN
cord-282507-swxs5pr1	186	36	the	the	DT
cord-282507-swxs5pr1	186	37	context	context	NN
cord-282507-swxs5pr1	186	38	of	of	IN
cord-282507-swxs5pr1	186	39	routine	routine	JJ
cord-282507-swxs5pr1	186	40	use	use	NN
cord-282507-swxs5pr1	186	41	,	,	,
cord-282507-swxs5pr1	186	42	will	will	MD
cord-282507-swxs5pr1	186	43	contribute	contribute	VB
cord-282507-swxs5pr1	186	44	to	to	IN
cord-282507-swxs5pr1	186	45	the	the	DT
cord-282507-swxs5pr1	186	46	future	future	JJ
cord-282507-swxs5pr1	186	47	decisions	decision	NNS
cord-282507-swxs5pr1	186	48	on	on	IN
cord-282507-swxs5pr1	186	49	the	the	DT
cord-282507-swxs5pr1	186	50	wider	wide	JJR
cord-282507-swxs5pr1	186	51	-	-	HYPH
cord-282507-swxs5pr1	186	52	scale	scale	NN
cord-282507-swxs5pr1	186	53	use	use	NN
cord-282507-swxs5pr1	186	54	of	of	IN
cord-282507-swxs5pr1	186	55	the	the	DT
cord-282507-swxs5pr1	186	56	vaccine	vaccine	NN
cord-282507-swxs5pr1	186	57	.	.	.
cord-282507-swxs5pr1	187	1	Herpes	Herpes	NNP
cord-282507-swxs5pr1	187	2	zoster	zoster	NN
cord-282507-swxs5pr1	187	3	(	(	-LRB-
cord-282507-swxs5pr1	187	4	HZ	HZ	NNP
cord-282507-swxs5pr1	187	5	)	)	-RRB-
cord-282507-swxs5pr1	187	6	,	,	,
cord-282507-swxs5pr1	187	7	also	also	RB
cord-282507-swxs5pr1	187	8	known	know	VBN
cord-282507-swxs5pr1	187	9	as	as	IN
cord-282507-swxs5pr1	187	10	shingles	shingle	NNS
cord-282507-swxs5pr1	187	11	is	be	VBZ
cord-282507-swxs5pr1	187	12	a	a	DT
cord-282507-swxs5pr1	187	13	common	common	JJ
cord-282507-swxs5pr1	187	14	,	,	,
cord-282507-swxs5pr1	187	15	painful	painful	JJ
cord-282507-swxs5pr1	187	16	disease	disease	NN
cord-282507-swxs5pr1	187	17	occurring	occur	VBG
cord-282507-swxs5pr1	187	18	principally	principally	RB
cord-282507-swxs5pr1	187	19	in	in	IN
cord-282507-swxs5pr1	187	20	adults	adult	NNS
cord-282507-swxs5pr1	187	21	aged	age	VBN
cord-282507-swxs5pr1	187	22	>	>	XX
cord-282507-swxs5pr1	187	23	50	50	CD
cord-282507-swxs5pr1	187	24	years	year	NNS
cord-282507-swxs5pr1	187	25	and	and	CC
cord-282507-swxs5pr1	187	26	immunocompromised	immunocompromised	JJ
cord-282507-swxs5pr1	187	27	individuals	individual	NNS
cord-282507-swxs5pr1	187	28	.	.	.
cord-282507-swxs5pr1	188	1	HZ	HZ	NNP
cord-282507-swxs5pr1	188	2	is	be	VBZ
cord-282507-swxs5pr1	188	3	caused	cause	VBN
cord-282507-swxs5pr1	188	4	by	by	IN
cord-282507-swxs5pr1	188	5	the	the	DT
cord-282507-swxs5pr1	188	6	reactivation	reactivation	NN
cord-282507-swxs5pr1	188	7	of	of	IN
cord-282507-swxs5pr1	188	8	the	the	DT
cord-282507-swxs5pr1	188	9	latent	latent	JJ
cord-282507-swxs5pr1	188	10	varicella	varicella	NN
cord-282507-swxs5pr1	188	11	-	-	HYPH
cord-282507-swxs5pr1	188	12	zoster	zoster	NN
cord-282507-swxs5pr1	188	13	virus	virus	NN
cord-282507-swxs5pr1	188	14	(	(	-LRB-
cord-282507-swxs5pr1	188	15	VZV	VZV	NNP
cord-282507-swxs5pr1	188	16	)	)	-RRB-
cord-282507-swxs5pr1	188	17	in	in	IN
cord-282507-swxs5pr1	188	18	the	the	DT
cord-282507-swxs5pr1	188	19	dorsal	dorsal	JJ
cord-282507-swxs5pr1	188	20	root	root	NN
cord-282507-swxs5pr1	188	21	or	or	CC
cord-282507-swxs5pr1	188	22	cranial	cranial	JJ
cord-282507-swxs5pr1	188	23	ganglia	ganglion	NNS
cord-282507-swxs5pr1	188	24	usually	usually	RB
cord-282507-swxs5pr1	188	25	many	many	JJ
cord-282507-swxs5pr1	188	26	years	year	NNS
cord-282507-swxs5pr1	188	27	after	after	IN
cord-282507-swxs5pr1	188	28	a	a	DT
cord-282507-swxs5pr1	188	29	primary	primary	JJ
cord-282507-swxs5pr1	188	30	VZV	VZV	NNP
cord-282507-swxs5pr1	188	31	infection	infection	NN
cord-282507-swxs5pr1	188	32	(	(	-LRB-
cord-282507-swxs5pr1	188	33	chickenpox	chickenpox	NN
cord-282507-swxs5pr1	188	34	)	)	-RRB-
cord-282507-swxs5pr1	188	35	that	that	WDT
cord-282507-swxs5pr1	188	36	occurs	occur	VBZ
cord-282507-swxs5pr1	188	37	during	during	IN
cord-282507-swxs5pr1	188	38	childhood	childhood	NN
cord-282507-swxs5pr1	188	39	.	.	.
cord-282507-swxs5pr1	189	1	HZ	HZ	NNP
cord-282507-swxs5pr1	189	2	can	can	MD
cord-282507-swxs5pr1	189	3	lead	lead	VB
cord-282507-swxs5pr1	189	4	to	to	IN
cord-282507-swxs5pr1	189	5	serious	serious	JJ
cord-282507-swxs5pr1	189	6	complications	complication	NNS
cord-282507-swxs5pr1	189	7	including	include	VBG
cord-282507-swxs5pr1	189	8	post	post	JJ
cord-282507-swxs5pr1	189	9	herpetic	herpetic	JJ
cord-282507-swxs5pr1	189	10	neuralgia	neuralgia	NN
cord-282507-swxs5pr1	189	11	(	(	-LRB-
cord-282507-swxs5pr1	189	12	PHN	PHN	NNP
cord-282507-swxs5pr1	189	13	)	)	-RRB-
cord-282507-swxs5pr1	189	14	.	.	.
cord-282507-swxs5pr1	190	1	A	a	DT
cord-282507-swxs5pr1	190	2	phase	phase	NN
cord-282507-swxs5pr1	190	3	I	-PRON-	PRP
cord-282507-swxs5pr1	190	4	/	/	SYM
cord-282507-swxs5pr1	190	5	II	II	NNP
cord-282507-swxs5pr1	190	6	trial	trial	NN
cord-282507-swxs5pr1	190	7	showed	show	VBD
cord-282507-swxs5pr1	190	8	that	that	IN
cord-282507-swxs5pr1	190	9	a	a	DT
cord-282507-swxs5pr1	190	10	subunit	subunit	NN
cord-282507-swxs5pr1	190	11	vaccine	vaccine	NN
cord-282507-swxs5pr1	190	12	containing	contain	VBG
cord-282507-swxs5pr1	190	13	the	the	DT
cord-282507-swxs5pr1	190	14	recombinant	recombinant	JJ
cord-282507-swxs5pr1	190	15	VZV	VZV	NNP
cord-282507-swxs5pr1	190	16	glycoprotein	glycoprotein	NN
cord-282507-swxs5pr1	190	17	E	e	NN
cord-282507-swxs5pr1	190	18	(	(	-LRB-
cord-282507-swxs5pr1	190	19	gE	gE	NNP
cord-282507-swxs5pr1	190	20	)	)	-RRB-
cord-282507-swxs5pr1	190	21	as	as	IN
cord-282507-swxs5pr1	190	22	Ag	Ag	NNP
cord-282507-swxs5pr1	190	23	and	and	CC
cord-282507-swxs5pr1	190	24	AS01	AS01	NNP
cord-282507-swxs5pr1	190	25	B	B	NNP
cord-282507-swxs5pr1	190	26	(	(	-LRB-
cord-282507-swxs5pr1	190	27	called	call	VBN
cord-282507-swxs5pr1	190	28	HZ	HZ	NNP
cord-282507-swxs5pr1	190	29	/	/	SYM
cord-282507-swxs5pr1	190	30	su	su	NNP
cord-282507-swxs5pr1	190	31	)	)	-RRB-
cord-282507-swxs5pr1	190	32	was	be	VBD
cord-282507-swxs5pr1	190	33	well	well	RB
cord-282507-swxs5pr1	190	34	tolerated	tolerate	VBN
cord-282507-swxs5pr1	190	35	and	and	CC
cord-282507-swxs5pr1	190	36	highly	highly	RB
cord-282507-swxs5pr1	190	37	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	190	38	with	with	IN
cord-282507-swxs5pr1	190	39	CD4	CD4	NNP
cord-282507-swxs5pr1	190	40	+	+	CC
cord-282507-swxs5pr1	190	41	T	T	NNP
cord-282507-swxs5pr1	190	42	cell	cell	NN
cord-282507-swxs5pr1	190	43	and	and	CC
cord-282507-swxs5pr1	190	44	humoral	humoral	JJ
cord-282507-swxs5pr1	190	45	immune	immune	JJ
cord-282507-swxs5pr1	190	46	responses	response	NNS
cord-282507-swxs5pr1	190	47	,	,	,
cord-282507-swxs5pr1	190	48	being	be	VBG
cord-282507-swxs5pr1	190	49	more	more	RBR
cord-282507-swxs5pr1	190	50	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	190	51	than	than	IN
cord-282507-swxs5pr1	190	52	a	a	DT
cord-282507-swxs5pr1	190	53	live	live	JJ
cord-282507-swxs5pr1	190	54	attenuated	attenuated	JJ
cord-282507-swxs5pr1	190	55	vaccine	vaccine	NN
cord-282507-swxs5pr1	190	56	(	(	-LRB-
cord-282507-swxs5pr1	190	57	Leroux	Leroux	NNP
cord-282507-swxs5pr1	190	58	-	-	HYPH
cord-282507-swxs5pr1	190	59	Roels	Roels	NNP
cord-282507-swxs5pr1	190	60	et	et	NNP
cord-282507-swxs5pr1	190	61	al	al	NNP
cord-282507-swxs5pr1	190	62	.	.	NNP
cord-282507-swxs5pr1	190	63	,	,	,
cord-282507-swxs5pr1	190	64	2012	2012	CD
cord-282507-swxs5pr1	190	65	)	)	-RRB-
cord-282507-swxs5pr1	190	66	.	.	.
cord-282507-swxs5pr1	191	1	A	a	DT
cord-282507-swxs5pr1	191	2	phase	phase	NN
cord-282507-swxs5pr1	191	3	II	ii	CD
cord-282507-swxs5pr1	191	4	trial	trial	NN
cord-282507-swxs5pr1	191	5	in	in	IN
cord-282507-swxs5pr1	191	6	adults	adult	NNS
cord-282507-swxs5pr1	191	7	>	>	NFP
cord-282507-swxs5pr1	191	8	60	60	CD
cord-282507-swxs5pr1	191	9	years	year	NNS
cord-282507-swxs5pr1	191	10	of	of	IN
cord-282507-swxs5pr1	191	11	age	age	NN
cord-282507-swxs5pr1	191	12	evaluating	evaluate	VBG
cord-282507-swxs5pr1	191	13	different	different	JJ
cord-282507-swxs5pr1	191	14	formulations	formulation	NNS
cord-282507-swxs5pr1	191	15	(	(	-LRB-
cord-282507-swxs5pr1	191	16	containing	contain	VBG
cord-282507-swxs5pr1	191	17	25	25	CD
cord-282507-swxs5pr1	191	18	,	,	,
cord-282507-swxs5pr1	191	19	50	50	CD
cord-282507-swxs5pr1	191	20	,	,	,
cord-282507-swxs5pr1	191	21	or	or	CC
cord-282507-swxs5pr1	192	1	100	100	CD
cord-282507-swxs5pr1	192	2	μg	μg	NNP
cord-282507-swxs5pr1	192	3	gE	gE	NNP
cord-282507-swxs5pr1	192	4	combined	combine	VBN
cord-282507-swxs5pr1	192	5	with	with	IN
cord-282507-swxs5pr1	192	6	AS01	AS01	NNP
cord-282507-swxs5pr1	192	7	)	)	-RRB-
cord-282507-swxs5pr1	192	8	and	and	CC
cord-282507-swxs5pr1	192	9	different	different	JJ
cord-282507-swxs5pr1	192	10	schedules	schedule	NNS
cord-282507-swxs5pr1	192	11	showed	show	VBD
cord-282507-swxs5pr1	192	12	that	that	IN
cord-282507-swxs5pr1	192	13	all	all	DT
cord-282507-swxs5pr1	192	14	formulations	formulation	NNS
cord-282507-swxs5pr1	192	15	elicited	elicit	VBD
cord-282507-swxs5pr1	192	16	robust	robust	JJ
cord-282507-swxs5pr1	192	17	humoral	humoral	JJ
cord-282507-swxs5pr1	192	18	and	and	CC
cord-282507-swxs5pr1	192	19	CD4	CD4	NNP
cord-282507-swxs5pr1	192	20	+	+	CC
cord-282507-swxs5pr1	192	21	T	T	NNP
cord-282507-swxs5pr1	192	22	cell	cell	NN
cord-282507-swxs5pr1	192	23	immune	immune	JJ
cord-282507-swxs5pr1	192	24	responses	response	NNS
cord-282507-swxs5pr1	192	25	that	that	WDT
cord-282507-swxs5pr1	192	26	persisted	persist	VBD
cord-282507-swxs5pr1	192	27	for	for	IN
cord-282507-swxs5pr1	192	28	at	at	RB
cord-282507-swxs5pr1	192	29	least	least	JJS
cord-282507-swxs5pr1	192	30	3	3	CD
cord-282507-swxs5pr1	192	31	years	year	NNS
cord-282507-swxs5pr1	192	32	after	after	IN
cord-282507-swxs5pr1	192	33	vaccination	vaccination	NN
cord-282507-swxs5pr1	192	34	.	.	.
cord-282507-swxs5pr1	193	1	Two	two	CD
cord-282507-swxs5pr1	193	2	doses	dose	NNS
cord-282507-swxs5pr1	193	3	of	of	IN
cord-282507-swxs5pr1	193	4	gE/	gE/	NNP
cord-282507-swxs5pr1	193	5	AS01	AS01	NNP
cord-282507-swxs5pr1	193	6	B	B	NNP
cord-282507-swxs5pr1	193	7	were	be	VBD
cord-282507-swxs5pr1	193	8	more	more	RBR
cord-282507-swxs5pr1	193	9	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	193	10	than	than	IN
cord-282507-swxs5pr1	193	11	one	one	CD
cord-282507-swxs5pr1	194	1	(	(	-LRB-
cord-282507-swxs5pr1	194	2	Chlibek	Chlibek	NNP
cord-282507-swxs5pr1	194	3	et	et	NNP
cord-282507-swxs5pr1	194	4	al	al	NNP
cord-282507-swxs5pr1	194	5	.	.	NNP
cord-282507-swxs5pr1	194	6	,	,	,
cord-282507-swxs5pr1	194	7	2014	2014	CD
cord-282507-swxs5pr1	194	8	)	)	-RRB-
cord-282507-swxs5pr1	194	9	.	.	.
cord-282507-swxs5pr1	195	1	In	in	IN
cord-282507-swxs5pr1	195	2	a	a	DT
cord-282507-swxs5pr1	195	3	follow	follow	NN
cord-282507-swxs5pr1	195	4	-	-	HYPH
cord-282507-swxs5pr1	195	5	up	up	NN
cord-282507-swxs5pr1	195	6	study	study	NN
cord-282507-swxs5pr1	195	7	conducted	conduct	VBN
cord-282507-swxs5pr1	195	8	on	on	IN
cord-282507-swxs5pr1	195	9	129	129	CD
cord-282507-swxs5pr1	195	10	healthy	healthy	JJ
cord-282507-swxs5pr1	195	11	adults	adult	NNS
cord-282507-swxs5pr1	195	12	,	,	,
cord-282507-swxs5pr1	195	13	it	-PRON-	PRP
cord-282507-swxs5pr1	195	14	was	be	VBD
cord-282507-swxs5pr1	195	15	shown	show	VBN
cord-282507-swxs5pr1	195	16	that	that	IN
cord-282507-swxs5pr1	195	17	the	the	DT
cord-282507-swxs5pr1	195	18	gE	gE	NNP
cord-282507-swxs5pr1	195	19	specific	specific	JJ
cord-282507-swxs5pr1	195	20	CD4	CD4	NNP
cord-282507-swxs5pr1	195	21	+	+	CC
cord-282507-swxs5pr1	195	22	T	T	NNP
cord-282507-swxs5pr1	195	23	cell	cell	NN
cord-282507-swxs5pr1	195	24	and	and	CC
cord-282507-swxs5pr1	195	25	anti	anti	NNP
cord-282507-swxs5pr1	195	26	-	-	JJ
cord-282507-swxs5pr1	195	27	gE	gE	NNP
cord-282507-swxs5pr1	195	28	antibody	antibody	NN
cord-282507-swxs5pr1	195	29	responses	response	NNS
cord-282507-swxs5pr1	195	30	persisted	persist	VBD
cord-282507-swxs5pr1	195	31	for	for	IN
cord-282507-swxs5pr1	195	32	6	6	CD
cord-282507-swxs5pr1	195	33	years	year	NNS
cord-282507-swxs5pr1	195	34	after	after	IN
cord-282507-swxs5pr1	195	35	two	two	CD
cord-282507-swxs5pr1	195	36	doses	dose	NNS
cord-282507-swxs5pr1	195	37	of	of	IN
cord-282507-swxs5pr1	195	38	50	50	CD
cord-282507-swxs5pr1	195	39	μg	μg	NN
cord-282507-swxs5pr1	195	40	gE	gE	NNP
cord-282507-swxs5pr1	195	41	/	/	SYM
cord-282507-swxs5pr1	195	42	AS01	AS01	NNP
cord-282507-swxs5pr1	195	43	B	B	NNP
cord-282507-swxs5pr1	195	44	,	,	,
cord-282507-swxs5pr1	195	45	without	without	IN
cord-282507-swxs5pr1	195	46	any	any	DT
cord-282507-swxs5pr1	195	47	safety	safety	NN
cord-282507-swxs5pr1	195	48	concerns	concern	NNS
cord-282507-swxs5pr1	195	49	.	.	.
cord-282507-swxs5pr1	196	1	Therefore	therefore	RB
cord-282507-swxs5pr1	196	2	,	,	,
cord-282507-swxs5pr1	196	3	the	the	DT
cord-282507-swxs5pr1	196	4	dose	dose	NN
cord-282507-swxs5pr1	196	5	of	of	IN
cord-282507-swxs5pr1	196	6	50	50	CD
cord-282507-swxs5pr1	196	7	μg	μg	NN
cord-282507-swxs5pr1	196	8	gE	gE	NNP
cord-282507-swxs5pr1	196	9	was	be	VBD
cord-282507-swxs5pr1	196	10	selected	select	VBN
cord-282507-swxs5pr1	196	11	for	for	IN
cord-282507-swxs5pr1	196	12	other	other	JJ
cord-282507-swxs5pr1	196	13	clinical	clinical	JJ
cord-282507-swxs5pr1	196	14	developments	development	NNS
cord-282507-swxs5pr1	196	15	.	.	.
cord-282507-swxs5pr1	197	1	A	a	DT
cord-282507-swxs5pr1	197	2	two	two	CD
cord-282507-swxs5pr1	197	3	randomized	randomized	JJ
cord-282507-swxs5pr1	197	4	placebo	placebo	NN
cord-282507-swxs5pr1	197	5	-	-	HYPH
cord-282507-swxs5pr1	197	6	controlled	control	VBN
cord-282507-swxs5pr1	197	7	phase	phase	NN
cord-282507-swxs5pr1	197	8	III	iii	CD
cord-282507-swxs5pr1	197	9	efficacy	efficacy	NN
cord-282507-swxs5pr1	197	10	trials	trial	NNS
cord-282507-swxs5pr1	197	11	in	in	IN
cord-282507-swxs5pr1	197	12	18	18	CD
cord-282507-swxs5pr1	197	13	countries	country	NNS
cord-282507-swxs5pr1	197	14	evaluated	evaluate	VBD
cord-282507-swxs5pr1	197	15	the	the	DT
cord-282507-swxs5pr1	197	16	efficacy	efficacy	NN
cord-282507-swxs5pr1	197	17	and	and	CC
cord-282507-swxs5pr1	197	18	safety	safety	NN
cord-282507-swxs5pr1	197	19	of	of	IN
cord-282507-swxs5pr1	197	20	HZ	HZ	NNP
cord-282507-swxs5pr1	197	21	/	/	SYM
cord-282507-swxs5pr1	197	22	su	su	NNP
cord-282507-swxs5pr1	197	23	as	as	IN
cord-282507-swxs5pr1	197	24	compared	compare	VBN
cord-282507-swxs5pr1	197	25	to	to	IN
cord-282507-swxs5pr1	197	26	placebo	placebo	NN
cord-282507-swxs5pr1	197	27	in	in	IN
cord-282507-swxs5pr1	197	28	older	old	JJR
cord-282507-swxs5pr1	197	29	adults	adult	NNS
cord-282507-swxs5pr1	197	30	(	(	-LRB-
cord-282507-swxs5pr1	197	31	>	>	XX
cord-282507-swxs5pr1	198	1	50	50	CD
cord-282507-swxs5pr1	198	2	and	and	CC
cord-282507-swxs5pr1	198	3	>	>	XX
cord-282507-swxs5pr1	198	4	70	70	CD
cord-282507-swxs5pr1	198	5	years	year	NNS
cord-282507-swxs5pr1	198	6	of	of	IN
cord-282507-swxs5pr1	198	7	age	age	NN
cord-282507-swxs5pr1	198	8	)	)	-RRB-
cord-282507-swxs5pr1	198	9	.	.	.
cord-282507-swxs5pr1	199	1	Participants	participant	NNS
cord-282507-swxs5pr1	199	2	received	receive	VBD
cord-282507-swxs5pr1	199	3	two	two	CD
cord-282507-swxs5pr1	199	4	i	-PRON-	PRP
cord-282507-swxs5pr1	199	5	m	be	VBP
cord-282507-swxs5pr1	199	6	doses	dose	NNS
cord-282507-swxs5pr1	199	7	of	of	IN
cord-282507-swxs5pr1	199	8	the	the	DT
cord-282507-swxs5pr1	199	9	vaccine	vaccine	NN
cord-282507-swxs5pr1	199	10	or	or	CC
cord-282507-swxs5pr1	199	11	placebo	placebo	NN
cord-282507-swxs5pr1	199	12	,	,	,
cord-282507-swxs5pr1	199	13	2	2	CD
cord-282507-swxs5pr1	199	14	months	month	NNS
cord-282507-swxs5pr1	199	15	apart	apart	RB
cord-282507-swxs5pr1	199	16	.	.	.
cord-282507-swxs5pr1	200	1	HZ	HZ	NNP
cord-282507-swxs5pr1	200	2	/	/	SYM
cord-282507-swxs5pr1	200	3	su	su	NNP
cord-282507-swxs5pr1	200	4	has	have	VBZ
cord-282507-swxs5pr1	200	5	demonstrated	demonstrate	VBN
cord-282507-swxs5pr1	200	6	high	high	JJ
cord-282507-swxs5pr1	200	7	efficacy	efficacy	NN
cord-282507-swxs5pr1	200	8	(	(	-LRB-
cord-282507-swxs5pr1	200	9	97.2	97.2	CD
cord-282507-swxs5pr1	200	10	%	%	NN
cord-282507-swxs5pr1	200	11	and	and	CC
cord-282507-swxs5pr1	200	12	91.3	91.3	CD
cord-282507-swxs5pr1	200	13	%	%	NN
cord-282507-swxs5pr1	200	14	for	for	IN
cord-282507-swxs5pr1	200	15	adults	adult	NNS
cord-282507-swxs5pr1	201	1	>	>	XX
cord-282507-swxs5pr1	202	1	50	50	CD
cord-282507-swxs5pr1	202	2	years	year	NNS
cord-282507-swxs5pr1	202	3	and	and	CC
cord-282507-swxs5pr1	202	4	>	>	XX
cord-282507-swxs5pr1	202	5	70	70	CD
cord-282507-swxs5pr1	202	6	years	year	NNS
cord-282507-swxs5pr1	202	7	,	,	,
cord-282507-swxs5pr1	202	8	respectively	respectively	RB
cord-282507-swxs5pr1	202	9	)	)	-RRB-
cord-282507-swxs5pr1	202	10	in	in	IN
cord-282507-swxs5pr1	202	11	preventing	prevent	VBG
cord-282507-swxs5pr1	202	12	HZ	HZ	NNP
cord-282507-swxs5pr1	202	13	and	and	CC
cord-282507-swxs5pr1	202	14	PHN	PHN	NNP
cord-282507-swxs5pr1	202	15	in	in	IN
cord-282507-swxs5pr1	202	16	all	all	DT
cord-282507-swxs5pr1	202	17	age	age	NN
cord-282507-swxs5pr1	202	18	groups	group	NNS
cord-282507-swxs5pr1	202	19	with	with	IN
cord-282507-swxs5pr1	202	20	an	an	DT
cord-282507-swxs5pr1	202	21	acceptable	acceptable	JJ
cord-282507-swxs5pr1	202	22	safety	safety	NN
cord-282507-swxs5pr1	202	23	profile	profile	NN
cord-282507-swxs5pr1	202	24	(	(	-LRB-
cord-282507-swxs5pr1	202	25	Lal	Lal	NNP
cord-282507-swxs5pr1	202	26	et	et	NNP
cord-282507-swxs5pr1	202	27	al	al	NNP
cord-282507-swxs5pr1	202	28	.	.	.
cord-282507-swxs5pr1	203	1	,	,	,
cord-282507-swxs5pr1	203	2	2015	2015	CD
cord-282507-swxs5pr1	203	3	;	;	:
cord-282507-swxs5pr1	203	4	Cunningham	Cunningham	NNP
cord-282507-swxs5pr1	203	5	et	et	NNP
cord-282507-swxs5pr1	203	6	al	al	NNP
cord-282507-swxs5pr1	203	7	.	.	NNP
cord-282507-swxs5pr1	203	8	,	,	,
cord-282507-swxs5pr1	203	9	2016	2016	CD
cord-282507-swxs5pr1	203	10	)	)	-RRB-
cord-282507-swxs5pr1	203	11	.	.	.
cord-282507-swxs5pr1	204	1	The	the	DT
cord-282507-swxs5pr1	204	2	robust	robust	JJ
cord-282507-swxs5pr1	204	3	immune	immune	JJ
cord-282507-swxs5pr1	204	4	responses	response	NNS
cord-282507-swxs5pr1	204	5	remained	remain	VBD
cord-282507-swxs5pr1	204	6	for	for	IN
cord-282507-swxs5pr1	204	7	3	3	CD
cord-282507-swxs5pr1	204	8	years	year	NNS
cord-282507-swxs5pr1	204	9	after	after	IN
cord-282507-swxs5pr1	204	10	vaccination	vaccination	NN
cord-282507-swxs5pr1	204	11	as	as	IN
cord-282507-swxs5pr1	204	12	assessed	assess	VBN
cord-282507-swxs5pr1	204	13	in	in	IN
cord-282507-swxs5pr1	204	14	subsets	subset	NNS
cord-282507-swxs5pr1	204	15	of	of	IN
cord-282507-swxs5pr1	204	16	participants	participant	NNS
cord-282507-swxs5pr1	204	17	of	of	IN
cord-282507-swxs5pr1	204	18	the	the	DT
cord-282507-swxs5pr1	204	19	phase	phase	NN
cord-282507-swxs5pr1	204	20	III	iii	CD
cord-282507-swxs5pr1	204	21	trials	trial	NNS
cord-282507-swxs5pr1	204	22	.	.	.
cord-282507-swxs5pr1	205	1	Persistent	persistent	JJ
cord-282507-swxs5pr1	205	2	anti	anti	NNP
cord-282507-swxs5pr1	205	3	-	-	NNP
cord-282507-swxs5pr1	205	4	gE	gE	NNP
cord-282507-swxs5pr1	205	5	Ab	Ab	NNP
cord-282507-swxs5pr1	205	6	and	and	CC
cord-282507-swxs5pr1	205	7	gE	gE	NNP
cord-282507-swxs5pr1	205	8	-	-	HYPH
cord-282507-swxs5pr1	205	9	specific	specific	JJ
cord-282507-swxs5pr1	205	10	polyfunctional	polyfunctional	JJ
cord-282507-swxs5pr1	205	11	CD4	CD4	NNP
cord-282507-swxs5pr1	205	12	+	+	CC
cord-282507-swxs5pr1	205	13	T	T	NNP
cord-282507-swxs5pr1	205	14	cell	cell	NN
cord-282507-swxs5pr1	205	15	responses	response	NNS
cord-282507-swxs5pr1	205	16	are	be	VBP
cord-282507-swxs5pr1	205	17	likely	likely	RB
cord-282507-swxs5pr1	205	18	important	important	JJ
cord-282507-swxs5pr1	205	19	mechanisms	mechanism	NNS
cord-282507-swxs5pr1	205	20	by	by	IN
cord-282507-swxs5pr1	205	21	which	which	WDT
cord-282507-swxs5pr1	205	22	HZ	HZ	NNP
cord-282507-swxs5pr1	205	23	/	/	SYM
cord-282507-swxs5pr1	205	24	su	su	NNP
cord-282507-swxs5pr1	205	25	confers	confer	VBZ
cord-282507-swxs5pr1	205	26	the	the	DT
cord-282507-swxs5pr1	205	27	high	high	JJ
cord-282507-swxs5pr1	205	28	efficacy	efficacy	NN
cord-282507-swxs5pr1	205	29	against	against	IN
cord-282507-swxs5pr1	205	30	HZ	HZ	NNP
cord-282507-swxs5pr1	206	1	(	(	-LRB-
cord-282507-swxs5pr1	206	2	Cunningham	Cunningham	NNP
cord-282507-swxs5pr1	206	3	et	et	NNP
cord-282507-swxs5pr1	206	4	al	al	NNP
cord-282507-swxs5pr1	206	5	.	.	NNP
cord-282507-swxs5pr1	206	6	,	,	,
cord-282507-swxs5pr1	206	7	2018	2018	CD
cord-282507-swxs5pr1	206	8	)	)	-RRB-
cord-282507-swxs5pr1	206	9	.	.	.
cord-282507-swxs5pr1	207	1	In	in	IN
cord-282507-swxs5pr1	207	2	an	an	DT
cord-282507-swxs5pr1	207	3	extension	extension	NN
cord-282507-swxs5pr1	207	4	study	study	NN
cord-282507-swxs5pr1	207	5	of	of	IN
cord-282507-swxs5pr1	207	6	the	the	DT
cord-282507-swxs5pr1	207	7	original	original	JJ
cord-282507-swxs5pr1	207	8	phase	phase	NN
cord-282507-swxs5pr1	207	9	II	ii	CD
cord-282507-swxs5pr1	207	10	trials	trial	NNS
cord-282507-swxs5pr1	207	11	reported	report	VBN
cord-282507-swxs5pr1	207	12	by	by	IN
cord-282507-swxs5pr1	207	13	Chlibek	Chlibek	NNP
cord-282507-swxs5pr1	207	14	et	et	NNP
cord-282507-swxs5pr1	207	15	al	al	NNP
cord-282507-swxs5pr1	207	16	.	.	.
cord-282507-swxs5pr1	208	1	(	(	-LRB-
cord-282507-swxs5pr1	208	2	2014	2014	CD
cord-282507-swxs5pr1	208	3	Chlibek	Chlibek	NNP
cord-282507-swxs5pr1	208	4	et	et	NNP
cord-282507-swxs5pr1	208	5	al	al	NNP
cord-282507-swxs5pr1	208	6	.	.	.
cord-282507-swxs5pr1	209	1	(	(	-LRB-
cord-282507-swxs5pr1	209	2	,	,	,
cord-282507-swxs5pr1	209	3	2016	2016	CD
cord-282507-swxs5pr1	209	4	,	,	,
cord-282507-swxs5pr1	209	5	it	-PRON-	PRP
cord-282507-swxs5pr1	209	6	was	be	VBD
cord-282507-swxs5pr1	209	7	observed	observe	VBN
cord-282507-swxs5pr1	209	8	that	that	IN
cord-282507-swxs5pr1	209	9	HZ/	hz/	UH
cord-282507-swxs5pr1	209	10	su	su	NNP
cord-282507-swxs5pr1	209	11	induces	induce	VBZ
cord-282507-swxs5pr1	209	12	cell	cell	NN
cord-282507-swxs5pr1	209	13	mediated	mediate	VBN
cord-282507-swxs5pr1	209	14	and	and	CC
cord-282507-swxs5pr1	209	15	humoral	humoral	JJ
cord-282507-swxs5pr1	209	16	immunity	immunity	NN
cord-282507-swxs5pr1	209	17	persisting	persist	VBG
cord-282507-swxs5pr1	209	18	up	up	IN
cord-282507-swxs5pr1	209	19	to	to	TO
cord-282507-swxs5pr1	209	20	9	9	CD
cord-282507-swxs5pr1	209	21	years	year	NNS
cord-282507-swxs5pr1	209	22	post	post	VB
cord-282507-swxs5pr1	209	23	initial	initial	JJ
cord-282507-swxs5pr1	209	24	vaccination	vaccination	NN
cord-282507-swxs5pr1	209	25	in	in	IN
cord-282507-swxs5pr1	209	26	adults	adult	NNS
cord-282507-swxs5pr1	209	27	>	>	NFP
cord-282507-swxs5pr1	209	28	60	60	CD
cord-282507-swxs5pr1	209	29	years	year	NNS
cord-282507-swxs5pr1	209	30	old	old	JJ
cord-282507-swxs5pr1	209	31	,	,	,
cord-282507-swxs5pr1	209	32	confirming	confirm	VBG
cord-282507-swxs5pr1	209	33	statistical	statistical	JJ
cord-282507-swxs5pr1	209	34	prediction	prediction	NN
cord-282507-swxs5pr1	209	35	models	model	NNS
cord-282507-swxs5pr1	209	36	based	base	VBN
cord-282507-swxs5pr1	209	37	on	on	IN
cord-282507-swxs5pr1	209	38	immune	immune	JJ
cord-282507-swxs5pr1	209	39	responses	response	NNS
cord-282507-swxs5pr1	209	40	measured	measure	VBN
cord-282507-swxs5pr1	209	41	at	at	IN
cord-282507-swxs5pr1	209	42	earlier	early	JJR
cord-282507-swxs5pr1	209	43	time	time	NN
cord-282507-swxs5pr1	209	44	points	point	NNS
cord-282507-swxs5pr1	209	45	.	.	.
cord-282507-swxs5pr1	210	1	Immune	immune	JJ
cord-282507-swxs5pr1	210	2	responses	response	NNS
cord-282507-swxs5pr1	210	3	are	be	VBP
cord-282507-swxs5pr1	210	4	predicted	predict	VBN
cord-282507-swxs5pr1	210	5	to	to	TO
cord-282507-swxs5pr1	210	6	persist	persist	VB
cord-282507-swxs5pr1	210	7	up	up	IN
cord-282507-swxs5pr1	210	8	to	to	TO
cord-282507-swxs5pr1	210	9	15	15	CD
cord-282507-swxs5pr1	210	10	years	year	NNS
cord-282507-swxs5pr1	210	11	after	after	IN
cord-282507-swxs5pr1	210	12	the	the	DT
cord-282507-swxs5pr1	210	13	initial	initial	JJ
cord-282507-swxs5pr1	210	14	vaccination	vaccination	NN
cord-282507-swxs5pr1	210	15	(	(	-LRB-
cord-282507-swxs5pr1	210	16	Schwarz	Schwarz	NNP
cord-282507-swxs5pr1	210	17	et	et	NNP
cord-282507-swxs5pr1	210	18	al	al	NNP
cord-282507-swxs5pr1	210	19	.	.	NNP
cord-282507-swxs5pr1	210	20	,	,	,
cord-282507-swxs5pr1	210	21	2018	2018	CD
cord-282507-swxs5pr1	210	22	)	)	-RRB-
cord-282507-swxs5pr1	210	23	.	.	.
cord-282507-swxs5pr1	211	1	The	the	DT
cord-282507-swxs5pr1	211	2	acceptable	acceptable	JJ
cord-282507-swxs5pr1	211	3	benefit/	benefit/	CD
cord-282507-swxs5pr1	211	4	risks	risk	NNS
cord-282507-swxs5pr1	211	5	profile	profile	NN
cord-282507-swxs5pr1	211	6	led	lead	VBD
cord-282507-swxs5pr1	211	7	to	to	IN
cord-282507-swxs5pr1	211	8	the	the	DT
cord-282507-swxs5pr1	211	9	licensing	licensing	NN
cord-282507-swxs5pr1	211	10	by	by	IN
cord-282507-swxs5pr1	211	11	the	the	DT
cord-282507-swxs5pr1	211	12	U.S.	U.S.	NNP
cord-282507-swxs5pr1	211	13	Food	Food	NNP
cord-282507-swxs5pr1	211	14	and	and	CC
cord-282507-swxs5pr1	211	15	Drug	Drug	NNP
cord-282507-swxs5pr1	211	16	Administration	Administration	NNP
cord-282507-swxs5pr1	211	17	(	(	-LRB-
cord-282507-swxs5pr1	211	18	FDA	FDA	NNP
cord-282507-swxs5pr1	211	19	)	)	-RRB-
cord-282507-swxs5pr1	211	20	in	in	IN
cord-282507-swxs5pr1	211	21	2017	2017	CD
cord-282507-swxs5pr1	211	22	of	of	IN
cord-282507-swxs5pr1	211	23	the	the	DT
cord-282507-swxs5pr1	211	24	HZ	HZ	NNP
cord-282507-swxs5pr1	211	25	/	/	SYM
cord-282507-swxs5pr1	211	26	su	su	NNP
cord-282507-swxs5pr1	211	27	vaccine	vaccine	NN
cord-282507-swxs5pr1	211	28	(	(	-LRB-
cord-282507-swxs5pr1	211	29	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	211	30	™	™	CD
cord-282507-swxs5pr1	211	31	)	)	-RRB-
cord-282507-swxs5pr1	211	32	and	and	CC
cord-282507-swxs5pr1	211	33	a	a	DT
cord-282507-swxs5pr1	211	34	marketing	marketing	NN
cord-282507-swxs5pr1	211	35	authorization	authorization	NN
cord-282507-swxs5pr1	211	36	valid	valid	JJ
cord-282507-swxs5pr1	211	37	throughout	throughout	IN
cord-282507-swxs5pr1	211	38	the	the	DT
cord-282507-swxs5pr1	211	39	EU	EU	NNP
cord-282507-swxs5pr1	211	40	on	on	IN
cord-282507-swxs5pr1	211	41	21	21	CD
cord-282507-swxs5pr1	211	42	March	March	NNP
cord-282507-swxs5pr1	211	43	2018	2018	CD
cord-282507-swxs5pr1	212	1	(	(	-LRB-
cord-282507-swxs5pr1	212	2	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	212	3	,	,	,
cord-282507-swxs5pr1	212	4	INN	INN	NNP
cord-282507-swxs5pr1	212	5	-	-	HYPH
cord-282507-swxs5pr1	212	6	herpes	herpes	NNP
cord-282507-swxs5pr1	212	7	zoster	zoster	NNP
cord-282507-swxs5pr1	212	8	vaccine	vaccine	NN
cord-282507-swxs5pr1	212	9	.	.	.
cord-282507-swxs5pr1	213	1	EMA/76073/2018	EMA/76073/2018	NNP
cord-282507-swxs5pr1	213	2	)	)	-RRB-
cord-282507-swxs5pr1	213	3	.	.	.
cord-282507-swxs5pr1	214	1	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	214	2	is	be	VBZ
cord-282507-swxs5pr1	214	3	preferred	prefer	VBN
cord-282507-swxs5pr1	214	4	to	to	IN
cord-282507-swxs5pr1	214	5	Zostavax	Zostavax	NNP
cord-282507-swxs5pr1	214	6	(	(	-LRB-
cord-282507-swxs5pr1	214	7	a	a	DT
cord-282507-swxs5pr1	214	8	live	live	JJ
cord-282507-swxs5pr1	214	9	attenuated	attenuated	JJ
cord-282507-swxs5pr1	214	10	vaccine	vaccine	NN
cord-282507-swxs5pr1	214	11	)	)	-RRB-
cord-282507-swxs5pr1	214	12	,	,	,
cord-282507-swxs5pr1	214	13	providing	provide	VBG
cord-282507-swxs5pr1	214	14	strong	strong	JJ
cord-282507-swxs5pr1	214	15	protection	protection	NN
cord-282507-swxs5pr1	214	16	against	against	IN
cord-282507-swxs5pr1	214	17	shingles	shingle	NNS
cord-282507-swxs5pr1	214	18	and	and	CC
cord-282507-swxs5pr1	214	19	PHN	PHN	NNP
cord-282507-swxs5pr1	214	20	.	.	.
cord-282507-swxs5pr1	215	1	First	first	RB
cord-282507-swxs5pr1	215	2	introduced	introduce	VBN
cord-282507-swxs5pr1	215	3	in	in	IN
cord-282507-swxs5pr1	215	4	1921	1921	CD
cord-282507-swxs5pr1	215	5	,	,	,
cord-282507-swxs5pr1	215	6	the	the	DT
cord-282507-swxs5pr1	215	7	Bacillus	Bacillus	NNP
cord-282507-swxs5pr1	215	8	Calmette	Calmette	NNP
cord-282507-swxs5pr1	215	9	-	-	HYPH
cord-282507-swxs5pr1	215	10	Guérin	Guérin	NNP
cord-282507-swxs5pr1	215	11	(	(	-LRB-
cord-282507-swxs5pr1	215	12	BCG	BCG	NNP
cord-282507-swxs5pr1	215	13	)	)	-RRB-
cord-282507-swxs5pr1	215	14	vaccine	vaccine	NN
cord-282507-swxs5pr1	215	15	is	be	VBZ
cord-282507-swxs5pr1	215	16	the	the	DT
cord-282507-swxs5pr1	215	17	only	only	RB
cord-282507-swxs5pr1	215	18	currently	currently	RB
cord-282507-swxs5pr1	215	19	licensed	license	VBN
cord-282507-swxs5pr1	215	20	vaccine	vaccine	NN
cord-282507-swxs5pr1	215	21	available	available	JJ
cord-282507-swxs5pr1	215	22	to	to	TO
cord-282507-swxs5pr1	215	23	protect	protect	VB
cord-282507-swxs5pr1	215	24	against	against	IN
cord-282507-swxs5pr1	215	25	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	215	26	(	(	-LRB-
cord-282507-swxs5pr1	215	27	TB	TB	NNP
cord-282507-swxs5pr1	215	28	)	)	-RRB-
cord-282507-swxs5pr1	215	29	,	,	,
cord-282507-swxs5pr1	215	30	a	a	DT
cord-282507-swxs5pr1	215	31	disease	disease	NN
cord-282507-swxs5pr1	215	32	caused	cause	VBN
cord-282507-swxs5pr1	215	33	by	by	IN
cord-282507-swxs5pr1	215	34	the	the	DT
cord-282507-swxs5pr1	215	35	bacteria	bacteria	NNS
cord-282507-swxs5pr1	215	36	Mycobacterium	Mycobacterium	NNP
cord-282507-swxs5pr1	215	37	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	215	38	(	(	-LRB-
cord-282507-swxs5pr1	215	39	M.tb	M.tb	NNP
cord-282507-swxs5pr1	215	40	.	.	.
cord-282507-swxs5pr1	215	41	)	)	-RRB-
cord-282507-swxs5pr1	215	42	.	.	.
cord-282507-swxs5pr1	216	1	It	-PRON-	PRP
cord-282507-swxs5pr1	216	2	protects	protect	VBZ
cord-282507-swxs5pr1	216	3	children	child	NNS
cord-282507-swxs5pr1	216	4	from	from	IN
cord-282507-swxs5pr1	216	5	meningeal	meningeal	JJ
cord-282507-swxs5pr1	216	6	and	and	CC
cord-282507-swxs5pr1	216	7	severe	severe	JJ
cord-282507-swxs5pr1	216	8	forms	form	NNS
cord-282507-swxs5pr1	216	9	disseminated	disseminate	VBN
cord-282507-swxs5pr1	216	10	of	of	IN
cord-282507-swxs5pr1	216	11	TB	TB	NNP
cord-282507-swxs5pr1	216	12	and	and	CC
cord-282507-swxs5pr1	216	13	death	death	NN
cord-282507-swxs5pr1	216	14	,	,	,
cord-282507-swxs5pr1	216	15	but	but	CC
cord-282507-swxs5pr1	216	16	offers	offer	VBZ
cord-282507-swxs5pr1	216	17	limited	limited	JJ
cord-282507-swxs5pr1	216	18	protection	protection	NN
cord-282507-swxs5pr1	216	19	against	against	IN
cord-282507-swxs5pr1	216	20	pulmonary	pulmonary	JJ
cord-282507-swxs5pr1	216	21	TB	TB	NNP
cord-282507-swxs5pr1	216	22	in	in	IN
cord-282507-swxs5pr1	216	23	adolescents	adolescent	NNS
cord-282507-swxs5pr1	216	24	and	and	CC
cord-282507-swxs5pr1	216	25	adults	adult	NNS
cord-282507-swxs5pr1	216	26	,	,	,
cord-282507-swxs5pr1	216	27	which	which	WDT
cord-282507-swxs5pr1	216	28	is	be	VBZ
cord-282507-swxs5pr1	216	29	the	the	DT
cord-282507-swxs5pr1	216	30	form	form	NN
cord-282507-swxs5pr1	216	31	of	of	IN
cord-282507-swxs5pr1	216	32	the	the	DT
cord-282507-swxs5pr1	216	33	disease	disease	NN
cord-282507-swxs5pr1	216	34	responsible	responsible	JJ
cord-282507-swxs5pr1	216	35	for	for	IN
cord-282507-swxs5pr1	216	36	the	the	DT
cord-282507-swxs5pr1	216	37	vast	vast	JJ
cord-282507-swxs5pr1	216	38	majority	majority	NN
cord-282507-swxs5pr1	216	39	of	of	IN
cord-282507-swxs5pr1	216	40	transmission	transmission	NN
cord-282507-swxs5pr1	216	41	and	and	CC
cord-282507-swxs5pr1	216	42	TB	TB	NNP
cord-282507-swxs5pr1	216	43	-	-	HYPH
cord-282507-swxs5pr1	216	44	related	relate	VBN
cord-282507-swxs5pr1	216	45	morbidity	morbidity	NN
cord-282507-swxs5pr1	216	46	and	and	CC
cord-282507-swxs5pr1	216	47	mortality	mortality	NN
cord-282507-swxs5pr1	216	48	.	.	.
cord-282507-swxs5pr1	217	1	Therefore	therefore	RB
cord-282507-swxs5pr1	217	2	,	,	,
cord-282507-swxs5pr1	217	3	there	there	EX
cord-282507-swxs5pr1	217	4	is	be	VBZ
cord-282507-swxs5pr1	217	5	an	an	DT
cord-282507-swxs5pr1	217	6	urgent	urgent	JJ
cord-282507-swxs5pr1	217	7	need	need	NN
cord-282507-swxs5pr1	217	8	for	for	IN
cord-282507-swxs5pr1	217	9	a	a	DT
cord-282507-swxs5pr1	217	10	new	new	JJ
cord-282507-swxs5pr1	217	11	and	and	CC
cord-282507-swxs5pr1	217	12	improved	improved	JJ
cord-282507-swxs5pr1	217	13	vaccine	vaccine	NN
cord-282507-swxs5pr1	217	14	against	against	IN
cord-282507-swxs5pr1	217	15	TB	TB	NNP
cord-282507-swxs5pr1	217	16	for	for	IN
cord-282507-swxs5pr1	217	17	controlling	control	VBG
cord-282507-swxs5pr1	217	18	this	this	DT
cord-282507-swxs5pr1	217	19	disease	disease	NN
cord-282507-swxs5pr1	217	20	that	that	WDT
cord-282507-swxs5pr1	217	21	continues	continue	VBZ
cord-282507-swxs5pr1	217	22	to	to	TO
cord-282507-swxs5pr1	217	23	pose	pose	VB
cord-282507-swxs5pr1	217	24	a	a	DT
cord-282507-swxs5pr1	217	25	global	global	JJ
cord-282507-swxs5pr1	217	26	health	health	NN
cord-282507-swxs5pr1	217	27	threat	threat	NN
cord-282507-swxs5pr1	217	28	with	with	IN
cord-282507-swxs5pr1	217	29	1.7	1.7	CD
cord-282507-swxs5pr1	217	30	million	million	CD
cord-282507-swxs5pr1	217	31	deaths	death	NNS
cord-282507-swxs5pr1	217	32	in	in	IN
cord-282507-swxs5pr1	217	33	2016	2016	CD
cord-282507-swxs5pr1	218	1	(	(	-LRB-
cord-282507-swxs5pr1	218	2	Van	Van	NNP
cord-282507-swxs5pr1	218	3	Der	Der	NNP
cord-282507-swxs5pr1	218	4	Meeren	Meeren	NNP
cord-282507-swxs5pr1	218	5	et	et	NNP
cord-282507-swxs5pr1	218	6	al	al	NNP
cord-282507-swxs5pr1	218	7	.	.	NNP
cord-282507-swxs5pr1	218	8	,	,	,
cord-282507-swxs5pr1	218	9	2018	2018	CD
cord-282507-swxs5pr1	218	10	)	)	-RRB-
cord-282507-swxs5pr1	218	11	.	.	.
cord-282507-swxs5pr1	219	1	The	the	DT
cord-282507-swxs5pr1	219	2	M72	M72	NNPS
cord-282507-swxs5pr1	219	3	/	/	SYM
cord-282507-swxs5pr1	219	4	AS01	AS01	NNP
cord-282507-swxs5pr1	219	5	candidate	candidate	NN
cord-282507-swxs5pr1	219	6	vaccine	vaccine	NN
cord-282507-swxs5pr1	219	7	contains	contain	VBZ
cord-282507-swxs5pr1	219	8	the	the	DT
cord-282507-swxs5pr1	219	9	recombinant	recombinant	JJ
cord-282507-swxs5pr1	219	10	fusion	fusion	NN
cord-282507-swxs5pr1	219	11	protein	protein	NN
cord-282507-swxs5pr1	219	12	derived	derive	VBN
cord-282507-swxs5pr1	219	13	from	from	IN
cord-282507-swxs5pr1	219	14	the	the	DT
cord-282507-swxs5pr1	219	15	two	two	CD
cord-282507-swxs5pr1	219	16	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	219	17	M.	M.	NNP
cord-282507-swxs5pr1	219	18	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	219	19	Ags	Ags	NNP
cord-282507-swxs5pr1	219	20	(	(	-LRB-
cord-282507-swxs5pr1	219	21	Mtb32A	Mtb32A	NNP
cord-282507-swxs5pr1	219	22	and	and	CC
cord-282507-swxs5pr1	219	23	Mtb39A	Mtb39A	NNPS
cord-282507-swxs5pr1	219	24	)	)	-RRB-
cord-282507-swxs5pr1	219	25	in	in	IN
cord-282507-swxs5pr1	219	26	AS01	AS01	NNP
cord-282507-swxs5pr1	219	27	.	.	.
cord-282507-swxs5pr1	220	1	A	a	DT
cord-282507-swxs5pr1	220	2	first	first	JJ
cord-282507-swxs5pr1	220	3	phase	phase	NN
cord-282507-swxs5pr1	220	4	I	-PRON-	PRP
cord-282507-swxs5pr1	220	5	/	/	SYM
cord-282507-swxs5pr1	220	6	II	II	NNP
cord-282507-swxs5pr1	220	7	randomized	randomize	VBN
cord-282507-swxs5pr1	220	8	,	,	,
cord-282507-swxs5pr1	220	9	controlled	control	VBN
cord-282507-swxs5pr1	220	10	clinical	clinical	JJ
cord-282507-swxs5pr1	220	11	study	study	NN
cord-282507-swxs5pr1	220	12	with	with	IN
cord-282507-swxs5pr1	220	13	M72	M72	NNP
cord-282507-swxs5pr1	221	1	/AS01	/AS01	NNP
cord-282507-swxs5pr1	221	2	was	be	VBD
cord-282507-swxs5pr1	221	3	carried	carry	VBN
cord-282507-swxs5pr1	221	4	out	out	RP
cord-282507-swxs5pr1	221	5	in	in	IN
cord-282507-swxs5pr1	221	6	Belgium	Belgium	NNP
cord-282507-swxs5pr1	221	7	in	in	IN
cord-282507-swxs5pr1	221	8	healthy	healthy	JJ
cord-282507-swxs5pr1	221	9	adults	adult	NNS
cord-282507-swxs5pr1	221	10	volunteers	volunteer	NNS
cord-282507-swxs5pr1	221	11	.	.	.
cord-282507-swxs5pr1	222	1	The	the	DT
cord-282507-swxs5pr1	222	2	results	result	NNS
cord-282507-swxs5pr1	222	3	showed	show	VBD
cord-282507-swxs5pr1	222	4	that	that	IN
cord-282507-swxs5pr1	222	5	the	the	DT
cord-282507-swxs5pr1	222	6	vaccine	vaccine	NN
cord-282507-swxs5pr1	222	7	was	be	VBD
cord-282507-swxs5pr1	222	8	clinically	clinically	RB
cord-282507-swxs5pr1	222	9	well	well	RB
cord-282507-swxs5pr1	222	10	tolerated	tolerate	VBN
cord-282507-swxs5pr1	222	11	and	and	CC
cord-282507-swxs5pr1	222	12	induced	induce	VBN
cord-282507-swxs5pr1	222	13	high	high	JJ
cord-282507-swxs5pr1	222	14	and	and	CC
cord-282507-swxs5pr1	222	15	persistent	persistent	JJ
cord-282507-swxs5pr1	222	16	(	(	-LRB-
cord-282507-swxs5pr1	222	17	up	up	IN
cord-282507-swxs5pr1	222	18	to	to	TO
cord-282507-swxs5pr1	222	19	three	three	CD
cord-282507-swxs5pr1	222	20	years	year	NNS
cord-282507-swxs5pr1	222	21	)	)	-RRB-
cord-282507-swxs5pr1	223	1	specific	specific	JJ
cord-282507-swxs5pr1	223	2	Th1	th1	CD
cord-282507-swxs5pr1	223	3	CD4	CD4	NNP
cord-282507-swxs5pr1	223	4	+	+	CC
cord-282507-swxs5pr1	224	1	T	t	NN
cord-282507-swxs5pr1	224	2	-	-	HYPH
cord-282507-swxs5pr1	224	3	cell	cell	NN
cord-282507-swxs5pr1	224	4	(	(	-LRB-
cord-282507-swxs5pr1	224	5	co	co	NN
cord-282507-swxs5pr1	224	6	-	-	JJ
cord-282507-swxs5pr1	224	7	expressing	expressing	JJ
cord-282507-swxs5pr1	224	8	CD40L	cd40l	NN
cord-282507-swxs5pr1	224	9	,	,	,
cord-282507-swxs5pr1	224	10	Il-2	Il-2	NNP
cord-282507-swxs5pr1	224	11	,	,	,
cord-282507-swxs5pr1	224	12	TNF	TNF	NNP
cord-282507-swxs5pr1	224	13	-	-	HYPH
cord-282507-swxs5pr1	224	14	α	α	NNP
cord-282507-swxs5pr1	224	15	and	and	CC
cord-282507-swxs5pr1	224	16	IFN	IFN	NNP
cord-282507-swxs5pr1	224	17	-	-	HYPH
cord-282507-swxs5pr1	224	18	γ	γ	NNP
cord-282507-swxs5pr1	224	19	)	)	-RRB-
cord-282507-swxs5pr1	224	20	and	and	CC
cord-282507-swxs5pr1	224	21	Ab	Ab	NNP
cord-282507-swxs5pr1	224	22	responses	response	NNS
cord-282507-swxs5pr1	224	23	,	,	,
cord-282507-swxs5pr1	224	24	supporting	support	VBG
cord-282507-swxs5pr1	224	25	its	-PRON-	PRP$
cord-282507-swxs5pr1	224	26	further	further	JJ
cord-282507-swxs5pr1	224	27	clinical	clinical	JJ
cord-282507-swxs5pr1	224	28	evaluation	evaluation	NN
cord-282507-swxs5pr1	224	29	in	in	IN
cord-282507-swxs5pr1	224	30	TB	TB	NNP
cord-282507-swxs5pr1	224	31	-	-	HYPH
cord-282507-swxs5pr1	224	32	endemic	endemic	JJ
cord-282507-swxs5pr1	224	33	settings	setting	NNS
cord-282507-swxs5pr1	224	34	(	(	-LRB-
cord-282507-swxs5pr1	224	35	Leroux	Leroux	NNP
cord-282507-swxs5pr1	224	36	-	-	HYPH
cord-282507-swxs5pr1	224	37	Roels	Roels	NNP
cord-282507-swxs5pr1	224	38	et	et	NNP
cord-282507-swxs5pr1	224	39	al	al	NNP
cord-282507-swxs5pr1	224	40	.	.	NNP
cord-282507-swxs5pr1	224	41	,	,	,
cord-282507-swxs5pr1	224	42	2013	2013	CD
cord-282507-swxs5pr1	224	43	)	)	-RRB-
cord-282507-swxs5pr1	224	44	.	.	.
cord-282507-swxs5pr1	225	1	Similar	similar	JJ
cord-282507-swxs5pr1	225	2	conclusions	conclusion	NNS
cord-282507-swxs5pr1	225	3	were	be	VBD
cord-282507-swxs5pr1	225	4	drawn	draw	VBN
cord-282507-swxs5pr1	225	5	in	in	IN
cord-282507-swxs5pr1	225	6	a	a	DT
cord-282507-swxs5pr1	225	7	phase	phase	NN
cord-282507-swxs5pr1	225	8	II	II	NNP
cord-282507-swxs5pr1	225	9	controlled	control	VBN
cord-282507-swxs5pr1	225	10	trial	trial	NN
cord-282507-swxs5pr1	225	11	conducted	conduct	VBN
cord-282507-swxs5pr1	225	12	on	on	IN
cord-282507-swxs5pr1	225	13	healthy	healthy	JJ
cord-282507-swxs5pr1	225	14	,	,	,
cord-282507-swxs5pr1	225	15	HIV	HIV	NNP
cord-282507-swxs5pr1	225	16	uninfected	uninfected	JJ
cord-282507-swxs5pr1	225	17	adolescents	adolescent	NNS
cord-282507-swxs5pr1	225	18	living	live	VBG
cord-282507-swxs5pr1	225	19	in	in	IN
cord-282507-swxs5pr1	225	20	an	an	DT
cord-282507-swxs5pr1	225	21	area	area	NN
cord-282507-swxs5pr1	225	22	with	with	IN
cord-282507-swxs5pr1	225	23	high	high	JJ
cord-282507-swxs5pr1	225	24	TB	TB	NNP
cord-282507-swxs5pr1	225	25	burden	burden	NN
cord-282507-swxs5pr1	225	26	in	in	IN
cord-282507-swxs5pr1	225	27	South	South	NNP
cord-282507-swxs5pr1	225	28	Africa	Africa	NNP
cord-282507-swxs5pr1	226	1	(	(	-LRB-
cord-282507-swxs5pr1	226	2	Penn	Penn	NNP
cord-282507-swxs5pr1	226	3	-	-	HYPH
cord-282507-swxs5pr1	226	4	Nicholson	Nicholson	NNP
cord-282507-swxs5pr1	226	5	et	et	NNP
cord-282507-swxs5pr1	226	6	al	al	NNP
cord-282507-swxs5pr1	226	7	.	.	NNP
cord-282507-swxs5pr1	226	8	,	,	,
cord-282507-swxs5pr1	226	9	2015	2015	CD
cord-282507-swxs5pr1	226	10	)	)	-RRB-
cord-282507-swxs5pr1	226	11	.	.	.
cord-282507-swxs5pr1	227	1	In	in	IN
cord-282507-swxs5pr1	227	2	a	a	DT
cord-282507-swxs5pr1	227	3	phase	phase	NN
cord-282507-swxs5pr1	227	4	II	ii	CD
cord-282507-swxs5pr1	227	5	study	study	NN
cord-282507-swxs5pr1	227	6	M72	M72	NNP
cord-282507-swxs5pr1	227	7	/	/	SYM
cord-282507-swxs5pr1	227	8	AS01	AS01	NNP
cord-282507-swxs5pr1	227	9	given	give	VBN
cord-282507-swxs5pr1	227	10	to	to	IN
cord-282507-swxs5pr1	227	11	infants	infant	NNS
cord-282507-swxs5pr1	227	12	after	after	IN
cord-282507-swxs5pr1	227	13	or	or	CC
cord-282507-swxs5pr1	227	14	concomitantly	concomitantly	RB
cord-282507-swxs5pr1	227	15	with	with	IN
cord-282507-swxs5pr1	228	1	expanded	expand	VBN
cord-282507-swxs5pr1	228	2	-	-	:
cord-282507-swxs5pr1	228	3	Programme	programme	NN
cord-282507-swxs5pr1	228	4	-	-	HYPH
cord-282507-swxs5pr1	228	5	on	on	IN
cord-282507-swxs5pr1	228	6	-	-	HYPH
cord-282507-swxs5pr1	228	7	Immunization	immunization	NN
cord-282507-swxs5pr1	228	8	(	(	-LRB-
cord-282507-swxs5pr1	228	9	EPI	EPI	NNP
cord-282507-swxs5pr1	228	10	)	)	-RRB-
cord-282507-swxs5pr1	228	11	vaccines	vaccine	NNS
cord-282507-swxs5pr1	228	12	had	have	VBD
cord-282507-swxs5pr1	228	13	an	an	DT
cord-282507-swxs5pr1	228	14	acceptable	acceptable	JJ
cord-282507-swxs5pr1	228	15	safety	safety	NN
cord-282507-swxs5pr1	228	16	profile	profile	NN
cord-282507-swxs5pr1	228	17	.	.	.
cord-282507-swxs5pr1	229	1	These	these	DT
cord-282507-swxs5pr1	229	2	results	result	NNS
cord-282507-swxs5pr1	229	3	suggested	suggest	VBD
cord-282507-swxs5pr1	229	4	no	no	DT
cord-282507-swxs5pr1	229	5	interference	interference	NN
cord-282507-swxs5pr1	229	6	of	of	IN
cord-282507-swxs5pr1	229	7	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	229	8	profiles	profile	NNS
cord-282507-swxs5pr1	229	9	occurred	occur	VBD
cord-282507-swxs5pr1	229	10	following	follow	VBG
cord-282507-swxs5pr1	229	11	co	co	NN
cord-282507-swxs5pr1	229	12	-	-	NN
cord-282507-swxs5pr1	229	13	administration	administration	NN
cord-282507-swxs5pr1	230	1	of	of	IN
cord-282507-swxs5pr1	230	2	M72	M72	NNP
cord-282507-swxs5pr1	230	3	/	/	SYM
cord-282507-swxs5pr1	230	4	AS01	AS01	NNP
cord-282507-swxs5pr1	230	5	and	and	CC
cord-282507-swxs5pr1	230	6	EPI	EPI	NNP
cord-282507-swxs5pr1	230	7	vaccines	vaccine	NNS
cord-282507-swxs5pr1	230	8	.	.	.
cord-282507-swxs5pr1	231	1	Two	two	CD
cord-282507-swxs5pr1	231	2	M72	M72	NNPS
cord-282507-swxs5pr1	231	3	/	/	SYM
cord-282507-swxs5pr1	231	4	AS01	AS01	NNP
cord-282507-swxs5pr1	231	5	doses	dose	NNS
cord-282507-swxs5pr1	231	6	elicited	elicit	VBD
cord-282507-swxs5pr1	231	7	higher	high	JJR
cord-282507-swxs5pr1	231	8	immune	immune	JJ
cord-282507-swxs5pr1	231	9	responses	response	NNS
cord-282507-swxs5pr1	231	10	than	than	IN
cord-282507-swxs5pr1	231	11	one	one	CD
cord-282507-swxs5pr1	231	12	dose	dose	NN
cord-282507-swxs5pr1	231	13	(	(	-LRB-
cord-282507-swxs5pr1	231	14	Ikodo	Ikodo	NNP
cord-282507-swxs5pr1	231	15	et	et	FW
cord-282507-swxs5pr1	231	16	al	al	NNP
cord-282507-swxs5pr1	231	17	.	.	NNP
cord-282507-swxs5pr1	231	18	,	,	,
cord-282507-swxs5pr1	231	19	2014	2014	CD
cord-282507-swxs5pr1	231	20	)	)	-RRB-
cord-282507-swxs5pr1	231	21	.	.	.
cord-282507-swxs5pr1	232	1	In	in	IN
cord-282507-swxs5pr1	232	2	a	a	DT
cord-282507-swxs5pr1	232	3	large	large	JJ
cord-282507-swxs5pr1	232	4	phase	phase	NN
cord-282507-swxs5pr1	232	5	IIb	iib	NN
cord-282507-swxs5pr1	232	6	trial	trial	NN
cord-282507-swxs5pr1	232	7	conducted	conduct	VBN
cord-282507-swxs5pr1	232	8	on	on	IN
cord-282507-swxs5pr1	232	9	3600	3600	CD
cord-282507-swxs5pr1	232	10	HIV	HIV	NNP
cord-282507-swxs5pr1	232	11	-	-	HYPH
cord-282507-swxs5pr1	232	12	uninfected	uninfected	JJ
cord-282507-swxs5pr1	232	13	adults	adult	NNS
cord-282507-swxs5pr1	232	14	latently	latently	RB
cord-282507-swxs5pr1	232	15	infected	infect	VBN
cord-282507-swxs5pr1	232	16	with	with	IN
cord-282507-swxs5pr1	232	17	Mtb	Mtb	NNP
cord-282507-swxs5pr1	232	18	in	in	IN
cord-282507-swxs5pr1	232	19	three	three	CD
cord-282507-swxs5pr1	232	20	African	african	JJ
cord-282507-swxs5pr1	232	21	countries	country	NNS
cord-282507-swxs5pr1	232	22	,	,	,
cord-282507-swxs5pr1	232	23	M72	M72	NNP
cord-282507-swxs5pr1	232	24	/	/	SYM
cord-282507-swxs5pr1	232	25	AS01	AS01	NNP
cord-282507-swxs5pr1	232	26	E	E	NNP
cord-282507-swxs5pr1	232	27	was	be	VBD
cord-282507-swxs5pr1	232	28	shown	show	VBN
cord-282507-swxs5pr1	232	29	to	to	TO
cord-282507-swxs5pr1	232	30	provide	provide	VB
cord-282507-swxs5pr1	232	31	54	54	CD
cord-282507-swxs5pr1	232	32	%	%	NN
cord-282507-swxs5pr1	232	33	protection	protection	NN
cord-282507-swxs5pr1	232	34	for	for	IN
cord-282507-swxs5pr1	232	35	Mtbinfected	Mtbinfected	NNP
cord-282507-swxs5pr1	232	36	adults	adult	NNS
cord-282507-swxs5pr1	232	37	against	against	IN
cord-282507-swxs5pr1	232	38	active	active	JJ
cord-282507-swxs5pr1	232	39	pulmonary	pulmonary	JJ
cord-282507-swxs5pr1	232	40	TB	tb	NN
cord-282507-swxs5pr1	232	41	,	,	,
cord-282507-swxs5pr1	232	42	without	without	IN
cord-282507-swxs5pr1	232	43	evident	evident	JJ
cord-282507-swxs5pr1	232	44	safety	safety	NN
cord-282507-swxs5pr1	232	45	concerns	concern	NNS
cord-282507-swxs5pr1	232	46	(	(	-LRB-
cord-282507-swxs5pr1	232	47	van	van	NNP
cord-282507-swxs5pr1	232	48	der	der	NNP
cord-282507-swxs5pr1	232	49	Meeren	Meeren	NNP
cord-282507-swxs5pr1	232	50	et	et	NNP
cord-282507-swxs5pr1	232	51	al	al	NNP
cord-282507-swxs5pr1	232	52	.	.	NNP
cord-282507-swxs5pr1	232	53	,	,	,
cord-282507-swxs5pr1	232	54	2018	2018	CD
cord-282507-swxs5pr1	232	55	)	)	-RRB-
cord-282507-swxs5pr1	232	56	.	.	.
cord-282507-swxs5pr1	233	1	These	these	DT
cord-282507-swxs5pr1	233	2	results	result	NNS
cord-282507-swxs5pr1	233	3	suggest	suggest	VBP
cord-282507-swxs5pr1	233	4	further	further	JJ
cord-282507-swxs5pr1	233	5	evaluations	evaluation	NNS
cord-282507-swxs5pr1	233	6	of	of	IN
cord-282507-swxs5pr1	233	7	M72	M72	NNP
cord-282507-swxs5pr1	233	8	/	/	SYM
cord-282507-swxs5pr1	233	9	AS01	AS01	NNP
cord-282507-swxs5pr1	233	10	as	as	IN
cord-282507-swxs5pr1	233	11	a	a	DT
cord-282507-swxs5pr1	233	12	possible	possible	JJ
cord-282507-swxs5pr1	233	13	vaccination	vaccination	NN
cord-282507-swxs5pr1	233	14	strategy	strategy	NN
cord-282507-swxs5pr1	233	15	against	against	IN
cord-282507-swxs5pr1	233	16	TB	TB	NNP
cord-282507-swxs5pr1	233	17	.	.	.
cord-282507-swxs5pr1	234	1	There	there	EX
cord-282507-swxs5pr1	234	2	were	be	VBD
cord-282507-swxs5pr1	234	3	approximately	approximately	RB
cord-282507-swxs5pr1	234	4	36.9	36.9	CD
cord-282507-swxs5pr1	234	5	million	million	CD
cord-282507-swxs5pr1	234	6	people	people	NNS
cord-282507-swxs5pr1	234	7	living	live	VBG
cord-282507-swxs5pr1	234	8	with	with	IN
cord-282507-swxs5pr1	234	9	HIV	HIV	NNP
cord-282507-swxs5pr1	234	10	at	at	IN
cord-282507-swxs5pr1	234	11	the	the	DT
cord-282507-swxs5pr1	234	12	end	end	NN
cord-282507-swxs5pr1	234	13	of	of	IN
cord-282507-swxs5pr1	234	14	2017	2017	CD
cord-282507-swxs5pr1	234	15	with	with	IN
cord-282507-swxs5pr1	234	16	1.8	1.8	CD
cord-282507-swxs5pr1	234	17	million	million	CD
cord-282507-swxs5pr1	234	18	people	people	NNS
cord-282507-swxs5pr1	234	19	becoming	become	VBG
cord-282507-swxs5pr1	234	20	newly	newly	RB
cord-282507-swxs5pr1	234	21	infected	infect	VBN
cord-282507-swxs5pr1	234	22	in	in	IN
cord-282507-swxs5pr1	234	23	2017	2017	CD
cord-282507-swxs5pr1	235	1	(	(	-LRB-
cord-282507-swxs5pr1	235	2	HIV	HIV	NNP
cord-282507-swxs5pr1	235	3	/	/	SYM
cord-282507-swxs5pr1	235	4	AIDS	AIDS	NNP
cord-282507-swxs5pr1	235	5	,	,	,
cord-282507-swxs5pr1	235	6	Key	key	JJ
cord-282507-swxs5pr1	235	7	facts	fact	NNS
cord-282507-swxs5pr1	235	8	,	,	,
cord-282507-swxs5pr1	235	9	19	19	CD
cord-282507-swxs5pr1	235	10	July	July	NNP
cord-282507-swxs5pr1	235	11	2018	2018	CD
cord-282507-swxs5pr1	235	12	)	)	-RRB-
cord-282507-swxs5pr1	235	13	.	.	.
cord-282507-swxs5pr1	236	1	While	while	IN
cord-282507-swxs5pr1	236	2	treatments	treatment	NNS
cord-282507-swxs5pr1	236	3	are	be	VBP
cord-282507-swxs5pr1	236	4	available	available	JJ
cord-282507-swxs5pr1	236	5	to	to	TO
cord-282507-swxs5pr1	236	6	treat	treat	VB
cord-282507-swxs5pr1	236	7	or	or	CC
cord-282507-swxs5pr1	236	8	to	to	TO
cord-282507-swxs5pr1	236	9	prevent	prevent	VB
cord-282507-swxs5pr1	236	10	HIV	HIV	NNP
cord-282507-swxs5pr1	236	11	infections	infection	NNS
cord-282507-swxs5pr1	236	12	,	,	,
cord-282507-swxs5pr1	236	13	there	there	EX
cord-282507-swxs5pr1	236	14	is	be	VBZ
cord-282507-swxs5pr1	236	15	no	no	DT
cord-282507-swxs5pr1	236	16	vaccine	vaccine	NN
cord-282507-swxs5pr1	236	17	currently	currently	RB
cord-282507-swxs5pr1	236	18	licensed	license	VBN
cord-282507-swxs5pr1	236	19	.	.	.
cord-282507-swxs5pr1	237	1	Despite	despite	IN
cord-282507-swxs5pr1	237	2	ongoing	ongoing	JJ
cord-282507-swxs5pr1	237	3	prevention	prevention	NN
cord-282507-swxs5pr1	237	4	efforts	effort	NNS
cord-282507-swxs5pr1	237	5	,	,	,
cord-282507-swxs5pr1	237	6	there	there	EX
cord-282507-swxs5pr1	237	7	is	be	VBZ
cord-282507-swxs5pr1	237	8	an	an	DT
cord-282507-swxs5pr1	237	9	urgent	urgent	JJ
cord-282507-swxs5pr1	237	10	need	need	NN
cord-282507-swxs5pr1	237	11	for	for	IN
cord-282507-swxs5pr1	237	12	a	a	DT
cord-282507-swxs5pr1	237	13	safe	safe	JJ
cord-282507-swxs5pr1	237	14	and	and	CC
cord-282507-swxs5pr1	237	15	effective	effective	JJ
cord-282507-swxs5pr1	237	16	prophylactic	prophylactic	JJ
cord-282507-swxs5pr1	237	17	vaccine	vaccine	NN
cord-282507-swxs5pr1	237	18	.	.	.
cord-282507-swxs5pr1	238	1	Prevention	prevention	NN
cord-282507-swxs5pr1	238	2	of	of	IN
cord-282507-swxs5pr1	238	3	infection	infection	NN
cord-282507-swxs5pr1	238	4	through	through	IN
cord-282507-swxs5pr1	238	5	induction	induction	NN
cord-282507-swxs5pr1	238	6	of	of	IN
cord-282507-swxs5pr1	238	7	neutralizing	neutralize	VBG
cord-282507-swxs5pr1	238	8	Abs	abs	NN
cord-282507-swxs5pr1	238	9	,	,	,
cord-282507-swxs5pr1	238	10	induction	induction	NN
cord-282507-swxs5pr1	238	11	of	of	IN
cord-282507-swxs5pr1	238	12	strong	strong	JJ
cord-282507-swxs5pr1	238	13	cellular	cellular	JJ
cord-282507-swxs5pr1	238	14	immune	immune	JJ
cord-282507-swxs5pr1	238	15	responses	response	NNS
cord-282507-swxs5pr1	238	16	in	in	IN
cord-282507-swxs5pr1	238	17	order	order	NN
cord-282507-swxs5pr1	238	18	to	to	TO
cord-282507-swxs5pr1	238	19	delay	delay	VB
cord-282507-swxs5pr1	238	20	progression	progression	NN
cord-282507-swxs5pr1	238	21	and	and	CC
cord-282507-swxs5pr1	238	22	reduce	reduce	VB
cord-282507-swxs5pr1	238	23	the	the	DT
cord-282507-swxs5pr1	238	24	transmission	transmission	NN
cord-282507-swxs5pr1	238	25	rate	rate	NN
cord-282507-swxs5pr1	238	26	in	in	IN
cord-282507-swxs5pr1	238	27	high	high	JJ
cord-282507-swxs5pr1	238	28	risk	risk	NN
cord-282507-swxs5pr1	238	29	population	population	NN
cord-282507-swxs5pr1	238	30	,	,	,
cord-282507-swxs5pr1	238	31	are	be	VBP
cord-282507-swxs5pr1	238	32	the	the	DT
cord-282507-swxs5pr1	238	33	major	major	JJ
cord-282507-swxs5pr1	238	34	aims	aim	NNS
cord-282507-swxs5pr1	238	35	for	for	IN
cord-282507-swxs5pr1	238	36	an	an	DT
cord-282507-swxs5pr1	238	37	HIV	HIV	NNP
cord-282507-swxs5pr1	238	38	vaccine	vaccine	NN
cord-282507-swxs5pr1	238	39	.	.	.
cord-282507-swxs5pr1	239	1	Although	although	IN
cord-282507-swxs5pr1	239	2	clinical	clinical	JJ
cord-282507-swxs5pr1	239	3	attempts	attempt	NNS
cord-282507-swxs5pr1	239	4	were	be	VBD
cord-282507-swxs5pr1	239	5	disappointing	disappointing	JJ
cord-282507-swxs5pr1	239	6	,	,	,
cord-282507-swxs5pr1	239	7	they	-PRON-	PRP
cord-282507-swxs5pr1	239	8	contributed	contribute	VBD
cord-282507-swxs5pr1	239	9	valuable	valuable	JJ
cord-282507-swxs5pr1	239	10	insights	insight	NNS
cord-282507-swxs5pr1	239	11	into	into	IN
cord-282507-swxs5pr1	239	12	immune	immune	JJ
cord-282507-swxs5pr1	239	13	protective	protective	JJ
cord-282507-swxs5pr1	239	14	immunity	immunity	NN
cord-282507-swxs5pr1	239	15	.	.	.
cord-282507-swxs5pr1	240	1	A	a	DT
cord-282507-swxs5pr1	240	2	randomized	randomized	JJ
cord-282507-swxs5pr1	240	3	double	double	JJ
cord-282507-swxs5pr1	240	4	-	-	HYPH
cord-282507-swxs5pr1	240	5	blind	blind	JJ
cord-282507-swxs5pr1	240	6	study	study	NN
cord-282507-swxs5pr1	240	7	conducted	conduct	VBN
cord-282507-swxs5pr1	240	8	on	on	IN
cord-282507-swxs5pr1	240	9	healthy	healthy	JJ
cord-282507-swxs5pr1	240	10	HIV	HIV	NNP
cord-282507-swxs5pr1	240	11	-	-	HYPH
cord-282507-swxs5pr1	240	12	seronegative	seronegative	JJ
cord-282507-swxs5pr1	240	13	adults	adult	NNS
cord-282507-swxs5pr1	240	14	showed	show	VBD
cord-282507-swxs5pr1	240	15	that	that	IN
cord-282507-swxs5pr1	240	16	a	a	DT
cord-282507-swxs5pr1	240	17	vaccine	vaccine	NN
cord-282507-swxs5pr1	240	18	formulation	formulation	NN
cord-282507-swxs5pr1	240	19	containing	contain	VBG
cord-282507-swxs5pr1	240	20	gp	gp	NNP
cord-282507-swxs5pr1	240	21	120	120	CD
cord-282507-swxs5pr1	240	22	,	,	,
cord-282507-swxs5pr1	240	23	Nef	Nef	NNP
cord-282507-swxs5pr1	240	24	and	and	CC
cord-282507-swxs5pr1	240	25	Tat	Tat	NNP
cord-282507-swxs5pr1	240	26	Ags	Ags	NNP
cord-282507-swxs5pr1	240	27	and	and	CC
cord-282507-swxs5pr1	240	28	AS01	AS01	NNP
cord-282507-swxs5pr1	240	29	B	B	NNP
cord-282507-swxs5pr1	240	30	induced	induce	VBD
cord-282507-swxs5pr1	240	31	strong	strong	JJ
cord-282507-swxs5pr1	240	32	Ab	Ab	NNP
cord-282507-swxs5pr1	240	33	response	response	NN
cord-282507-swxs5pr1	240	34	and	and	CC
cord-282507-swxs5pr1	240	35	CD4	CD4	NNP
cord-282507-swxs5pr1	240	36	+	+	CC
cord-282507-swxs5pr1	240	37	T	T	NNP
cord-282507-swxs5pr1	240	38	cell	cell	NN
cord-282507-swxs5pr1	240	39	responses	response	NNS
cord-282507-swxs5pr1	240	40	characterized	characterize	VBN
cord-282507-swxs5pr1	240	41	by	by	IN
cord-282507-swxs5pr1	240	42	high	high	JJ
cord-282507-swxs5pr1	240	43	lymphoproliferative	lymphoproliferative	JJ
cord-282507-swxs5pr1	240	44	capacity	capacity	NN
cord-282507-swxs5pr1	240	45	and	and	CC
cord-282507-swxs5pr1	240	46	Il-2	il-2	NN
cord-282507-swxs5pr1	240	47	production	production	NN
cord-282507-swxs5pr1	240	48	,	,	,
cord-282507-swxs5pr1	240	49	that	that	WDT
cord-282507-swxs5pr1	240	50	were	be	VBD
cord-282507-swxs5pr1	240	51	maintained	maintain	VBN
cord-282507-swxs5pr1	240	52	up	up	RP
cord-282507-swxs5pr1	240	53	to	to	TO
cord-282507-swxs5pr1	240	54	18	18	CD
cord-282507-swxs5pr1	240	55	months	month	NNS
cord-282507-swxs5pr1	240	56	after	after	IN
cord-282507-swxs5pr1	240	57	the	the	DT
cord-282507-swxs5pr1	240	58	last	last	JJ
cord-282507-swxs5pr1	240	59	vaccine	vaccine	NN
cord-282507-swxs5pr1	240	60	dose	dose	NN
cord-282507-swxs5pr1	240	61	.	.	.
cord-282507-swxs5pr1	241	1	A	a	DT
cord-282507-swxs5pr1	241	2	CD8	CD8	NNP
cord-282507-swxs5pr1	241	3	+	+	CC
cord-282507-swxs5pr1	241	4	T	T	NNP
cord-282507-swxs5pr1	241	5	cell	cell	NN
cord-282507-swxs5pr1	241	6	response	response	NN
cord-282507-swxs5pr1	241	7	was	be	VBD
cord-282507-swxs5pr1	241	8	not	not	RB
cord-282507-swxs5pr1	241	9	observed	observe	VBN
cord-282507-swxs5pr1	242	1	(	(	-LRB-
cord-282507-swxs5pr1	242	2	Leroux	Leroux	NNP
cord-282507-swxs5pr1	242	3	-	-	HYPH
cord-282507-swxs5pr1	242	4	Roels	Roels	NNP
cord-282507-swxs5pr1	242	5	et	et	NNP
cord-282507-swxs5pr1	242	6	al	al	NNP
cord-282507-swxs5pr1	242	7	.	.	NNP
cord-282507-swxs5pr1	242	8	,	,	,
cord-282507-swxs5pr1	242	9	2010	2010	CD
cord-282507-swxs5pr1	242	10	)	)	-RRB-
cord-282507-swxs5pr1	242	11	.	.	.
cord-282507-swxs5pr1	243	1	This	this	DT
cord-282507-swxs5pr1	243	2	study	study	NN
cord-282507-swxs5pr1	243	3	conducted	conduct	VBN
cord-282507-swxs5pr1	243	4	with	with	IN
cord-282507-swxs5pr1	243	5	different	different	JJ
cord-282507-swxs5pr1	243	6	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	243	7	underlined	underline	VBD
cord-282507-swxs5pr1	243	8	the	the	DT
cord-282507-swxs5pr1	243	9	superiority	superiority	NN
cord-282507-swxs5pr1	243	10	of	of	IN
cord-282507-swxs5pr1	243	11	responses	response	NNS
cord-282507-swxs5pr1	243	12	with	with	IN
cord-282507-swxs5pr1	243	13	AS01	AS01	NNP
cord-282507-swxs5pr1	243	14	B	B	NNP
cord-282507-swxs5pr1	243	15	in	in	IN
cord-282507-swxs5pr1	243	16	comparison	comparison	NN
cord-282507-swxs5pr1	243	17	with	with	IN
cord-282507-swxs5pr1	243	18	other	other	JJ
cord-282507-swxs5pr1	243	19	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	243	20	,	,	,
cord-282507-swxs5pr1	243	21	confirming	confirm	VBG
cord-282507-swxs5pr1	243	22	previous	previous	JJ
cord-282507-swxs5pr1	243	23	findings	finding	NNS
cord-282507-swxs5pr1	243	24	.	.	.
cord-282507-swxs5pr1	244	1	Another	another	DT
cord-282507-swxs5pr1	244	2	candidate	candidate	NN
cord-282507-swxs5pr1	244	3	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	244	4	vaccine	vaccine	NN
cord-282507-swxs5pr1	244	5	consisting	consist	VBG
cord-282507-swxs5pr1	244	6	of	of	IN
cord-282507-swxs5pr1	244	7	a	a	DT
cord-282507-swxs5pr1	244	8	recombinant	recombinant	JJ
cord-282507-swxs5pr1	244	9	fusion	fusion	NN
cord-282507-swxs5pr1	244	10	protein	protein	NN
cord-282507-swxs5pr1	244	11	(	(	-LRB-
cord-282507-swxs5pr1	244	12	F4	F4	NNP
cord-282507-swxs5pr1	244	13	)	)	-RRB-
cord-282507-swxs5pr1	244	14	encoding	encode	VBG
cord-282507-swxs5pr1	244	15	four	four	CD
cord-282507-swxs5pr1	244	16	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	244	17	clade	clade	NN
cord-282507-swxs5pr1	244	18	B	B	NNP
cord-282507-swxs5pr1	244	19	Ags	Ags	NNP
cord-282507-swxs5pr1	244	20	(	(	-LRB-
cord-282507-swxs5pr1	244	21	p17	p17	NN
cord-282507-swxs5pr1	244	22	,	,	,
cord-282507-swxs5pr1	244	23	p24	p24	NN
cord-282507-swxs5pr1	244	24	,	,	,
cord-282507-swxs5pr1	244	25	reverse	reverse	JJ
cord-282507-swxs5pr1	244	26	transcriptase	transcriptase	NN
cord-282507-swxs5pr1	244	27	(	(	-LRB-
cord-282507-swxs5pr1	244	28	RT	RT	NNP
cord-282507-swxs5pr1	244	29	)	)	-RRB-
cord-282507-swxs5pr1	244	30	and	and	CC
cord-282507-swxs5pr1	244	31	Nef	Nef	NNP
cord-282507-swxs5pr1	244	32	)	)	-RRB-
cord-282507-swxs5pr1	245	1	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	245	2	with	with	IN
cord-282507-swxs5pr1	245	3	AS01	AS01	NNP
cord-282507-swxs5pr1	245	4	was	be	VBD
cord-282507-swxs5pr1	245	5	studied	study	VBN
cord-282507-swxs5pr1	245	6	in	in	IN
cord-282507-swxs5pr1	245	7	a	a	DT
cord-282507-swxs5pr1	245	8	phase	phase	NN
cord-282507-swxs5pr1	245	9	I	-PRON-	PRP
cord-282507-swxs5pr1	245	10	/	/	SYM
cord-282507-swxs5pr1	245	11	II	ii	CD
cord-282507-swxs5pr1	245	12	trials	trial	NNS
cord-282507-swxs5pr1	245	13	with	with	IN
cord-282507-swxs5pr1	245	14	healthy	healthy	JJ
cord-282507-swxs5pr1	245	15	HIV	HIV	NNP
cord-282507-swxs5pr1	245	16	-	-	HYPH
cord-282507-swxs5pr1	245	17	seronegative	seronegative	JJ
cord-282507-swxs5pr1	245	18	volunteers	volunteer	NNS
cord-282507-swxs5pr1	245	19	(	(	-LRB-
cord-282507-swxs5pr1	245	20	Van	Van	NNP
cord-282507-swxs5pr1	245	21	Braeckel	Braeckel	NNP
cord-282507-swxs5pr1	245	22	et	et	FW
cord-282507-swxs5pr1	245	23	al	al	NNP
cord-282507-swxs5pr1	245	24	.	.	NNP
cord-282507-swxs5pr1	245	25	,	,	,
cord-282507-swxs5pr1	245	26	2011	2011	CD
cord-282507-swxs5pr1	245	27	)	)	-RRB-
cord-282507-swxs5pr1	245	28	.	.	.
cord-282507-swxs5pr1	246	1	This	this	DT
cord-282507-swxs5pr1	246	2	vaccine	vaccine	NN
cord-282507-swxs5pr1	246	3	was	be	VBD
cord-282507-swxs5pr1	246	4	shown	show	VBN
cord-282507-swxs5pr1	246	5	to	to	TO
cord-282507-swxs5pr1	246	6	be	be	VB
cord-282507-swxs5pr1	246	7	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	246	8	with	with	IN
cord-282507-swxs5pr1	246	9	an	an	DT
cord-282507-swxs5pr1	246	10	acceptable	acceptable	JJ
cord-282507-swxs5pr1	246	11	safety	safety	NN
cord-282507-swxs5pr1	246	12	profile	profile	NN
cord-282507-swxs5pr1	246	13	.	.	.
cord-282507-swxs5pr1	247	1	After	after	IN
cord-282507-swxs5pr1	247	2	two	two	CD
cord-282507-swxs5pr1	247	3	doses	dose	NNS
cord-282507-swxs5pr1	247	4	of	of	IN
cord-282507-swxs5pr1	247	5	10	10	CD
cord-282507-swxs5pr1	247	6	μg	μg	NNS
cord-282507-swxs5pr1	247	7	,	,	,
cord-282507-swxs5pr1	247	8	strong	strong	JJ
cord-282507-swxs5pr1	247	9	polyfunctional	polyfunctional	NNP
cord-282507-swxs5pr1	247	10	(	(	-LRB-
cord-282507-swxs5pr1	247	11	CD40L	cd40l	NN
cord-282507-swxs5pr1	247	12	,	,	,
cord-282507-swxs5pr1	247	13	Il-2	Il-2	NNP
cord-282507-swxs5pr1	247	14	,	,	,
cord-282507-swxs5pr1	248	1	TNF	TNF	NNP
cord-282507-swxs5pr1	248	2	-	-	HYPH
cord-282507-swxs5pr1	248	3	α	α	NNP
cord-282507-swxs5pr1	248	4	,	,	,
cord-282507-swxs5pr1	248	5	IFN	IFN	NNP
cord-282507-swxs5pr1	248	6	-	-	HYPH
cord-282507-swxs5pr1	248	7	γ	γ	NN
cord-282507-swxs5pr1	248	8	phenotype	phenotype	NN
cord-282507-swxs5pr1	248	9	)	)	-RRB-
cord-282507-swxs5pr1	248	10	and	and	CC
cord-282507-swxs5pr1	248	11	persistent	persistent	JJ
cord-282507-swxs5pr1	248	12	CD4	CD4	NNP
cord-282507-swxs5pr1	248	13	+	+	CC
cord-282507-swxs5pr1	248	14	T	t	NN
cord-282507-swxs5pr1	248	15	cell	cell	NN
cord-282507-swxs5pr1	248	16	responses	response	NNS
cord-282507-swxs5pr1	248	17	were	be	VBD
cord-282507-swxs5pr1	248	18	induced	induce	VBN
cord-282507-swxs5pr1	248	19	,	,	,
cord-282507-swxs5pr1	248	20	suggesting	suggest	VBG
cord-282507-swxs5pr1	248	21	that	that	IN
cord-282507-swxs5pr1	248	22	this	this	DT
cord-282507-swxs5pr1	248	23	vaccine	vaccine	NN
cord-282507-swxs5pr1	248	24	merits	merit	VBZ
cord-282507-swxs5pr1	248	25	further	further	JJ
cord-282507-swxs5pr1	248	26	evaluation	evaluation	NN
cord-282507-swxs5pr1	248	27	both	both	CC
cord-282507-swxs5pr1	248	28	in	in	IN
cord-282507-swxs5pr1	248	29	a	a	DT
cord-282507-swxs5pr1	248	30	prophylactic	prophylactic	JJ
cord-282507-swxs5pr1	248	31	setting	setting	NN
cord-282507-swxs5pr1	248	32	and	and	CC
cord-282507-swxs5pr1	248	33	as	as	IN
cord-282507-swxs5pr1	248	34	a	a	DT
cord-282507-swxs5pr1	248	35	potentially	potentially	RB
cord-282507-swxs5pr1	248	36	disease	disease	NN
cord-282507-swxs5pr1	248	37	-	-	HYPH
cord-282507-swxs5pr1	248	38	modifying	modify	VBG
cord-282507-swxs5pr1	248	39	therapeutic	therapeutic	JJ
cord-282507-swxs5pr1	248	40	vaccine	vaccine	NN
cord-282507-swxs5pr1	248	41	in	in	IN
cord-282507-swxs5pr1	248	42	HIV-1infected	HIV-1infected	NNP
cord-282507-swxs5pr1	248	43	subjects	subject	NNS
cord-282507-swxs5pr1	248	44	.	.	.
cord-282507-swxs5pr1	249	1	A	a	DT
cord-282507-swxs5pr1	249	2	phase	phase	NN
cord-282507-swxs5pr1	249	3	I	-PRON-	PRP
cord-282507-swxs5pr1	249	4	clinical	clinical	JJ
cord-282507-swxs5pr1	249	5	study	study	NN
cord-282507-swxs5pr1	249	6	in	in	IN
cord-282507-swxs5pr1	249	7	such	such	JJ
cord-282507-swxs5pr1	249	8	subjects	subject	NNS
cord-282507-swxs5pr1	249	9	has	have	VBZ
cord-282507-swxs5pr1	249	10	been	be	VBN
cord-282507-swxs5pr1	249	11	initiated	initiate	VBN
cord-282507-swxs5pr1	250	1	(	(	-LRB-
cord-282507-swxs5pr1	250	2	Harrer	Harrer	NNP
cord-282507-swxs5pr1	250	3	et	et	FW
cord-282507-swxs5pr1	250	4	al	al	NNP
cord-282507-swxs5pr1	250	5	.	.	NNP
cord-282507-swxs5pr1	250	6	,	,	,
cord-282507-swxs5pr1	250	7	2014	2014	CD
cord-282507-swxs5pr1	250	8	)	)	-RRB-
cord-282507-swxs5pr1	250	9	.	.	.
cord-282507-swxs5pr1	251	1	A	a	DT
cord-282507-swxs5pr1	251	2	phase	phase	NN
cord-282507-swxs5pr1	251	3	II	ii	CD
cord-282507-swxs5pr1	251	4	study	study	NN
cord-282507-swxs5pr1	251	5	was	be	VBD
cord-282507-swxs5pr1	251	6	conducted	conduct	VBN
cord-282507-swxs5pr1	251	7	with	with	IN
cord-282507-swxs5pr1	251	8	the	the	DT
cord-282507-swxs5pr1	251	9	F4	F4	NNP
cord-282507-swxs5pr1	251	10	/	/	SYM
cord-282507-swxs5pr1	251	11	AS01	AS01	NNP
cord-282507-swxs5pr1	251	12	B	B	NNP
cord-282507-swxs5pr1	251	13	candidate	candidate	NN
cord-282507-swxs5pr1	251	14	vaccine	vaccine	NN
cord-282507-swxs5pr1	251	15	on	on	IN
cord-282507-swxs5pr1	251	16	healthy	healthy	JJ
cord-282507-swxs5pr1	251	17	adults	adult	NNS
cord-282507-swxs5pr1	251	18	in	in	IN
cord-282507-swxs5pr1	251	19	order	order	NN
cord-282507-swxs5pr1	251	20	to	to	TO
cord-282507-swxs5pr1	251	21	evaluate	evaluate	VB
cord-282507-swxs5pr1	251	22	the	the	DT
cord-282507-swxs5pr1	251	23	effect	effect	NN
cord-282507-swxs5pr1	251	24	of	of	IN
cord-282507-swxs5pr1	251	25	chloroquine	chloroquine	NN
cord-282507-swxs5pr1	251	26	on	on	IN
cord-282507-swxs5pr1	251	27	the	the	DT
cord-282507-swxs5pr1	251	28	specific	specific	JJ
cord-282507-swxs5pr1	251	29	CD8	CD8	NNP
cord-282507-swxs5pr1	251	30	+	+	CC
cord-282507-swxs5pr1	251	31	T	T	NNP
cord-282507-swxs5pr1	251	32	cell	cell	NN
cord-282507-swxs5pr1	251	33	responses	response	NNS
cord-282507-swxs5pr1	251	34	and	and	CC
cord-282507-swxs5pr1	251	35	the	the	DT
cord-282507-swxs5pr1	251	36	safety	safety	NN
cord-282507-swxs5pr1	251	37	profile	profile	NN
cord-282507-swxs5pr1	251	38	of	of	IN
cord-282507-swxs5pr1	251	39	a	a	DT
cord-282507-swxs5pr1	251	40	booster	booster	NN
cord-282507-swxs5pr1	251	41	dose	dose	NN
cord-282507-swxs5pr1	251	42	(	(	-LRB-
cord-282507-swxs5pr1	251	43	Leroux	Leroux	NNP
cord-282507-swxs5pr1	251	44	-	-	HYPH
cord-282507-swxs5pr1	251	45	Roels	Roels	NNP
cord-282507-swxs5pr1	251	46	et	et	NNP
cord-282507-swxs5pr1	251	47	al	al	NNP
cord-282507-swxs5pr1	251	48	.	.	NNP
cord-282507-swxs5pr1	251	49	,	,	,
cord-282507-swxs5pr1	251	50	2014b	2014b	CD
cord-282507-swxs5pr1	251	51	)	)	-RRB-
cord-282507-swxs5pr1	251	52	.	.	.
cord-282507-swxs5pr1	252	1	The	the	DT
cord-282507-swxs5pr1	252	2	results	result	NNS
cord-282507-swxs5pr1	252	3	showed	show	VBD
cord-282507-swxs5pr1	252	4	that	that	IN
cord-282507-swxs5pr1	252	5	a	a	DT
cord-282507-swxs5pr1	252	6	booster	booster	NN
cord-282507-swxs5pr1	252	7	dose	dose	NN
cord-282507-swxs5pr1	252	8	,	,	,
cord-282507-swxs5pr1	252	9	administered	administer	VBN
cord-282507-swxs5pr1	252	10	alone	alone	RB
cord-282507-swxs5pr1	252	11	or	or	CC
cord-282507-swxs5pr1	252	12	two	two	CD
cord-282507-swxs5pr1	252	13	days	day	NNS
cord-282507-swxs5pr1	252	14	after	after	IN
cord-282507-swxs5pr1	252	15	chloroquine	chloroquine	NN
cord-282507-swxs5pr1	252	16	induced	induce	VBD
cord-282507-swxs5pr1	252	17	a	a	DT
cord-282507-swxs5pr1	252	18	strong	strong	JJ
cord-282507-swxs5pr1	252	19	Ab	Ab	NNP
cord-282507-swxs5pr1	252	20	immune	immune	JJ
cord-282507-swxs5pr1	252	21	response	response	NN
cord-282507-swxs5pr1	252	22	and	and	CC
cord-282507-swxs5pr1	252	23	robust	robust	JJ
cord-282507-swxs5pr1	252	24	F4	F4	NNP
cord-282507-swxs5pr1	252	25	-specific	-specific	NN
cord-282507-swxs5pr1	252	26	CD4	CD4	NNP
cord-282507-swxs5pr1	252	27	+	+	CC
cord-282507-swxs5pr1	252	28	T	T	NNP
cord-282507-swxs5pr1	252	29	cell	cell	NN
cord-282507-swxs5pr1	252	30	response	response	NN
cord-282507-swxs5pr1	252	31	,	,	,
cord-282507-swxs5pr1	252	32	but	but	CC
cord-282507-swxs5pr1	252	33	no	no	DT
cord-282507-swxs5pr1	252	34	significant	significant	JJ
cord-282507-swxs5pr1	252	35	CD8	CD8	NNP
cord-282507-swxs5pr1	252	36	+	+	CC
cord-282507-swxs5pr1	252	37	T	T	NNP
cord-282507-swxs5pr1	252	38	cell	cell	NN
cord-282507-swxs5pr1	252	39	response	response	NN
cord-282507-swxs5pr1	252	40	.	.	.
cord-282507-swxs5pr1	253	1	This	this	DT
cord-282507-swxs5pr1	253	2	suggest	suggest	VBP
cord-282507-swxs5pr1	253	3	that	that	IN
cord-282507-swxs5pr1	253	4	two	two	CD
cord-282507-swxs5pr1	253	5	primary	primary	JJ
cord-282507-swxs5pr1	253	6	doses	dose	NNS
cord-282507-swxs5pr1	253	7	of	of	IN
cord-282507-swxs5pr1	253	8	the	the	DT
cord-282507-swxs5pr1	253	9	F4	F4	NNP
cord-282507-swxs5pr1	253	10	/	/	SYM
cord-282507-swxs5pr1	253	11	AS01	AS01	NNP
cord-282507-swxs5pr1	253	12	B	B	NNP
cord-282507-swxs5pr1	253	13	vaccine	vaccine	NN
cord-282507-swxs5pr1	253	14	induce	induce	VB
cord-282507-swxs5pr1	253	15	long	long	RB
cord-282507-swxs5pr1	253	16	-	-	HYPH
cord-282507-swxs5pr1	253	17	lasting	last	VBG
cord-282507-swxs5pr1	253	18	memory	memory	NN
cord-282507-swxs5pr1	253	19	B	b	NN
cord-282507-swxs5pr1	253	20	cell	cell	NN
cord-282507-swxs5pr1	253	21	and	and	CC
cord-282507-swxs5pr1	253	22	CD4	CD4	NNP
cord-282507-swxs5pr1	253	23	+	+	CC
cord-282507-swxs5pr1	253	24	T	T	NNP
cord-282507-swxs5pr1	253	25	cell	cell	NN
cord-282507-swxs5pr1	253	26	responses	response	NNS
cord-282507-swxs5pr1	253	27	in	in	IN
cord-282507-swxs5pr1	253	28	healthy	healthy	JJ
cord-282507-swxs5pr1	253	29	adults	adult	NNS
cord-282507-swxs5pr1	253	30	,	,	,
cord-282507-swxs5pr1	253	31	confirming	confirm	VBG
cord-282507-swxs5pr1	253	32	previous	previous	JJ
cord-282507-swxs5pr1	253	33	findings	finding	NNS
cord-282507-swxs5pr1	253	34	of	of	IN
cord-282507-swxs5pr1	253	35	the	the	DT
cord-282507-swxs5pr1	253	36	phase	phase	NN
cord-282507-swxs5pr1	253	37	I	-PRON-	PRP
cord-282507-swxs5pr1	253	38	/	/	SYM
cord-282507-swxs5pr1	253	39	II	II	NNP
cord-282507-swxs5pr1	253	40	study	study	NN
cord-282507-swxs5pr1	253	41	(	(	-LRB-
cord-282507-swxs5pr1	253	42	Leroux	Leroux	NNP
cord-282507-swxs5pr1	253	43	-	-	HYPH
cord-282507-swxs5pr1	253	44	Roels	Roels	NNP
cord-282507-swxs5pr1	253	45	et	et	NNP
cord-282507-swxs5pr1	253	46	al	al	NNP
cord-282507-swxs5pr1	253	47	.	.	NNP
cord-282507-swxs5pr1	253	48	,	,	,
cord-282507-swxs5pr1	253	49	2014b	2014b	CD
cord-282507-swxs5pr1	253	50	)	)	-RRB-
cord-282507-swxs5pr1	253	51	.	.	.
cord-282507-swxs5pr1	254	1	This	this	DT
cord-282507-swxs5pr1	254	2	vaccine	vaccine	NN
cord-282507-swxs5pr1	254	3	was	be	VBD
cord-282507-swxs5pr1	254	4	shown	show	VBN
cord-282507-swxs5pr1	254	5	to	to	TO
cord-282507-swxs5pr1	254	6	be	be	VB
cord-282507-swxs5pr1	254	7	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	254	8	with	with	IN
cord-282507-swxs5pr1	254	9	a	a	DT
cord-282507-swxs5pr1	254	10	clinically	clinically	RB
cord-282507-swxs5pr1	254	11	acceptable	acceptable	JJ
cord-282507-swxs5pr1	254	12	safety	safety	NN
cord-282507-swxs5pr1	254	13	profile	profile	NN
cord-282507-swxs5pr1	254	14	,	,	,
cord-282507-swxs5pr1	254	15	but	but	CC
cord-282507-swxs5pr1	254	16	does	do	VBZ
cord-282507-swxs5pr1	254	17	n't	not	RB
cord-282507-swxs5pr1	254	18	show	show	VB
cord-282507-swxs5pr1	254	19	significant	significant	JJ
cord-282507-swxs5pr1	254	20	viral	viral	JJ
cord-282507-swxs5pr1	254	21	efficacy	efficacy	NN
cord-282507-swxs5pr1	254	22	in	in	IN
cord-282507-swxs5pr1	254	23	antiretroviral	antiretroviral	JJ
cord-282507-swxs5pr1	254	24	therapy	therapy	NN
cord-282507-swxs5pr1	254	25	-	-	HYPH
cord-282507-swxs5pr1	254	26	naïve	naïve	JJ
cord-282507-swxs5pr1	254	27	HIV-1-infected	hiv-1-infecte	VBN
cord-282507-swxs5pr1	254	28	adults	adult	NNS
cord-282507-swxs5pr1	254	29	,	,	,
cord-282507-swxs5pr1	254	30	results	result	NNS
cord-282507-swxs5pr1	254	31	confirmed	confirm	VBN
cord-282507-swxs5pr1	254	32	in	in	IN
cord-282507-swxs5pr1	254	33	a	a	DT
cord-282507-swxs5pr1	254	34	long	long	JJ
cord-282507-swxs5pr1	254	35	term	term	NN
cord-282507-swxs5pr1	254	36	study	study	NN
cord-282507-swxs5pr1	254	37	(	(	-LRB-
cord-282507-swxs5pr1	254	38	Dinges	Dinges	NNP
cord-282507-swxs5pr1	254	39	et	et	FW
cord-282507-swxs5pr1	254	40	al	al	NNP
cord-282507-swxs5pr1	254	41	.	.	NNP
cord-282507-swxs5pr1	254	42	,	,	,
cord-282507-swxs5pr1	254	43	2016	2016	CD
cord-282507-swxs5pr1	254	44	;	;	:
cord-282507-swxs5pr1	254	45	Harrer	Harrer	NNP
cord-282507-swxs5pr1	254	46	et	et	NNP
cord-282507-swxs5pr1	254	47	al	al	NNP
cord-282507-swxs5pr1	254	48	.	.	NNP
cord-282507-swxs5pr1	254	49	,	,	,
cord-282507-swxs5pr1	254	50	2018	2018	CD
cord-282507-swxs5pr1	254	51	)	)	-RRB-
cord-282507-swxs5pr1	254	52	.	.	.
cord-282507-swxs5pr1	255	1	The	the	DT
cord-282507-swxs5pr1	255	2	use	use	NN
cord-282507-swxs5pr1	255	3	of	of	IN
cord-282507-swxs5pr1	255	4	immunotherapeutic	immunotherapeutic	JJ
cord-282507-swxs5pr1	255	5	vaccines	vaccine	NNS
cord-282507-swxs5pr1	255	6	in	in	IN
cord-282507-swxs5pr1	255	7	cancer	cancer	NN
cord-282507-swxs5pr1	255	8	patients	patient	NNS
cord-282507-swxs5pr1	255	9	is	be	VBZ
cord-282507-swxs5pr1	255	10	aimed	aim	VBN
cord-282507-swxs5pr1	255	11	at	at	IN
cord-282507-swxs5pr1	255	12	inducing	induce	VBG
cord-282507-swxs5pr1	255	13	immune	immune	JJ
cord-282507-swxs5pr1	255	14	responses	response	NNS
cord-282507-swxs5pr1	255	15	against	against	IN
cord-282507-swxs5pr1	255	16	existing	exist	VBG
cord-282507-swxs5pr1	255	17	tumors	tumor	NNS
cord-282507-swxs5pr1	255	18	rather	rather	RB
cord-282507-swxs5pr1	255	19	than	than	IN
cord-282507-swxs5pr1	255	20	protecting	protect	VBG
cord-282507-swxs5pr1	255	21	healthy	healthy	JJ
cord-282507-swxs5pr1	255	22	individuals	individual	NNS
cord-282507-swxs5pr1	255	23	.	.	.
cord-282507-swxs5pr1	256	1	They	-PRON-	PRP
cord-282507-swxs5pr1	256	2	have	have	VBP
cord-282507-swxs5pr1	256	3	been	be	VBN
cord-282507-swxs5pr1	256	4	used	use	VBN
cord-282507-swxs5pr1	256	5	in	in	IN
cord-282507-swxs5pr1	256	6	phase	phase	NN
cord-282507-swxs5pr1	256	7	II	II	NNP
cord-282507-swxs5pr1	256	8	and	and	CC
cord-282507-swxs5pr1	256	9	III	iii	CD
cord-282507-swxs5pr1	256	10	trials	trial	NNS
cord-282507-swxs5pr1	256	11	against	against	IN
cord-282507-swxs5pr1	256	12	melanoma	melanoma	NN
cord-282507-swxs5pr1	256	13	and	and	CC
cord-282507-swxs5pr1	256	14	lung	lung	NN
cord-282507-swxs5pr1	256	15	cancer	cancer	NN
cord-282507-swxs5pr1	256	16	after	after	IN
cord-282507-swxs5pr1	256	17	surgical	surgical	JJ
cord-282507-swxs5pr1	256	18	resection	resection	NN
cord-282507-swxs5pr1	256	19	,	,	,
cord-282507-swxs5pr1	256	20	and	and	CC
cord-282507-swxs5pr1	256	21	the	the	DT
cord-282507-swxs5pr1	256	22	disappointing	disappointing	JJ
cord-282507-swxs5pr1	256	23	results	result	NNS
cord-282507-swxs5pr1	256	24	of	of	IN
cord-282507-swxs5pr1	256	25	the	the	DT
cord-282507-swxs5pr1	256	26	most	most	RBS
cord-282507-swxs5pr1	256	27	recent	recent	JJ
cord-282507-swxs5pr1	256	28	studies	study	NNS
cord-282507-swxs5pr1	256	29	will	will	MD
cord-282507-swxs5pr1	256	30	be	be	VB
cord-282507-swxs5pr1	256	31	shortly	shortly	RB
cord-282507-swxs5pr1	256	32	presented	present	VBN
cord-282507-swxs5pr1	256	33	here	here	RB
cord-282507-swxs5pr1	256	34	.	.	.
cord-282507-swxs5pr1	257	1	Enhanced	enhanced	JJ
cord-282507-swxs5pr1	257	2	production	production	NN
cord-282507-swxs5pr1	257	3	of	of	IN
cord-282507-swxs5pr1	257	4	ganglioside	ganglioside	NN
cord-282507-swxs5pr1	257	5	GM2	GM2	NNP
cord-282507-swxs5pr1	257	6	is	be	VBZ
cord-282507-swxs5pr1	257	7	observed	observe	VBN
cord-282507-swxs5pr1	257	8	in	in	IN
cord-282507-swxs5pr1	257	9	different	different	JJ
cord-282507-swxs5pr1	257	10	human	human	JJ
cord-282507-swxs5pr1	257	11	tumor	tumor	NN
cord-282507-swxs5pr1	257	12	types	type	NNS
cord-282507-swxs5pr1	257	13	including	include	VBG
cord-282507-swxs5pr1	257	14	melanoma	melanoma	NN
cord-282507-swxs5pr1	257	15	.	.	.
cord-282507-swxs5pr1	258	1	Anti	anti	JJ
cord-282507-swxs5pr1	258	2	-	-	JJ
cord-282507-swxs5pr1	258	3	GM2	gm2	JJ
cord-282507-swxs5pr1	258	4	vaccines	vaccine	NNS
cord-282507-swxs5pr1	258	5	such	such	JJ
cord-282507-swxs5pr1	258	6	as	as	IN
cord-282507-swxs5pr1	258	7	GM2	GM2	NNP
cord-282507-swxs5pr1	258	8	conjugated	conjugate	VBN
cord-282507-swxs5pr1	258	9	to	to	IN
cord-282507-swxs5pr1	258	10	a	a	DT
cord-282507-swxs5pr1	258	11	carrier	carrier	NN
cord-282507-swxs5pr1	258	12	keyhole	keyhole	NN
cord-282507-swxs5pr1	258	13	limpet	limpet	NN
cord-282507-swxs5pr1	258	14	hemocyanin	hemocyanin	NNP
cord-282507-swxs5pr1	258	15	(	(	-LRB-
cord-282507-swxs5pr1	258	16	KLH	KLH	NNP
cord-282507-swxs5pr1	258	17	)	)	-RRB-
cord-282507-swxs5pr1	258	18	and	and	CC
cord-282507-swxs5pr1	258	19	administered	administer	VBN
cord-282507-swxs5pr1	258	20	with	with	IN
cord-282507-swxs5pr1	258	21	QS-21	QS-21	NNP
cord-282507-swxs5pr1	258	22	induced	induce	VBD
cord-282507-swxs5pr1	258	23	high	high	JJ
cord-282507-swxs5pr1	258	24	IgM	igm	NN
cord-282507-swxs5pr1	258	25	and	and	CC
cord-282507-swxs5pr1	258	26	IgG	IgG	NNP
cord-282507-swxs5pr1	258	27	Ab	Ab	NNP
cord-282507-swxs5pr1	258	28	responses	response	NNS
cord-282507-swxs5pr1	258	29	but	but	CC
cord-282507-swxs5pr1	258	30	failed	fail	VBD
cord-282507-swxs5pr1	258	31	to	to	TO
cord-282507-swxs5pr1	258	32	show	show	VB
cord-282507-swxs5pr1	258	33	a	a	DT
cord-282507-swxs5pr1	258	34	beneficial	beneficial	JJ
cord-282507-swxs5pr1	258	35	effect	effect	NN
cord-282507-swxs5pr1	258	36	in	in	IN
cord-282507-swxs5pr1	258	37	melanoma	melanoma	NN
cord-282507-swxs5pr1	258	38	patients	patient	NNS
cord-282507-swxs5pr1	258	39	as	as	IN
cord-282507-swxs5pr1	258	40	it	-PRON-	PRP
cord-282507-swxs5pr1	258	41	was	be	VBD
cord-282507-swxs5pr1	258	42	shown	show	VBN
cord-282507-swxs5pr1	258	43	in	in	IN
cord-282507-swxs5pr1	258	44	a	a	DT
cord-282507-swxs5pr1	258	45	phase	phase	NN
cord-282507-swxs5pr1	258	46	III	iii	CD
cord-282507-swxs5pr1	258	47	clinical	clinical	JJ
cord-282507-swxs5pr1	258	48	trial	trial	NN
cord-282507-swxs5pr1	258	49	in	in	IN
cord-282507-swxs5pr1	258	50	term	term	NN
cord-282507-swxs5pr1	258	51	of	of	IN
cord-282507-swxs5pr1	258	52	relapse	relapse	NN
cord-282507-swxs5pr1	258	53	free	free	JJ
cord-282507-swxs5pr1	258	54	survival	survival	NN
cord-282507-swxs5pr1	258	55	,	,	,
cord-282507-swxs5pr1	258	56	distant	distant	JJ
cord-282507-swxs5pr1	258	57	metastasis	metastasis	NN
cord-282507-swxs5pr1	258	58	-	-	HYPH
cord-282507-swxs5pr1	258	59	free	free	JJ
cord-282507-swxs5pr1	258	60	survival	survival	NN
cord-282507-swxs5pr1	258	61	and	and	CC
cord-282507-swxs5pr1	258	62	overall	overall	JJ
cord-282507-swxs5pr1	258	63	survival	survival	NN
cord-282507-swxs5pr1	259	1	(	(	-LRB-
cord-282507-swxs5pr1	259	2	Eggermont	Eggermont	NNP
cord-282507-swxs5pr1	259	3	et	et	FW
cord-282507-swxs5pr1	259	4	al	al	NNP
cord-282507-swxs5pr1	259	5	.	.	NNP
cord-282507-swxs5pr1	259	6	,	,	,
cord-282507-swxs5pr1	259	7	2013	2013	CD
cord-282507-swxs5pr1	259	8	)	)	-RRB-
cord-282507-swxs5pr1	259	9	.	.	.
cord-282507-swxs5pr1	260	1	A	a	DT
cord-282507-swxs5pr1	260	2	five	five	CD
cord-282507-swxs5pr1	260	3	-	-	HYPH
cord-282507-swxs5pr1	260	4	years	year	NNS
cord-282507-swxs5pr1	260	5	survival	survival	NN
cord-282507-swxs5pr1	260	6	occurs	occur	VBZ
cord-282507-swxs5pr1	260	7	for	for	IN
cord-282507-swxs5pr1	260	8	less	less	JJR
cord-282507-swxs5pr1	260	9	than	than	IN
cord-282507-swxs5pr1	260	10	50	50	CD
cord-282507-swxs5pr1	260	11	%	%	NN
cord-282507-swxs5pr1	260	12	of	of	IN
cord-282507-swxs5pr1	260	13	the	the	DT
cord-282507-swxs5pr1	260	14	patients	patient	NNS
cord-282507-swxs5pr1	260	15	with	with	IN
cord-282507-swxs5pr1	260	16	completely	completely	RB
cord-282507-swxs5pr1	260	17	resected	resect	VBN
cord-282507-swxs5pr1	260	18	non	non	JJ
cord-282507-swxs5pr1	260	19	-	-	JJ
cord-282507-swxs5pr1	260	20	small	small	JJ
cord-282507-swxs5pr1	260	21	-	-	HYPH
cord-282507-swxs5pr1	260	22	cell	cell	NN
cord-282507-swxs5pr1	260	23	-	-	HYPH
cord-282507-swxs5pr1	260	24	lung	lung	NN
cord-282507-swxs5pr1	260	25	cancer	cancer	NN
cord-282507-swxs5pr1	260	26	(	(	-LRB-
cord-282507-swxs5pr1	260	27	NSCLC	NSCLC	NNP
cord-282507-swxs5pr1	260	28	)	)	-RRB-
cord-282507-swxs5pr1	260	29	.	.	.
cord-282507-swxs5pr1	261	1	Therapeutic	therapeutic	JJ
cord-282507-swxs5pr1	261	2	cancer	cancer	NN
cord-282507-swxs5pr1	261	3	vaccination	vaccination	NN
cord-282507-swxs5pr1	261	4	has	have	VBZ
cord-282507-swxs5pr1	261	5	the	the	DT
cord-282507-swxs5pr1	261	6	potential	potential	NN
cord-282507-swxs5pr1	261	7	for	for	IN
cord-282507-swxs5pr1	261	8	eliminating	eliminate	VBG
cord-282507-swxs5pr1	261	9	remaining	remain	VBG
cord-282507-swxs5pr1	261	10	cancer	cancer	NN
cord-282507-swxs5pr1	261	11	cells	cell	NNS
cord-282507-swxs5pr1	261	12	after	after	IN
cord-282507-swxs5pr1	261	13	complete	complete	JJ
cord-282507-swxs5pr1	261	14	resection	resection	NN
cord-282507-swxs5pr1	261	15	,	,	,
cord-282507-swxs5pr1	261	16	thereby	thereby	RB
cord-282507-swxs5pr1	261	17	decreasing	decrease	VBG
cord-282507-swxs5pr1	261	18	relapse	relapse	NN
cord-282507-swxs5pr1	261	19	rates	rate	NNS
cord-282507-swxs5pr1	261	20	and	and	CC
cord-282507-swxs5pr1	261	21	improving	improve	VBG
cord-282507-swxs5pr1	261	22	survival	survival	NN
cord-282507-swxs5pr1	261	23	(	(	-LRB-
cord-282507-swxs5pr1	261	24	Vansteenkiste	Vansteenkiste	NNP
cord-282507-swxs5pr1	261	25	et	et	NNP
cord-282507-swxs5pr1	261	26	al	al	NNP
cord-282507-swxs5pr1	261	27	.	.	NNP
cord-282507-swxs5pr1	261	28	,	,	,
cord-282507-swxs5pr1	261	29	2016	2016	CD
cord-282507-swxs5pr1	261	30	)	)	-RRB-
cord-282507-swxs5pr1	261	31	.	.	.
cord-282507-swxs5pr1	262	1	Ag	Ag	NNP
cord-282507-swxs5pr1	262	2	-	-	HYPH
cord-282507-swxs5pr1	262	3	specific	specific	JJ
cord-282507-swxs5pr1	262	4	immunotherapies	immunotherapy	NNS
cord-282507-swxs5pr1	262	5	enhance	enhance	VBP
cord-282507-swxs5pr1	262	6	T	t	NN
cord-282507-swxs5pr1	262	7	-	-	HYPH
cord-282507-swxs5pr1	262	8	cell	cell	NN
cord-282507-swxs5pr1	262	9	responses	response	NNS
cord-282507-swxs5pr1	262	10	against	against	IN
cord-282507-swxs5pr1	262	11	specifically	specifically	RB
cord-282507-swxs5pr1	262	12	expressed	express	VBN
cord-282507-swxs5pr1	262	13	tumor	tumor	NN
cord-282507-swxs5pr1	262	14	Ags	Ags	NNP
cord-282507-swxs5pr1	262	15	.	.	.
cord-282507-swxs5pr1	263	1	In	in	IN
cord-282507-swxs5pr1	263	2	this	this	DT
cord-282507-swxs5pr1	263	3	context	context	NN
cord-282507-swxs5pr1	263	4	,	,	,
cord-282507-swxs5pr1	263	5	the	the	DT
cord-282507-swxs5pr1	263	6	use	use	NN
cord-282507-swxs5pr1	263	7	of	of	IN
cord-282507-swxs5pr1	263	8	MAGE	MAGE	NNP
cord-282507-swxs5pr1	263	9	-	-	HYPH
cord-282507-swxs5pr1	263	10	A3	A3	NNP
cord-282507-swxs5pr1	263	11	(	(	-LRB-
cord-282507-swxs5pr1	263	12	Melanoma	Melanoma	NNP
cord-282507-swxs5pr1	263	13	AntiGEn	AntiGEn	NNP
cord-282507-swxs5pr1	263	14	family	family	NN
cord-282507-swxs5pr1	263	15	A	a	NN
cord-282507-swxs5pr1	263	16	,	,	,
cord-282507-swxs5pr1	263	17	3	3	CD
cord-282507-swxs5pr1	263	18	)	)	-RRB-
cord-282507-swxs5pr1	263	19	as	as	IN
cord-282507-swxs5pr1	263	20	Ag	Ag	NNP
cord-282507-swxs5pr1	263	21	,	,	,
cord-282507-swxs5pr1	263	22	which	which	WDT
cord-282507-swxs5pr1	263	23	is	be	VBZ
cord-282507-swxs5pr1	263	24	expressed	express	VBN
cord-282507-swxs5pr1	263	25	in	in	IN
cord-282507-swxs5pr1	263	26	a	a	DT
cord-282507-swxs5pr1	263	27	wide	wide	JJ
cord-282507-swxs5pr1	263	28	array	array	NN
cord-282507-swxs5pr1	263	29	of	of	IN
cord-282507-swxs5pr1	263	30	malignancies	malignancy	NNS
cord-282507-swxs5pr1	263	31	can	can	MD
cord-282507-swxs5pr1	263	32	be	be	VB
cord-282507-swxs5pr1	263	33	an	an	DT
cord-282507-swxs5pr1	263	34	application	application	NN
cord-282507-swxs5pr1	263	35	in	in	IN
cord-282507-swxs5pr1	263	36	cancer	cancer	NN
cord-282507-swxs5pr1	263	37	immunotherapy	immunotherapy	NN
cord-282507-swxs5pr1	263	38	(	(	-LRB-
cord-282507-swxs5pr1	263	39	Esfandiary	Esfandiary	NNP
cord-282507-swxs5pr1	263	40	and	and	CC
cord-282507-swxs5pr1	263	41	Ghafouri	Ghafouri	NNP
cord-282507-swxs5pr1	263	42	-	-	HYPH
cord-282507-swxs5pr1	263	43	Fard	Fard	NNP
cord-282507-swxs5pr1	263	44	,	,	,
cord-282507-swxs5pr1	263	45	2015	2015	CD
cord-282507-swxs5pr1	263	46	)	)	-RRB-
cord-282507-swxs5pr1	263	47	.	.	.
cord-282507-swxs5pr1	264	1	The	the	DT
cord-282507-swxs5pr1	264	2	MAGE	MAGE	NNP
cord-282507-swxs5pr1	264	3	-	-	HYPH
cord-282507-swxs5pr1	264	4	A3	A3	NNP
cord-282507-swxs5pr1	264	5	/	/	SYM
cord-282507-swxs5pr1	264	6	AS015	as015	NN
cord-282507-swxs5pr1	264	7	immunotheraputic	immunotheraputic	JJ
cord-282507-swxs5pr1	264	8	vaccine	vaccine	NN
cord-282507-swxs5pr1	264	9	was	be	VBD
cord-282507-swxs5pr1	264	10	assessed	assess	VBN
cord-282507-swxs5pr1	264	11	for	for	IN
cord-282507-swxs5pr1	264	12	clinical	clinical	JJ
cord-282507-swxs5pr1	264	13	efficacy	efficacy	NN
cord-282507-swxs5pr1	264	14	in	in	IN
cord-282507-swxs5pr1	264	15	an	an	DT
cord-282507-swxs5pr1	264	16	international	international	JJ
cord-282507-swxs5pr1	264	17	,	,	,
cord-282507-swxs5pr1	264	18	multicenter	multicenter	JJ
cord-282507-swxs5pr1	264	19	phase	phase	NN
cord-282507-swxs5pr1	264	20	III	iii	CD
cord-282507-swxs5pr1	264	21	study	study	NN
cord-282507-swxs5pr1	264	22	in	in	IN
cord-282507-swxs5pr1	264	23	surgically	surgically	RB
cord-282507-swxs5pr1	264	24	resected	resect	VBN
cord-282507-swxs5pr1	264	25	NSCLCs	NSCLCs	NNP
cord-282507-swxs5pr1	264	26	.	.	.
cord-282507-swxs5pr1	265	1	This	this	DT
cord-282507-swxs5pr1	265	2	study	study	NN
cord-282507-swxs5pr1	265	3	confirmed	confirm	VBD
cord-282507-swxs5pr1	265	4	the	the	DT
cord-282507-swxs5pr1	265	5	acceptable	acceptable	JJ
cord-282507-swxs5pr1	265	6	clinical	clinical	JJ
cord-282507-swxs5pr1	265	7	safety	safety	NN
cord-282507-swxs5pr1	265	8	profile	profile	NN
cord-282507-swxs5pr1	265	9	of	of	IN
cord-282507-swxs5pr1	265	10	the	the	DT
cord-282507-swxs5pr1	265	11	vaccine	vaccine	NN
cord-282507-swxs5pr1	265	12	,	,	,
cord-282507-swxs5pr1	265	13	but	but	CC
cord-282507-swxs5pr1	265	14	did	do	VBD
cord-282507-swxs5pr1	265	15	not	not	RB
cord-282507-swxs5pr1	265	16	improve	improve	VB
cord-282507-swxs5pr1	265	17	overall	overall	JJ
cord-282507-swxs5pr1	265	18	survival	survival	NN
cord-282507-swxs5pr1	265	19	.	.	.
cord-282507-swxs5pr1	266	1	Therefore	therefore	RB
cord-282507-swxs5pr1	266	2	,	,	,
cord-282507-swxs5pr1	266	3	its	-PRON-	PRP$
cord-282507-swxs5pr1	266	4	further	further	JJ
cord-282507-swxs5pr1	266	5	development	development	NN
cord-282507-swxs5pr1	266	6	for	for	IN
cord-282507-swxs5pr1	266	7	use	use	NN
cord-282507-swxs5pr1	266	8	in	in	IN
cord-282507-swxs5pr1	266	9	NSLCs	NSLCs	NNP
cord-282507-swxs5pr1	266	10	has	have	VBZ
cord-282507-swxs5pr1	266	11	been	be	VBN
cord-282507-swxs5pr1	266	12	stopped	stop	VBN
cord-282507-swxs5pr1	266	13	(	(	-LRB-
cord-282507-swxs5pr1	266	14	Vansteenkiste	Vansteenkiste	NNP
cord-282507-swxs5pr1	266	15	et	et	NNP
cord-282507-swxs5pr1	266	16	al	al	NNP
cord-282507-swxs5pr1	266	17	.	.	NNP
cord-282507-swxs5pr1	266	18	,	,	,
cord-282507-swxs5pr1	266	19	2016	2016	CD
cord-282507-swxs5pr1	266	20	)	)	-RRB-
cord-282507-swxs5pr1	266	21	.	.	.
cord-282507-swxs5pr1	267	1	Similar	similar	JJ
cord-282507-swxs5pr1	267	2	conclusions	conclusion	NNS
cord-282507-swxs5pr1	267	3	were	be	VBD
cord-282507-swxs5pr1	267	4	drawn	draw	VBN
cord-282507-swxs5pr1	267	5	from	from	IN
cord-282507-swxs5pr1	267	6	a	a	DT
cord-282507-swxs5pr1	267	7	phase	phase	NN
cord-282507-swxs5pr1	267	8	III	iii	CD
cord-282507-swxs5pr1	267	9	trial	trial	NN
cord-282507-swxs5pr1	267	10	of	of	IN
cord-282507-swxs5pr1	267	11	a	a	DT
cord-282507-swxs5pr1	267	12	MAGE	MAGE	NNP
cord-282507-swxs5pr1	267	13	-	-	HYPH
cord-282507-swxs5pr1	267	14	A3	A3	NNP
cord-282507-swxs5pr1	267	15	/	/	SYM
cord-282507-swxs5pr1	267	16	AS015	as015	NN
cord-282507-swxs5pr1	267	17	vaccine	vaccine	NN
cord-282507-swxs5pr1	267	18	in	in	IN
cord-282507-swxs5pr1	267	19	patients	patient	NNS
cord-282507-swxs5pr1	267	20	with	with	IN
cord-282507-swxs5pr1	267	21	resected	resected	JJ
cord-282507-swxs5pr1	267	22	,	,	,
cord-282507-swxs5pr1	267	23	MAGE	MAGE	NNP
cord-282507-swxs5pr1	267	24	-	-	HYPH
cord-282507-swxs5pr1	267	25	A3-positive	A3-positive	NNP
cord-282507-swxs5pr1	267	26	,	,	,
cord-282507-swxs5pr1	267	27	stage	stage	NN
cord-282507-swxs5pr1	267	28	III	iii	CD
cord-282507-swxs5pr1	267	29	melanoma	melanoma	NN
cord-282507-swxs5pr1	267	30	,	,	,
cord-282507-swxs5pr1	267	31	which	which	WDT
cord-282507-swxs5pr1	267	32	led	lead	VBD
cord-282507-swxs5pr1	267	33	to	to	IN
cord-282507-swxs5pr1	267	34	the	the	DT
cord-282507-swxs5pr1	267	35	arrest	arrest	NN
cord-282507-swxs5pr1	267	36	of	of	IN
cord-282507-swxs5pr1	267	37	the	the	DT
cord-282507-swxs5pr1	267	38	clinical	clinical	JJ
cord-282507-swxs5pr1	267	39	development	development	NN
cord-282507-swxs5pr1	267	40	of	of	IN
cord-282507-swxs5pr1	267	41	this	this	DT
cord-282507-swxs5pr1	267	42	vaccine	vaccine	NN
cord-282507-swxs5pr1	267	43	for	for	IN
cord-282507-swxs5pr1	267	44	use	use	NN
cord-282507-swxs5pr1	267	45	in	in	IN
cord-282507-swxs5pr1	267	46	melanoma	melanoma	NN
cord-282507-swxs5pr1	267	47	(	(	-LRB-
cord-282507-swxs5pr1	267	48	Dreno	Dreno	NNP
cord-282507-swxs5pr1	267	49	et	et	FW
cord-282507-swxs5pr1	267	50	al	al	NNP
cord-282507-swxs5pr1	267	51	.	.	NNP
cord-282507-swxs5pr1	267	52	,	,	,
cord-282507-swxs5pr1	267	53	2018	2018	CD
cord-282507-swxs5pr1	267	54	)	)	-RRB-
cord-282507-swxs5pr1	267	55	.	.	.
cord-282507-swxs5pr1	268	1	The	the	DT
cord-282507-swxs5pr1	268	2	pathogenesis	pathogenesis	NN
cord-282507-swxs5pr1	268	3	of	of	IN
cord-282507-swxs5pr1	268	4	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	268	5	disease	disease	NN
cord-282507-swxs5pr1	268	6	(	(	-LRB-
cord-282507-swxs5pr1	268	7	AD	ad	NN
cord-282507-swxs5pr1	268	8	)	)	-RRB-
cord-282507-swxs5pr1	268	9	is	be	VBZ
cord-282507-swxs5pr1	268	10	associated	associate	VBN
cord-282507-swxs5pr1	268	11	with	with	IN
cord-282507-swxs5pr1	268	12	the	the	DT
cord-282507-swxs5pr1	268	13	accumulation	accumulation	NN
cord-282507-swxs5pr1	268	14	of	of	IN
cord-282507-swxs5pr1	268	15	amyloid	amyloid	NN
cord-282507-swxs5pr1	268	16	β	β	NN
cord-282507-swxs5pr1	268	17	(	(	-LRB-
cord-282507-swxs5pr1	268	18	Aβ	Aβ	NNP
cord-282507-swxs5pr1	268	19	)	)	-RRB-
cord-282507-swxs5pr1	268	20	and/or	and/or	CC
cord-282507-swxs5pr1	268	21	hyperphosphorylated	hyperphosphorylated	NNP
cord-282507-swxs5pr1	268	22	tau	tau	NNP
cord-282507-swxs5pr1	268	23	proteins	protein	NNS
cord-282507-swxs5pr1	268	24	in	in	IN
cord-282507-swxs5pr1	268	25	the	the	DT
cord-282507-swxs5pr1	268	26	brain	brain	NN
cord-282507-swxs5pr1	268	27	.	.	.
cord-282507-swxs5pr1	269	1	Active	active	JJ
cord-282507-swxs5pr1	269	2	immunotherapy	immunotherapy	NN
cord-282507-swxs5pr1	269	3	of	of	IN
cord-282507-swxs5pr1	269	4	AD	ad	NN
cord-282507-swxs5pr1	269	5	is	be	VBZ
cord-282507-swxs5pr1	269	6	the	the	DT
cord-282507-swxs5pr1	269	7	most	most	RBS
cord-282507-swxs5pr1	269	8	extensively	extensively	RB
cord-282507-swxs5pr1	269	9	studied	study	VBN
cord-282507-swxs5pr1	269	10	approach	approach	NN
cord-282507-swxs5pr1	269	11	,	,	,
cord-282507-swxs5pr1	269	12	in	in	IN
cord-282507-swxs5pr1	269	13	order	order	NN
cord-282507-swxs5pr1	269	14	to	to	TO
cord-282507-swxs5pr1	269	15	evaluate	evaluate	VB
cord-282507-swxs5pr1	269	16	its	-PRON-	PRP$
cord-282507-swxs5pr1	269	17	ability	ability	NN
cord-282507-swxs5pr1	269	18	to	to	TO
cord-282507-swxs5pr1	269	19	elicite	elicite	VB
cord-282507-swxs5pr1	269	20	anti	anti	NNP
cord-282507-swxs5pr1	269	21	-	-	NNP
cord-282507-swxs5pr1	269	22	Aβ	aβ	JJ
cord-282507-swxs5pr1	269	23	antibodies	antibody	NNS
cord-282507-swxs5pr1	269	24	,	,	,
cord-282507-swxs5pr1	269	25	to	to	TO
cord-282507-swxs5pr1	269	26	induce	induce	VB
cord-282507-swxs5pr1	269	27	Aβ	Aβ	NNP
cord-282507-swxs5pr1	269	28	clearance	clearance	NN
cord-282507-swxs5pr1	269	29	,	,	,
cord-282507-swxs5pr1	269	30	and	and	CC
cord-282507-swxs5pr1	269	31	reduce	reduce	VB
cord-282507-swxs5pr1	269	32	Aβ	Aβ	NNP
cord-282507-swxs5pr1	269	33	accumulation	accumulation	NN
cord-282507-swxs5pr1	269	34	in	in	IN
cord-282507-swxs5pr1	269	35	the	the	DT
cord-282507-swxs5pr1	269	36	brain	brain	NN
cord-282507-swxs5pr1	269	37	.	.	.
cord-282507-swxs5pr1	270	1	Vaccination	vaccination	NN
cord-282507-swxs5pr1	270	2	with	with	IN
cord-282507-swxs5pr1	270	3	a	a	DT
cord-282507-swxs5pr1	270	4	full	full	JJ
cord-282507-swxs5pr1	270	5	length	length	NN
cord-282507-swxs5pr1	271	1	Aβ	aβ	NN
cord-282507-swxs5pr1	271	2	peptide	peptide	JJ
cord-282507-swxs5pr1	271	3	(	(	-LRB-
cord-282507-swxs5pr1	271	4	Aβ	Aβ	NNP
cord-282507-swxs5pr1	271	5	1	1	CD
cord-282507-swxs5pr1	271	6	-	-	SYM
cord-282507-swxs5pr1	271	7	42	42	CD
cord-282507-swxs5pr1	271	8	)	)	-RRB-
cord-282507-swxs5pr1	271	9	successfully	successfully	RB
cord-282507-swxs5pr1	271	10	elicited	elicit	VBD
cord-282507-swxs5pr1	271	11	anti	anti	JJ
cord-282507-swxs5pr1	271	12	-	-	JJ
cord-282507-swxs5pr1	271	13	Aβ	Aβ	NNP
cord-282507-swxs5pr1	271	14	-	-	HYPH
cord-282507-swxs5pr1	271	15	Ab	Ab	NNP
cord-282507-swxs5pr1	271	16	in	in	IN
cord-282507-swxs5pr1	271	17	human	human	JJ
cord-282507-swxs5pr1	271	18	subjects	subject	NNS
cord-282507-swxs5pr1	271	19	with	with	IN
cord-282507-swxs5pr1	271	20	AD	ad	NN
cord-282507-swxs5pr1	271	21	,	,	,
cord-282507-swxs5pr1	271	22	but	but	CC
cord-282507-swxs5pr1	271	23	adverse	adverse	JJ
cord-282507-swxs5pr1	271	24	effects	effect	NNS
cord-282507-swxs5pr1	271	25	such	such	JJ
cord-282507-swxs5pr1	271	26	as	as	IN
cord-282507-swxs5pr1	271	27	meningoencephalitis	meningoencephalitis	NNP
cord-282507-swxs5pr1	271	28	were	be	VBD
cord-282507-swxs5pr1	271	29	observed	observe	VBN
cord-282507-swxs5pr1	271	30	,	,	,
cord-282507-swxs5pr1	271	31	attributed	attribute	VBN
cord-282507-swxs5pr1	271	32	to	to	IN
cord-282507-swxs5pr1	271	33	T	T	NNP
cord-282507-swxs5pr1	271	34	cell	cell	NN
cord-282507-swxs5pr1	271	35	activation	activation	NN
cord-282507-swxs5pr1	271	36	(	(	-LRB-
cord-282507-swxs5pr1	271	37	Winblad	Winblad	NNP
cord-282507-swxs5pr1	271	38	et	et	NNP
cord-282507-swxs5pr1	271	39	al	al	NNP
cord-282507-swxs5pr1	271	40	.	.	NNP
cord-282507-swxs5pr1	271	41	,	,	,
cord-282507-swxs5pr1	271	42	2014	2014	CD
cord-282507-swxs5pr1	271	43	)	)	-RRB-
cord-282507-swxs5pr1	271	44	.	.	.
cord-282507-swxs5pr1	272	1	To	to	TO
cord-282507-swxs5pr1	272	2	avoid	avoid	VB
cord-282507-swxs5pr1	272	3	this	this	DT
cord-282507-swxs5pr1	272	4	safety	safety	NN
cord-282507-swxs5pr1	272	5	issue	issue	NN
cord-282507-swxs5pr1	272	6	,	,	,
cord-282507-swxs5pr1	272	7	a	a	DT
cord-282507-swxs5pr1	272	8	N	n	CD
cord-282507-swxs5pr1	272	9	-	-	HYPH
cord-282507-swxs5pr1	272	10	terminal	terminal	NN
cord-282507-swxs5pr1	272	11	(	(	-LRB-
cord-282507-swxs5pr1	272	12	Aβ	Aβ	NNP
cord-282507-swxs5pr1	272	13	1−7	1−7	CD
cord-282507-swxs5pr1	272	14	)	)	-RRB-
cord-282507-swxs5pr1	272	15	peptide	peptide	NN
cord-282507-swxs5pr1	272	16	conjugated	conjugate	VBN
cord-282507-swxs5pr1	272	17	to	to	IN
cord-282507-swxs5pr1	272	18	a	a	DT
cord-282507-swxs5pr1	272	19	carrier	carrier	NN
cord-282507-swxs5pr1	272	20	protein	protein	NN
cord-282507-swxs5pr1	272	21	called	call	VBD
cord-282507-swxs5pr1	272	22	vanutide	vanutide	NNP
cord-282507-swxs5pr1	272	23	cridificar	cridificar	NNP
cord-282507-swxs5pr1	272	24	(	(	-LRB-
cord-282507-swxs5pr1	272	25	ACC-001	ACC-001	NNP
cord-282507-swxs5pr1	272	26	)	)	-RRB-
cord-282507-swxs5pr1	272	27	was	be	VBD
cord-282507-swxs5pr1	272	28	produced	produce	VBN
cord-282507-swxs5pr1	272	29	.	.	.
cord-282507-swxs5pr1	273	1	In	in	IN
cord-282507-swxs5pr1	273	2	preclinical	preclinical	JJ
cord-282507-swxs5pr1	273	3	studies	study	NNS
cord-282507-swxs5pr1	273	4	,	,	,
cord-282507-swxs5pr1	273	5	it	-PRON-	PRP
cord-282507-swxs5pr1	273	6	was	be	VBD
cord-282507-swxs5pr1	273	7	shown	show	VBN
cord-282507-swxs5pr1	273	8	to	to	TO
cord-282507-swxs5pr1	273	9	generate	generate	VB
cord-282507-swxs5pr1	273	10	Nterminal	Nterminal	NNP
cord-282507-swxs5pr1	273	11	Aβ	Aβ	NNP
cord-282507-swxs5pr1	273	12	Abs	abs	NN
cord-282507-swxs5pr1	273	13	in	in	IN
cord-282507-swxs5pr1	273	14	adult	adult	NN
cord-282507-swxs5pr1	273	15	nonhuman	nonhuman	NN
cord-282507-swxs5pr1	273	16	primates	primate	NNS
cord-282507-swxs5pr1	273	17	without	without	IN
cord-282507-swxs5pr1	273	18	inducing	induce	VBG
cord-282507-swxs5pr1	273	19	Aβ	Aβ	NNP
cord-282507-swxs5pr1	273	20	-	-	HYPH
cord-282507-swxs5pr1	273	21	directed	direct	VBN
cord-282507-swxs5pr1	273	22	T	T	NNP
cord-282507-swxs5pr1	273	23	cell	cell	NN
cord-282507-swxs5pr1	273	24	response	response	NN
cord-282507-swxs5pr1	273	25	,	,	,
cord-282507-swxs5pr1	273	26	supporting	support	VBG
cord-282507-swxs5pr1	273	27	further	further	JJ
cord-282507-swxs5pr1	273	28	clinical	clinical	JJ
cord-282507-swxs5pr1	273	29	studies	study	NNS
cord-282507-swxs5pr1	273	30	.	.	.
cord-282507-swxs5pr1	274	1	Several	several	JJ
cord-282507-swxs5pr1	274	2	phase	phase	NN
cord-282507-swxs5pr1	274	3	II	ii	CD
cord-282507-swxs5pr1	274	4	trials	trial	NNS
cord-282507-swxs5pr1	274	5	in	in	IN
cord-282507-swxs5pr1	274	6	patients	patient	NNS
cord-282507-swxs5pr1	274	7	with	with	IN
cord-282507-swxs5pr1	274	8	mild	mild	JJ
cord-282507-swxs5pr1	274	9	to	to	IN
cord-282507-swxs5pr1	274	10	moderate	moderate	JJ
cord-282507-swxs5pr1	274	11	AD	ad	NN
cord-282507-swxs5pr1	274	12	were	be	VBD
cord-282507-swxs5pr1	274	13	conducted	conduct	VBN
cord-282507-swxs5pr1	274	14	in	in	IN
cord-282507-swxs5pr1	274	15	USA	USA	NNP
cord-282507-swxs5pr1	274	16	,	,	,
cord-282507-swxs5pr1	274	17	Europe	Europe	NNP
cord-282507-swxs5pr1	274	18	,	,	,
cord-282507-swxs5pr1	274	19	and	and	CC
cord-282507-swxs5pr1	274	20	Japan	Japan	NNP
cord-282507-swxs5pr1	274	21	by	by	IN
cord-282507-swxs5pr1	274	22	using	use	VBG
cord-282507-swxs5pr1	274	23	3	3	CD
cord-282507-swxs5pr1	274	24	doses	dose	NNS
cord-282507-swxs5pr1	274	25	of	of	IN
cord-282507-swxs5pr1	274	26	ACC-001	ACC-001	NNP
cord-282507-swxs5pr1	274	27	(	(	-LRB-
cord-282507-swxs5pr1	274	28	3	3	CD
cord-282507-swxs5pr1	274	29	,	,	,
cord-282507-swxs5pr1	274	30	10	10	CD
cord-282507-swxs5pr1	274	31	and	and	CC
cord-282507-swxs5pr1	274	32	30	30	CD
cord-282507-swxs5pr1	274	33	μg	μg	NNP
cord-282507-swxs5pr1	274	34	)	)	-RRB-
cord-282507-swxs5pr1	274	35	with	with	IN
cord-282507-swxs5pr1	274	36	and	and	CC
cord-282507-swxs5pr1	274	37	without	without	IN
cord-282507-swxs5pr1	274	38	the	the	DT
cord-282507-swxs5pr1	274	39	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	274	40	QS-21	QS-21	NNP
cord-282507-swxs5pr1	274	41	(	(	-LRB-
cord-282507-swxs5pr1	274	42	50	50	CD
cord-282507-swxs5pr1	274	43	μg	μg	NNS
cord-282507-swxs5pr1	274	44	)	)	-RRB-
cord-282507-swxs5pr1	274	45	or	or	CC
cord-282507-swxs5pr1	274	46	placebo	placebo	NN
cord-282507-swxs5pr1	274	47	to	to	TO
cord-282507-swxs5pr1	274	48	investigate	investigate	VB
cord-282507-swxs5pr1	274	49	doserange	doserange	NNP
cord-282507-swxs5pr1	274	50	,	,	,
cord-282507-swxs5pr1	274	51	safety	safety	NN
cord-282507-swxs5pr1	274	52	,	,	,
cord-282507-swxs5pr1	274	53	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	274	54	and	and	CC
cord-282507-swxs5pr1	274	55	long	long	JJ
cord-282507-swxs5pr1	274	56	term	term	NN
cord-282507-swxs5pr1	274	57	treatment	treatment	NN
cord-282507-swxs5pr1	274	58	(	(	-LRB-
cord-282507-swxs5pr1	274	59	Arai	Arai	NNP
cord-282507-swxs5pr1	274	60	et	et	NNP
cord-282507-swxs5pr1	274	61	al	al	NNP
cord-282507-swxs5pr1	274	62	.	.	NNP
cord-282507-swxs5pr1	274	63	,	,	,
cord-282507-swxs5pr1	274	64	2015	2015	CD
cord-282507-swxs5pr1	274	65	;	;	:
cord-282507-swxs5pr1	274	66	Pasquier	Pasquier	NNP
cord-282507-swxs5pr1	274	67	et	et	NNP
cord-282507-swxs5pr1	274	68	al	al	NNP
cord-282507-swxs5pr1	274	69	.	.	NNP
cord-282507-swxs5pr1	274	70	,	,	,
cord-282507-swxs5pr1	274	71	2016	2016	CD
cord-282507-swxs5pr1	274	72	)	)	-RRB-
cord-282507-swxs5pr1	274	73	.	.	.
cord-282507-swxs5pr1	275	1	ACC-001+QS-21	ACC-001+QS-21	NNP
cord-282507-swxs5pr1	275	2	elicited	elicit	VBD
cord-282507-swxs5pr1	275	3	high	high	JJ
cord-282507-swxs5pr1	275	4	,	,	,
cord-282507-swxs5pr1	275	5	sustained	sustained	JJ
cord-282507-swxs5pr1	275	6	anti	anti	JJ
cord-282507-swxs5pr1	275	7	-	-	JJ
cord-282507-swxs5pr1	275	8	Aβ	aβ	JJ
cord-282507-swxs5pr1	275	9	IgG	igg	NN
cord-282507-swxs5pr1	275	10	Ab	ab	NN
cord-282507-swxs5pr1	275	11	titers	titer	NNS
cord-282507-swxs5pr1	275	12	compared	compare	VBN
cord-282507-swxs5pr1	275	13	with	with	IN
cord-282507-swxs5pr1	275	14	ACC-001	ACC-001	NNP
cord-282507-swxs5pr1	275	15	alone	alone	RB
cord-282507-swxs5pr1	275	16	,	,	,
cord-282507-swxs5pr1	275	17	highlighting	highlight	VBG
cord-282507-swxs5pr1	275	18	the	the	DT
cord-282507-swxs5pr1	275	19	role	role	NN
cord-282507-swxs5pr1	275	20	of	of	IN
cord-282507-swxs5pr1	275	21	QS-21	QS-21	NNP
cord-282507-swxs5pr1	275	22	in	in	IN
cord-282507-swxs5pr1	275	23	this	this	DT
cord-282507-swxs5pr1	275	24	effect	effect	NN
cord-282507-swxs5pr1	275	25	.	.	.
cord-282507-swxs5pr1	276	1	No	no	DT
cord-282507-swxs5pr1	276	2	difference	difference	NN
cord-282507-swxs5pr1	276	3	was	be	VBD
cord-282507-swxs5pr1	276	4	observed	observe	VBN
cord-282507-swxs5pr1	276	5	among	among	IN
cord-282507-swxs5pr1	276	6	the	the	DT
cord-282507-swxs5pr1	276	7	three	three	CD
cord-282507-swxs5pr1	276	8	doses	dose	NNS
cord-282507-swxs5pr1	276	9	tested	test	VBN
cord-282507-swxs5pr1	276	10	.	.	.
cord-282507-swxs5pr1	277	1	Furthermore	furthermore	RB
cord-282507-swxs5pr1	277	2	,	,	,
cord-282507-swxs5pr1	277	3	ACC-001	acc-001	UH
cord-282507-swxs5pr1	277	4	at	at	RB
cord-282507-swxs5pr1	277	5	all	all	DT
cord-282507-swxs5pr1	277	6	dose	dose	NN
cord-282507-swxs5pr1	277	7	levels	level	NNS
cord-282507-swxs5pr1	277	8	with	with	IN
cord-282507-swxs5pr1	277	9	or	or	CC
cord-282507-swxs5pr1	277	10	without	without	IN
cord-282507-swxs5pr1	277	11	QS-21	QS-21	NNP
cord-282507-swxs5pr1	277	12	was	be	VBD
cord-282507-swxs5pr1	277	13	generally	generally	RB
cord-282507-swxs5pr1	277	14	safe	safe	JJ
cord-282507-swxs5pr1	277	15	and	and	CC
cord-282507-swxs5pr1	277	16	well	well	RB
cord-282507-swxs5pr1	277	17	tolerated	tolerate	VBN
cord-282507-swxs5pr1	277	18	,	,	,
cord-282507-swxs5pr1	277	19	but	but	CC
cord-282507-swxs5pr1	277	20	exploratory	exploratory	JJ
cord-282507-swxs5pr1	277	21	cognitive	cognitive	JJ
cord-282507-swxs5pr1	277	22	evaluations	evaluation	NNS
cord-282507-swxs5pr1	277	23	did	do	VBD
cord-282507-swxs5pr1	277	24	not	not	RB
cord-282507-swxs5pr1	277	25	show	show	VB
cord-282507-swxs5pr1	277	26	differences	difference	NNS
cord-282507-swxs5pr1	277	27	between	between	IN
cord-282507-swxs5pr1	277	28	treatment	treatment	NN
cord-282507-swxs5pr1	277	29	groups	group	NNS
cord-282507-swxs5pr1	277	30	and	and	CC
cord-282507-swxs5pr1	277	31	placebo	placebo	NN
cord-282507-swxs5pr1	277	32	.	.	.
cord-282507-swxs5pr1	278	1	Similar	similar	JJ
cord-282507-swxs5pr1	278	2	safety	safety	NN
cord-282507-swxs5pr1	278	3	,	,	,
cord-282507-swxs5pr1	278	4	tolerability	tolerability	NN
cord-282507-swxs5pr1	278	5	and	and	CC
cord-282507-swxs5pr1	278	6	anti	anti	JJ
cord-282507-swxs5pr1	278	7	-	-	JJ
cord-282507-swxs5pr1	278	8	Aβ	aβ	JJ
cord-282507-swxs5pr1	278	9	-	-	HYPH
cord-282507-swxs5pr1	278	10	IgG	igg	NN
cord-282507-swxs5pr1	278	11	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	278	12	profiles	profile	NNS
cord-282507-swxs5pr1	278	13	were	be	VBD
cord-282507-swxs5pr1	278	14	observed	observe	VBN
cord-282507-swxs5pr1	278	15	in	in	IN
cord-282507-swxs5pr1	278	16	long	long	JJ
cord-282507-swxs5pr1	278	17	term	term	NN
cord-282507-swxs5pr1	278	18	phase	phase	NN
cord-282507-swxs5pr1	278	19	II	II	NNP
cord-282507-swxs5pr1	278	20	extensions	extension	NNS
cord-282507-swxs5pr1	278	21	studies	study	NNS
cord-282507-swxs5pr1	278	22	,	,	,
cord-282507-swxs5pr1	278	23	suggesting	suggest	VBG
cord-282507-swxs5pr1	278	24	that	that	IN
cord-282507-swxs5pr1	278	25	side	side	NN
cord-282507-swxs5pr1	278	26	effects	effect	NNS
cord-282507-swxs5pr1	278	27	do	do	VBP
cord-282507-swxs5pr1	278	28	not	not	RB
cord-282507-swxs5pr1	278	29	limit	limit	VB
cord-282507-swxs5pr1	278	30	in	in	IN
cord-282507-swxs5pr1	278	31	principle	principle	JJ
cord-282507-swxs5pr1	278	32	anti	anti	JJ
cord-282507-swxs5pr1	278	33	-	-	JJ
cord-282507-swxs5pr1	278	34	amyloid	amyloid	JJ
cord-282507-swxs5pr1	278	35	active	active	JJ
cord-282507-swxs5pr1	278	36	immunotherapy	immunotherapy	NN
cord-282507-swxs5pr1	278	37	(	(	-LRB-
cord-282507-swxs5pr1	278	38	Hüll	Hüll	NNP
cord-282507-swxs5pr1	278	39	et	et	NNP
cord-282507-swxs5pr1	278	40	al	al	NNP
cord-282507-swxs5pr1	278	41	.	.	NNP
cord-282507-swxs5pr1	278	42	,	,	,
cord-282507-swxs5pr1	278	43	2017	2017	CD
cord-282507-swxs5pr1	278	44	)	)	-RRB-
cord-282507-swxs5pr1	278	45	.	.	.
cord-282507-swxs5pr1	279	1	However	however	RB
cord-282507-swxs5pr1	279	2	,	,	,
cord-282507-swxs5pr1	279	3	larger	large	JJR
cord-282507-swxs5pr1	279	4	trials	trial	NNS
cord-282507-swxs5pr1	279	5	of	of	IN
cord-282507-swxs5pr1	279	6	adequate	adequate	JJ
cord-282507-swxs5pr1	279	7	duration	duration	NN
cord-282507-swxs5pr1	279	8	,	,	,
cord-282507-swxs5pr1	279	9	with	with	IN
cord-282507-swxs5pr1	279	10	optimized	optimize	VBN
cord-282507-swxs5pr1	279	11	dosing	dosing	NN
cord-282507-swxs5pr1	279	12	may	may	MD
cord-282507-swxs5pr1	279	13	be	be	VB
cord-282507-swxs5pr1	279	14	needed	need	VBN
cord-282507-swxs5pr1	279	15	to	to	TO
cord-282507-swxs5pr1	279	16	attest	attest	VB
cord-282507-swxs5pr1	279	17	efficacy	efficacy	NN
cord-282507-swxs5pr1	279	18	of	of	IN
cord-282507-swxs5pr1	279	19	anti	anti	JJ
cord-282507-swxs5pr1	279	20	-	-	JJ
cord-282507-swxs5pr1	279	21	Aβ	aβ	JJ
cord-282507-swxs5pr1	279	22	vaccine	vaccine	NN
cord-282507-swxs5pr1	279	23	therapy	therapy	NN
cord-282507-swxs5pr1	279	24	for	for	IN
cord-282507-swxs5pr1	279	25	AD	ad	NN
cord-282507-swxs5pr1	279	26	.	.	.
cord-282507-swxs5pr1	280	1	This	this	DT
cord-282507-swxs5pr1	280	2	overview	overview	NN
cord-282507-swxs5pr1	280	3	provides	provide	VBZ
cord-282507-swxs5pr1	280	4	a	a	DT
cord-282507-swxs5pr1	280	5	summary	summary	NN
cord-282507-swxs5pr1	280	6	of	of	IN
cord-282507-swxs5pr1	280	7	recent	recent	JJ
cord-282507-swxs5pr1	280	8	reports	report	NNS
cord-282507-swxs5pr1	280	9	on	on	IN
cord-282507-swxs5pr1	280	10	the	the	DT
cord-282507-swxs5pr1	280	11	mechanism	mechanism	NN
cord-282507-swxs5pr1	280	12	of	of	IN
cord-282507-swxs5pr1	280	13	action	action	NN
cord-282507-swxs5pr1	280	14	of	of	IN
cord-282507-swxs5pr1	280	15	QS-21	QS-21	NNP
cord-282507-swxs5pr1	280	16	,	,	,
cord-282507-swxs5pr1	280	17	a	a	DT
cord-282507-swxs5pr1	280	18	promising	promising	JJ
cord-282507-swxs5pr1	280	19	triterpene	triterpene	JJ
cord-282507-swxs5pr1	280	20	glycoside	glycoside	NN
cord-282507-swxs5pr1	280	21	vaccine	vaccine	NN
cord-282507-swxs5pr1	280	22	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	280	23	isolated	isolate	VBN
cord-282507-swxs5pr1	280	24	from	from	IN
cord-282507-swxs5pr1	280	25	Quillaja	Quillaja	NNP
cord-282507-swxs5pr1	280	26	Saponaria	Saponaria	NNP
cord-282507-swxs5pr1	280	27	and	and	CC
cord-282507-swxs5pr1	280	28	the	the	DT
cord-282507-swxs5pr1	280	29	most	most	RBS
cord-282507-swxs5pr1	280	30	relevant	relevant	JJ
cord-282507-swxs5pr1	280	31	clinical	clinical	JJ
cord-282507-swxs5pr1	280	32	applications	application	NNS
cord-282507-swxs5pr1	280	33	.	.	.
cord-282507-swxs5pr1	281	1	This	this	DT
cord-282507-swxs5pr1	281	2	compound	compound	NN
cord-282507-swxs5pr1	281	3	showed	show	VBD
cord-282507-swxs5pr1	281	4	a	a	DT
cord-282507-swxs5pr1	281	5	potent	potent	JJ
cord-282507-swxs5pr1	281	6	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	281	7	activity	activity	NN
cord-282507-swxs5pr1	281	8	stimulating	stimulate	VBG
cord-282507-swxs5pr1	281	9	humoral	humoral	JJ
cord-282507-swxs5pr1	281	10	and	and	CC
cord-282507-swxs5pr1	281	11	cell	cell	NN
cord-282507-swxs5pr1	281	12	-	-	HYPH
cord-282507-swxs5pr1	281	13	mediated	mediate	VBN
cord-282507-swxs5pr1	281	14	immunity	immunity	NN
cord-282507-swxs5pr1	281	15	against	against	IN
cord-282507-swxs5pr1	281	16	a	a	DT
cord-282507-swxs5pr1	281	17	wide	wide	JJ
cord-282507-swxs5pr1	281	18	variety	variety	NN
cord-282507-swxs5pr1	281	19	of	of	IN
cord-282507-swxs5pr1	281	20	Ags	Ags	NNP
cord-282507-swxs5pr1	281	21	and	and	CC
cord-282507-swxs5pr1	281	22	presented	present	VBD
cord-282507-swxs5pr1	281	23	advantages	advantage	NNS
cord-282507-swxs5pr1	281	24	over	over	IN
cord-282507-swxs5pr1	281	25	aluminium	aluminium	NN
cord-282507-swxs5pr1	281	26	salts	salt	NNS
cord-282507-swxs5pr1	281	27	by	by	IN
cord-282507-swxs5pr1	281	28	inducing	induce	VBG
cord-282507-swxs5pr1	281	29	a	a	DT
cord-282507-swxs5pr1	281	30	Th1type	th1type	CC
cord-282507-swxs5pr1	281	31	immune	immune	JJ
cord-282507-swxs5pr1	281	32	response	response	NN
cord-282507-swxs5pr1	281	33	,	,	,
cord-282507-swxs5pr1	281	34	necessary	necessary	JJ
cord-282507-swxs5pr1	281	35	for	for	IN
cord-282507-swxs5pr1	281	36	controlling	control	VBG
cord-282507-swxs5pr1	281	37	most	most	JJS
cord-282507-swxs5pr1	281	38	intracellular	intracellular	JJ
cord-282507-swxs5pr1	281	39	pathogens	pathogen	NNS
cord-282507-swxs5pr1	281	40	.	.	.
cord-282507-swxs5pr1	282	1	It	-PRON-	PRP
cord-282507-swxs5pr1	282	2	is	be	VBZ
cord-282507-swxs5pr1	282	3	unlikely	unlikely	JJ
cord-282507-swxs5pr1	282	4	that	that	IN
cord-282507-swxs5pr1	282	5	a	a	DT
cord-282507-swxs5pr1	282	6	single	single	JJ
cord-282507-swxs5pr1	282	7	mechanism	mechanism	NN
cord-282507-swxs5pr1	282	8	of	of	IN
cord-282507-swxs5pr1	282	9	action	action	NN
cord-282507-swxs5pr1	282	10	could	could	MD
cord-282507-swxs5pr1	282	11	explain	explain	VB
cord-282507-swxs5pr1	282	12	its	-PRON-	PRP$
cord-282507-swxs5pr1	282	13	effects	effect	NNS
cord-282507-swxs5pr1	282	14	as	as	IN
cord-282507-swxs5pr1	282	15	an	an	DT
cord-282507-swxs5pr1	282	16	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	282	17	.	.	.
cord-282507-swxs5pr1	283	1	This	this	DT
cord-282507-swxs5pr1	283	2	contribution	contribution	NN
cord-282507-swxs5pr1	283	3	highlights	highlight	VBZ
cord-282507-swxs5pr1	283	4	:	:	:
cord-282507-swxs5pr1	283	5	1	1	LS
cord-282507-swxs5pr1	283	6	)	)	-RRB-
cord-282507-swxs5pr1	283	7	the	the	DT
cord-282507-swxs5pr1	283	8	role	role	NN
cord-282507-swxs5pr1	283	9	of	of	IN
cord-282507-swxs5pr1	283	10	QS-21	QS-21	NNP
cord-282507-swxs5pr1	283	11	acting	act	VBG
cord-282507-swxs5pr1	283	12	on	on	IN
cord-282507-swxs5pr1	283	13	both	both	DT
cord-282507-swxs5pr1	283	14	APCs	apc	NNS
cord-282507-swxs5pr1	283	15	and	and	CC
cord-282507-swxs5pr1	283	16	T	t	NN
cord-282507-swxs5pr1	283	17	cells	cell	NNS
cord-282507-swxs5pr1	283	18	.	.	.
cord-282507-swxs5pr1	284	1	The	the	DT
cord-282507-swxs5pr1	284	2	interaction	interaction	NN
cord-282507-swxs5pr1	284	3	between	between	IN
cord-282507-swxs5pr1	284	4	the	the	DT
cord-282507-swxs5pr1	284	5	aldehyde	aldehyde	NN
cord-282507-swxs5pr1	284	6	function	function	NN
cord-282507-swxs5pr1	284	7	and	and	CC
cord-282507-swxs5pr1	284	8	T	t	NN
cord-282507-swxs5pr1	284	9	-	-	HYPH
cord-282507-swxs5pr1	284	10	cell	cell	NN
cord-282507-swxs5pr1	284	11	receptors	receptor	NNS
cord-282507-swxs5pr1	284	12	such	such	JJ
cord-282507-swxs5pr1	284	13	as	as	IN
cord-282507-swxs5pr1	284	14	CD2	CD2	NNP
cord-282507-swxs5pr1	284	15	,	,	,
cord-282507-swxs5pr1	284	16	delivering	deliver	VBG
cord-282507-swxs5pr1	284	17	co	co	JJ
cord-282507-swxs5pr1	284	18	-	-	JJ
cord-282507-swxs5pr1	284	19	stimulatory	stimulatory	JJ
cord-282507-swxs5pr1	284	20	signals	signal	NNS
cord-282507-swxs5pr1	284	21	together	together	RB
cord-282507-swxs5pr1	284	22	with	with	IN
cord-282507-swxs5pr1	284	23	the	the	DT
cord-282507-swxs5pr1	284	24	presentation	presentation	NN
cord-282507-swxs5pr1	284	25	of	of	IN
cord-282507-swxs5pr1	284	26	the	the	DT
cord-282507-swxs5pr1	284	27	Ag	Ag	NNP
cord-282507-swxs5pr1	284	28	peptides	peptide	NNS
cord-282507-swxs5pr1	284	29	by	by	IN
cord-282507-swxs5pr1	284	30	APCs	apc	NNS
cord-282507-swxs5pr1	284	31	to	to	IN
cord-282507-swxs5pr1	284	32	the	the	DT
cord-282507-swxs5pr1	284	33	T	t	NN
cord-282507-swxs5pr1	284	34	-	-	HYPH
cord-282507-swxs5pr1	284	35	cell	cell	NN
cord-282507-swxs5pr1	284	36	resulted	result	VBD
cord-282507-swxs5pr1	284	37	in	in	IN
cord-282507-swxs5pr1	284	38	the	the	DT
cord-282507-swxs5pr1	284	39	activation	activation	NN
cord-282507-swxs5pr1	284	40	of	of	IN
cord-282507-swxs5pr1	284	41	T	T	NNP
cord-282507-swxs5pr1	284	42	lymphocytes	lymphocyte	NNS
cord-282507-swxs5pr1	284	43	and	and	CC
cord-282507-swxs5pr1	284	44	secretions	secretion	NNS
cord-282507-swxs5pr1	284	45	of	of	IN
cord-282507-swxs5pr1	284	46	Th1	th1	NN
cord-282507-swxs5pr1	284	47	cytokines	cytokine	NNS
cord-282507-swxs5pr1	284	48	,	,	,
cord-282507-swxs5pr1	284	49	an	an	DT
cord-282507-swxs5pr1	284	50	important	important	JJ
cord-282507-swxs5pr1	284	51	immune	immune	JJ
cord-282507-swxs5pr1	284	52	effector	effector	NN
cord-282507-swxs5pr1	284	53	mechanism	mechanism	NN
cord-282507-swxs5pr1	284	54	for	for	IN
cord-282507-swxs5pr1	284	55	the	the	DT
cord-282507-swxs5pr1	284	56	elimination	elimination	NN
cord-282507-swxs5pr1	284	57	of	of	IN
cord-282507-swxs5pr1	284	58	infected	infected	JJ
cord-282507-swxs5pr1	284	59	cells	cell	NNS
cord-282507-swxs5pr1	284	60	.	.	.
cord-282507-swxs5pr1	285	1	2	2	LS
cord-282507-swxs5pr1	285	2	)	)	-RRB-
cord-282507-swxs5pr1	285	3	a	a	DT
cord-282507-swxs5pr1	285	4	novel	novel	JJ
cord-282507-swxs5pr1	285	5	mechanism	mechanism	NN
cord-282507-swxs5pr1	285	6	of	of	IN
cord-282507-swxs5pr1	285	7	action	action	NN
cord-282507-swxs5pr1	285	8	based	base	VBN
cord-282507-swxs5pr1	285	9	on	on	IN
cord-282507-swxs5pr1	285	10	the	the	DT
cord-282507-swxs5pr1	285	11	activation	activation	NN
cord-282507-swxs5pr1	285	12	of	of	IN
cord-282507-swxs5pr1	285	13	caspase	caspase	NN
cord-282507-swxs5pr1	285	14	1dependent	1dependent	CD
cord-282507-swxs5pr1	285	15	NLRP3	nlrp3	NN
cord-282507-swxs5pr1	285	16	inflammasome	inflammasome	NNP
cord-282507-swxs5pr1	285	17	in	in	IN
cord-282507-swxs5pr1	285	18	mouse	mouse	NN
cord-282507-swxs5pr1	285	19	APCs	apc	NNS
cord-282507-swxs5pr1	285	20	,	,	,
cord-282507-swxs5pr1	285	21	leading	lead	VBG
cord-282507-swxs5pr1	285	22	to	to	IN
cord-282507-swxs5pr1	285	23	the	the	DT
cord-282507-swxs5pr1	285	24	secretion	secretion	NN
cord-282507-swxs5pr1	285	25	of	of	IN
cord-282507-swxs5pr1	285	26	proinflammatory	proinflammatory	JJ
cord-282507-swxs5pr1	285	27	cytokine	cytokine	NN
cord-282507-swxs5pr1	285	28	Il-1β	Il-1β	NNP
cord-282507-swxs5pr1	285	29	/	/	SYM
cord-282507-swxs5pr1	285	30	Il-18	Il-18	NNP
cord-282507-swxs5pr1	285	31	,	,	,
cord-282507-swxs5pr1	285	32	which	which	WDT
cord-282507-swxs5pr1	285	33	are	be	VBP
cord-282507-swxs5pr1	285	34	important	important	JJ
cord-282507-swxs5pr1	285	35	for	for	IN
cord-282507-swxs5pr1	285	36	Th1	th1	NN
cord-282507-swxs5pr1	285	37	responses	response	NNS
cord-282507-swxs5pr1	285	38	.	.	.
cord-282507-swxs5pr1	286	1	3	3	LS
cord-282507-swxs5pr1	286	2	)	)	-RRB-
cord-282507-swxs5pr1	287	1	the	the	DT
cord-282507-swxs5pr1	287	2	synthesis	synthesis	NN
cord-282507-swxs5pr1	287	3	of	of	IN
cord-282507-swxs5pr1	287	4	nearly	nearly	RB
cord-282507-swxs5pr1	287	5	50	50	CD
cord-282507-swxs5pr1	287	6	structural	structural	JJ
cord-282507-swxs5pr1	287	7	analogs	analog	NNS
cord-282507-swxs5pr1	287	8	of	of	IN
cord-282507-swxs5pr1	287	9	QS-21	QS-21	NNP
cord-282507-swxs5pr1	287	10	and	and	CC
cord-282507-swxs5pr1	287	11	detailed	detailed	JJ
cord-282507-swxs5pr1	287	12	SAR	SAR	NNP
cord-282507-swxs5pr1	287	13	studies	study	NNS
cord-282507-swxs5pr1	287	14	leading	lead	VBG
cord-282507-swxs5pr1	287	15	to	to	IN
cord-282507-swxs5pr1	287	16	more	more	RBR
cord-282507-swxs5pr1	287	17	easily	easily	RB
cord-282507-swxs5pr1	287	18	available	available	JJ
cord-282507-swxs5pr1	287	19	,	,	,
cord-282507-swxs5pr1	287	20	and	and	CC
cord-282507-swxs5pr1	287	21	stable	stable	JJ
cord-282507-swxs5pr1	287	22	molecules	molecule	NNS
cord-282507-swxs5pr1	287	23	with	with	IN
cord-282507-swxs5pr1	287	24	an	an	DT
cord-282507-swxs5pr1	287	25	improved	improved	JJ
cord-282507-swxs5pr1	287	26	activity	activity	NN
cord-282507-swxs5pr1	287	27	/	/	SYM
cord-282507-swxs5pr1	287	28	toxicity	toxicity	NN
cord-282507-swxs5pr1	287	29	profile	profile	NN
cord-282507-swxs5pr1	287	30	,	,	,
cord-282507-swxs5pr1	287	31	among	among	IN
cord-282507-swxs5pr1	287	32	them	-PRON-	PRP
cord-282507-swxs5pr1	287	33	a	a	DT
cord-282507-swxs5pr1	287	34	novel	novel	NN
cord-282507-swxs5pr1	287	35	aryl	aryl	NN
cord-282507-swxs5pr1	287	36	iodinated	iodinate	VBN
cord-282507-swxs5pr1	287	37	simplified	simplified	JJ
cord-282507-swxs5pr1	287	38	echinocystic	echinocystic	JJ
cord-282507-swxs5pr1	287	39	derivative	derivative	NN
cord-282507-swxs5pr1	287	40	showing	show	VBG
cord-282507-swxs5pr1	287	41	a	a	DT
cord-282507-swxs5pr1	287	42	potent	potent	JJ
cord-282507-swxs5pr1	287	43	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	287	44	activity	activity	NN
cord-282507-swxs5pr1	287	45	and	and	CC
cord-282507-swxs5pr1	287	46	considerably	considerably	RB
cord-282507-swxs5pr1	287	47	attenuated	attenuated	JJ
cord-282507-swxs5pr1	287	48	toxicity	toxicity	NN
cord-282507-swxs5pr1	287	49	.	.	.
cord-282507-swxs5pr1	288	1	4	4	LS
cord-282507-swxs5pr1	288	2	)	)	-RRB-
cord-282507-swxs5pr1	289	1	the	the	DT
cord-282507-swxs5pr1	289	2	signaling	signal	VBG
cord-282507-swxs5pr1	289	3	pathways	pathway	NNS
cord-282507-swxs5pr1	289	4	of	of	IN
cord-282507-swxs5pr1	289	5	QS-21	QS-21	NNP
cord-282507-swxs5pr1	289	6	when	when	WRB
cord-282507-swxs5pr1	289	7	formulated	formulate	VBN
cord-282507-swxs5pr1	289	8	in	in	IN
cord-282507-swxs5pr1	289	9	a	a	DT
cord-282507-swxs5pr1	289	10	liposome	liposome	NN
cord-282507-swxs5pr1	289	11	,	,	,
cord-282507-swxs5pr1	289	12	such	such	JJ
cord-282507-swxs5pr1	289	13	as	as	IN
cord-282507-swxs5pr1	289	14	the	the	DT
cord-282507-swxs5pr1	289	15	rapid	rapid	JJ
cord-282507-swxs5pr1	289	16	accumulation	accumulation	NN
cord-282507-swxs5pr1	289	17	in	in	IN
cord-282507-swxs5pr1	289	18	dLN	dln	NN
cord-282507-swxs5pr1	289	19	resident	resident	NN
cord-282507-swxs5pr1	290	1	CD169	CD169	NNP
cord-282507-swxs5pr1	291	1	+	+	CC
cord-282507-swxs5pr1	291	2	macrophages	macrophage	NNS
cord-282507-swxs5pr1	291	3	,	,	,
cord-282507-swxs5pr1	291	4	where	where	WRB
cord-282507-swxs5pr1	291	5	it	-PRON-	PRP
cord-282507-swxs5pr1	291	6	induces	induce	VBZ
cord-282507-swxs5pr1	291	7	caspase-1	caspase-1	NNP
cord-282507-swxs5pr1	291	8	activation	activation	NN
cord-282507-swxs5pr1	291	9	and	and	CC
cord-282507-swxs5pr1	291	10	HMGB1	HMGB1	NNP
cord-282507-swxs5pr1	291	11	release	release	NN
cord-282507-swxs5pr1	291	12	.	.	.
cord-282507-swxs5pr1	292	1	These	these	DT
cord-282507-swxs5pr1	292	2	events	event	NNS
cord-282507-swxs5pr1	292	3	orchestrate	orchestrate	VBP
cord-282507-swxs5pr1	292	4	the	the	DT
cord-282507-swxs5pr1	292	5	recruitment	recruitment	NN
cord-282507-swxs5pr1	292	6	of	of	IN
cord-282507-swxs5pr1	292	7	innate	innate	JJ
cord-282507-swxs5pr1	292	8	immune	immune	JJ
cord-282507-swxs5pr1	292	9	cells	cell	NNS
cord-282507-swxs5pr1	292	10	and	and	CC
cord-282507-swxs5pr1	292	11	activation	activation	NN
cord-282507-swxs5pr1	292	12	of	of	IN
cord-282507-swxs5pr1	292	13	DCs	dc	NNS
cord-282507-swxs5pr1	292	14	leading	lead	VBG
cord-282507-swxs5pr1	292	15	to	to	IN
cord-282507-swxs5pr1	292	16	T	T	NNP
cord-282507-swxs5pr1	292	17	cell	cell	NN
cord-282507-swxs5pr1	292	18	priming	priming	NN
cord-282507-swxs5pr1	292	19	.	.	.
cord-282507-swxs5pr1	293	1	A	a	DT
cord-282507-swxs5pr1	293	2	direct	direct	JJ
cord-282507-swxs5pr1	293	3	activation	activation	NN
cord-282507-swxs5pr1	293	4	of	of	IN
cord-282507-swxs5pr1	293	5	DCs	DCs	NNP
cord-282507-swxs5pr1	293	6	was	be	VBD
cord-282507-swxs5pr1	293	7	also	also	RB
cord-282507-swxs5pr1	293	8	reported	report	VBN
cord-282507-swxs5pr1	293	9	,	,	,
cord-282507-swxs5pr1	293	10	resulting	result	VBG
cord-282507-swxs5pr1	293	11	in	in	IN
cord-282507-swxs5pr1	293	12	release	release	NN
cord-282507-swxs5pr1	293	13	of	of	IN
cord-282507-swxs5pr1	293	14	cathepsin	cathepsin	NN
cord-282507-swxs5pr1	293	15	B	B	NNP
cord-282507-swxs5pr1	293	16	which	which	WDT
cord-282507-swxs5pr1	293	17	contribute	contribute	VBP
cord-282507-swxs5pr1	293	18	to	to	IN
cord-282507-swxs5pr1	293	19	specific	specific	JJ
cord-282507-swxs5pr1	293	20	T	t	NN
cord-282507-swxs5pr1	293	21	cell	cell	NN
cord-282507-swxs5pr1	293	22	responses	response	NNS
cord-282507-swxs5pr1	293	23	in	in	IN
cord-282507-swxs5pr1	293	24	vivo	vivo	NN
cord-282507-swxs5pr1	293	25	.	.	.
cord-282507-swxs5pr1	294	1	5	5	LS
cord-282507-swxs5pr1	294	2	)	)	-RRB-
cord-282507-swxs5pr1	295	1	the	the	DT
cord-282507-swxs5pr1	295	2	development	development	NN
cord-282507-swxs5pr1	295	3	of	of	IN
cord-282507-swxs5pr1	295	4	Adjuvant	Adjuvant	NNP
cord-282507-swxs5pr1	295	5	Systems	Systems	NNP
cord-282507-swxs5pr1	295	6	(	(	-LRB-
cord-282507-swxs5pr1	295	7	AS	as	IN
cord-282507-swxs5pr1	295	8	)	)	-RRB-
cord-282507-swxs5pr1	295	9	including	include	VBG
cord-282507-swxs5pr1	295	10	a	a	DT
cord-282507-swxs5pr1	295	11	combination	combination	NN
cord-282507-swxs5pr1	295	12	of	of	IN
cord-282507-swxs5pr1	295	13	immunostimulants	immunostimulant	NNS
cord-282507-swxs5pr1	295	14	in	in	IN
cord-282507-swxs5pr1	295	15	a	a	DT
cord-282507-swxs5pr1	295	16	formulation	formulation	NN
cord-282507-swxs5pr1	295	17	,	,	,
cord-282507-swxs5pr1	295	18	such	such	JJ
cord-282507-swxs5pr1	295	19	as	as	IN
cord-282507-swxs5pr1	295	20	AS01	AS01	NNP
cord-282507-swxs5pr1	295	21	(	(	-LRB-
cord-282507-swxs5pr1	295	22	QS-21/	QS-21/	NNP
cord-282507-swxs5pr1	295	23	MPL	MPL	NNP
cord-282507-swxs5pr1	295	24	in	in	IN
cord-282507-swxs5pr1	295	25	a	a	DT
cord-282507-swxs5pr1	295	26	liposome	liposome	NN
cord-282507-swxs5pr1	295	27	)	)	-RRB-
cord-282507-swxs5pr1	295	28	,	,	,
cord-282507-swxs5pr1	295	29	in	in	IN
cord-282507-swxs5pr1	295	30	which	which	WDT
cord-282507-swxs5pr1	295	31	they	-PRON-	PRP
cord-282507-swxs5pr1	295	32	were	be	VBD
cord-282507-swxs5pr1	295	33	shown	show	VBN
cord-282507-swxs5pr1	295	34	to	to	TO
cord-282507-swxs5pr1	295	35	act	act	VB
cord-282507-swxs5pr1	295	36	synergistically	synergistically	RB
cord-282507-swxs5pr1	295	37	in	in	IN
cord-282507-swxs5pr1	295	38	enhancing	enhance	VBG
cord-282507-swxs5pr1	295	39	CMI	CMI	NNP
cord-282507-swxs5pr1	295	40	responses	response	NNS
cord-282507-swxs5pr1	295	41	.	.	.
cord-282507-swxs5pr1	296	1	6	6	LS
cord-282507-swxs5pr1	296	2	)	)	-RRB-
cord-282507-swxs5pr1	297	1	the	the	DT
cord-282507-swxs5pr1	297	2	high	high	JJ
cord-282507-swxs5pr1	297	3	number	number	NN
cord-282507-swxs5pr1	297	4	of	of	IN
cord-282507-swxs5pr1	297	5	clinical	clinical	JJ
cord-282507-swxs5pr1	297	6	applications	application	NNS
cord-282507-swxs5pr1	297	7	in	in	IN
cord-282507-swxs5pr1	297	8	term	term	NN
cord-282507-swxs5pr1	297	9	of	of	IN
cord-282507-swxs5pr1	297	10	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	297	11	,	,	,
cord-282507-swxs5pr1	297	12	efficacy	efficacy	NN
cord-282507-swxs5pr1	297	13	,	,	,
cord-282507-swxs5pr1	297	14	safety	safety	NN
cord-282507-swxs5pr1	297	15	of	of	IN
cord-282507-swxs5pr1	297	16	QS-21	QS-21	NNP
cord-282507-swxs5pr1	297	17	alone	alone	RB
cord-282507-swxs5pr1	297	18	or	or	CC
cord-282507-swxs5pr1	297	19	in	in	IN
cord-282507-swxs5pr1	297	20	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	297	21	systems	system	NNS
cord-282507-swxs5pr1	297	22	in	in	IN
cord-282507-swxs5pr1	297	23	many	many	JJ
cord-282507-swxs5pr1	297	24	prophylactic	prophylactic	JJ
cord-282507-swxs5pr1	297	25	vaccines	vaccine	NNS
cord-282507-swxs5pr1	297	26	against	against	IN
cord-282507-swxs5pr1	297	27	complex	complex	JJ
cord-282507-swxs5pr1	297	28	pathogens	pathogen	NNS
cord-282507-swxs5pr1	297	29	,	,	,
cord-282507-swxs5pr1	297	30	e.g.	e.g.	RB
cord-282507-swxs5pr1	297	31	malaria	malaria	NN
cord-282507-swxs5pr1	297	32	,	,	,
cord-282507-swxs5pr1	297	33	herpes	herpes	NNP
cord-282507-swxs5pr1	297	34	zoster	zoster	NN
cord-282507-swxs5pr1	297	35	,	,	,
cord-282507-swxs5pr1	297	36	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	297	37	,	,	,
cord-282507-swxs5pr1	297	38	HIV	HIV	NNP
cord-282507-swxs5pr1	297	39	,	,	,
cord-282507-swxs5pr1	297	40	and	and	CC
cord-282507-swxs5pr1	297	41	therapeutic	therapeutic	JJ
cord-282507-swxs5pr1	297	42	vaccines	vaccine	NNS
cord-282507-swxs5pr1	297	43	,	,	,
cord-282507-swxs5pr1	297	44	e.g.	e.g.	RB
cord-282507-swxs5pr1	297	45	cancer	cancer	NN
cord-282507-swxs5pr1	297	46	,	,	,
cord-282507-swxs5pr1	297	47	AD	ad	NN
cord-282507-swxs5pr1	297	48	.	.	.
cord-282507-swxs5pr1	297	49	7	7	CD
cord-282507-swxs5pr1	297	50	)	)	-RRB-
cord-282507-swxs5pr1	298	1	the	the	DT
cord-282507-swxs5pr1	298	2	licensing	licensing	NN
cord-282507-swxs5pr1	298	3	by	by	IN
cord-282507-swxs5pr1	298	4	the	the	DT
cord-282507-swxs5pr1	298	5	US	US	NNP
cord-282507-swxs5pr1	298	6	FDA	FDA	NNP
cord-282507-swxs5pr1	298	7	in	in	IN
cord-282507-swxs5pr1	298	8	2017	2017	CD
cord-282507-swxs5pr1	298	9	of	of	IN
cord-282507-swxs5pr1	298	10	a	a	DT
cord-282507-swxs5pr1	298	11	vaccine	vaccine	NN
cord-282507-swxs5pr1	298	12	against	against	IN
cord-282507-swxs5pr1	298	13	shingles	shingle	NNS
cord-282507-swxs5pr1	298	14	called	call	VBN
cord-282507-swxs5pr1	298	15	HZ	HZ	NNP
cord-282507-swxs5pr1	298	16	/	/	SYM
cord-282507-swxs5pr1	298	17	su	su	NNP
cord-282507-swxs5pr1	298	18	(	(	-LRB-
cord-282507-swxs5pr1	298	19	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	298	20	™	™	CD
cord-282507-swxs5pr1	298	21	)	)	-RRB-
cord-282507-swxs5pr1	298	22	containing	contain	VBG
cord-282507-swxs5pr1	298	23	gE	gE	NNP
cord-282507-swxs5pr1	298	24	/	/	SYM
cord-282507-swxs5pr1	298	25	AS01	AS01	NNP
cord-282507-swxs5pr1	298	26	and	and	CC
cord-282507-swxs5pr1	298	27	its	-PRON-	PRP$
cord-282507-swxs5pr1	298	28	commercialization	commercialization	NN
cord-282507-swxs5pr1	298	29	in	in	IN
cord-282507-swxs5pr1	298	30	the	the	DT
cord-282507-swxs5pr1	298	31	EU	EU	NNP
cord-282507-swxs5pr1	298	32	since	since	IN
cord-282507-swxs5pr1	298	33	march	march	NNP
cord-282507-swxs5pr1	298	34	2018	2018	CD
cord-282507-swxs5pr1	298	35	.	.	.
cord-282507-swxs5pr1	299	1	8)	8)	NNP
cord-282507-swxs5pr1	300	1	the	the	DT
cord-282507-swxs5pr1	300	2	first	first	JJ
cord-282507-swxs5pr1	300	3	malaria	malaria	NN
cord-282507-swxs5pr1	300	4	vaccine	vaccine	NN
cord-282507-swxs5pr1	300	5	(	(	-LRB-
cord-282507-swxs5pr1	300	6	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	300	7	™	™	CD
cord-282507-swxs5pr1	300	8	)	)	-RRB-
cord-282507-swxs5pr1	300	9	containing	contain	VBG
cord-282507-swxs5pr1	300	10	RTS	RTS	NNP
cord-282507-swxs5pr1	300	11	,	,	,
cord-282507-swxs5pr1	300	12	S	S	NNP
cord-282507-swxs5pr1	300	13	/	/	SYM
cord-282507-swxs5pr1	300	14	AS01	AS01	NNP
cord-282507-swxs5pr1	300	15	receiving	receive	VBG
cord-282507-swxs5pr1	300	16	a	a	DT
cord-282507-swxs5pr1	300	17	regulatory	regulatory	JJ
cord-282507-swxs5pr1	300	18	approval	approval	NN
cord-282507-swxs5pr1	300	19	by	by	IN
cord-282507-swxs5pr1	300	20	the	the	DT
cord-282507-swxs5pr1	300	21	EMA	EMA	NNP
cord-282507-swxs5pr1	300	22	in	in	IN
cord-282507-swxs5pr1	300	23	2015	2015	CD
cord-282507-swxs5pr1	300	24	for	for	IN
cord-282507-swxs5pr1	300	25	use	use	NN
cord-282507-swxs5pr1	300	26	outside	outside	IN
cord-282507-swxs5pr1	300	27	of	of	IN
cord-282507-swxs5pr1	300	28	Europe	Europe	NNP
cord-282507-swxs5pr1	300	29	and	and	CC
cord-282507-swxs5pr1	300	30	being	be	VBG
cord-282507-swxs5pr1	300	31	currently	currently	RB
cord-282507-swxs5pr1	300	32	under	under	IN
cord-282507-swxs5pr1	300	33	exploration	exploration	NN
cord-282507-swxs5pr1	300	34	in	in	IN
cord-282507-swxs5pr1	300	35	sub	sub	JJ
cord-282507-swxs5pr1	300	36	-	-	JJ
cord-282507-swxs5pr1	300	37	Saharan	saharan	JJ
cord-282507-swxs5pr1	300	38	regions	region	NNS
cord-282507-swxs5pr1	300	39	for	for	IN
cord-282507-swxs5pr1	300	40	its	-PRON-	PRP$
cord-282507-swxs5pr1	300	41	use	use	NN
cord-282507-swxs5pr1	300	42	in	in	IN
cord-282507-swxs5pr1	300	43	routine	routine	NN
cord-282507-swxs5pr1	300	44	.	.	.
cord-282507-swxs5pr1	301	1	9	9	LS
cord-282507-swxs5pr1	301	2	)	)	-RRB-
cord-282507-swxs5pr1	301	3	the	the	DT
cord-282507-swxs5pr1	301	4	disappointing	disappointing	JJ
cord-282507-swxs5pr1	301	5	phase	phase	NN
cord-282507-swxs5pr1	301	6	III	iii	CD
cord-282507-swxs5pr1	301	7	clinical	clinical	JJ
cord-282507-swxs5pr1	301	8	results	result	NNS
cord-282507-swxs5pr1	301	9	in	in	IN
cord-282507-swxs5pr1	301	10	term	term	NN
cord-282507-swxs5pr1	301	11	of	of	IN
cord-282507-swxs5pr1	301	12	disease	disease	NN
cord-282507-swxs5pr1	301	13	-	-	HYPH
cord-282507-swxs5pr1	301	14	free	free	JJ
cord-282507-swxs5pr1	301	15	survival	survival	NN
cord-282507-swxs5pr1	301	16	of	of	IN
cord-282507-swxs5pr1	301	17	patient	patient	NN
cord-282507-swxs5pr1	301	18	with	with	IN
cord-282507-swxs5pr1	301	19	immunotherapeutic	immunotherapeutic	JJ
cord-282507-swxs5pr1	301	20	vaccines	vaccine	NNS
cord-282507-swxs5pr1	301	21	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	301	22	with	with	IN
cord-282507-swxs5pr1	301	23	QS-21	QS-21	NNP
cord-282507-swxs5pr1	301	24	/	/	SYM
cord-282507-swxs5pr1	301	25	AS015	as015	NN
cord-282507-swxs5pr1	301	26	against	against	IN
cord-282507-swxs5pr1	301	27	NSCLC	NSCLC	NNP
cord-282507-swxs5pr1	301	28	and	and	CC
cord-282507-swxs5pr1	301	29	melanoma	melanoma	NN
cord-282507-swxs5pr1	301	30	despite	despite	IN
cord-282507-swxs5pr1	301	31	promising	promising	JJ
cord-282507-swxs5pr1	301	32	results	result	NNS
cord-282507-swxs5pr1	301	33	of	of	IN
cord-282507-swxs5pr1	301	34	phase	phase	NN
cord-282507-swxs5pr1	301	35	II	ii	CD
cord-282507-swxs5pr1	301	36	trials	trial	NNS
cord-282507-swxs5pr1	301	37	.	.	.
cord-282507-swxs5pr1	302	1	10	10	CD
cord-282507-swxs5pr1	302	2	)	)	-RRB-
cord-282507-swxs5pr1	303	1	the	the	DT
cord-282507-swxs5pr1	303	2	encouraging	encourage	VBG
cord-282507-swxs5pr1	303	3	results	result	NNS
cord-282507-swxs5pr1	303	4	of	of	IN
cord-282507-swxs5pr1	303	5	a	a	DT
cord-282507-swxs5pr1	303	6	phase	phase	NN
cord-282507-swxs5pr1	303	7	II	II	NNP
cord-282507-swxs5pr1	303	8	trial	trial	NN
cord-282507-swxs5pr1	303	9	confirming	confirm	VBG
cord-282507-swxs5pr1	303	10	that	that	IN
cord-282507-swxs5pr1	303	11	the	the	DT
cord-282507-swxs5pr1	303	12	long	long	JJ
cord-282507-swxs5pr1	303	13	term	term	NN
cord-282507-swxs5pr1	303	14	treatment	treatment	NN
cord-282507-swxs5pr1	303	15	with	with	IN
cord-282507-swxs5pr1	303	16	the	the	DT
cord-282507-swxs5pr1	303	17	immunotherapeutic	immunotherapeutic	NNP
cord-282507-swxs5pr1	303	18	vaccine	vaccine	NNP
cord-282507-swxs5pr1	303	19	vanutide	vanutide	NNP
cord-282507-swxs5pr1	303	20	cridificar	cridificar	NNP
cord-282507-swxs5pr1	303	21	(	(	-LRB-
cord-282507-swxs5pr1	303	22	ACC-001	ACC-001	NNP
cord-282507-swxs5pr1	303	23	)	)	-RRB-
cord-282507-swxs5pr1	303	24	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	303	25	with	with	IN
cord-282507-swxs5pr1	303	26	QS-21	QS-21	NNP
cord-282507-swxs5pr1	303	27	against	against	IN
cord-282507-swxs5pr1	303	28	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	303	29	's	's	POS
cord-282507-swxs5pr1	303	30	disease	disease	NN
cord-282507-swxs5pr1	303	31	was	be	VBD
cord-282507-swxs5pr1	303	32	well	well	RB
cord-282507-swxs5pr1	303	33	tolerated	tolerate	VBN
cord-282507-swxs5pr1	303	34	with	with	IN
cord-282507-swxs5pr1	303	35	an	an	DT
cord-282507-swxs5pr1	303	36	acceptable	acceptable	JJ
cord-282507-swxs5pr1	303	37	safety	safety	NN
cord-282507-swxs5pr1	303	38	profile	profile	NN
cord-282507-swxs5pr1	303	39	.	.	.
cord-282507-swxs5pr1	304	1	The	the	DT
cord-282507-swxs5pr1	304	2	development	development	NN
cord-282507-swxs5pr1	304	3	of	of	IN
cord-282507-swxs5pr1	304	4	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	304	5	in	in	IN
cord-282507-swxs5pr1	304	6	vaccines	vaccine	NNS
cord-282507-swxs5pr1	304	7	represents	represent	VBZ
cord-282507-swxs5pr1	304	8	an	an	DT
cord-282507-swxs5pr1	304	9	area	area	NN
cord-282507-swxs5pr1	304	10	in	in	IN
cord-282507-swxs5pr1	304	11	constant	constant	JJ
cord-282507-swxs5pr1	304	12	evolution	evolution	NN
cord-282507-swxs5pr1	304	13	with	with	IN
cord-282507-swxs5pr1	304	14	substantial	substantial	JJ
cord-282507-swxs5pr1	304	15	advances	advance	NNS
cord-282507-swxs5pr1	304	16	over	over	IN
cord-282507-swxs5pr1	304	17	the	the	DT
cord-282507-swxs5pr1	304	18	past	past	JJ
cord-282507-swxs5pr1	304	19	two	two	CD
cord-282507-swxs5pr1	304	20	decades	decade	NNS
cord-282507-swxs5pr1	304	21	.	.	.
cord-282507-swxs5pr1	305	1	QS-21	QS-21	NNP
cord-282507-swxs5pr1	305	2	in	in	IN
cord-282507-swxs5pr1	305	3	ASs	ass	NN
cord-282507-swxs5pr1	305	4	is	be	VBZ
cord-282507-swxs5pr1	305	5	a	a	DT
cord-282507-swxs5pr1	305	6	key	key	JJ
cord-282507-swxs5pr1	305	7	component	component	NN
cord-282507-swxs5pr1	305	8	of	of	IN
cord-282507-swxs5pr1	305	9	multiple	multiple	JJ
cord-282507-swxs5pr1	305	10	vaccines	vaccine	NNS
cord-282507-swxs5pr1	305	11	targeting	target	VBG
cord-282507-swxs5pr1	305	12	infections	infection	NNS
cord-282507-swxs5pr1	305	13	and	and	CC
cord-282507-swxs5pr1	305	14	endemic	endemic	JJ
cord-282507-swxs5pr1	305	15	diseases	disease	NNS
cord-282507-swxs5pr1	305	16	in	in	IN
cord-282507-swxs5pr1	305	17	developing	develop	VBG
cord-282507-swxs5pr1	305	18	countries	country	NNS
cord-282507-swxs5pr1	305	19	.	.	.
cord-282507-swxs5pr1	306	1	Recent	recent	JJ
cord-282507-swxs5pr1	306	2	research	research	NN
cord-282507-swxs5pr1	306	3	has	have	VBZ
cord-282507-swxs5pr1	306	4	led	lead	VBN
cord-282507-swxs5pr1	306	5	to	to	IN
cord-282507-swxs5pr1	306	6	the	the	DT
cord-282507-swxs5pr1	306	7	commercialization	commercialization	NN
cord-282507-swxs5pr1	306	8	of	of	IN
cord-282507-swxs5pr1	306	9	Shingrix	Shingrix	NNP
cord-282507-swxs5pr1	306	10	™	™	NN
cord-282507-swxs5pr1	306	11	and	and	CC
cord-282507-swxs5pr1	306	12	the	the	DT
cord-282507-swxs5pr1	306	13	approval	approval	NN
cord-282507-swxs5pr1	306	14	of	of	IN
cord-282507-swxs5pr1	306	15	Mosquirix	Mosquirix	NNP
cord-282507-swxs5pr1	306	16	™	™	CD
cord-282507-swxs5pr1	306	17	,	,	,
cord-282507-swxs5pr1	306	18	two	two	CD
cord-282507-swxs5pr1	306	19	vaccines	vaccine	NNS
cord-282507-swxs5pr1	306	20	against	against	IN
cord-282507-swxs5pr1	306	21	HZ	hz	NN
cord-282507-swxs5pr1	306	22	in	in	IN
cord-282507-swxs5pr1	306	23	adults	adult	NNS
cord-282507-swxs5pr1	306	24	and	and	CC
cord-282507-swxs5pr1	306	25	malaria	malaria	NN
cord-282507-swxs5pr1	306	26	in	in	IN
cord-282507-swxs5pr1	306	27	children	child	NNS
cord-282507-swxs5pr1	306	28	,	,	,
cord-282507-swxs5pr1	306	29	respectively	respectively	RB
cord-282507-swxs5pr1	306	30	,	,	,
cord-282507-swxs5pr1	306	31	which	which	WDT
cord-282507-swxs5pr1	306	32	contain	contain	VBP
cord-282507-swxs5pr1	306	33	QS-21	QS-21	NNP
cord-282507-swxs5pr1	306	34	as	as	IN
cord-282507-swxs5pr1	306	35	a	a	DT
cord-282507-swxs5pr1	306	36	part	part	NN
cord-282507-swxs5pr1	306	37	of	of	IN
cord-282507-swxs5pr1	306	38	their	-PRON-	PRP$
cord-282507-swxs5pr1	306	39	formulation	formulation	NN
cord-282507-swxs5pr1	306	40	.	.	.
cord-282507-swxs5pr1	307	1	To	to	TO
cord-282507-swxs5pr1	307	2	ensure	ensure	VB
cord-282507-swxs5pr1	307	3	a	a	DT
cord-282507-swxs5pr1	307	4	continuous	continuous	JJ
cord-282507-swxs5pr1	307	5	supply	supply	NN
cord-282507-swxs5pr1	307	6	of	of	IN
cord-282507-swxs5pr1	307	7	this	this	DT
cord-282507-swxs5pr1	307	8	exciting	exciting	JJ
cord-282507-swxs5pr1	307	9	molecule	molecule	NN
cord-282507-swxs5pr1	307	10	,	,	,
cord-282507-swxs5pr1	307	11	the	the	DT
cord-282507-swxs5pr1	307	12	researchers	researcher	NNS
cord-282507-swxs5pr1	307	13	aimed	aim	VBN
cord-282507-swxs5pr1	307	14	in	in	IN
cord-282507-swxs5pr1	307	15	the	the	DT
cord-282507-swxs5pr1	307	16	near	near	JJ
cord-282507-swxs5pr1	307	17	future	future	NN
cord-282507-swxs5pr1	307	18	to	to	TO
cord-282507-swxs5pr1	307	19	find	find	VB
cord-282507-swxs5pr1	307	20	an	an	DT
cord-282507-swxs5pr1	307	21	alternative	alternative	JJ
cord-282507-swxs5pr1	307	22	innovative	innovative	JJ
cord-282507-swxs5pr1	307	23	process	process	NN
cord-282507-swxs5pr1	307	24	of	of	IN
cord-282507-swxs5pr1	307	25	producing	produce	VBG
cord-282507-swxs5pr1	307	26	this	this	DT
cord-282507-swxs5pr1	307	27	compound	compound	NN
cord-282507-swxs5pr1	307	28	on	on	IN
cord-282507-swxs5pr1	307	29	a	a	DT
cord-282507-swxs5pr1	307	30	large	large	JJ
cord-282507-swxs5pr1	307	31	scale	scale	NN
cord-282507-swxs5pr1	307	32	based	base	VBN
cord-282507-swxs5pr1	307	33	on	on	IN
cord-282507-swxs5pr1	307	34	plant	plant	NN
cord-282507-swxs5pr1	307	35	cell	cell	NN
cord-282507-swxs5pr1	307	36	-	-	HYPH
cord-282507-swxs5pr1	307	37	culture	culture	NN
cord-282507-swxs5pr1	307	38	.	.	.
cord-282507-swxs5pr1	308	1	This	this	DT
cord-282507-swxs5pr1	308	2	might	may	MD
cord-282507-swxs5pr1	308	3	overcome	overcome	VB
cord-282507-swxs5pr1	308	4	some	some	DT
cord-282507-swxs5pr1	308	5	limitations	limitation	NNS
cord-282507-swxs5pr1	308	6	of	of	IN
cord-282507-swxs5pr1	308	7	the	the	DT
cord-282507-swxs5pr1	308	8	current	current	JJ
cord-282507-swxs5pr1	308	9	traditional	traditional	JJ
cord-282507-swxs5pr1	308	10	techniques	technique	NNS
cord-282507-swxs5pr1	308	11	of	of	IN
cord-282507-swxs5pr1	308	12	extraction	extraction	NN
cord-282507-swxs5pr1	308	13	with	with	IN
cord-282507-swxs5pr1	308	14	tedious	tedious	JJ
cord-282507-swxs5pr1	308	15	purification	purification	NN
cord-282507-swxs5pr1	308	16	processes	process	NNS
cord-282507-swxs5pr1	308	17	and	and	CC
cord-282507-swxs5pr1	308	18	chemical	chemical	NN
cord-282507-swxs5pr1	308	19	synthesis	synthesis	NN
cord-282507-swxs5pr1	308	20	involving	involve	VBG
cord-282507-swxs5pr1	308	21	many	many	JJ
cord-282507-swxs5pr1	308	22	complex	complex	JJ
cord-282507-swxs5pr1	308	23	reactions	reaction	NNS
cord-282507-swxs5pr1	308	24	.	.	.
cord-282507-swxs5pr1	309	1	However	however	RB
cord-282507-swxs5pr1	309	2	,	,	,
cord-282507-swxs5pr1	309	3	the	the	DT
cord-282507-swxs5pr1	309	4	synthetic	synthetic	JJ
cord-282507-swxs5pr1	309	5	technology	technology	NN
cord-282507-swxs5pr1	309	6	initially	initially	RB
cord-282507-swxs5pr1	309	7	used	use	VBD
cord-282507-swxs5pr1	309	8	for	for	IN
cord-282507-swxs5pr1	309	9	the	the	DT
cord-282507-swxs5pr1	309	10	first	first	JJ
cord-282507-swxs5pr1	309	11	synthesis	synthesis	NN
cord-282507-swxs5pr1	309	12	of	of	IN
cord-282507-swxs5pr1	309	13	QS-21	QS-21	NNP
cord-282507-swxs5pr1	309	14	,	,	,
cord-282507-swxs5pr1	309	15	was	be	VBD
cord-282507-swxs5pr1	309	16	subsequently	subsequently	RB
cord-282507-swxs5pr1	309	17	applied	apply	VBN
cord-282507-swxs5pr1	309	18	to	to	IN
cord-282507-swxs5pr1	309	19	preparing	prepare	VBG
cord-282507-swxs5pr1	309	20	novel	novel	JJ
cord-282507-swxs5pr1	309	21	structural	structural	JJ
cord-282507-swxs5pr1	309	22	analogs	analog	NNS
cord-282507-swxs5pr1	309	23	with	with	IN
cord-282507-swxs5pr1	309	24	potent	potent	JJ
cord-282507-swxs5pr1	309	25	activity	activity	NN
cord-282507-swxs5pr1	309	26	and	and	CC
cord-282507-swxs5pr1	309	27	low	low	JJ
cord-282507-swxs5pr1	309	28	toxicity	toxicity	NN
cord-282507-swxs5pr1	309	29	,	,	,
cord-282507-swxs5pr1	309	30	leading	lead	VBG
cord-282507-swxs5pr1	309	31	to	to	IN
cord-282507-swxs5pr1	309	32	SAR	SAR	NNP
cord-282507-swxs5pr1	309	33	studies	study	NNS
cord-282507-swxs5pr1	309	34	and	and	CC
cord-282507-swxs5pr1	309	35	a	a	DT
cord-282507-swxs5pr1	309	36	better	well	JJR
cord-282507-swxs5pr1	309	37	understanding	understanding	NN
cord-282507-swxs5pr1	309	38	of	of	IN
cord-282507-swxs5pr1	309	39	the	the	DT
cord-282507-swxs5pr1	309	40	mode	mode	NN
cord-282507-swxs5pr1	309	41	of	of	IN
cord-282507-swxs5pr1	309	42	action	action	NN
cord-282507-swxs5pr1	309	43	.	.	.
cord-282507-swxs5pr1	310	1	Further	further	JJ
cord-282507-swxs5pr1	310	2	work	work	NN
cord-282507-swxs5pr1	310	3	in	in	IN
cord-282507-swxs5pr1	310	4	this	this	DT
cord-282507-swxs5pr1	310	5	area	area	NN
cord-282507-swxs5pr1	310	6	could	could	MD
cord-282507-swxs5pr1	310	7	facilitate	facilitate	VB
cord-282507-swxs5pr1	310	8	novel	novel	JJ
cord-282507-swxs5pr1	310	9	saponin	saponin	NN
cord-282507-swxs5pr1	310	10	design	design	NN
cord-282507-swxs5pr1	310	11	that	that	WDT
cord-282507-swxs5pr1	310	12	will	will	MD
cord-282507-swxs5pr1	310	13	lead	lead	VB
cord-282507-swxs5pr1	310	14	to	to	IN
cord-282507-swxs5pr1	310	15	the	the	DT
cord-282507-swxs5pr1	310	16	discovery	discovery	NN
cord-282507-swxs5pr1	310	17	of	of	IN
cord-282507-swxs5pr1	310	18	new	new	JJ
cord-282507-swxs5pr1	310	19	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	310	20	and	and	CC
cord-282507-swxs5pr1	310	21	improved	improve	VBN
cord-282507-swxs5pr1	310	22	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	310	23	-	-	HYPH
cord-282507-swxs5pr1	310	24	antigen	antigen	NN
cord-282507-swxs5pr1	310	25	combinations	combination	NNS
cord-282507-swxs5pr1	310	26	for	for	IN
cord-282507-swxs5pr1	310	27	future	future	JJ
cord-282507-swxs5pr1	310	28	vaccines	vaccine	NNS
cord-282507-swxs5pr1	310	29	,	,	,
cord-282507-swxs5pr1	310	30	particularly	particularly	RB
cord-282507-swxs5pr1	310	31	against	against	IN
cord-282507-swxs5pr1	310	32	infectious	infectious	JJ
cord-282507-swxs5pr1	310	33	tropical	tropical	JJ
cord-282507-swxs5pr1	310	34	diseases	disease	NNS
cord-282507-swxs5pr1	310	35	such	such	JJ
cord-282507-swxs5pr1	310	36	as	as	IN
cord-282507-swxs5pr1	310	37	Dengue	Dengue	NNP
cord-282507-swxs5pr1	310	38	,	,	,
cord-282507-swxs5pr1	310	39	Leishmaniasis	leishmaniasis	NN
cord-282507-swxs5pr1	310	40	,	,	,
cord-282507-swxs5pr1	310	41	and	and	CC
cord-282507-swxs5pr1	310	42	Chagas	Chagas	NNP
cord-282507-swxs5pr1	310	43	diseases	disease	NNS
cord-282507-swxs5pr1	310	44	,	,	,
cord-282507-swxs5pr1	310	45	which	which	WDT
cord-282507-swxs5pr1	310	46	continue	continue	VBP
cord-282507-swxs5pr1	310	47	to	to	TO
cord-282507-swxs5pr1	310	48	cause	cause	VB
cord-282507-swxs5pr1	310	49	significant	significant	JJ
cord-282507-swxs5pr1	310	50	morbidity	morbidity	NN
cord-282507-swxs5pr1	310	51	and	and	CC
cord-282507-swxs5pr1	310	52	mortality	mortality	NN
cord-282507-swxs5pr1	310	53	in	in	IN
cord-282507-swxs5pr1	310	54	developing	develop	VBG
cord-282507-swxs5pr1	310	55	countries	country	NNS
cord-282507-swxs5pr1	310	56	.	.	.
cord-282507-swxs5pr1	311	1	Evaluation	evaluation	NN
cord-282507-swxs5pr1	311	2	of	of	IN
cord-282507-swxs5pr1	311	3	the	the	DT
cord-282507-swxs5pr1	311	4	safety	safety	NN
cord-282507-swxs5pr1	311	5	and	and	CC
cord-282507-swxs5pr1	311	6	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	311	7	of	of	IN
cord-282507-swxs5pr1	311	8	the	the	DT
cord-282507-swxs5pr1	311	9	RTS	RTS	NNP
cord-282507-swxs5pr1	311	10	,	,	,
cord-282507-swxs5pr1	311	11	S	S	NNP
cord-282507-swxs5pr1	311	12	/	/	SYM
cord-282507-swxs5pr1	311	13	AS01	AS01	NNP
cord-282507-swxs5pr1	311	14	E	E	NNP
cord-282507-swxs5pr1	311	15	malaria	malaria	NN
cord-282507-swxs5pr1	311	16	candidate	candidate	NN
cord-282507-swxs5pr1	311	17	vaccine	vaccine	NN
cord-282507-swxs5pr1	311	18	when	when	WRB
cord-282507-swxs5pr1	311	19	integrated	integrate	VBN
cord-282507-swxs5pr1	311	20	in	in	IN
cord-282507-swxs5pr1	311	21	the	the	DT
cord-282507-swxs5pr1	311	22	expanded	expand	VBN
cord-282507-swxs5pr1	311	23	program	program	NN
cord-282507-swxs5pr1	311	24	of	of	IN
cord-282507-swxs5pr1	311	25	immunization	immunization	NN
cord-282507-swxs5pr1	311	26	Clinical	clinical	JJ
cord-282507-swxs5pr1	311	27	development	development	NN
cord-282507-swxs5pr1	311	28	of	of	IN
cord-282507-swxs5pr1	311	29	RTS	RTS	NNP
cord-282507-swxs5pr1	311	30	,	,	,
cord-282507-swxs5pr1	311	31	S	S	NNP
cord-282507-swxs5pr1	311	32	/	/	SYM
cord-282507-swxs5pr1	311	33	AS	as	IN
cord-282507-swxs5pr1	311	34	malaria	malaria	NN
cord-282507-swxs5pr1	311	35	vaccine	vaccine	NN
cord-282507-swxs5pr1	311	36	,	,	,
cord-282507-swxs5pr1	311	37	a	a	DT
cord-282507-swxs5pr1	311	38	systematic	systematic	JJ
cord-282507-swxs5pr1	311	39	review	review	NN
cord-282507-swxs5pr1	311	40	of	of	IN
cord-282507-swxs5pr1	311	41	clinical	clinical	JJ
cord-282507-swxs5pr1	311	42	phase	phase	NN
cord-282507-swxs5pr1	311	43	I	I	NNP
cord-282507-swxs5pr1	311	44	-	-	HYPH
cord-282507-swxs5pr1	311	45	III	III	NNP
cord-282507-swxs5pr1	311	46	trials	trial	NNS
cord-282507-swxs5pr1	311	47	T	T	NNP
cord-282507-swxs5pr1	311	48	cell	cell	NN
cord-282507-swxs5pr1	311	49	responses	response	NNS
cord-282507-swxs5pr1	311	50	to	to	IN
cord-282507-swxs5pr1	311	51	the	the	DT
cord-282507-swxs5pr1	311	52	RTS	RTS	NNP
cord-282507-swxs5pr1	311	53	,	,	,
cord-282507-swxs5pr1	311	54	S	S	NNP
cord-282507-swxs5pr1	311	55	/	/	SYM
cord-282507-swxs5pr1	311	56	AS01	AS01	NNP
cord-282507-swxs5pr1	311	57	E	E	NNP
cord-282507-swxs5pr1	311	58	and	and	CC
cord-282507-swxs5pr1	311	59	RTS	RTS	NNP
cord-282507-swxs5pr1	311	60	,	,	,
cord-282507-swxs5pr1	311	61	S	S	NNP
cord-282507-swxs5pr1	311	62	/	/	SYM
cord-282507-swxs5pr1	311	63	AS02	AS02	NNP
cord-282507-swxs5pr1	311	64	D	D	NNP
cord-282507-swxs5pr1	311	65	malaria	malaria	NN
cord-282507-swxs5pr1	311	66	candidate	candidate	NN
cord-282507-swxs5pr1	311	67	vaccines	vaccine	NNS
cord-282507-swxs5pr1	311	68	administered	administer	VBN
cord-282507-swxs5pr1	311	69	according	accord	VBG
cord-282507-swxs5pr1	311	70	to	to	IN
cord-282507-swxs5pr1	311	71	different	different	JJ
cord-282507-swxs5pr1	311	72	schedules	schedule	NNS
cord-282507-swxs5pr1	311	73	to	to	IN
cord-282507-swxs5pr1	311	74	Ghanaian	ghanaian	JJ
cord-282507-swxs5pr1	311	75	children	child	NNS
cord-282507-swxs5pr1	311	76	Vanutide	Vanutide	NNP
cord-282507-swxs5pr1	311	77	cridificar	cridificar	NNP
cord-282507-swxs5pr1	311	78	and	and	CC
cord-282507-swxs5pr1	311	79	the	the	DT
cord-282507-swxs5pr1	311	80	QS-21	QS-21	NNP
cord-282507-swxs5pr1	311	81	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	311	82	in	in	IN
cord-282507-swxs5pr1	311	83	Japanese	japanese	JJ
cord-282507-swxs5pr1	311	84	subjects	subject	NNS
cord-282507-swxs5pr1	311	85	with	with	IN
cord-282507-swxs5pr1	311	86	mild	mild	JJ
cord-282507-swxs5pr1	311	87	to	to	TO
cord-282507-swxs5pr1	311	88	moderate	moderate	JJ
cord-282507-swxs5pr1	311	89	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	311	90	disease	disease	NN
cord-282507-swxs5pr1	311	91	:	:	:
cord-282507-swxs5pr1	311	92	results	result	NNS
cord-282507-swxs5pr1	311	93	from	from	IN
cord-282507-swxs5pr1	311	94	two	two	CD
cord-282507-swxs5pr1	311	95	phase	phase	NN
cord-282507-swxs5pr1	311	96	2	2	CD
cord-282507-swxs5pr1	311	97	studies	study	NNS
cord-282507-swxs5pr1	311	98	Mechanisms	Mechanisms	NNPS
cord-282507-swxs5pr1	311	99	of	of	IN
cord-282507-swxs5pr1	311	100	action	action	NN
cord-282507-swxs5pr1	311	101	of	of	IN
cord-282507-swxs5pr1	311	102	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	311	103	Detection	detection	NN
cord-282507-swxs5pr1	311	104	of	of	IN
cord-282507-swxs5pr1	311	105	liposomal	liposomal	JJ
cord-282507-swxs5pr1	311	106	cholesterol	cholesterol	NN
cord-282507-swxs5pr1	311	107	and	and	CC
cord-282507-swxs5pr1	311	108	monophosphoryl	monophosphoryl	NNP
cord-282507-swxs5pr1	312	1	lipid	lipid	NN
cord-282507-swxs5pr1	312	2	A	a	NN
cord-282507-swxs5pr1	312	3	by	by	IN
cord-282507-swxs5pr1	312	4	QS-21	QS-21	NNP
cord-282507-swxs5pr1	312	5	saponin	saponin	NN
cord-282507-swxs5pr1	312	6	and	and	CC
cord-282507-swxs5pr1	312	7	Limulus	Limulus	NNP
cord-282507-swxs5pr1	312	8	polyphemus	polyphemus	NN
cord-282507-swxs5pr1	312	9	amebocyte	amebocyte	NN
cord-282507-swxs5pr1	312	10	lysate	lysate	NN
cord-282507-swxs5pr1	312	11	Safety	Safety	NNP
cord-282507-swxs5pr1	312	12	and	and	CC
cord-282507-swxs5pr1	312	13	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	312	14	of	of	IN
cord-282507-swxs5pr1	312	15	three	three	CD
cord-282507-swxs5pr1	312	16	different	different	JJ
cord-282507-swxs5pr1	312	17	formulations	formulation	NNS
cord-282507-swxs5pr1	312	18	of	of	IN
cord-282507-swxs5pr1	312	19	an	an	DT
cord-282507-swxs5pr1	312	20	adjuvanted	adjuvanted	JJ
cord-282507-swxs5pr1	312	21	varicella	varicella	NN
cord-282507-swxs5pr1	312	22	-	-	HYPH
cord-282507-swxs5pr1	312	23	zoster	zoster	NN
cord-282507-swxs5pr1	312	24	virus	virus	NN
cord-282507-swxs5pr1	312	25	subunit	subunit	NN
cord-282507-swxs5pr1	312	26	vaccine	vaccine	NN
cord-282507-swxs5pr1	312	27	in	in	IN
cord-282507-swxs5pr1	312	28	older	old	JJR
cord-282507-swxs5pr1	312	29	adults	adult	NNS
cord-282507-swxs5pr1	312	30	:	:	:
cord-282507-swxs5pr1	312	31	a	a	DT
cord-282507-swxs5pr1	312	32	phase	phase	NN
cord-282507-swxs5pr1	312	33	II	ii	CD
cord-282507-swxs5pr1	312	34	,	,	,
cord-282507-swxs5pr1	312	35	randomized	randomize	VBN
cord-282507-swxs5pr1	312	36	controlled	control	VBN
cord-282507-swxs5pr1	312	37	study	study	NN
cord-282507-swxs5pr1	312	38	Long	long	JJ
cord-282507-swxs5pr1	312	39	-	-	HYPH
cord-282507-swxs5pr1	312	40	term	term	NN
cord-282507-swxs5pr1	312	41	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	312	42	and	and	CC
cord-282507-swxs5pr1	312	43	safety	safety	NN
cord-282507-swxs5pr1	312	44	of	of	IN
cord-282507-swxs5pr1	312	45	an	an	DT
cord-282507-swxs5pr1	312	46	investigational	investigational	JJ
cord-282507-swxs5pr1	312	47	herpes	herpes	NNP
cord-282507-swxs5pr1	312	48	zoster	zoster	NNP
cord-282507-swxs5pr1	312	49	subunit	subunit	NNP
cord-282507-swxs5pr1	312	50	vaccine	vaccine	NN
cord-282507-swxs5pr1	312	51	in	in	IN
cord-282507-swxs5pr1	312	52	older	old	JJR
cord-282507-swxs5pr1	312	53	adults	adult	NNS
cord-282507-swxs5pr1	313	1	Cellular	cellular	JJ
cord-282507-swxs5pr1	313	2	and	and	CC
cord-282507-swxs5pr1	313	3	molecular	molecular	JJ
cord-282507-swxs5pr1	313	4	synergy	synergy	NN
cord-282507-swxs5pr1	313	5	in	in	IN
cord-282507-swxs5pr1	313	6	AS01-adjuvanted	as01-adjuvanted	CD
cord-282507-swxs5pr1	313	7	vaccines	vaccine	NNS
cord-282507-swxs5pr1	313	8	results	result	NNS
cord-282507-swxs5pr1	313	9	in	in	IN
cord-282507-swxs5pr1	313	10	an	an	DT
cord-282507-swxs5pr1	313	11	early	early	JJ
cord-282507-swxs5pr1	313	12	IFNγ	IFNγ	NNS
cord-282507-swxs5pr1	313	13	response	response	NN
cord-282507-swxs5pr1	313	14	promoting	promote	VBG
cord-282507-swxs5pr1	313	15	vaccine	vaccine	NN
cord-282507-swxs5pr1	313	16	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	313	17	Efficacy	Efficacy	NNP
cord-282507-swxs5pr1	313	18	of	of	IN
cord-282507-swxs5pr1	313	19	Herpes	Herpes	NNP
cord-282507-swxs5pr1	313	20	-	-	HYPH
cord-282507-swxs5pr1	313	21	Zoster	Zoster	NNP
cord-282507-swxs5pr1	313	22	subunit	subunit	NN
cord-282507-swxs5pr1	313	23	vaccine	vaccine	NN
cord-282507-swxs5pr1	313	24	in	in	IN
cord-282507-swxs5pr1	313	25	adults	adult	NNS
cord-282507-swxs5pr1	313	26	70	70	CD
cord-282507-swxs5pr1	313	27	years	year	NNS
cord-282507-swxs5pr1	313	28	of	of	IN
cord-282507-swxs5pr1	313	29	age	age	NN
cord-282507-swxs5pr1	313	30	or	or	CC
cord-282507-swxs5pr1	313	31	older	old	JJR
cord-282507-swxs5pr1	313	32	Immune	immune	JJ
cord-282507-swxs5pr1	313	33	responses	response	NNS
cord-282507-swxs5pr1	313	34	to	to	IN
cord-282507-swxs5pr1	313	35	a	a	DT
cord-282507-swxs5pr1	313	36	recombinant	recombinant	JJ
cord-282507-swxs5pr1	313	37	glycoprotein	glycoprotein	NN
cord-282507-swxs5pr1	313	38	E	E	NNP
cord-282507-swxs5pr1	313	39	Herpes	Herpes	NNP
cord-282507-swxs5pr1	313	40	Zoster	Zoster	NNP
cord-282507-swxs5pr1	313	41	vaccine	vaccine	NN
cord-282507-swxs5pr1	313	42	in	in	IN
cord-282507-swxs5pr1	313	43	adults	adult	NNS
cord-282507-swxs5pr1	313	44	aged	age	VBN
cord-282507-swxs5pr1	313	45	50	50	CD
cord-282507-swxs5pr1	313	46	years	year	NNS
cord-282507-swxs5pr1	313	47	or	or	CC
cord-282507-swxs5pr1	313	48	older	old	JJR
cord-282507-swxs5pr1	313	49	Correlates	correlate	NNS
cord-282507-swxs5pr1	313	50	of	of	IN
cord-282507-swxs5pr1	313	51	adjuvanticity	adjuvanticity	NN
cord-282507-swxs5pr1	313	52	:	:	:
cord-282507-swxs5pr1	313	53	a	a	DT
cord-282507-swxs5pr1	313	54	review	review	NN
cord-282507-swxs5pr1	313	55	on	on	IN
cord-282507-swxs5pr1	313	56	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	313	57	in	in	IN
cord-282507-swxs5pr1	313	58	licenced	licence	VBN
cord-282507-swxs5pr1	313	59	vaccines	vaccine	NNS
cord-282507-swxs5pr1	313	60	Cellmediated	cellmediate	VBN
cord-282507-swxs5pr1	313	61	immune	immune	JJ
cord-282507-swxs5pr1	313	62	responses	response	NNS
cord-282507-swxs5pr1	313	63	to	to	IN
cord-282507-swxs5pr1	313	64	a	a	DT
cord-282507-swxs5pr1	313	65	varicella	varicella	NN
cord-282507-swxs5pr1	313	66	-	-	HYPH
cord-282507-swxs5pr1	313	67	zoster	zoster	NN
cord-282507-swxs5pr1	313	68	virus	virus	NN
cord-282507-swxs5pr1	313	69	glycoprotein	glycoprotein	NN
cord-282507-swxs5pr1	313	70	E	e	NN
cord-282507-swxs5pr1	313	71	vaccine	vaccine	NN
cord-282507-swxs5pr1	313	72	using	use	VBG
cord-282507-swxs5pr1	313	73	both	both	CC
cord-282507-swxs5pr1	313	74	a	a	DT
cord-282507-swxs5pr1	313	75	TLR	TLR	NNP
cord-282507-swxs5pr1	313	76	agonist	agonist	NN
cord-282507-swxs5pr1	313	77	and	and	CC
cord-282507-swxs5pr1	313	78	QS-21	QS-21	NNP
cord-282507-swxs5pr1	313	79	in	in	IN
cord-282507-swxs5pr1	314	1	mice	mouse	NNS
cord-282507-swxs5pr1	314	2	Central	central	JJ
cord-282507-swxs5pr1	314	3	role	role	NN
cord-282507-swxs5pr1	314	4	of	of	IN
cord-282507-swxs5pr1	314	5	CD169	CD169	NNP
cord-282507-swxs5pr1	314	6	+	+	CC
cord-282507-swxs5pr1	315	1	lymph	lymph	NNP
cord-282507-swxs5pr1	315	2	node	node	NN
cord-282507-swxs5pr1	315	3	resident	resident	JJ
cord-282507-swxs5pr1	315	4	macrophages	macrophage	NNS
cord-282507-swxs5pr1	315	5	in	in	IN
cord-282507-swxs5pr1	315	6	the	the	DT
cord-282507-swxs5pr1	315	7	adjuvanticity	adjuvanticity	NN
cord-282507-swxs5pr1	315	8	of	of	IN
cord-282507-swxs5pr1	315	9	the	the	DT
cord-282507-swxs5pr1	315	10	QS-21	QS-21	NNP
cord-282507-swxs5pr1	315	11	component	component	NN
cord-282507-swxs5pr1	315	12	of	of	IN
cord-282507-swxs5pr1	315	13	AS01	AS01	NNP
cord-282507-swxs5pr1	315	14	Enhancement	Enhancement	NNP
cord-282507-swxs5pr1	315	15	of	of	IN
cord-282507-swxs5pr1	315	16	adaptive	adaptive	JJ
cord-282507-swxs5pr1	315	17	immunity	immunity	NN
cord-282507-swxs5pr1	315	18	by	by	IN
cord-282507-swxs5pr1	315	19	the	the	DT
cord-282507-swxs5pr1	315	20	human	human	JJ
cord-282507-swxs5pr1	315	21	vaccine	vaccine	NN
cord-282507-swxs5pr1	315	22	adjuvant	adjuvant	NNP
cord-282507-swxs5pr1	316	1	AS01	AS01	NNP
cord-282507-swxs5pr1	316	2	depends	depend	VBZ
cord-282507-swxs5pr1	316	3	on	on	IN
cord-282507-swxs5pr1	316	4	activated	activate	VBN
cord-282507-swxs5pr1	316	5	dendritic	dendritic	JJ
cord-282507-swxs5pr1	316	6	cells	cell	NNS
cord-282507-swxs5pr1	316	7	Adjuvant	Adjuvant	NNP
cord-282507-swxs5pr1	316	8	system	system	NN
cord-282507-swxs5pr1	317	1	AS01	AS01	NNP
cord-282507-swxs5pr1	317	2	:	:	:
cord-282507-swxs5pr1	317	3	helping	help	VBG
cord-282507-swxs5pr1	317	4	to	to	TO
cord-282507-swxs5pr1	317	5	overcome	overcome	VB
cord-282507-swxs5pr1	317	6	the	the	DT
cord-282507-swxs5pr1	317	7	challenges	challenge	NNS
cord-282507-swxs5pr1	317	8	of	of	IN
cord-282507-swxs5pr1	317	9	modern	modern	JJ
cord-282507-swxs5pr1	317	10	vaccines	vaccine	NNS
cord-282507-swxs5pr1	317	11	The	the	DT
cord-282507-swxs5pr1	317	12	F4	F4	NNP
cord-282507-swxs5pr1	317	13	/	/	SYM
cord-282507-swxs5pr1	317	14	AS01	AS01	NNP
cord-282507-swxs5pr1	317	15	B	B	NNP
cord-282507-swxs5pr1	317	16	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	317	17	vaccine	vaccine	NN
cord-282507-swxs5pr1	317	18	candidate	candidate	NN
cord-282507-swxs5pr1	317	19	is	be	VBZ
cord-282507-swxs5pr1	317	20	safe	safe	JJ
cord-282507-swxs5pr1	317	21	and	and	CC
cord-282507-swxs5pr1	317	22	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	317	23	,	,	,
cord-282507-swxs5pr1	317	24	but	but	CC
cord-282507-swxs5pr1	317	25	does	do	VBZ
cord-282507-swxs5pr1	317	26	n't	not	RB
cord-282507-swxs5pr1	317	27	show	show	VB
cord-282507-swxs5pr1	317	28	viral	viral	JJ
cord-282507-swxs5pr1	317	29	efficacy	efficacy	NN
cord-282507-swxs5pr1	317	30	in	in	IN
cord-282507-swxs5pr1	317	31	antiretroviral	antiretroviral	JJ
cord-282507-swxs5pr1	317	32	therapy	therapy	NN
cord-282507-swxs5pr1	317	33	-	-	HYPH
cord-282507-swxs5pr1	317	34	naïve	naïve	JJ
cord-282507-swxs5pr1	317	35	,	,	,
cord-282507-swxs5pr1	317	36	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	317	37	infected	infect	VBN
cord-282507-swxs5pr1	317	38	adults	adult	NNS
cord-282507-swxs5pr1	317	39	:	:	:
cord-282507-swxs5pr1	317	40	a	a	DT
cord-282507-swxs5pr1	317	41	randomized	randomized	JJ
cord-282507-swxs5pr1	317	42	controlled	control	VBN
cord-282507-swxs5pr1	317	43	trial	trial	NN
cord-282507-swxs5pr1	317	44	Vaccine	vaccine	NN
cord-282507-swxs5pr1	317	45	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	317	46	:	:	:
cord-282507-swxs5pr1	317	47	from	from	IN
cord-282507-swxs5pr1	317	48	1920	1920	CD
cord-282507-swxs5pr1	317	49	to	to	IN
cord-282507-swxs5pr1	317	50	2015	2015	CD
cord-282507-swxs5pr1	317	51	and	and	CC
cord-282507-swxs5pr1	317	52	beyond	beyond	IN
cord-282507-swxs5pr1	317	53	.	.	.
cord-282507-swxs5pr1	318	1	Vaccines	Vaccines	NNP
cord-282507-swxs5pr1	318	2	MAGE	MAGE	NNP
cord-282507-swxs5pr1	318	3	-	-	HYPH
cord-282507-swxs5pr1	318	4	A3	A3	NNP
cord-282507-swxs5pr1	318	5	immunotherapeutic	immunotherapeutic	NN
cord-282507-swxs5pr1	318	6	as	as	IN
cord-282507-swxs5pr1	318	7	ajuvant	ajuvant	NNP
cord-282507-swxs5pr1	318	8	therapy	therapy	NN
cord-282507-swxs5pr1	318	9	for	for	IN
cord-282507-swxs5pr1	318	10	patients	patient	NNS
cord-282507-swxs5pr1	318	11	with	with	IN
cord-282507-swxs5pr1	318	12	resected	resected	JJ
cord-282507-swxs5pr1	318	13	,	,	,
cord-282507-swxs5pr1	318	14	MAGE	MAGE	NNP
cord-282507-swxs5pr1	318	15	-	-	HYPH
cord-282507-swxs5pr1	318	16	A3-positive	A3-positive	NNP
cord-282507-swxs5pr1	318	17	,	,	,
cord-282507-swxs5pr1	318	18	stage	stage	NN
cord-282507-swxs5pr1	318	19	III	iii	CD
cord-282507-swxs5pr1	318	20	melanoma	melanoma	NN
cord-282507-swxs5pr1	318	21	(	(	-LRB-
cord-282507-swxs5pr1	318	22	DERMA	DERMA	NNP
cord-282507-swxs5pr1	318	23	)	)	-RRB-
cord-282507-swxs5pr1	318	24	:	:	:
cord-282507-swxs5pr1	318	25	a	a	DT
cord-282507-swxs5pr1	318	26	double	double	JJ
cord-282507-swxs5pr1	318	27	blind	blind	JJ
cord-282507-swxs5pr1	318	28	,	,	,
cord-282507-swxs5pr1	318	29	randomized	randomized	JJ
cord-282507-swxs5pr1	318	30	,	,	,
cord-282507-swxs5pr1	318	31	placebo	placebo	NN
cord-282507-swxs5pr1	318	32	-	-	HYPH
cord-282507-swxs5pr1	318	33	controlled	control	VBN
cord-282507-swxs5pr1	318	34	Adjuvant	Adjuvant	NNP
cord-282507-swxs5pr1	318	35	ganglioside	ganglioside	NN
cord-282507-swxs5pr1	319	1	GM2-KLH	GM2-KLH	NNP
cord-282507-swxs5pr1	319	2	/	/	SYM
cord-282507-swxs5pr1	319	3	QS-21	QS-21	NNP
cord-282507-swxs5pr1	319	4	vaccination	vaccination	NN
cord-282507-swxs5pr1	319	5	versus	versus	IN
cord-282507-swxs5pr1	319	6	observation	observation	NN
cord-282507-swxs5pr1	319	7	after	after	IN
cord-282507-swxs5pr1	319	8	resection	resection	NN
cord-282507-swxs5pr1	319	9	of	of	IN
cord-282507-swxs5pr1	319	10	primary	primary	JJ
cord-282507-swxs5pr1	319	11	tumor	tumor	NN
cord-282507-swxs5pr1	320	1	>	>	XX
cord-282507-swxs5pr1	321	1	1.5	1.5	CD
cord-282507-swxs5pr1	321	2	mm	mm	NNS
cord-282507-swxs5pr1	321	3	in	in	IN
cord-282507-swxs5pr1	321	4	patients	patient	NNS
cord-282507-swxs5pr1	321	5	with	with	IN
cord-282507-swxs5pr1	321	6	stage	stage	NN
cord-282507-swxs5pr1	321	7	II	ii	CD
cord-282507-swxs5pr1	321	8	melanoma	melanoma	NN
cord-282507-swxs5pr1	321	9	:	:	:
cord-282507-swxs5pr1	321	10	results	result	NNS
cord-282507-swxs5pr1	321	11	of	of	IN
cord-282507-swxs5pr1	321	12	the	the	DT
cord-282507-swxs5pr1	321	13	EORTC	EORTC	NNP
cord-282507-swxs5pr1	321	14	18961	18961	CD
cord-282507-swxs5pr1	321	15	randomized	randomized	JJ
cord-282507-swxs5pr1	321	16	phase	phase	NN
cord-282507-swxs5pr1	321	17	III	iii	CD
cord-282507-swxs5pr1	321	18	trial	trial	NN
cord-282507-swxs5pr1	321	19	MAGE	MAGE	NNP
cord-282507-swxs5pr1	321	20	-	-	HYPH
cord-282507-swxs5pr1	321	21	A3	A3	NNP
cord-282507-swxs5pr1	321	22	:	:	:
cord-282507-swxs5pr1	321	23	an	an	DT
cord-282507-swxs5pr1	321	24	immunogenic	immunogenic	JJ
cord-282507-swxs5pr1	321	25	target	target	NN
cord-282507-swxs5pr1	321	26	used	use	VBN
cord-282507-swxs5pr1	321	27	in	in	IN
cord-282507-swxs5pr1	321	28	clinical	clinical	JJ
cord-282507-swxs5pr1	321	29	practice	practice	NN
cord-282507-swxs5pr1	321	30	Design	design	NN
cord-282507-swxs5pr1	321	31	,	,	,
cord-282507-swxs5pr1	321	32	synthesis	synthesis	NN
cord-282507-swxs5pr1	321	33	and	and	CC
cord-282507-swxs5pr1	321	34	evaluation	evaluation	NN
cord-282507-swxs5pr1	321	35	of	of	IN
cord-282507-swxs5pr1	321	36	optimized	optimize	VBN
cord-282507-swxs5pr1	321	37	saponin	saponin	NN
cord-282507-swxs5pr1	321	38	variants	variant	NNS
cord-282507-swxs5pr1	321	39	derived	derive	VBN
cord-282507-swxs5pr1	321	40	from	from	IN
cord-282507-swxs5pr1	321	41	the	the	DT
cord-282507-swxs5pr1	321	42	vaccine	vaccine	NN
cord-282507-swxs5pr1	321	43	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	321	44	QS-21	QS-21	NNP
cord-282507-swxs5pr1	321	45	Development	Development	NNP
cord-282507-swxs5pr1	321	46	of	of	IN
cord-282507-swxs5pr1	321	47	a	a	DT
cord-282507-swxs5pr1	321	48	minimal	minimal	JJ
cord-282507-swxs5pr1	321	49	saponin	saponin	NN
cord-282507-swxs5pr1	321	50	vaccine	vaccine	NN
cord-282507-swxs5pr1	321	51	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	321	52	bsed	bse	VBN
cord-282507-swxs5pr1	321	53	on	on	IN
cord-282507-swxs5pr1	321	54	QS-21	QS-21	NNP
cord-282507-swxs5pr1	321	55	Development	Development	NNP
cord-282507-swxs5pr1	321	56	of	of	IN
cord-282507-swxs5pr1	321	57	improved	improved	JJ
cord-282507-swxs5pr1	321	58	vaccine	vaccine	NN
cord-282507-swxs5pr1	321	59	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	321	60	based	base	VBN
cord-282507-swxs5pr1	321	61	on	on	IN
cord-282507-swxs5pr1	321	62	the	the	DT
cord-282507-swxs5pr1	321	63	saponin	saponin	NN
cord-282507-swxs5pr1	321	64	natural	natural	JJ
cord-282507-swxs5pr1	321	65	product	product	NN
cord-282507-swxs5pr1	321	66	QS-21	QS-21	NNP
cord-282507-swxs5pr1	321	67	through	through	IN
cord-282507-swxs5pr1	321	68	chemical	chemical	JJ
cord-282507-swxs5pr1	321	69	synthesis	synthesis	NN
cord-282507-swxs5pr1	321	70	From	from	IN
cord-282507-swxs5pr1	321	71	discovery	discovery	NN
cord-282507-swxs5pr1	321	72	to	to	IN
cord-282507-swxs5pr1	321	73	licensure	licensure	NN
cord-282507-swxs5pr1	321	74	,	,	,
cord-282507-swxs5pr1	321	75	the	the	DT
cord-282507-swxs5pr1	321	76	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	321	77	system	system	NN
cord-282507-swxs5pr1	321	78	story	story	NN
cord-282507-swxs5pr1	321	79	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-282507-swxs5pr1	321	80	Adjuvant	Adjuvant	NNP
cord-282507-swxs5pr1	321	81	Systems	Systems	NNPS
cord-282507-swxs5pr1	321	82	in	in	IN
cord-282507-swxs5pr1	321	83	vaccines	vaccine	NNS
cord-282507-swxs5pr1	321	84	:	:	:
cord-282507-swxs5pr1	321	85	concepts	concept	NNS
cord-282507-swxs5pr1	321	86	,	,	,
cord-282507-swxs5pr1	321	87	achievements	achievement	NNS
cord-282507-swxs5pr1	321	88	and	and	CC
cord-282507-swxs5pr1	321	89	perspectives	perspective	NNS
cord-282507-swxs5pr1	321	90	Understanding	understand	VBG
cord-282507-swxs5pr1	321	91	Modern	modern	JJ
cord-282507-swxs5pr1	321	92	Vaccines	vaccine	NNS
cord-282507-swxs5pr1	321	93	:	:	:
cord-282507-swxs5pr1	321	94	Perspectives	perspective	NNS
cord-282507-swxs5pr1	321	95	in	in	IN
cord-282507-swxs5pr1	321	96	Vaccinology	Vaccinology	NNP
cord-282507-swxs5pr1	321	97	1	1	CD
cord-282507-swxs5pr1	322	1	The	the	DT
cord-282507-swxs5pr1	322	2	perfect	perfect	JJ
cord-282507-swxs5pr1	322	3	mix	mix	NN
cord-282507-swxs5pr1	322	4	:	:	:
cord-282507-swxs5pr1	322	5	recent	recent	JJ
cord-282507-swxs5pr1	322	6	progress	progress	NN
cord-282507-swxs5pr1	322	7	in	in	IN
cord-282507-swxs5pr1	322	8	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	322	9	research	research	NN
cord-282507-swxs5pr1	322	10	Safetey	safetey	NN
cord-282507-swxs5pr1	322	11	and	and	CC
cord-282507-swxs5pr1	322	12	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	322	13	of	of	IN
cord-282507-swxs5pr1	322	14	an	an	DT
cord-282507-swxs5pr1	322	15	adjuvanted	adjuvanted	JJ
cord-282507-swxs5pr1	322	16	protein	protein	NN
cord-282507-swxs5pr1	322	17	therapeutic	therapeutic	JJ
cord-282507-swxs5pr1	322	18	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	322	19	vaccine	vaccine	NN
cord-282507-swxs5pr1	322	20	in	in	IN
cord-282507-swxs5pr1	322	21	subjects	subject	NNS
cord-282507-swxs5pr1	322	22	with	with	IN
cord-282507-swxs5pr1	322	23	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	322	24	infection	infection	NN
cord-282507-swxs5pr1	322	25	:	:	:
cord-282507-swxs5pr1	322	26	a	a	DT
cord-282507-swxs5pr1	322	27	randomized	randomized	JJ
cord-282507-swxs5pr1	322	28	placebo	placebo	NN
cord-282507-swxs5pr1	322	29	-	-	HYPH
cord-282507-swxs5pr1	322	30	controlled	control	VBN
cord-282507-swxs5pr1	322	31	study	study	NN
cord-282507-swxs5pr1	322	32	Long	long	JJ
cord-282507-swxs5pr1	322	33	-	-	HYPH
cord-282507-swxs5pr1	322	34	term	term	NN
cord-282507-swxs5pr1	322	35	follow	follow	NN
cord-282507-swxs5pr1	322	36	-	-	HYPH
cord-282507-swxs5pr1	322	37	up	up	NN
cord-282507-swxs5pr1	322	38	of	of	IN
cord-282507-swxs5pr1	322	39	HIV-1-infected	hiv-1-infecte	VBN
cord-282507-swxs5pr1	322	40	adults	adult	NNS
cord-282507-swxs5pr1	322	41	who	who	WP
cord-282507-swxs5pr1	322	42	received	receive	VBD
cord-282507-swxs5pr1	322	43	the	the	DT
cord-282507-swxs5pr1	322	44	F4	f4	NN
cord-282507-swxs5pr1	322	45	/	/	SYM
cord-282507-swxs5pr1	322	46	AS01B	as01b	NN
cord-282507-swxs5pr1	322	47	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	322	48	vaccine	vaccine	NN
cord-282507-swxs5pr1	322	49	candidate	candidate	NN
cord-282507-swxs5pr1	322	50	in	in	IN
cord-282507-swxs5pr1	322	51	two	two	CD
cord-282507-swxs5pr1	322	52	randomized	randomized	JJ
cord-282507-swxs5pr1	322	53	controlled	control	VBN
cord-282507-swxs5pr1	322	54	trials	trial	NNS
cord-282507-swxs5pr1	322	55	Long	long	JJ
cord-282507-swxs5pr1	322	56	term	term	NN
cord-282507-swxs5pr1	322	57	extensions	extension	NNS
cord-282507-swxs5pr1	322	58	of	of	IN
cord-282507-swxs5pr1	322	59	randomized	randomized	JJ
cord-282507-swxs5pr1	322	60	vaccination	vaccination	NN
cord-282507-swxs5pr1	322	61	trials	trial	NNS
cord-282507-swxs5pr1	322	62	of	of	IN
cord-282507-swxs5pr1	322	63	ACC-001	ACC-001	NNP
cord-282507-swxs5pr1	322	64	and	and	CC
cord-282507-swxs5pr1	322	65	QS-21	QS-21	NNP
cord-282507-swxs5pr1	322	66	in	in	IN
cord-282507-swxs5pr1	322	67	mild	mild	JJ
cord-282507-swxs5pr1	322	68	to	to	TO
cord-282507-swxs5pr1	322	69	moderate	moderate	JJ
cord-282507-swxs5pr1	322	70	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	322	71	's	's	POS
cord-282507-swxs5pr1	322	72	disease	disease	NN
cord-282507-swxs5pr1	322	73	Safety	Safety	NNP
cord-282507-swxs5pr1	322	74	and	and	CC
cord-282507-swxs5pr1	322	75	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	322	76	of	of	IN
cord-282507-swxs5pr1	322	77	the	the	DT
cord-282507-swxs5pr1	322	78	M72	M72	NNPS
cord-282507-swxs5pr1	322	79	/	/	SYM
cord-282507-swxs5pr1	322	80	AS01	AS01	NNP
cord-282507-swxs5pr1	322	81	candidate	candidate	NN
cord-282507-swxs5pr1	322	82	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	322	83	vaccine	vaccine	NN
cord-282507-swxs5pr1	322	84	when	when	WRB
cord-282507-swxs5pr1	322	85	given	give	VBN
cord-282507-swxs5pr1	322	86	as	as	IN
cord-282507-swxs5pr1	322	87	a	a	DT
cord-282507-swxs5pr1	322	88	booster	booster	NN
cord-282507-swxs5pr1	322	89	to	to	IN
cord-282507-swxs5pr1	322	90	BCG	BCG	NNP
cord-282507-swxs5pr1	322	91	in	in	IN
cord-282507-swxs5pr1	322	92	Gambian	gambian	JJ
cord-282507-swxs5pr1	322	93	infants	infant	NNS
cord-282507-swxs5pr1	322	94	:	:	:
cord-282507-swxs5pr1	322	95	an	an	DT
cord-282507-swxs5pr1	322	96	open	open	JJ
cord-282507-swxs5pr1	322	97	-	-	HYPH
cord-282507-swxs5pr1	322	98	label	label	NN
cord-282507-swxs5pr1	322	99	randomized	randomize	VBN
cord-282507-swxs5pr1	322	100	controlled	control	VBN
cord-282507-swxs5pr1	322	101	trial	trial	NN
cord-282507-swxs5pr1	322	102	System	System	NNP
cord-282507-swxs5pr1	322	103	analysis	analysis	NN
cord-282507-swxs5pr1	322	104	of	of	IN
cord-282507-swxs5pr1	322	105	protective	protective	JJ
cord-282507-swxs5pr1	322	106	immune	immune	JJ
cord-282507-swxs5pr1	322	107	responses	response	NNS
cord-282507-swxs5pr1	322	108	to	to	IN
cord-282507-swxs5pr1	322	109	RTS	RTS	NNP
cord-282507-swxs5pr1	322	110	,	,	,
cord-282507-swxs5pr1	322	111	S	S	NNP
cord-282507-swxs5pr1	322	112	malaria	malaria	NN
cord-282507-swxs5pr1	322	113	vaccination	vaccination	NN
cord-282507-swxs5pr1	322	114	in	in	IN
cord-282507-swxs5pr1	322	115	humans	human	NNS
cord-282507-swxs5pr1	322	116	Saponins	Saponins	NNP
cord-282507-swxs5pr1	322	117	as	as	IN
cord-282507-swxs5pr1	322	118	vaccine	vaccine	NN
cord-282507-swxs5pr1	322	119	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	322	120	Separation	separation	NN
cord-282507-swxs5pr1	322	121	and	and	CC
cord-282507-swxs5pr1	322	122	characterization	characterization	NN
cord-282507-swxs5pr1	322	123	of	of	IN
cord-282507-swxs5pr1	322	124	saponins	saponin	NNS
cord-282507-swxs5pr1	322	125	with	with	IN
cord-282507-swxs5pr1	322	126	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	322	127	activity	activity	NN
cord-282507-swxs5pr1	322	128	from	from	IN
cord-282507-swxs5pr1	322	129	Quillaja	Quillaja	NNP
cord-282507-swxs5pr1	323	1	saponaria	saponaria	NNP
cord-282507-swxs5pr1	323	2	Molina	Molina	NNP
cord-282507-swxs5pr1	323	3	cortex	cortex	NN
cord-282507-swxs5pr1	323	4	Randomized	Randomized	NNP
cord-282507-swxs5pr1	323	5	,	,	,
cord-282507-swxs5pr1	323	6	doubleblind	doubleblind	NN
cord-282507-swxs5pr1	323	7	,	,	,
cord-282507-swxs5pr1	323	8	phase	phase	NN
cord-282507-swxs5pr1	323	9	2a	2a	CD
cord-282507-swxs5pr1	323	10	trial	trial	NN
cord-282507-swxs5pr1	323	11	of	of	IN
cord-282507-swxs5pr1	323	12	falciparum	falciparum	NN
cord-282507-swxs5pr1	323	13	malaria	malaria	NN
cord-282507-swxs5pr1	323	14	vaccines	vaccine	NNS
cord-282507-swxs5pr1	323	15	RTS	RTS	NNP
cord-282507-swxs5pr1	323	16	,	,	,
cord-282507-swxs5pr1	323	17	S	S	NNP
cord-282507-swxs5pr1	323	18	/	/	SYM
cord-282507-swxs5pr1	323	19	AS01	AS01	NNP
cord-282507-swxs5pr1	323	20	B	B	NNP
cord-282507-swxs5pr1	323	21	and	and	CC
cord-282507-swxs5pr1	323	22	RTS	RTS	NNP
cord-282507-swxs5pr1	323	23	,	,	,
cord-282507-swxs5pr1	323	24	S	S	NNP
cord-282507-swxs5pr1	323	25	/	/	SYM
cord-282507-swxs5pr1	323	26	AS02	AS02	NNP
cord-282507-swxs5pr1	323	27	A	A	NNP
cord-282507-swxs5pr1	323	28	in	in	IN
cord-282507-swxs5pr1	323	29	malaria	malaria	NN
cord-282507-swxs5pr1	323	30	-	-	HYPH
cord-282507-swxs5pr1	323	31	naïve	naïve	JJ
cord-282507-swxs5pr1	323	32	adults	adult	NNS
cord-282507-swxs5pr1	323	33	:	:	:
cord-282507-swxs5pr1	323	34	safety	safety	NN
cord-282507-swxs5pr1	323	35	,	,	,
cord-282507-swxs5pr1	323	36	efficacy	efficacy	NN
cord-282507-swxs5pr1	323	37	,	,	,
cord-282507-swxs5pr1	323	38	and	and	CC
cord-282507-swxs5pr1	323	39	immunologic	immunologic	JJ
cord-282507-swxs5pr1	323	40	associates	associate	NNS
cord-282507-swxs5pr1	323	41	of	of	IN
cord-282507-swxs5pr1	323	42	protection	protection	NNP
cord-282507-swxs5pr1	323	43	A	a	DT
cord-282507-swxs5pr1	323	44	review	review	NN
cord-282507-swxs5pr1	323	45	of	of	IN
cord-282507-swxs5pr1	323	46	the	the	DT
cord-282507-swxs5pr1	323	47	biological	biological	JJ
cord-282507-swxs5pr1	323	48	and	and	CC
cord-282507-swxs5pr1	323	49	pharmacological	pharmacological	JJ
cord-282507-swxs5pr1	323	50	activities	activity	NNS
cord-282507-swxs5pr1	323	51	of	of	IN
cord-282507-swxs5pr1	323	52	saponins	saponin	NNS
cord-282507-swxs5pr1	323	53	Bioactive	Bioactive	NNP
cord-282507-swxs5pr1	323	54	saponins	saponin	NNS
cord-282507-swxs5pr1	323	55	from	from	IN
cord-282507-swxs5pr1	323	56	plants	plant	NNS
cord-282507-swxs5pr1	323	57	:	:	:
cord-282507-swxs5pr1	323	58	an	an	DT
cord-282507-swxs5pr1	323	59	update	update	NN
cord-282507-swxs5pr1	323	60	New	new	JJ
cord-282507-swxs5pr1	323	61	perspectives	perspective	NNS
cord-282507-swxs5pr1	323	62	for	for	IN
cord-282507-swxs5pr1	323	63	natural	natural	JJ
cord-282507-swxs5pr1	323	64	triterpene	triterpene	JJ
cord-282507-swxs5pr1	323	65	glycosides	glycoside	NNS
cord-282507-swxs5pr1	323	66	as	as	IN
cord-282507-swxs5pr1	323	67	potential	potential	JJ
cord-282507-swxs5pr1	323	68	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	323	69	Saponins	Saponins	NNP
cord-282507-swxs5pr1	323	70	as	as	IN
cord-282507-swxs5pr1	323	71	immunoadjuvants	immunoadjuvant	NNS
cord-282507-swxs5pr1	323	72	and	and	CC
cord-282507-swxs5pr1	323	73	immunostimulants	immunostimulant	VBZ
cord-282507-swxs5pr1	323	74	Bioactive	Bioactive	NNP
cord-282507-swxs5pr1	323	75	saponins	saponin	NNS
cord-282507-swxs5pr1	323	76	with	with	IN
cord-282507-swxs5pr1	323	77	cancer	cancer	NN
cord-282507-swxs5pr1	323	78	related	relate	VBN
cord-282507-swxs5pr1	323	79	and	and	CC
cord-282507-swxs5pr1	323	80	immunomodulatory	immunomodulatory	JJ
cord-282507-swxs5pr1	323	81	activity	activity	NN
cord-282507-swxs5pr1	323	82	:	:	:
cord-282507-swxs5pr1	323	83	recent	recent	JJ
cord-282507-swxs5pr1	323	84	developments	development	NNS
cord-282507-swxs5pr1	323	85	Efficacy	Efficacy	NNP
cord-282507-swxs5pr1	323	86	of	of	IN
cord-282507-swxs5pr1	323	87	an	an	DT
cord-282507-swxs5pr1	323	88	adjuvanted	adjuvanted	JJ
cord-282507-swxs5pr1	323	89	Herpes	Herpes	NNP
cord-282507-swxs5pr1	323	90	Zoster	Zoster	NNP
cord-282507-swxs5pr1	323	91	subunit	subunit	NN
cord-282507-swxs5pr1	323	92	vaccine	vaccine	NN
cord-282507-swxs5pr1	323	93	in	in	IN
cord-282507-swxs5pr1	323	94	older	old	JJR
cord-282507-swxs5pr1	323	95	adults	adult	NNS
cord-282507-swxs5pr1	324	1	Recent	recent	JJ
cord-282507-swxs5pr1	324	2	advances	advance	NNS
cord-282507-swxs5pr1	324	3	of	of	IN
cord-282507-swxs5pr1	324	4	vaccine	vaccine	NN
cord-282507-swxs5pr1	324	5	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	324	6	for	for	IN
cord-282507-swxs5pr1	324	7	infectious	infectious	JJ
cord-282507-swxs5pr1	324	8	diseases	disease	NNS
cord-282507-swxs5pr1	324	9	Evaluation	Evaluation	NNP
cord-282507-swxs5pr1	324	10	of	of	IN
cord-282507-swxs5pr1	324	11	the	the	DT
cord-282507-swxs5pr1	324	12	immune	immune	JJ
cord-282507-swxs5pr1	324	13	response	response	NN
cord-282507-swxs5pr1	324	14	to	to	IN
cord-282507-swxs5pr1	324	15	RTS	RTS	NNP
cord-282507-swxs5pr1	324	16	,	,	,
cord-282507-swxs5pr1	324	17	S	S	NNP
cord-282507-swxs5pr1	324	18	/	/	SYM
cord-282507-swxs5pr1	324	19	AS01	AS01	NNP
cord-282507-swxs5pr1	324	20	and	and	CC
cord-282507-swxs5pr1	324	21	RTS	RTS	NNP
cord-282507-swxs5pr1	325	1	,	,	,
cord-282507-swxs5pr1	325	2	S	S	NNP
cord-282507-swxs5pr1	325	3	/	/	SYM
cord-282507-swxs5pr1	325	4	AS02	AS02	NNP
cord-282507-swxs5pr1	325	5	adjuvanted	adjuvante	VBD
cord-282507-swxs5pr1	325	6	vaccines	vaccine	NNS
cord-282507-swxs5pr1	325	7	Immunogenicity	Immunogenicity	NNP
cord-282507-swxs5pr1	325	8	and	and	CC
cord-282507-swxs5pr1	325	9	safety	safety	NN
cord-282507-swxs5pr1	325	10	of	of	IN
cord-282507-swxs5pr1	325	11	a	a	DT
cord-282507-swxs5pr1	325	12	booster	booster	NN
cord-282507-swxs5pr1	325	13	dose	dose	NN
cord-282507-swxs5pr1	325	14	of	of	IN
cord-282507-swxs5pr1	325	15	an	an	DT
cord-282507-swxs5pr1	325	16	investigantional	investigantional	JJ
cord-282507-swxs5pr1	325	17	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	325	18	polyprotein	polyprotein	NNP
cord-282507-swxs5pr1	325	19	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	325	20	vaccine	vaccine	NN
cord-282507-swxs5pr1	325	21	in	in	IN
cord-282507-swxs5pr1	325	22	healthy	healthy	JJ
cord-282507-swxs5pr1	325	23	adults	adult	NNS
cord-282507-swxs5pr1	325	24	and	and	CC
cord-282507-swxs5pr1	325	25	effect	effect	NN
cord-282507-swxs5pr1	325	26	of	of	IN
cord-282507-swxs5pr1	325	27	administered	administer	VBN
cord-282507-swxs5pr1	325	28	chloroquine	chloroquine	NN
cord-282507-swxs5pr1	325	29	Improved	Improved	NNP
cord-282507-swxs5pr1	325	30	CD4	CD4	NNP
cord-282507-swxs5pr1	325	31	+	+	CC
cord-282507-swxs5pr1	325	32	T	t	NN
cord-282507-swxs5pr1	325	33	cell	cell	NN
cord-282507-swxs5pr1	325	34	responses	response	NNS
cord-282507-swxs5pr1	325	35	to	to	IN
cord-282507-swxs5pr1	325	36	Mycobacterium	Mycobacterium	NNP
cord-282507-swxs5pr1	325	37	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	325	38	in	in	IN
cord-282507-swxs5pr1	325	39	PPD	PPD	NNP
cord-282507-swxs5pr1	325	40	negative	negative	JJ
cord-282507-swxs5pr1	325	41	adults	adult	NNS
cord-282507-swxs5pr1	325	42	by	by	IN
cord-282507-swxs5pr1	325	43	M72	M72	NNP
cord-282507-swxs5pr1	325	44	/	/	SYM
cord-282507-swxs5pr1	325	45	AS01	AS01	NNP
cord-282507-swxs5pr1	325	46	as	as	IN
cord-282507-swxs5pr1	325	47	compared	compare	VBN
cord-282507-swxs5pr1	325	48	to	to	IN
cord-282507-swxs5pr1	325	49	the	the	DT
cord-282507-swxs5pr1	325	50	M72	M72	NNPS
cord-282507-swxs5pr1	325	51	/	/	SYM
cord-282507-swxs5pr1	325	52	AS02	AS02	NNP
cord-282507-swxs5pr1	326	1	and	and	CC
cord-282507-swxs5pr1	326	2	Mtb72F	Mtb72F	NNP
cord-282507-swxs5pr1	326	3	/	/	SYM
cord-282507-swxs5pr1	326	4	AS02	AS02	NNP
cord-282507-swxs5pr1	326	5	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	326	6	candidate	candidate	NN
cord-282507-swxs5pr1	326	7	vaccine	vaccine	NN
cord-282507-swxs5pr1	326	8	formulations	formulation	NNS
cord-282507-swxs5pr1	326	9	:	:	:
cord-282507-swxs5pr1	326	10	a	a	DT
cord-282507-swxs5pr1	326	11	randomized	randomized	JJ
cord-282507-swxs5pr1	326	12	trial	trial	NN
cord-282507-swxs5pr1	326	13	Strong	strong	JJ
cord-282507-swxs5pr1	326	14	and	and	CC
cord-282507-swxs5pr1	326	15	persistent	persistent	JJ
cord-282507-swxs5pr1	326	16	CD4	CD4	NNP
cord-282507-swxs5pr1	326	17	+	+	CC
cord-282507-swxs5pr1	326	18	T	t	NN
cord-282507-swxs5pr1	326	19	-	-	HYPH
cord-282507-swxs5pr1	326	20	cell	cell	NN
cord-282507-swxs5pr1	326	21	response	response	NN
cord-282507-swxs5pr1	326	22	in	in	IN
cord-282507-swxs5pr1	326	23	healthy	healthy	JJ
cord-282507-swxs5pr1	326	24	adults	adult	NNS
cord-282507-swxs5pr1	326	25	immunized	immunize	VBN
cord-282507-swxs5pr1	326	26	with	with	IN
cord-282507-swxs5pr1	326	27	a	a	DT
cord-282507-swxs5pr1	326	28	candidate	candidate	NN
cord-282507-swxs5pr1	326	29	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	326	30	vaccine	vaccine	NN
cord-282507-swxs5pr1	326	31	containing	contain	VBG
cord-282507-swxs5pr1	326	32	gp	gp	NNP
cord-282507-swxs5pr1	326	33	120	120	CD
cord-282507-swxs5pr1	326	34	,	,	,
cord-282507-swxs5pr1	326	35	Nef	Nef	NNP
cord-282507-swxs5pr1	326	36	and	and	CC
cord-282507-swxs5pr1	326	37	Tat	Tat	NNP
cord-282507-swxs5pr1	326	38	antigens	antigen	NNS
cord-282507-swxs5pr1	326	39	formulated	formulate	VBN
cord-282507-swxs5pr1	326	40	in	in	IN
cord-282507-swxs5pr1	326	41	three	three	CD
cord-282507-swxs5pr1	326	42	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	326	43	systems	system	NNS
cord-282507-swxs5pr1	326	44	A	a	DT
cord-282507-swxs5pr1	326	45	phase	phase	NN
cord-282507-swxs5pr1	326	46	1/2	1/2	CD
cord-282507-swxs5pr1	326	47	clinical	clinical	JJ
cord-282507-swxs5pr1	326	48	trial	trial	NN
cord-282507-swxs5pr1	326	49	evaluating	evaluate	VBG
cord-282507-swxs5pr1	326	50	safety	safety	NN
cord-282507-swxs5pr1	326	51	and	and	CC
cord-282507-swxs5pr1	326	52	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	326	53	of	of	IN
cord-282507-swxs5pr1	326	54	a	a	DT
cord-282507-swxs5pr1	326	55	varicella	varicella	NN
cord-282507-swxs5pr1	326	56	zoster	zoster	NN
cord-282507-swxs5pr1	326	57	glycoprotein	glycoprotein	NN
cord-282507-swxs5pr1	326	58	E	E	NNP
cord-282507-swxs5pr1	326	59	subunit	subunit	NN
cord-282507-swxs5pr1	326	60	vaccine	vaccine	NN
cord-282507-swxs5pr1	326	61	candidate	candidate	NN
cord-282507-swxs5pr1	326	62	in	in	IN
cord-282507-swxs5pr1	326	63	young	young	JJ
cord-282507-swxs5pr1	326	64	and	and	CC
cord-282507-swxs5pr1	326	65	older	old	JJR
cord-282507-swxs5pr1	326	66	adults	adult	NNS
cord-282507-swxs5pr1	326	67	Vaccine	Vaccine	NNP
cord-282507-swxs5pr1	326	68	potentiation	potentiation	NN
cord-282507-swxs5pr1	326	69	by	by	IN
cord-282507-swxs5pr1	326	70	combination	combination	NN
cord-282507-swxs5pr1	326	71	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	326	72	Amphiphilic	Amphiphilic	NNP
cord-282507-swxs5pr1	326	73	nature	nature	NN
cord-282507-swxs5pr1	326	74	of	of	IN
cord-282507-swxs5pr1	326	75	saponins	saponin	NNS
cord-282507-swxs5pr1	326	76	and	and	CC
cord-282507-swxs5pr1	326	77	their	-PRON-	PRP$
cord-282507-swxs5pr1	326	78	effects	effect	NNS
cord-282507-swxs5pr1	326	79	on	on	IN
cord-282507-swxs5pr1	326	80	artificial	artificial	JJ
cord-282507-swxs5pr1	326	81	and	and	CC
cord-282507-swxs5pr1	326	82	biological	biological	JJ
cord-282507-swxs5pr1	326	83	membranes	membrane	NNS
cord-282507-swxs5pr1	326	84	and	and	CC
cord-282507-swxs5pr1	326	85	potential	potential	JJ
cord-282507-swxs5pr1	326	86	consequences	consequence	NNS
cord-282507-swxs5pr1	326	87	for	for	IN
cord-282507-swxs5pr1	326	88	red	red	JJ
cord-282507-swxs5pr1	326	89	blood	blood	NN
cord-282507-swxs5pr1	326	90	and	and	CC
cord-282507-swxs5pr1	326	91	cancer	cancer	NN
cord-282507-swxs5pr1	326	92	cells	cell	NNS
cord-282507-swxs5pr1	326	93	Vaccine	vaccine	NN
cord-282507-swxs5pr1	326	94	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	326	95	:	:	:
cord-282507-swxs5pr1	326	96	role	role	NN
cord-282507-swxs5pr1	326	97	and	and	CC
cord-282507-swxs5pr1	326	98	mechanisms	mechanism	NNS
cord-282507-swxs5pr1	326	99	of	of	IN
cord-282507-swxs5pr1	326	100	action	action	NN
cord-282507-swxs5pr1	326	101	in	in	IN
cord-282507-swxs5pr1	326	102	vaccine	vaccine	NN
cord-282507-swxs5pr1	326	103	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	326	104	Elucidating	elucidate	VBG
cord-282507-swxs5pr1	326	105	the	the	DT
cord-282507-swxs5pr1	326	106	mechanisms	mechanism	NNS
cord-282507-swxs5pr1	326	107	of	of	IN
cord-282507-swxs5pr1	326	108	action	action	NN
cord-282507-swxs5pr1	326	109	of	of	IN
cord-282507-swxs5pr1	326	110	saponin	saponin	NN
cord-282507-swxs5pr1	326	111	-	-	HYPH
cord-282507-swxs5pr1	326	112	derived	derive	VBN
cord-282507-swxs5pr1	326	113	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	326	114	Identification	identification	NN
cord-282507-swxs5pr1	326	115	of	of	IN
cord-282507-swxs5pr1	326	116	QS-21	QS-21	NNP
cord-282507-swxs5pr1	326	117	as	as	IN
cord-282507-swxs5pr1	326	118	an	an	DT
cord-282507-swxs5pr1	326	119	inflammasome	inflammasome	NN
cord-282507-swxs5pr1	326	120	-	-	HYPH
cord-282507-swxs5pr1	326	121	activating	activate	VBG
cord-282507-swxs5pr1	326	122	molecular	molecular	JJ
cord-282507-swxs5pr1	326	123	component	component	NN
cord-282507-swxs5pr1	326	124	of	of	IN
cord-282507-swxs5pr1	326	125	saponin	saponin	NN
cord-282507-swxs5pr1	326	126	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	326	127	Characterization	characterization	NN
cord-282507-swxs5pr1	326	128	of	of	IN
cord-282507-swxs5pr1	326	129	T	t	NN
cord-282507-swxs5pr1	326	130	-	-	HYPH
cord-282507-swxs5pr1	326	131	cell	cell	NN
cord-282507-swxs5pr1	326	132	immune	immune	JJ
cord-282507-swxs5pr1	326	133	responses	response	NNS
cord-282507-swxs5pr1	326	134	in	in	IN
cord-282507-swxs5pr1	326	135	clinical	clinical	JJ
cord-282507-swxs5pr1	326	136	trials	trial	NNS
cord-282507-swxs5pr1	326	137	of	of	IN
cord-282507-swxs5pr1	326	138	the	the	DT
cord-282507-swxs5pr1	326	139	candidate	candidate	NN
cord-282507-swxs5pr1	326	140	RTS	RTS	NNP
cord-282507-swxs5pr1	326	141	,	,	,
cord-282507-swxs5pr1	326	142	S	S	NNP
cord-282507-swxs5pr1	326	143	malaria	malaria	NN
cord-282507-swxs5pr1	326	144	vaccine	vaccine	NN
cord-282507-swxs5pr1	326	145	Efficacy	Efficacy	NNP
cord-282507-swxs5pr1	326	146	of	of	IN
cord-282507-swxs5pr1	326	147	RTS	RTS	NNP
cord-282507-swxs5pr1	326	148	,	,	,
cord-282507-swxs5pr1	326	149	S	S	NNP
cord-282507-swxs5pr1	326	150	/	/	SYM
cord-282507-swxs5pr1	326	151	AS01	AS01	NNP
cord-282507-swxs5pr1	326	152	E	E	NNP
cord-282507-swxs5pr1	326	153	malaria	malaria	NN
cord-282507-swxs5pr1	326	154	vaccine	vaccine	NN
cord-282507-swxs5pr1	326	155	and	and	CC
cord-282507-swxs5pr1	326	156	exploratory	exploratory	JJ
cord-282507-swxs5pr1	326	157	analysis	analysis	NN
cord-282507-swxs5pr1	326	158	on	on	IN
cord-282507-swxs5pr1	326	159	anti	anti	JJ
cord-282507-swxs5pr1	326	160	-	-	JJ
cord-282507-swxs5pr1	326	161	circumsporozoite	circumsporozoite	JJ
cord-282507-swxs5pr1	326	162	antibody	antibody	NN
cord-282507-swxs5pr1	326	163	titres	titre	NNS
cord-282507-swxs5pr1	326	164	and	and	CC
cord-282507-swxs5pr1	326	165	protection	protection	NN
cord-282507-swxs5pr1	326	166	in	in	IN
cord-282507-swxs5pr1	326	167	children	child	NNS
cord-282507-swxs5pr1	326	168	aged	age	VBN
cord-282507-swxs5pr1	326	169	5	5	CD
cord-282507-swxs5pr1	326	170	-	-	SYM
cord-282507-swxs5pr1	326	171	17	17	CD
cord-282507-swxs5pr1	326	172	months	month	NNS
cord-282507-swxs5pr1	326	173	in	in	IN
cord-282507-swxs5pr1	326	174	Kenya	Kenya	NNP
cord-282507-swxs5pr1	326	175	and	and	CC
cord-282507-swxs5pr1	326	176	Tanzania	Tanzania	NNP
cord-282507-swxs5pr1	326	177	:	:	:
cord-282507-swxs5pr1	326	178	a	a	DT
cord-282507-swxs5pr1	326	179	randomized	randomized	JJ
cord-282507-swxs5pr1	326	180	controlled	control	VBN
cord-282507-swxs5pr1	326	181	trial	trial	NN
cord-282507-swxs5pr1	326	182	Two	two	CD
cord-282507-swxs5pr1	326	183	phase	phase	NN
cord-282507-swxs5pr1	326	184	2	2	CD
cord-282507-swxs5pr1	326	185	multiple	multiple	JJ
cord-282507-swxs5pr1	326	186	ascending	ascend	VBG
cord-282507-swxs5pr1	326	187	dose	dose	NN
cord-282507-swxs5pr1	326	188	studies	study	NNS
cord-282507-swxs5pr1	326	189	of	of	IN
cord-282507-swxs5pr1	326	190	vanutide	vanutide	NNP
cord-282507-swxs5pr1	326	191	cridificar	cridificar	NNP
cord-282507-swxs5pr1	326	192	(	(	-LRB-
cord-282507-swxs5pr1	326	193	ACC-001	ACC-001	NNP
cord-282507-swxs5pr1	326	194	)	)	-RRB-
cord-282507-swxs5pr1	326	195	and	and	CC
cord-282507-swxs5pr1	326	196	QS-21	QS-21	NNP
cord-282507-swxs5pr1	326	197	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	326	198	in	in	IN
cord-282507-swxs5pr1	326	199	mild	mild	NN
cord-282507-swxs5pr1	326	200	-	-	HYPH
cord-282507-swxs5pr1	326	201	to	to	IN
cord-282507-swxs5pr1	326	202	-	-	HYPH
cord-282507-swxs5pr1	326	203	moderate	moderate	JJ
cord-282507-swxs5pr1	326	204	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	326	205	's	's	POS
cord-282507-swxs5pr1	326	206	disease	disease	NN
cord-282507-swxs5pr1	327	1	The	the	DT
cord-282507-swxs5pr1	327	2	vaccine	vaccine	NN
cord-282507-swxs5pr1	327	3	study	study	NN
cord-282507-swxs5pr1	327	4	team	team	NN
cord-282507-swxs5pr1	327	5	,	,	,
cord-282507-swxs5pr1	327	6	2015	2015	CD
cord-282507-swxs5pr1	327	7	.	.	.
cord-282507-swxs5pr1	328	1	Safety	safety	NN
cord-282507-swxs5pr1	328	2	and	and	CC
cord-282507-swxs5pr1	328	3	immunogenicity	immunogenicity	NN
cord-282507-swxs5pr1	328	4	of	of	IN
cord-282507-swxs5pr1	328	5	vaccine	vaccine	NN
cord-282507-swxs5pr1	328	6	M72	M72	NNP
cord-282507-swxs5pr1	328	7	/	/	SYM
cord-282507-swxs5pr1	328	8	AS01	AS01	NNP
cord-282507-swxs5pr1	328	9	E	E	NNP
cord-282507-swxs5pr1	328	10	in	in	IN
cord-282507-swxs5pr1	328	11	adolescents	adolescent	NNS
cord-282507-swxs5pr1	328	12	in	in	IN
cord-282507-swxs5pr1	328	13	a	a	DT
cord-282507-swxs5pr1	328	14	TB	TB	NNP
cord-282507-swxs5pr1	328	15	endemic	endemic	NN
cord-282507-swxs5pr1	328	16	setting	set	VBG
cord-282507-swxs5pr1	328	17	Key	key	JJ
cord-282507-swxs5pr1	328	18	roles	role	NNS
cord-282507-swxs5pr1	328	19	of	of	IN
cord-282507-swxs5pr1	328	20	adjuvants	adjuvant	NNS
cord-282507-swxs5pr1	328	21	in	in	IN
cord-282507-swxs5pr1	328	22	modern	modern	JJ
cord-282507-swxs5pr1	328	23	vaccines	vaccine	NNS
cord-282507-swxs5pr1	328	24	Efficacy	efficacy	NN
cord-282507-swxs5pr1	328	25	and	and	CC
cord-282507-swxs5pr1	328	26	safety	safety	NN
cord-282507-swxs5pr1	328	27	of	of	IN
cord-282507-swxs5pr1	328	28	the	the	DT
cord-282507-swxs5pr1	328	29	RTS	RTS	NNP
cord-282507-swxs5pr1	328	30	,	,	,
cord-282507-swxs5pr1	328	31	S	S	NNP
cord-282507-swxs5pr1	328	32	/	/	SYM
cord-282507-swxs5pr1	328	33	AS01	AS01	NNP
cord-282507-swxs5pr1	328	34	malaria	malaria	NN
cord-282507-swxs5pr1	328	35	vaccine	vaccine	NN
cord-282507-swxs5pr1	328	36	during	during	IN
cord-282507-swxs5pr1	328	37	18	18	CD
cord-282507-swxs5pr1	328	38	months	month	NNS
cord-282507-swxs5pr1	328	39	after	after	IN
cord-282507-swxs5pr1	328	40	vaccination	vaccination	NN
cord-282507-swxs5pr1	328	41	:	:	:
cord-282507-swxs5pr1	328	42	a	a	DT
cord-282507-swxs5pr1	328	43	phase	phase	NN
cord-282507-swxs5pr1	328	44	3	3	CD
cord-282507-swxs5pr1	328	45	randomized	randomize	VBN
cord-282507-swxs5pr1	328	46	,	,	,
cord-282507-swxs5pr1	328	47	controlled	control	VBN
cord-282507-swxs5pr1	328	48	trial	trial	NN
cord-282507-swxs5pr1	328	49	in	in	IN
cord-282507-swxs5pr1	328	50	children	child	NNS
cord-282507-swxs5pr1	328	51	and	and	CC
cord-282507-swxs5pr1	328	52	young	young	JJ
cord-282507-swxs5pr1	328	53	infants	infant	NNS
cord-282507-swxs5pr1	328	54	at	at	IN
cord-282507-swxs5pr1	328	55	11	11	CD
cord-282507-swxs5pr1	328	56	African	african	JJ
cord-282507-swxs5pr1	328	57	sites	site	NNS
cord-282507-swxs5pr1	328	58	Efficacy	efficacy	NN
cord-282507-swxs5pr1	328	59	and	and	CC
cord-282507-swxs5pr1	328	60	safety	safety	NN
cord-282507-swxs5pr1	328	61	of	of	IN
cord-282507-swxs5pr1	328	62	RTS	RTS	NNP
cord-282507-swxs5pr1	328	63	,	,	,
cord-282507-swxs5pr1	328	64	S	S	NNP
cord-282507-swxs5pr1	328	65	/	/	SYM
cord-282507-swxs5pr1	328	66	AS01	AS01	NNP
cord-282507-swxs5pr1	328	67	malaria	malaria	NN
cord-282507-swxs5pr1	328	68	vaccine	vaccine	NN
cord-282507-swxs5pr1	328	69	with	with	IN
cord-282507-swxs5pr1	328	70	or	or	CC
cord-282507-swxs5pr1	328	71	without	without	IN
cord-282507-swxs5pr1	328	72	a	a	DT
cord-282507-swxs5pr1	328	73	booster	booster	NN
cord-282507-swxs5pr1	328	74	dose	dose	NN
cord-282507-swxs5pr1	328	75	in	in	IN
cord-282507-swxs5pr1	328	76	infants	infant	NNS
cord-282507-swxs5pr1	328	77	and	and	CC
cord-282507-swxs5pr1	328	78	children	child	NNS
cord-282507-swxs5pr1	328	79	in	in	IN
cord-282507-swxs5pr1	328	80	Africa	Africa	NNP
cord-282507-swxs5pr1	328	81	:	:	:
cord-282507-swxs5pr1	328	82	final	final	JJ
cord-282507-swxs5pr1	328	83	results	result	NNS
cord-282507-swxs5pr1	328	84	of	of	IN
cord-282507-swxs5pr1	328	85	a	a	DT
cord-282507-swxs5pr1	328	86	phase	phase	NN
cord-282507-swxs5pr1	328	87	3	3	CD
cord-282507-swxs5pr1	328	88	,	,	,
cord-282507-swxs5pr1	328	89	individually	individually	RB
cord-282507-swxs5pr1	328	90	randomised	randomised	JJ
cord-282507-swxs5pr1	328	91	,	,	,
cord-282507-swxs5pr1	328	92	controlled	control	VBN
cord-282507-swxs5pr1	328	93	trial	trial	NN
cord-282507-swxs5pr1	328	94	Vaccines	vaccine	NNS
cord-282507-swxs5pr1	328	95	"	"	''
cord-282507-swxs5pr1	328	96	,	,	,
cord-282507-swxs5pr1	328	97	Section	section	NN
cord-282507-swxs5pr1	328	98	1	1	CD
cord-282507-swxs5pr1	328	99	,	,	,
cord-282507-swxs5pr1	328	100	General	general	JJ
cord-282507-swxs5pr1	328	101	aspects	aspect	NNS
cord-282507-swxs5pr1	328	102	of	of	IN
cord-282507-swxs5pr1	328	103	Vaccination	Vaccination	NNP
cord-282507-swxs5pr1	328	104	A	a	DT
cord-282507-swxs5pr1	328	105	systematic	systematic	JJ
cord-282507-swxs5pr1	328	106	review	review	NN
cord-282507-swxs5pr1	328	107	and	and	CC
cord-282507-swxs5pr1	328	108	metaanalysis	metaanalysis	NN
cord-282507-swxs5pr1	328	109	on	on	IN
cord-282507-swxs5pr1	328	110	the	the	DT
cord-282507-swxs5pr1	328	111	safety	safety	NN
cord-282507-swxs5pr1	328	112	of	of	IN
cord-282507-swxs5pr1	328	113	newly	newly	RB
cord-282507-swxs5pr1	328	114	adjuvanted	adjuvante	VBN
cord-282507-swxs5pr1	328	115	vaccines	vaccine	NNS
cord-282507-swxs5pr1	328	116	amound	amound	NN
cord-282507-swxs5pr1	328	117	children	child	NNS
cord-282507-swxs5pr1	328	118	Persistence	persistence	NN
cord-282507-swxs5pr1	328	119	of	of	IN
cord-282507-swxs5pr1	328	120	immune	immune	JJ
cord-282507-swxs5pr1	328	121	response	response	NN
cord-282507-swxs5pr1	328	122	to	to	IN
cord-282507-swxs5pr1	328	123	an	an	DT
cord-282507-swxs5pr1	328	124	adjuvanted	adjuvanted	JJ
cord-282507-swxs5pr1	328	125	varicella	varicella	NN
cord-282507-swxs5pr1	328	126	-	-	HYPH
cord-282507-swxs5pr1	328	127	zoster	zoster	NN
cord-282507-swxs5pr1	328	128	virus	virus	NN
cord-282507-swxs5pr1	328	129	subunit	subunit	NN
cord-282507-swxs5pr1	328	130	vaccine	vaccine	NN
cord-282507-swxs5pr1	328	131	for	for	IN
cord-282507-swxs5pr1	328	132	up	up	IN
cord-282507-swxs5pr1	328	133	to	to	TO
cord-282507-swxs5pr1	328	134	year	year	NN
cord-282507-swxs5pr1	328	135	nine	nine	CD
cord-282507-swxs5pr1	328	136	in	in	IN
cord-282507-swxs5pr1	328	137	older	old	JJR
cord-282507-swxs5pr1	328	138	adults	adult	NNS
cord-282507-swxs5pr1	329	1	An	an	DT
cord-282507-swxs5pr1	329	2	adjuvanted	adjuvanted	JJ
cord-282507-swxs5pr1	329	3	polyprotein	polyprotein	NNP
cord-282507-swxs5pr1	329	4	HIV-1	HIV-1	NNP
cord-282507-swxs5pr1	329	5	vaccine	vaccine	NN
cord-282507-swxs5pr1	329	6	induces	induce	VBZ
cord-282507-swxs5pr1	330	1	polyfunctional	polyfunctional	NNP
cord-282507-swxs5pr1	330	2	cross	cross	JJ
cord-282507-swxs5pr1	330	3	-	-	JJ
cord-282507-swxs5pr1	330	4	reactive	reactive	JJ
cord-282507-swxs5pr1	330	5	CD4	CD4	NNP
cord-282507-swxs5pr1	330	6	+	+	CC
cord-282507-swxs5pr1	330	7	T	t	NN
cord-282507-swxs5pr1	330	8	cell	cell	NN
cord-282507-swxs5pr1	330	9	responses	response	NNS
cord-282507-swxs5pr1	330	10	in	in	IN
cord-282507-swxs5pr1	330	11	seronegative	seronegative	JJ
cord-282507-swxs5pr1	330	12	volunteers	volunteer	NNS
cord-282507-swxs5pr1	330	13	Predicting	predict	VBG
cord-282507-swxs5pr1	330	14	RTS	RTS	NNP
cord-282507-swxs5pr1	330	15	,	,	,
cord-282507-swxs5pr1	330	16	S	S	NNP
cord-282507-swxs5pr1	330	17	vaccine	vaccine	NN
cord-282507-swxs5pr1	330	18	-	-	HYPH
cord-282507-swxs5pr1	330	19	mediated	mediate	VBN
cord-282507-swxs5pr1	330	20	protection	protection	NN
cord-282507-swxs5pr1	330	21	from	from	IN
cord-282507-swxs5pr1	330	22	transcriptomes	transcriptome	NNS
cord-282507-swxs5pr1	330	23	in	in	IN
cord-282507-swxs5pr1	330	24	a	a	DT
cord-282507-swxs5pr1	330	25	malaria	malaria	NN
cord-282507-swxs5pr1	330	26	-	-	HYPH
cord-282507-swxs5pr1	330	27	challenge	challenge	NN
cord-282507-swxs5pr1	330	28	clinical	clinical	JJ
cord-282507-swxs5pr1	330	29	trial	trial	NN
cord-282507-swxs5pr1	330	30	Phase	Phase	NNP
cord-282507-swxs5pr1	330	31	2b	2b	CD
cord-282507-swxs5pr1	330	32	controlled	control	VBN
cord-282507-swxs5pr1	330	33	trial	trial	NN
cord-282507-swxs5pr1	330	34	of	of	IN
cord-282507-swxs5pr1	330	35	M72	M72	NNP
cord-282507-swxs5pr1	330	36	/	/	SYM
cord-282507-swxs5pr1	330	37	AS01	AS01	NNP
cord-282507-swxs5pr1	330	38	E	E	NNP
cord-282507-swxs5pr1	330	39	vaccine	vaccine	NN
cord-282507-swxs5pr1	330	40	to	to	TO
cord-282507-swxs5pr1	330	41	prevent	prevent	VB
cord-282507-swxs5pr1	330	42	tuberculosis	tuberculosis	NN
cord-282507-swxs5pr1	330	43	Vaccine	vaccine	NN
cord-282507-swxs5pr1	330	44	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	330	45	systems	system	NNS
cord-282507-swxs5pr1	330	46	containing	contain	VBG
cord-282507-swxs5pr1	330	47	monophosphoryl	monophosphoryl	NNP
cord-282507-swxs5pr1	330	48	lipid	lipid	VBG
cord-282507-swxs5pr1	330	49	A	A	NNP
cord-282507-swxs5pr1	330	50	and	and	CC
cord-282507-swxs5pr1	330	51	QS-21	QS-21	NNP
cord-282507-swxs5pr1	330	52	induce	induce	VB
cord-282507-swxs5pr1	330	53	strong	strong	JJ
cord-282507-swxs5pr1	330	54	and	and	CC
cord-282507-swxs5pr1	330	55	persistent	persistent	JJ
cord-282507-swxs5pr1	330	56	humoral	humoral	JJ
cord-282507-swxs5pr1	330	57	and	and	CC
cord-282507-swxs5pr1	330	58	T	T	NNP
cord-282507-swxs5pr1	330	59	cell	cell	NN
cord-282507-swxs5pr1	330	60	responses	response	NNS
cord-282507-swxs5pr1	330	61	against	against	IN
cord-282507-swxs5pr1	330	62	hepatitis	hepatitis	NNP
cord-282507-swxs5pr1	330	63	B	B	NNP
cord-282507-swxs5pr1	330	64	surface	surface	NN
cord-282507-swxs5pr1	330	65	antigen	antigen	NN
cord-282507-swxs5pr1	330	66	in	in	IN
cord-282507-swxs5pr1	330	67	healthy	healthy	JJ
cord-282507-swxs5pr1	330	68	adult	adult	NN
cord-282507-swxs5pr1	330	69	volonteers	volonteer	NNS
cord-282507-swxs5pr1	330	70	Efficacy	Efficacy	NNP
cord-282507-swxs5pr1	330	71	of	of	IN
cord-282507-swxs5pr1	330	72	the	the	DT
cord-282507-swxs5pr1	330	73	MAGE	MAGE	NNP
cord-282507-swxs5pr1	330	74	-	-	HYPH
cord-282507-swxs5pr1	330	75	A3	A3	NNP
cord-282507-swxs5pr1	330	76	immunotherapeutic	immunotherapeutic	NN
cord-282507-swxs5pr1	330	77	as	as	IN
cord-282507-swxs5pr1	330	78	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	330	79	therapy	therapy	NN
cord-282507-swxs5pr1	330	80	in	in	IN
cord-282507-swxs5pr1	330	81	patients	patient	NNS
cord-282507-swxs5pr1	330	82	with	with	IN
cord-282507-swxs5pr1	330	83	resected	resected	JJ
cord-282507-swxs5pr1	330	84	MAGE	MAGE	NNP
cord-282507-swxs5pr1	330	85	-	-	HYPH
cord-282507-swxs5pr1	330	86	A3-positive	A3-positive	NNP
cord-282507-swxs5pr1	330	87	non	non	JJ
cord-282507-swxs5pr1	330	88	-	-	JJ
cord-282507-swxs5pr1	330	89	small	small	JJ
cord-282507-swxs5pr1	330	90	-	-	HYPH
cord-282507-swxs5pr1	330	91	cell	cell	NN
cord-282507-swxs5pr1	330	92	lung	lung	NN
cord-282507-swxs5pr1	330	93	cancer	cancer	NN
cord-282507-swxs5pr1	330	94	(	(	-LRB-
cord-282507-swxs5pr1	330	95	MAGRIT	MAGRIT	NNP
cord-282507-swxs5pr1	330	96	)	)	-RRB-
cord-282507-swxs5pr1	330	97	:	:	:
cord-282507-swxs5pr1	331	1	a	a	DT
cord-282507-swxs5pr1	331	2	randomized	randomized	JJ
cord-282507-swxs5pr1	331	3	,	,	,
cord-282507-swxs5pr1	331	4	double	double	JJ
cord-282507-swxs5pr1	331	5	-	-	HYPH
cord-282507-swxs5pr1	331	6	blind	blind	JJ
cord-282507-swxs5pr1	331	7	,	,	,
cord-282507-swxs5pr1	331	8	placebo	placebo	NN
cord-282507-swxs5pr1	331	9	-	-	HYPH
cord-282507-swxs5pr1	331	10	controlled	control	VBN
cord-282507-swxs5pr1	331	11	Quillaja	Quillaja	NNP
cord-282507-swxs5pr1	331	12	saponin	saponin	NN
cord-282507-swxs5pr1	331	13	variants	variant	NNS
cord-282507-swxs5pr1	331	14	with	with	IN
cord-282507-swxs5pr1	331	15	central	central	JJ
cord-282507-swxs5pr1	331	16	glycosidic	glycosidic	JJ
cord-282507-swxs5pr1	331	17	linkage	linkage	NN
cord-282507-swxs5pr1	331	18	modifications	modification	NNS
cord-282507-swxs5pr1	331	19	exhibit	exhibit	VBP
cord-282507-swxs5pr1	331	20	distinct	distinct	JJ
cord-282507-swxs5pr1	331	21	conformations	conformation	NNS
cord-282507-swxs5pr1	331	22	and	and	CC
cord-282507-swxs5pr1	331	23	adjuvant	adjuvant	NN
cord-282507-swxs5pr1	331	24	activities	activity	NNS
cord-282507-swxs5pr1	331	25	Lysosome	Lysosome	NNP
cord-282507-swxs5pr1	331	26	-	-	HYPH
cord-282507-swxs5pr1	331	27	dependent	dependent	JJ
cord-282507-swxs5pr1	331	28	activation	activation	NN
cord-282507-swxs5pr1	331	29	of	of	IN
cord-282507-swxs5pr1	331	30	human	human	JJ
cord-282507-swxs5pr1	331	31	dendritic	dendritic	JJ
cord-282507-swxs5pr1	331	32	cells	cell	NNS
cord-282507-swxs5pr1	331	33	by	by	IN
cord-282507-swxs5pr1	331	34	the	the	DT
cord-282507-swxs5pr1	331	35	vaccine	vaccine	NN
cord-282507-swxs5pr1	332	1	adjuvant	adjuvant	JJ
cord-282507-swxs5pr1	332	2	QS-21	QS-21	NNP
cord-282507-swxs5pr1	333	1	The	the	DT
cord-282507-swxs5pr1	333	2	relationship	relationship	NN
cord-282507-swxs5pr1	333	3	between	between	IN
cord-282507-swxs5pr1	333	4	RTS	RTS	NNP
cord-282507-swxs5pr1	333	5	,	,	,
cord-282507-swxs5pr1	333	6	S	S	NNP
cord-282507-swxs5pr1	333	7	vaccine	vaccine	NN
cord-282507-swxs5pr1	333	8	-	-	HYPH
cord-282507-swxs5pr1	333	9	induced	induce	VBN
cord-282507-swxs5pr1	333	10	antibodies	antibody	NNS
cord-282507-swxs5pr1	333	11	,	,	,
cord-282507-swxs5pr1	333	12	CD4	CD4	NNP
cord-282507-swxs5pr1	333	13	+	+	CC
cord-282507-swxs5pr1	333	14	T	T	NNP
cord-282507-swxs5pr1	333	15	cell	cell	NN
cord-282507-swxs5pr1	333	16	responses	response	NNS
cord-282507-swxs5pr1	333	17	and	and	CC
cord-282507-swxs5pr1	333	18	protection	protection	NN
cord-282507-swxs5pr1	333	19	against	against	IN
cord-282507-swxs5pr1	333	20	Plasmodium	Plasmodium	NNP
cord-282507-swxs5pr1	333	21	falciparum	falciparum	NN
cord-282507-swxs5pr1	333	22	infection	infection	NN
cord-282507-swxs5pr1	333	23	Active	active	JJ
cord-282507-swxs5pr1	333	24	immunotherapy	immunotherapy	NN
cord-282507-swxs5pr1	333	25	options	option	NNS
cord-282507-swxs5pr1	333	26	for	for	IN
cord-282507-swxs5pr1	333	27	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	333	28	's	's	POS
cord-282507-swxs5pr1	333	29	disease	disease	NN
cord-282507-swxs5pr1	333	30	.	.	.
cord-282507-swxs5pr1	334	1	Alzheimer	Alzheimer	NNP
cord-282507-swxs5pr1	334	2	's	's	POS
cord-282507-swxs5pr1	334	3	Res	Res	NNP
cord-282507-swxs5pr1	334	4	.	.	.
cord-282507-swxs5pr1	335	1	Ther	ther	UH
cord-282507-swxs5pr1	335	2	.	.	.
cord-282507-swxs5pr1	335	3	6	6	CD
cord-282507-swxs5pr1	335	4	,	,	,
cord-282507-swxs5pr1	335	5	7	7	CD
cord-282507-swxs5pr1	335	6	.	.	.
cord-282507-swxs5pr1	336	1	World	World	NNP
cord-282507-swxs5pr1	336	2	Health	Health	NNP
cord-282507-swxs5pr1	336	3	Organisation	Organisation	NNP
cord-282507-swxs5pr1	336	4	,	,	,
cord-282507-swxs5pr1	336	5	2016	2016	CD
cord-282507-swxs5pr1	336	6	.	.	.
cord-282507-swxs5pr1	337	1	Malaria	Malaria	NNP
cord-282507-swxs5pr1	337	2	vaccine	vaccine	NN
cord-282507-swxs5pr1	337	3	:	:	:
cord-282507-swxs5pr1	337	4	WHO	who	WP
cord-282507-swxs5pr1	337	5	position	position	VBP
cord-282507-swxs5pr1	337	6	paper	paper	NN
cord-282507-swxs5pr1	337	7	first-malaria-vaccine-receivespositive-scientific-opinion-ema_en.pdf	first-malaria-vaccine-receivespositive-scientific-opinion-ema_en.pdf	NN
cord-282507-swxs5pr1	337	8	.	.	.
cord-282507-swxs5pr1	338	1	EMA	EMA	NNP
cord-282507-swxs5pr1	338	2	press	press	NN
cord-282507-swxs5pr1	338	3	release	release	NN
cord-282507-swxs5pr1	338	4	2015	2015	CD
cord-282507-swxs5pr1	338	5	.	.	.
cord-282507-swxs5pr1	339	1	First	first	JJ
cord-282507-swxs5pr1	339	2	malaria	malaria	NN
cord-282507-swxs5pr1	339	3	vaccine	vaccine	NN
cord-282507-swxs5pr1	339	4	receives	receive	VBZ
cord-282507-swxs5pr1	339	5	positive	positive	JJ
cord-282507-swxs5pr1	339	6	scientific	scientific	JJ
cord-282507-swxs5pr1	339	7	opinion	opinion	NN
cord-282507-swxs5pr1	339	8	from	from	IN
cord-282507-swxs5pr1	339	9	EMA	EMA	NNP
cord-282507-swxs5pr1	340	1	There	there	EX
cord-282507-swxs5pr1	340	2	are	be	VBP
cord-282507-swxs5pr1	340	3	no	no	DT
cord-282507-swxs5pr1	340	4	conflicts	conflict	NNS
cord-282507-swxs5pr1	340	5	of	of	IN
cord-282507-swxs5pr1	340	6	interest	interest	NN
cord-282507-swxs5pr1	340	7	associated	associate	VBN
cord-282507-swxs5pr1	340	8	with	with	IN
cord-282507-swxs5pr1	340	9	this	this	DT
cord-282507-swxs5pr1	340	10	publication	publication	NN
cord-282507-swxs5pr1	340	11	.	.	.